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Abstract  
Microbial pesticides have been developed for a hundred years, but many of these crop 
protection products have not been successful in the market. The history of microbial pest 
control products is summarized, the companies involved are reviewed, and the reasons for 
failure in obtaining success are briefly described. The need for a model that facilitates the 
development and commercialization of these products is recognized. The entomopathogenic 
bacteria, fungi, viruses and nematodes utilized as biocontrol agents are briefly introduced. 
The aim of this thesis is to develop a rational and structured approach that will increase the 
chances of achieving success with microbial pest control products. Finally, this chapter 
presents an outline of this thesis. Terminology and definitions used are provided in the 
Appendix for products, methods of control, and control strategies. 
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Introduction 
 
Microbial pest control products 
Numerous microbial pest control products for control of arthropod pests have been developed 
in the past and are developed at present. In theory, they offer one of the most sustainable and 
ecologically acceptable means of crop protection for modern agriculture. Generally, they are 
intended to replace synthetic chemical pesticides as our society requires sustainable pest 
control solutions that are safe to humans and to the environment. Research on new biocontrol 
agents, frequently initiated by academic scientists, promises elegant solutions. Companies 
translate these research results into the development of a commercial product. Many of these 
new products, however, do not become successful in the market, and companies fail to 
achieve a profitable business. Annual sales of microbial pesticides are reported to be $750 
million globally, amounting only to 2.5% of the chemical market (Evans, 2008). An 
imperative question is whether it is possible to identify the obstacles and constraints to the 
development of a reliable, efficacious and commercially-viable product? Can the currently 
frustrating situation be improved? I believe that successful products can be developed when a 
rational and structured pathway is followed for the entire process of development and 
commercialization of a microbial pest control product. A model describing such a pathway 
has not been presented to date. In this study I will critically evaluate the situation at present 
from a commercial perspective, and propose a systematic model that will guide future product 
developers to a successful microbial product for control of arthropod pests. For terms and 
definitions used in this thesis, see Appendix 1 at the end of this chapter. For acronyms and 
abbreviations used in this thesis, see List of Acronyms and Abbreviations on pages ix-x.  
 
The early history of microbial control 
The idea of using entomopathogenic microorganisms to control insect pests is about one 
hundred and fifty years old. The discovery of disease-causing microorganisms in the 
silkworm industry was the first step. Spreading these microorganisms in the field to reduce a 
pest insect was the second step towards the concept of microbial control. Steinhaus (1956) 
described the early observations on diseased insects and the rise of the idea of the use of 
microbial control in the 19th century in a fascinating paper. Famous men as Agostini Bassi in 
Italy, Louis Pasteur in France, J.L. Leconte and H.A. Hagen in the USA were the first to 
suggest the use of diseases of insects to kill harmful insects in crops (Steinhaus, 1956). In his 
paper in 1879, Hagen suggested mass production of the disease-causing organism and 
spraying those over the infested plants and to wait for the epizootic effect to reduce the pest. 
He suggested a greenhouse trial against worms and the potato bug, and considered the dose 
and the application method. Furthermore, he stated that “…..the remedy is very cheap, easy to 
be prepared, not obnoxious to man or domestic animals, and if successful a benefit to 
mankind” (Steinhaus, 1956). This statement can probably be seen as the first conceptual idea 
of the development of a microbial pest control product including biological, technical, 
economical and safety-related considerations. All these aspects then considered by Hagen are 
still relevant today for the development of a biopesticide. 
 Simultaneously, Metchnikoff envisaged the use of a fungus, Metarhizium anisopliae, to 
control insects in Russia’s agriculture. He succeeded in growing the fungus on a sterilized, 
artificial medium. Large-scale production and field applications were conducted by 
Krassiltschik for control of various insect pests in the 1880’s (Steinhaus, 1956). Similar 
developments occurred in the 1880-1890’s with Beauveria bassiana in the USA (Lord, 2005).  
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The first microbial pest control products 
In the first decade of the 1900’s bacteria were discovered as insect pathogens, the first being 
Bacillus thuringiensis (Bt) in 1911, shortly followed by B. popilliae (Lord, 2005). Both 
pathogens were further investigated, production was started, and products developed and 
used. The first commercial biopesticide was Sporeine, based on B. thuringiensis and available 
in 1938 in France. The first attempts to use entomopathogenic nematodes were conducted 
with Steinernema glaseri in the late 1930’s in the USA. The programme stopped because of 
World War II and results of field applications were not assessed. The first fungal product was 
developed in the former USSR in 1965. This product, Boverin, was based on B. bassiana, and 
used to control the Colorado potato beetle and the codling moth (De Faria and Wraight, 
2007). Although baculoviruses were found to cause epizootics in the 1940’s, a commercial 
product was only developed in the 1970’s (Ignoffo, 1973). The first product was VironH for 
control of Helicoverpa zea. These events are highlighted by Lord (2005) and earlier authors 
referred to by Lord.  
 
The rise and struggle of the biopesticide industry 
Serious industrial developments with biopesticides started in the 1960-1970’s with products 
based on Bt. Large agrichemical companies such as Sandoz and Solvay started to produce 
products and the first commercial biopesticides were registered and launched on the market in 
the USA and in Europe in the early 1960’s.  
The research on insect pathogens has grown extensively the last four decades and the 
literature on insect pathogens and on their potential as microbial control agents is vast. During 
this period, many companies have employed activities with biopesticides and numerous 
products have been developed, registered, and introduced on the market. The use of 
biopesticides is constantly increasing. However, their overall use is merely a few percent of 
the total worldwide use of plant protection products. Many products have not been successful, 
and numerous companies have failed. According to Lisansky (CPL, 2006a) over four hundred 
companies have been active at different times with commercialization of microbial pesticides, 
and the majority of these companies has left the field of biopesticides. Gelernter (2005) 
provided an overview of these commercial developments within the biopesticide industry 
from 1950 to 2005. The challenges that entrepreneurs face when they try to develop and 
commercialize microbial pest control products have been outlined by many authors working 
in the biopesticide industry (Jaronsky, 1986; Cross and Polonenko, 1996; Marrone, 1999; Van 
der Pas et al., 2000; Warrior, 2000; Benuzzi et al., 2004, Georgis, 2002; Krause et al., 2008). 
The reasons for failure have been reported many times and the dominant issues are: variable 
quality and efficacy of biocontrol products, their costs compared to their efficacy, competition 
with chemicals, registration, overestimation of the market size, underestimation of the 
assumption that market adoption will be easy, underestimation of the total required budget 
and the time to market, and the often less than optimal collaboration between academic 
scientists and the product developers in the industry.   
 
Hurdles and constraints 
The failure of many of these initiatives with biopesticides has been a serious problem. Vast 
sums of money have been spent and were largely wasted. This still occurs today. As a result, 
the development of biological and sustainable plant protection products is hardly 
accomplished. The demand for these kinds of products is rising in our societies, but the 
potential that microorganisms offer to control pests is not met. Lessons should be learned 
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from this history with the commercialization of biopesticides. In the scientific literature, many 
authors report research topics related to the development and commercialization of a 
microbial control agent. Usually, this refers to biological and technical subjects, and 
sometimes to regulatory aspects. Few authors addressed market and commercial aspects, and 
even fewer focussed on economic considerations. There is no extensive treatment of the entire 
developmental process in the literature. Several authors have observed too that, despite 
abundant research on microbial pest control agents, commercialization of products has only 
been accomplished in a limited number of cases (Cross and Polonenko, 1996; Fravel, 1999; 
Stewart, 2001; Hallett, 2005; CPL, 2007; Droby et al., 2009). 
A statement of Dent (1997) emphasizes the need for a systematic approach to efficiently 
develop new biological products: “Microbial insecticide research is usually funded piecemeal, 
largely by the public sector, and rarely involves multi-disciplinary teams that develop a 
microbial insecticide from start to finish. The general knowledge base in microbial 
insecticides is built up in a haphazard way, through uncoordinated efforts of many scientists 
all pursuing their own individual research objectives and interests. This contrasts markedly 
with the more focussed factory-like screening and development process which characterizes 
agrochemical R & D that produces new chemical insecticides.” Later, other researchers have 
expressed similar self-criticism with regard to their attitude towards research on biocontrol 
agents and are calling upon colleagues to maximize efforts to attaining more commercial 
successes (Fravel, 1999; Stewart, 2001). Scientists again recognized the lack of direction in 
their research approaches when it relates to biopesticide development. Ash (2009) stated that 
“researchers should also be encouraged to abandon referring to their “pet pathogen” as a 
bioherbicide candidate. Long after they have failed to demonstrate economic and biological 
rationale for the production of a bioherbicide the researcher continues to research and publish 
on the system they have studied for so long”. Not only in bioherbicides is the phenomena of 
“pet pathogens” noticeable, and resources could be spent more efficiently when the 
development of a biopesticide is the goal.  
At the same time, companies contemplating the development of a microbial pest control 
product made and still make serious mistakes in their assumptions on their knowledge and 
skills, the market potential and many other aspects of commercialization of these products 
(Gelernter, 2005; CPL, 2006a). Many potential products remain on the shelf of the academic 
scientists because of the enormous challenge of developing it into a successful product. Still 
today, I see research conducted in the way Dent (1997) described more then ten years ago. On 
the other hand, I also see more and more public and private research collaborating with the 
goal to develop microbial products from the onset of a project. Small biocontrol companies 
need to adopt appropriate aspects of the approach of large agrochemical R & D companies to 
enhance their product development. Both academic scientists and biopesticide developers in 
industry need to collaborate earlier in a project and should be more focussed on the entire 
process of product development and commercialization. With a well-coordinated research 
between academics and industry, and a clear focus on the final product and market, more 
biopesticides are likely to reach the market and become successful. 
Registration is often cited as the main hurdle in the commercialization of microbial pest 
control products. It is a long and expensive procedure. Moreover, many dossier requirements 
do not address the specific nature of these products appropriately which makes registration 
even more difficult. Regulatory innovation and harmonization are required at EU level and at 
national level to remedy this situation (Chandler et al., 2008a). Concerning registration 
worldwide, the OECD’s Pesticide Programme strives to facilitate and improve registration 
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procedures of crop protection products in member countries by harmonization (Sigman, 
2005). The OECD Biopesticide Steering Group is working on several issues related to data 
requirements for microbials (Meeussen, 2007).  
 
The need for a roadmap for the development of a microbial pest control product   
The development of a biopesticide requires many steps from concept to product, and a well-
targeted project strategy is necessary to reach success. This has lead to the question: “can a 
pathway be developed that leads to a successful biopesticide”. This question has been posed 
in various wordings by many scientists, not only in the field of bioinsecticides (Jaronski, 
1986; Dent, 1997; Dent et al., 1999; Lidert, 2001; Jackson et al., 1992; Bateman, 2004; 
Benuzzi, 2004 ), but also the field of biofungicides (Campbell, 1986; Woodhead et al., 1990; 
Mathre et al., 1999), bioherbicides (Cross and Polonenko, 1996; Leggett and Gleddie, 1995; 
Stewart, 2001; Hallett, 2005; Ash, 2009), and post-harvest pest and disease control products 
(Droby et al., 2009). It is obvious that there is a need for a general model on the development 
and a successful commercialization of a microbial pesticide.  
Numerous authors have briefly treated one or more steps in the product development; 
few have addressed all steps in a systemic and structured way. Several authors have briefly 
described models and provided flow diagrams with the consecutive steps of product 
development (Lisansky, 1985; Törmälä, 1995; Hofstein and Chapple, 1999; Marrone, 1999; 
Butt et al., 2001; Montesinos, 2003; Jijakli, 2003; Fravel, 2005; Kiewnick, 2007). Most of 
these attempts focused on biological features of the candidate biocontrol agents, some 
included biological and technical aspects of mass production and formulation, and others 
reviewed aspects of regulatory importance. Few addressed economic, market-related and 
commercial elements, but these are key considerations in each step of the product 
development. Furthermore, the developmental process up to regulatory approval to sell is just 
half the story, only hereafter the product and company are really tested to perform well in the 
market. 
There is one well-documented example originating from the academic world. It 
concerns the Lubilosa project where a mycoinsecticide was developed for control of locusts 
and grasshoppers by a large multi-disciplinary team of researchers. From the outset, the 
development of a mycoinsecticide was foreseen and all required steps were identified and 
executed in a systematic way (Lomer, 1999a; Dent, 1998). Also, continuous feedback with 
regard to economical, sociological and practical application aspects was provided between the 
teams (Bateman, 1997; De Groote, 1997). The flow scheme (figure 1.1) used in the Lubilosa 
project (Dent, 1998) is similar to the one developed earlier by Lisansky (1985) and based on 
his industrial experience. The Lubilosa flow scheme is the most complete one that I have 
found in the literature. Industry, however, has not described their way of working with regard 
to biopesticide development. Understandably, proprietary considerations have prevented an 
elaborate process description, and secondly, writing publications is low on the priority list 
within industry.  
Clearly, a model that describes and critically evaluates all steps of the developmental 
process and includes biological, technical, regulatory and economic factors is lacking. Such a 
general model would facilitate this process and provide guidance for product developers. This 
information may also increase the chance that new product ideas make it to the market in a 
successful way. In order to be successful with a product in the market, the economics of the 
whole process and the final product must result in a profit for the company.  
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Figure 1.1.   Scheme of development of a microbial pest control product used in the Lubilosa 
           programme (Dent, 1998) 
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Insect pathogens as microbial control agents 
Four groups of microbial pathogens are typically found in insects: bacteria, fungi, viruses, and 
protozoa. Their biological properties determine their utility as agents for the control of insects 
(Federici, 1999a). In addition to these microorganisms, entomopathogenic nematodes will be 
treated because many of the same principles apply to the use of these organisms as biocontrol 
agents in the form of a microbial pest control product. In this thesis, genetically modified 
organisms (GMOs) and those control products based on GMOs are not reviewed and 
discussed, although there are GMO-based microbial pest control products (MPCPs) 
developed and available. A small number of MPCPs with genetically modified Bacillus 
thuringiensis strains are approved in the USA. Genetically modified plants incorporated with 
Bt genes are also available on the market. Sometimes these are also categorized as 
biopesticides. GMO-based biopesticides are at present not allowed in Europe, and even when 
allowed, registration would be extremely expensive and complicated. These kinds of 
biopesticides are not foreseen for the European market for the near future. 
 
Bacteria 
Most bacteria that provide potential as a bioinsecticide belong to the spore-forming bacteria 
of the genus Bacillus (Bacillaceae). The major species used in biocontrol is B. thuringiensis. 
Other species are B. sphaericus and Paenibacillus popilliae, and one species from the genus 
Serratia. A brief overview of bacteria, their biology, mode of action, and ecology in relation 
to their potential as biocontrol agents is provided by Garczynski and Siegel (2007). The 
number of bacterial species used in biocontrol to date is limited. The number of isolates is 
numerous, whereby any isolate may present unique features that offer potential for a new 
product. Hundreds of products have been developed with B. thuringiensis, whereas only a 
handful based on other bacteria (Garczynski and Siegel, 2007; Copping, 2009). Bacterial 
insecticides have been primarily developed for control of lepidopteran and dipteran pest. A 
few products have been developed for control of beetle larvae.  
 
Fungi 
Two groups of fungi are generally found to cause diseases in insects. These pathogens belong 
to the orders Entomophthorales and Hypocreales (formerly called Hyphomecetes). The 
higher-level phylogenetic classification of fungi, including entomopathogenic fungi, has been 
modified considerably, for more information I refer to Hibbett et al. (2007) and Humber 
(2007, 2008). Several other entomopathogenic fungi from other taxonomic groups are known. 
Over 700 species of fungi are known to infest insects (Wraight et al., 2007). For more 
information on the entomopathogenic fungi, their biology, taxonomy and ecology with regard 
to biocontrol I refer to Chandler et al. (2000), Shah and Pell (2003), and Wraight et al. (2007).  
Entomophthoralean fungi are important in nature as insect pathogens and they play an 
significant role in suppression of insects, often through epizootics. They are primarily found 
on aphids, caterpillars and flies. More information on the biology and occurrence of these 
fungi can be obtained from Pell et al. (2001). These fungi are not used as microbial 
insecticides to date because of the difficulty of mass production. They are not further 
discussed in this thesis.  
Hypocrealean fungi are interesting fungi for use as biocontrol agents. An overview of 
this group of entomopathogenic fungi and their biology and ecology in relation to their use as 
biocontrol agents is presented by Inglis et al. (2001). They are found on members of many 
insect orders, and on other arthropods such as mites and ticks. Numerous mycoinsecticides 
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have been developed based on these fungi, particularly on the species B. bassiana and M. 
anisopliae (Copping, 2009). This group offers great potential for commercial use.  
 
Viruses 
Viruses are obligate intracellular parasites, and numerous viruses (around 1000) are specific 
to insects. Three principal groups if insect viruses have been found in the families of 
Baculoviridae, Entomopoxvirinae and Reoviridae. These families are characterized by the 
formation of occlusion bodies, in which the virus particles (virions) are occluded in a 
protective proteinaceous matrix. This characteristic provides these viruses the possibility to be 
used as a biocontrol agent. A brief overview of viruses, their biology and ecology in relation 
to their potential as biocontrol agents is provided by Cory and Evans (2007). Baculoviruses 
are the most often used and most successful biocontrol agents from this group of pathogens. 
The family Baculoviridae is divided in four genera: Alphabaculovirus, Betabaculovirus, 
Deltabaculovirus, and Gammabaculovirus (Jehle et al., 2006; www.ictvonline.org/virus 
TaxInfo.asp). There are two types of rod-shaped viruses, known as nucleopolyhedroviruses 
(NPVs) and granuloviruses (GVs). NPVs (over 500 isolates) are infectious to Lepidoptera, 
Hymenoptera, and Diptera. GVs (over 100 isolates) are only known from Lepidoptera 
(Federici, 1999; Cory and Evans, 2007). About fifteen products have been developed based 
on baculoviruses (Copping, 2009). Only the group of baculoviruses will be dealt with in this 
thesis. 
 
Protozoa and Microsporidia 
Protozoa consists of a large and diverse group of unicellular microorganisms. Some 
protozoans are parasitic on insects and cause chronic diseases. Epizootics cause a decline in 
insect populations in nature and this offers potential to use them as biocontrol agents, 
particularly members of the Microsporidia. They are, however, no longer grouped with 
Protozoa. Hibbett et al. (2007) reclassified Microsporidia as a phylum within the kingdom of 
Fungi. Thirteen thousand Microsporidia have been described. A brief overview of 
entomopathogenic microsporidia, their biology and ecology in relation to their potential as 
microbial insecticides is provided by Solter and Becnel (2007). Only one microsporidium has 
been developed for use as an insecticide: Nosema locustae, for control of grasshoppers. A few 
products based on this microorganism have been registered in the USA. Another species, 
Vairimorpha necatrix, has been developed for control of Lepidopteran pests, but was never 
commercialized (Solter and Becnel, 2007). The potential for the Protozoa and Microsporidia 
as microbial pest control products is limited due to the difficulty of the mass production of 
these obligate parasites, and the slow effect on the pest population. Therefore, these two 
group of pathogens are not further covered in this thesis. 
 
Nematodes 
More than thirty nematode families (Nematoda, roundworms) are associated with insects. 
Only members of seven families are considered to have potential as biocontrol agents. Species 
of the Heterorhabditidae and Steinernematidae have received most attention in research and in 
application for control of insect pests (Stock and Hunt, 2006). A member of the family 
Rhabditidae, Phasmarhabditis hermaphrodita, is parasitic to slugs and has been developed as 
a biological molluscide. There are about ten species of the Heterorhabditidae known and over 
thirty species of the Steinernematidae (Stock and Hunt, 2006), several Heterorhabditis and 
Steinernema species have been developed as biological insecticides. They contain symbiotic 
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bacteria, respectively species of the genera Photorabdus and Xenorhabdus, which cause rapid 
death in infected insects. More information on these nematodes and their symbiotic bacteria 
can be found in Gaugler (2002) and Grewal et al. (2005). The possibility of mass production 
in an artificial medium gives these species utility as biological insecticides. These 
entomopathogenic nematodes are the subject of the development of microbial pest control 
products covered in this thesis.  
 
 
Aim of this thesis 
The development and commercialization of a biopesticide is an expensive and time-
consuming process. Biocontrol product developers are dealing with a complicated project in 
which a living organism is the key element. Such a project entails many phases where each 
phase is a research project by itself, and successive phases are strongly interconnected. The 
new product development project often involves the development of new technology, and 
presents a highly complex matrix of biological, technical, regulatory and commercial 
challenges. A continuous feedback within the multi-disciplinary project team, with persons 
with biological skills, technical skills, and market knowledge, is required in order to optimize 
time and resources. Along the way, numerous decisions have to be taken on hundreds of 
subjects. The entire process will take many years and costs many millions of Euros. In a 
business environment, the ultimate objective is to sell the product in such a way that sufficient 
revenues are generated to achieve return on investment, and to make a profit that allows the 
company to develop more products, to accomplish a strong position in the marketplace, and to 
become a sustainable and profitable enterprise. Ultimately, the financial aspects of the product 
development are determinative for a company. This requires an accurate development and 
business plan that addresses all steps in a systematic way and that focuses on a cost-effective 
product that brings the grower an effective solution and meets his expectations. The path to 
the market is full of obstacles, and a potential product can fail at any point along the way. The 
time period from idea-to-launch should be as short as possible, and the required budget as low 
as possible. These are crucial business elements. The time from market introduction to sales 
volume is the other relevant phase where return on investment should be achieved. The 
biocontrol industry is small and young, often new players ‘invent the wheel again’, and time 
and money are lost. Therefore, there is a need for a general pathway that describes all phases 
including the critical steps and decisions that guides an enterprise through the development of 
new products in an optimal way. 
 The principal aim of this thesis is to examine and evaluate the current situation, to 
understand why projects and products fail, to understand the needs of the market, and to 
examine what knowledge, techniques and resources are required to improve the development 
of a microbial pest control product. With this understanding I will develop a complete and 
structured roadmap for the successful development and commercialization of a microbial pest 
control product for the control of insect and mite pests. All subjects will be covered, from the 
identification and description of the pest problem for which a solution is needed, to 
successfully selling the product. The emphasis will be on the entire process of development 
and commercialization from a business point of view. Economic considerations will be 
highlighted, next to biological, technical and regulatory aspects. Special emphasis is given on 
criteria for decisions that have to be made continuously in such a complex process. A 
systematic approach is provided in which each phase is elaborately discussed, and for each 
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step relevant considerations and decision criteria will be presented along with useful 
recommendations.  
This pathway will be divided in the following processes: selection of the microbial 
agent, production and product development, quality control, registration, implementation, and 
commercialization. Other aims of this thesis are referring to these processes:  
• identification of selection criteria for a microbial pest control agent; 
• identification of critical parameters in production and product development; 
• establishment of a reliable quality control procedure; 
• recommendations for the generation of a registration dossier, and a review of other 
relevant regulations; 
• identification of the most important issues with regard to successful implementation of a 
new product in an Integrated Pest Management (IPM) system 
• identification of critical success and failure factors in the commercialization of a 
microbial pest control product, and identification of the most successful business model; 
• and a synthesis of the processes that will facilitate the product development and 
commercialization.  
Each process will be considered in detail in the consecutive chapters. Both product-related 
and company-related factors will be treated. Information available in the literature, from 
academia as well as from industrial scientists, will be reviewed and analyzed. Key elements 
and considerations will be identified and highlighted. Decision criteria will be defined and 
outlined, alongside with transparent tools that help take the right decisions. Requirements and 
recommendations will be provided, both for the new product and the company, to increase the 
chance of a successful outcome. In the last chapter a synthesis will be provided along with 
flow diagrams that illustrate the various steps and interconnections between phases in a 
structured way. These diagrams present the roadmap from idea to successful marketing of the 
product. This proposed systematic roadmap should facilitate the development and 
commercialization of new microbial pest control products, and provide guidance for 
entrepreneurs who contemplate to initiate activities in this field of biopesticides. Ultimately, it 
may increase the chances for success in the market for newly developed microbials. A future 
outlook for biopesticides will be provided based on the current market and society 
developments.   
In this thesis I focus on microbial pesticides that are based on entomopathogenic 
bacteria, fungi, baculoviruses, and nematodes,. Protozoa are only briefly mentioned since they 
are rarely used as a control agent for a biopesticide. Furthermore, the thesis emphasizes the 
situation in Europe, particularly with reference to registration, and products developed for use 
in protected crops. The systematic approach, however, could also be applied for other 
microbial products for control of plant diseases, post-harvest diseases, weeds and other pest 
organisms. This approach is also relevant for biocontrol products developed for other markets. 
It could even be used in the development of a plant protection product based on natural 
substances, plant extracts, pheromones, and others. Many developmental and commercial 
factors are similar for each type of pesticide, including even chemical pesticides.  
 
 
Outline of this thesis  
Chapter 1 introduces the challenge of the development of microbial pest control products and 
microbial control. The history of the concept of microbial control is presented and the 
industrial product developments over time. The need for a roadmap to develop biopesticides 
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is proposed in order to provide successful products in the market. The aim of this thesis is to 
present a model that guides product developers towards a successful project. The terminology 
used is provided. The groups of insect pathogens used in microbial plant protection products 
are presented: bacteria, fungi, baculoviruses, and entomopathogenic nematodes. Finally, an 
outline of the chapters in this thesis is given. 
Chapter 2 discusses the exploratory phase of finding a new microbial pest control 
agent, and the actual screening phase of species and strains of collected entomopathogenic 
microorganisms. Crucial characteristics of each type of pathogen relevant to their utility as 
crop protection product are noted. Three decisive selection criteria will be identified. The 
importance of various biological parameters related to these criteria is discussed. Testing 
methods will be critically reviewed and recommendations for standardization of methods and 
test conditions will be presented. The consecutive steps in the screening process will be listed 
with emphasis on economic considerations. 
 Chapter 3 deals with the mass production and product development of a microbial pest 
control agent. Mass production is reviewed for each category of pathogen and the economic 
feasibility of mass production systems is identified. The vital issues in downstream 
processing, medium optimization, equipment, and inoculum stability are examined and 
recommendations are provided for a cost-effective mass production. Four functions of 
formulation are identified, formulation requirements are analyzed, and recommendations are 
provided for each type of pathogen. The economics of mass production and the end-use 
product are analyzed and a cost price model will be presented. Finally, key factors are 
determined for successful production and product development, and recommendations are 
reported to achieve optimal production, formulation and end-use product.   
Chapter 4 covers quality control of the production process and the final product, with 
emphasis on the latter. A manufacturer establishes product specifications and these are 
checked for every batch. Pivotal aspects of product control are discussed for each type of 
pathogen. Registration requirements are reviewed. Complete quality control procedures and 
data for validation must be established, although there are no officially recognized criteria. 
Practical challenges in quality control procedures are reviewed per type of pathogen. 
Recommendations for standardization and criteria will be provided. Research needs are 
identified that may facilitate quality control in the future. The benefits of quality control for 
the manufacturer and the end-user will be identified.  
Chapter 5 reports on regulations related to the use of microbial pest control agents and 
products. Microorganisms are subject to registration as a ‘plant protection product’ (PPP), 
whereas nematodes are usually covered by different regulations. Registration requirements are 
reviewed, particularly for the European Union. For several topics, data requirements are 
unclear or even lacking; procedures are both long and expensive. Initiatives to ameliorate 
these impediments are reviewed. Various other regulations, such as laws on biodiversity, 
importation and release of exotic organisms, and safe handling, apply to the use of 
microorganisms, and are briefly treated. Intellectual property rights are important for a 
company. The possibility to obtain a patent for a biopesticide and the value thereof will be 
discussed. Regulations form a major obstacle in the commercialization of biopesticides, and 
improvements and recommendations are provided to facilitate the approval processes in the 
future. The role that the biocontrol industry should have in this political field is outlined.  
Chapter 6 presents key factors to cost-effective implementation of a microbial pest 
control product, namely the application strategy, compatibility, and knowledge transfer to the 
user. This requires the design of a comprehensive integrated pest management programme in 
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which the microbial pest control product is to be incorporated. The first element is an optimal 
application strategy per targeted pest and cropping system. The second element is the 
incorporation of the microbial pest control product in an IPM system. Compatibility with 
chemical pesticides and with beneficial organisms must be established and critical aspects 
will be mentioned for each type of pathogen. The risk of resistance will be briefly discussed. 
Adoption of new products needs knowledge transfer in the entire supply chain to the grower, 
and pivotal considerations including economic aspects will be reviewed. Requirements and 
recommendations will be provided on how to accomplish a successful implementation. Some 
considerations will be presented with regard to the compatibility profile, the advantages and 
the disadvantages of biopesticides, the cost of the implementation process, and to the potential 
of combined use of biopesticides. 
Chapter 7 reviews the critical factors in the successful commercialization of microbial 
pest control products. The history of the biopesticide industry will be highlighted. Currently 
available products will be presented, as well the biopesticide markets in Europe and the 
Netherlands. The main crops in which biopesticides are used are presented as well as the most 
successful products. Profitability of products in relation to their market size will be analyzed. 
Critical success and failure factors for a biopesticide company and for a microbial pest control 
product are analyzed, and recommendations will be provided on essential factors that need to 
be considered. Tools will be provided to facilitate decision-making in the commercialization 
process. Company profiles will be reviewed, and a business model will be identified that 
currently performs best. An estimate of the developmental time and costs for a microbial pest 
control product is provided. The distribution and sale strategy is reviewed, and various salient 
options are discussed. Crucial factors will be identified, and recommendations will be 
provided that will increase the chances to develop a successful biopesticide and to become a 
profitable and sustainable biopesticide company. 
Chapter 8 provides a roadmap to success, and future prospects for use of microbial 
control products. The roadmap to successful development and commercialization of a 
microbial pest control product is amply illustrated in newly designed flow diagrams. 
Diagrams are presented for the screening phase, the product development phase, and the 
implementation phase. Relevant input criteria and requirements are provided. Output 
information leads to consecutive steps and ‘go/no go’-decisions. A future perspective on the 
biopesticide market is presented with limiting and promoting factors and trends. The most 
important drivers are concerns about food safety and the environment, new research and 
technology, changes in the regulatory climate, and the arrival of exotic pests. The biopesticide 
industry has reached a level of maturity and critical mass that forms a solid base for further 
expansion. The future of the market size and growth is estimated, and an outlook of the way 
forward is presented. 
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Appendix: Terminology and definitions 
 
Microbial pest control agents and products 
The term biopesticide is widely used, and definitions vary. Definitions of the term 
biopesticide may include microbial organisms, pheromones, insect and plant regulators, plant 
extracts, transgenic plants as well as macroorganisms. Various institutions have defined 
biopesticides and sub-sets thereof such as microbial pesticides and microorganisms. 
Regulatory agencies have provided exact definitions of microorganisms, and for plant 
protection products containing microorganisms as the active ingredient.  
The EU has defined 'micro-organism' as: ‘a microbiological entity, cellular or non-
cellular, capable of replication or of transferring genetic material’. The definition applies to, 
but is not limited to, bacteria, fungi, protozoa, viruses and viroids (EC, 1991a, 2001). This 
definition has been slightly modified in the new Regulation on plant protection products (EC, 
2009a):  “any microbiological entity, including lower fungi and viruses, cellular or non-
cellular, capable of replication or of transferring genetic material”. The Directives nor the new 
Regulation define a microbial plant protection product exactly, but do provide the following 
description: a microbial plant protection product may contain viable and nonviable micro-
organisms (including viruses) and formulation substances. It may also contain relevant 
metabolites/toxins produced during growth, residues from the growth medium, and microbial 
contaminants. The terms biopesticide and microbial pesticide are not used in the Directives 
and the Regulation. 
The OECD (OECD, 2003; 2004a, b) uses the following definitions:  
- microbial pest control agent (MPCA)(= active substance): a microorganism (bacterium, 
alga, fungus, protozoan, virus, mycoplasma, rickettsia) and any associated metabolites, to 
which the effects of pest control are attributed; 
- microbial pest control product (MPCP) (= microbial plant protection product): a product 
containing a MPCA that is registered or labeled with instructions for direct use or application 
for pest control purposes. 
 Further, the OECD uses the term ‘microbial pesticide’, however, it is not precisely 
defined. The word ‘biopesticide’ is not used in their guidance documents; it is only used of 
the naming of the OECD BioPesticide Steering Group (BPSG). 
In the definition of the Environmental Protection Agency (EPA) in the USA, 
biopesticides include naturally occurring substances that control pests (biochemical 
pesticides), microorganisms that control pests (microbial pesticides), and pesticidal 
substances produced by plants containing added genetic material (plant-incorporated 
protectants) (ww.epa.gov). The definition of a microbial pesticide is as follows: a microbial 
agent intended for preventing, destroying, repelling, or mitigating any pest, or intended for 
use as a plant regulator, defoliant, or desiccant, that: 
(1) is a eucaryotic microorganism, including, but not limited to, protozoa, algae, and fungi; 
(2) is a procaryotic microorganism, including, but not limited to, Eubacteria and 
Archaebacteria; or 
(3) is a parasitically replicating microscopic element, including, but not limited to, viruses. 
The definition applies to, but is not limited to, bacteria, fungi, protozoa, viruses and viroids 
(EPA, 2007a). The term microbial pest control agents (MPCA) is used in the data 
requirements, the term microbial pest control product (MPCP) is not used, however.  
In this thesis I will use the term Microbial Pest Control Agent (MPCA). The term 
MPCA includes microorganisms such as algae, bacteria, fungi, protozoa, yeasts, viruses and 
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viroids, and any associated metabolites that are involved in the mode of action. I also include 
entomopathogenic nematodes under this definition for reasons explained below and for the 
sake of convenience.  
I will use the term Microbial Pest Control Product (MPCP) for plant protection 
products that contain a MPCA, as I have defined above, as the active ingredient or active 
substance. It includes all microbial pesticide uses such as control of insects, mites, plant 
diseases, plant nematodes, and weeds.  
I will also use the term ‘biopesticide’ for these products; other synonyms used in this 
thesis are ‘biological pesticide’, ‘microbial pesticide’ or simply a ‘microbial’. I will use 
these four terms interchangeably with MPCP. In my opinion, the term biopesticide should 
strictly be used for products based on living organisms, including viruses and viroids, as also 
recommended by Eilenberg et al. (2001). Products based on plant extracts, pheromones, etc., 
should not be called biopesticides, but biochemical pesticides (as the US-EPA does) or natural 
pesticides. Sometimes they are referred to as ‘biorationals’. When I refer to a broader 
definition of biopesticides which includes pheromones, insect and plant regulators, plant 
extracts, and macroorganisms, this will be indicated in the text.   
 
Biological control and microbial control 
I will use the terminology with regard to ‘biological control’ as proposed by Eilenberg et al. 
(2001). The term ‘biological control’ will be used interchangeably with ‘biocontrol’ as this is 
widely accepted. ‘Biological control’ is defined by Eilenberg et al. (2001) as ‘the use of living 
organisms to suppress the population density or impact of a specific pest organism, making it 
less abundant or less damaging than it would otherwise be’.  The authors emphasized the use 
of living organisms, and include viruses. They excluded the use of genes and metabolites 
when used alone. Any associated metabolites, however, to which the effects of pest control 
are (partly) attributed, such as the Bt toxins, should be inclusive in this definition. In that case, 
I agree with this definition and will follow it. The term ‘microbial control’ is used to 
describe the use of living microorganisms as biological control agents, and is considered a 
sub-set of biological control. The term ‘microbial control’ was first used by Steinhaus in 1949 
(Steinhaus, 1949) and defined as follows: “that phase of biological control concerned with the 
employment by man of microorganisms for the control and reduction of the number of 
animals (or plants) in particular area or a given population.” An early definition of the term 
‘biopesticide’ could not be traced after an extensive search of the literature. EPA defined the 
term ‘biopesticide’ in the early 1990’s, but, as earlier said, in my opinion unsatisfactory.   
In this thesis I will use the term ‘microbial control’ when microorganisms or 
entomopathogenic nematodes are used for pest control purposes. Nematodes are not generally 
defined as microorganisms. They are, however, usually grouped along with bacteria, fungi, 
viruses, etc. in microbial crop protection, and this probably originates from the research 
discipline, insect pathology, in which they are studied. This separates them from the 
entomological research field on natural enemies/beneficial arthropods such as predators and 
parasitoids. On the other hand, nematodes as well as parasitic and predacious arthropods are 
referred to as invertebrate biocontrol agents (IBCA) and ‘macrobials’. Regulatory authorities 
usually regulate nematodes in the same way as ‘macrobials’. In most countries, pesticide 
regulations for microorganisms do not include nematodes. The positioning of 
entomopathogenic nematodes is not always logical considering their taxonomy, biology and 
regulatory position. In the biocontrol industry, nematodes are mostly produced by companies 
which are also involved in microorganisms. The mass production, product development, and 
General introduction and outline 
___________________________________________________________________________ 
 15
method of application of bacteria, fungi, baculoviruses and nematodes have many similarities. 
I will position them as microbial pest control agents along with the microorganisms used as 
biocontrol agents, unless specified differently. Where relevant, I will separate them from true 
microorganisms as, for instance, in a regulatory context. 
 
Biocontrol strategies 
Biological control can be divided in four strategies: ‘Classical biological control’, 
‘Inoculation biological control’, ‘Inundation biological control’ and ‘Conservation 
biological control’. I follow the definitions as provided by Eilenberg et al. (2001). In this 
thesis I will only discuss the use of biocontrol agents according to the strategy of ‘inundation 
biological control’. Classical biocontrol, inoculation biocontrol and conservation biocontrol 
with insect pathogens will not be covered in this thesis. Inundation biological control is 
defined as ‘The use of living organisms to control pests when control is achieved exclusively 
by the released organisms themselves’.  Eilenberg et al. (2001) stated that the success solely 
depends on the released population and not on their progeny, and that this involves storage, 
formulation and application. The mass release provides immediate effects on the pest, and 
there is no expectation of long term control. That is precisely my perspective on biological 
insecticides. The word ‘released’ is debatable in this definition since it suggests release from 
certain release points from where active dispersion and successive reproduction is expected. 
This is generally not the case with insect pathogens which are broadly applied (often 
sprayed), and contradicts the assumption that the released generation will have an immediate 
effect on the pest population. Inundation biocontrol implies an intervention by man via a 
certain way of application. In the field of microbial control agents many authors refer to this 
as ‘inundative applications’ (Federici, 1999a; Lacey et al., 2001; Inglis et al., 2001). 
Therefore the word ‘released’ in the definition should be replaced by ‘applied’ to my opinion 
when we speak about inundative microbial control.  
 Biopesticides are often used within IPM systems, and can be important pest control 
tools in such systems. I will use the definition of IPM as provided by van Lenteren (1993): 
“Integrated Pest Management is a durable, environmentally and economically justifiable 
system in which damage caused by pests, diseases and weeds is prevented through the use of 
natural factors which limit the population growth of these organisms, if needed, supplemented 
with appropriate control measures”.  
 
Taxonomy 
In this thesis examples of microbial pest control agents will be used to illustrate certain cases. 
Some of these will refer to the fungus Verticillium lecanii. Many isolates formerly classified 
as V. lecanii, however, have recently been re-classified and are considered to represent the 
new species Lecanicillium attenuatum, L. lecanii, L. muscarium, L. longisporum and L. 
nodulosum (Zare and Gams, 2001). I will use the new names when it is known that the 
species or strains in question were verified using the new nomenclature. Not all strains 
formerly identified as V. lecanii have, however, been re-classified by Zare and Gams (2001) 
or others. I will use the old name “Verticillium lecanii “ when it concerns taxa from which it 
is not clear whether the isolates have been re-identified and re-classified. Furthermore, I will 
use the latest taxonomic nomenclature where possible. But due to ongoing re-classifications 
of microorganisms and the problems of re-identification of isolates as described for V. lecanii, 
there may be reference to the literature that no longer refers to the correct taxa, and may 
therefore not be appropriate. The reader should note that this could also apply to other taxa.  
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Abstract  
In science, three different approaches are recognized in finding a new microbial pest control 
agent: a serendipity approach, an agent-oriented approach, and a goal-oriented approach. In 
the (bio)pesticide industry two approaches are distinguished: the problem-solving approach 
and an opportunity approach. A comparison is made between academic and industrial 
research with regard to the finding and the development of a microbial pest control agent. It is 
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concluded that there is a need for well-defined selection criteria and a complete process 
description for the entire development of a microbial pest control product. An elaborate 
description of the pest problem that needs to be solved is the basis of the selection process of 
a microbial pest control agent. It provides direction to the search for a solution. Information 
on a potential solution may be found for in the literature, in ongoing academic or industrial 
research, by contacts, and by exploration in nature. Entomopathogens need to be collected, 
purified and identified. The first level of selection is on the type of pathogen, potentially 
bacteria, fungi, viruses, protozoa, and entomopathogenic nematodes. The second level is at 
the species and strain level. The potential of a certain type of pathogen for different kinds of 
greenhouse pests is provided in a table based on existing knowledge. Strain selection, and 
methods and criteria from literature are reviewed. This study identifies three decisive 
selection criteria for a commercial microbial insecticide: mortality, production efficiency, and 
safety. Relevant factors in the screening process related to mortality are dose rate, mode of 
action, speed of kill, host range, sensitivity to abiotic factors, and persistence. Second, the 
possibility of mass production with high yields is a critical criterion. Third, safety to humans 
and to the environment is a selection criterion in relation to registration requirements and 
expenses. The selection process should deliver determinative information on efficacy, 
production and registration on which one or at the most three to four strains are chosen for 
further development. The importance of these parameters in the selection process is presented 
per type of pathogen. Bio-assays must be well-standardized and must mimic field conditions 
as closely as possible in order to provide useful data. The important steps in the screening 
process are identified as the collection of isolates, laboratory screening on efficacy, laboratory 
screening on production efficiency, assessment of mode of action and toxicological 
properties, efficacy in small glasshouse trials, followed by efficacy trials under near-
commercial conditions. It is usually impossible to market the biologically perfect strain. 
Instead, the best strain(s) is used that provides a well-balanced compromise between efficacy 
and economics. This strain is subject to further developmental steps. 
 
 
Introduction 
 
The search for and the selection of a new agent is the first step in the developmental process 
of a microbial pest control product (MPCP). It requires a screening procedure with relevant 
evaluation criteria for a commercial product. This selection step should address appropriate 
biological, technical and economic aspects that play a key role in the entire product 
development, and in the marketing of the product. The criteria differ per type of organism and 
depend on the ultimate use of the product. Although each product demands its specific 
criteria, several general criteria can be identified. The actual screening process is preceded by 
an exploratory phase in which the problem that needs to be solved is well-described as well as 
the foreseen solution. During this phase the research direction must be established and applied 
to the entire process. 
Approaches used to find and select a microbial pest control agent by academic and 
industrial scientists are compared. Apparently, well-defined selection criteria are not provided 
in the current literature. Therefore, these will be identified in this chapter. Biological 
characteristics of the four types of insect pathogens are reviewed in relation to screening 
methods as well as to critical factors in the selection of isolates. The most important selection 
criteria and biological parameters related to these criteria will be described, and arguments 
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will be provided as to why these criteria are determinative for a commercial product. In the 
conclusion, I will discuss the results of the selection procedure in relation to the decision 
whether to continue the development of a new product based on (one of) the selected 
isolate(s). Further, I will provide recommendations for the use of bio-assays in the screening 
process and the other steps in the selection procedure. 
 
Different approaches in finding a new pest control agent 
Predators, parasitoids and insect pathogens are used as biocontrol agents in biological control 
of pests. In the finding of a biocontrol agent and the development of it into a biocontrol 
product, the first two require a similar approach. Pathogens, however, demand different 
evaluation criteria. On the other hand, many aspects are similar for arthropods and insect 
pathogens, particularly commercial considerations. 
For arthropods, Van Lenteren and Manzaroli (1999) described the various steps and the 
strategy in the development of a biological control programme for a greenhouse crop with a 
specific natural enemy. In biocontrol programmes, natural enemies were often found by trial 
and error, chiefly by empirical procedures. Van Lenteren and Manzaroli described pre-
introductory evaluation criteria and tried to come to a more efficient and less time-consuming 
procedure, reducing the number of potential candidates for field testing to a few. They 
presented a flow diagram with the most important criteria in an evaluation programme for 
natural enemies for inundative releases.  
Similar to the field of biocontrol with arthropods, an evaluation approach for insect 
pathogens as biocontrol agents has only been briefly presented in the literature by several 
authors. But few authors described the entire process of finding a new microbial control agent 
and its development into a successful commercial product. Burges (1981a) described three 
approaches to the discovery and development of a microbial pest control agent (MPCA):  
1) a serendipity approach, where a promising agent is noticed in a particular pest and 
further developed against that pest. As an example he referred to Bacillus popilliae 
against the Japanese beetle, Popillia japonica;  
2) an agent-oriented approach, where a known agent is developed for as many as possible 
pests. The example here is Bacillus thuringiensis (Bt) for control of various lepidopteran 
pests; 
3) a goal-oriented approach, where a MPCA is sought for control of a certain pest. An 
example here is a virus against the palm rhinoceros beetle Oryctes rhinoceros.  
According to Burges the third approach has been the least successful, but one that could be 
further developed for integrated pest control programmes which have gaps where particular 
pests are difficult to control when broad-spectrum chemicals are no longer used. Burges 
(1981a) clearly recognized all the prerequisites for the development of a microbial pest 
control agent. He realized that “market size and competitiveness are vital” and that “important 
other commercial considerations include wide host spectrum, long shelf-life and production 
technology, and safety and registration costs”. In the early days of microbial biocontrol this 
could be described as the applied scientific approach. 
In the commercial development of biocontrol agents two approaches can be 
distinguished: 
1) a problem-solving approach: I would argue that the problem solving approach is the 
most common and most successful one in commercial biocontrol in the last twenty-five 
years, certainly in protected crops. A certain pest cannot be controlled well enough in 
the existing integrated pest management (IPM) programme and a new solution has to be 
Chapter 2 
___________________________________________________________________________ 
 20 
found in order to safeguard the system or to help control the pest. Any type of biological 
control agent (BCA) is then, in theory, considered and can be searched for and 
developed following appropriate selection criteria. This problem solving approach is 
seen in IPM programmes in greenhouse crops where natural enemies are already being 
used and where a new predator or parasitoid is sought when a new pest occurs;  
2) an opportunity approach: an opportunity presents itself when a novel BCA is found 
fortuitously, and someone recognizes based on experience and general insight, that a 
new product could be developed for which a market may exist. This could be a new 
product in a new market or a product for an existing market, which requires penetration 
among existing products, often chemicals. This approach is not often seen in 
commercial biocontrol of pests, and certainly not with beneficial arthropods.  
One could say that the chemical pesticide industry works according to this opportunity 
principle. Companies try to make as many new chemical molecules as possible and then they 
screen them for biological activity against a number of pests, diseases and weeds. Within the 
agrochemical industry this was often called “the spray and pray” approach (Evans, 2006). By 
means of automated high through-put screening systems, chemical companies can nowadays 
test an enormous amount of new molecules. The newest systems can even design, create and 
test more than 150,000 compounds per day by a biochemical screening method, resulting in 
testing more than 500,000 molecules per year in vivo for biological activity (Stenzel, 2004). If 
a good activity against certain targets is found, the development of a molecule is continued. A 
broad spectrum of activity increases the chances of a successful product that needs to compete 
with existing pesticides. Target markets are the worldwide agricultural crops.  
The biotechnology company Agraquest, USA, employed this approach and they have 
been screening over 20,000 microbial organisms in a similar way (see www.agraquest.com). 
It is the first company active in the field of micro-organisms that duplicates this screening 
approach. They collect, produce and test as many isolates as they can find and also identify 
the compounds (metabolites) produced by the micro-organisms. Further field testing, 
production and formulation leads to the final product for which markets have to be developed 
(Marrone, 1999). This approach is also used by Marrone Bio Innovations Inc. 
(www.marronebioinnovations.com). This screening method has clearly been successful with 
the large chemical pesticide industry, but whether this will succeed with microbial products 
still remains to be seen.  
 
Academic research on the selection and development of a microbial pest control agent 
Entomopathogens have been studied for a long time in academic research and numerous 
authors mention and investigate aspects of the development of a MPCA. The literature on 
entomopathogens as biocontrol agents is vast and many handbooks and papers have been 
written on bacteria (Charles et al., 2000; Entwistle et al., 1993), on fungi (Burge, 1988; Butt 
et al., 2001a; Butt, 2002; Ferron et al, 1991; Hall and Menn, 1999; Lacey et al.,1996; 
Lisansky and Hall, 1983; McCoy et al., 1988; Vurro et al., 2001), on baculoviruses 
(Miller,1997; Moscardi, 1999; Shuler et al., 1995), and on entomopathogenic nematodes 
(Gaugler and Kaya, 1990; Gaugler, 2002; Grewal et al., 2005a). In most of these publications, 
however, key selection criteria are lacking as well as a description of the entire process of the 
development of a MPCA.  
For example, in early work in this area, Ferron (1978) presented a detailed overview of 
the development of biological control of insect pests by entomogenous fungi and the situation 
up to the mid 70’s. He described the features of a fungus that has a potential as a biocontrol 
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agent, such as mode of action, development of mycosis and saprophytic development of the 
fungus, the effects of abiotic factors, the quantity of spores needed to kill the host, etc. He 
mentioned also the importance of strain selection, the capacity of mass production of spores 
and the development of a final preparation, and the safety to vertebrates. There is, however, 
no attempt to order the traits in importance or to define a systematic approach for the entire 
process. In contrast, Hall (1981a) gave an example in which the development of a MPCA, 
Verticillium lecanii, was clearly foreseen. All relevant aspects for the development of a 
product were investigated (see Box 2.1). 
 
 
BOX 2.1.   The development of Verticillium lecanii as a biopesticide 
 
The entomopathogenic fungus Verticillium lecanii, of which isolates are recently reclassified and 
included in the new species Lecanicillium muscarium, L. longisporum, L. lecanii and other species 
(Zare and Gams, 2001), is frequently found on many kinds of insects, mainly on Homoptera, but also 
on mites and nematodes, and as a soil saprophyte, and even as a parasite on powdery mildews and 
rusts. It was noticed by growers in vegetable crops on aphids and whitefly nymphs already in the early 
1920s in northern Europe, mainly in the UK. Hussey found it in 1956 in a commercial cucumber 
greenhouse on whiteflies in the UK. The research group at GCRI (Glasshouse Crops Research 
Institute at Littlehampton, UK) was the first to recognize that this fungus could be used to control 
aphids and whitefly in greenhouse crops and Hall studied the fungus in detail (Hall, 1981a). 
Resistance to chemical insecticides in Myzus persicae, a dominant pest in chrysanthemums, was the 
incentive for this project. During this study the apparent biological life cycle parameters were assessed 
as well as the abiotic factors influencing the fungus. 
 From the context it is clear that the development into a commercial preparation was in the back 
of the mind of the researcher. Screening of strains was carried out on a limited scale, but the emphasis 
was clearly on biological growth parameters and host virulence in the laboratory. Hall also studied 
storage of conidiospores and of blastospores, environmental factors influencing field performance, 
spore dispersal, and spread of infection. Greenhouse trials were performed in chrysanthemum on 
several aphid species with “formulated” spore suspensions. Spore concentrations were tested, as were 
application time and frequency. Trials were also carried out in cucumber against the cotton aphid 
Aphis gossypii and against the greenhouse whitefly Trialeurodes vaporariorum. Production was 
studied and critical aspects were considered such as culture purity, production of conidiospores versus 
blastospores and the costs of the chosen methods. Commercial mass production was not yet possible 
and Hall considered the possibility of culturing spores for immediate use by the growers. Quality 
control was also evaluated. Spore viability and potency were assessed in a bio-assay on the host insect 
compared to a chemical standard. Compatibility with natural enemies used in the greenhouses was 
tested, as was compatibility with insecticides and fungicides. Pollinators were considered, but not 
tested. The toxicological profile of the fungus was checked in literature and toxicological animal tests 
were performed to obtain an indication about the safety of the product to animals and to humans.  
The above example shows that in Hall’s research many of the aspects of developing a fungus 
into a commercial biopesticide were studied (Hall, 1981a). When we consider that these were the early 
days of developing a fungal microbial insecticide, this was a solid approach.  
The route to commercialization started when Tate & Lyle, a UK based food ingredient and sugar 
manufacturer, contacted GCRI in 1978. Tate & Lyle tried to diversify their business and one of their 
new interests was the area of biopesticides. The company was building a new fermentation plant to 
produce alginate and it was looking for microbial products that could be produced by liquid  
fermentation. They contacted research institutes and the one on the doorstep happened to be working 
on a promising fungus. The ensuing cooperation resulted in the development of Vertalec and Mycotal 
(S. Lisansky, pers. comm.). 
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In the extensive overview presented in the book of Burges (1981b) on the progress of 
“Microbial Control of Pests and Plant Diseases, 1970 – 1980”, on all the types of MPCAs 
neither Burges nor the contributing authors described any selection criteria or methodical 
developmental process for BCAs. In later work, like in the overview “Microbial Insecticides: 
Novelty or Necessity?” (Evans, 1997a) still no reference was given to a developmental 
process for a MPCA, despite the 15 years between the book of Burges (1981b) and this book. 
The same holds for the review of Lacey and Goettel (1996) on the developments in microbial 
control products of insect pests and their prospects for the 21st century.  
In the study of Fransen (1987) on the development of Aschersonia aleyrodes as a 
microbial biocontrol agent for whiteflies aspects of the development of a commercial 
microbial agent are systematically considered (see Box 2.2.). She listed fungal characteristics, 
host characteristics and environmental influences. She investigated primarily the biological 
parameters of the fungus and its interaction with the greenhouse whitefly and its parasitoid 
Encarsia formosa, however. Some attention was indeed paid to the production of the fungus 
and the formulation. Storage, safety and integration with chemicals were itemized but not 
studied. Results on the studied evaluation criteria were summarized with the purpose of 
making a decision on the potential of A. aleyrodis as a commercial biopesticide.  
 
 
BOX 2.2.   Why Aschersonia aleyrodis was not developed as a biopesticide 
 
In the early 1990’s, Koppert tried to develop A. aleyrodis into a mycoinsecticide for control of the 
greenhouse whitefly. This fungus was expected to perform better at lower relative humidity (RH) 
conditions, as compared to the high RH requirements of L. muscarium. Moreover, whitefly larvae 
infected with A. aleyrodis turn orange and the effect is therefore clearly visible to growers, in contrast 
to larvae killed by L. muscarium. Visible effects of a treatment were considered to be a convincing 
feature for the marketing of the product.  
We started to produce and conduct field trials with one strain. Spore production is initiated by 
light, and it was complicated, thus expensive, to build bioreactors in which light could be installed. 
Secondly, strain attenuation was a problem and the strain easily lost its ability to sporulate. In field 
trials in tomato and cucumber, mortality by A. aleyrodis was similar (at 60 and 75% RH) to L. 
muscarium (Mycotal) and even lower at 80% RH (van der Pas et al., 1996). These two aspects led to 
the decision not to continue with the product development, and not to invest money and time for 
registration. The underlying decisive factors were the difficulty in production and the moderate 
efficacy.  
In retrospect, one could argue that we did not select the most effective strain and we did not pay 
enough attention to the attenuation of the strain. This example taught us to continuously re-evaluate 
technical and economic aspects and that decisions have to be taken after every step in the 
developmental process in order to prevent losses in investment further in that process. Of course, such 
a decision should be taken the earlier the better, but also involves a risk of discarding a potential 
product too early. 
 
 
The study of Fransen, however, concerned only one strain and selection of a virulent 
strain was not part of it. Meekes (2001) followed the approach of Fransen and specifically 
focused on the identification of a virulent strain of Aschersonia spp. for the control of the 
greenhouse whitefly T. vaporariorum and the tobacco whitefly Bemisia tabaci. Two 
significant aspects were investigated in more detail: the production of spores and virulence to 
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two dominant pest species and based on the results many strains were eliminated. Many 
aspects of the development of a microbial control agent were considered such as dispersal, 
persistence, production and formulation, safety and compatibility with other control methods 
as well as the influence of environmental factors. Finally, a table is presented in which the 
results are listed and on which a further decision could be based. This study exemplifies how 
screening of a potential strain for the development of a microbial pesticide should be 
approached, as it emphasized decisive factors such as efficacy and production efficiency. 
 
The development of a microbial pest control agent from finding to product launch by 
industry 
In the research to develop an MPCA we often see in academic studies a focus on particular 
biological aspects of the MPCA. In order to arrive at the launch of a successful product all 
steps in the developmental process must be conducted. A commercial producer has to carry 
out all these steps. In the literature, however, we rarely find a description of a complete and 
systematic approach. In a few projects the entire process is described. An early example from 
the biocontrol industry is given by Lisansky (1985) based on the experience with L. 
muscarium and L. longisporum. He presented a diagram that covers all the steps, from 
defining the pest problem to selling the product and after-sales service, and he briefly 
described the considerations per step. Screening of strains is not mentioned, however, nor did 
he give critical aspects that lead to decision-making in the process. 
 Bayer initiated the development of a biopesticide around 1990 and developed Bio-1020; 
a mycoinsecticide based on a strain of Metarhizium anisopliae for control of the black vine 
weevil. A brief development scheme, mainly focused on production, was given on the 
developmental steps for a microbial product (Andersch, 1992). No details were given on what 
the determinative considerations were, while one expects the largest agrochemical company 
in the world to have clear decision criteria for such a developmental process. 
  In the field of entomopathogenic nematodes (EPNs), Biosys, an American EPN 
producing company, recognized three stages in research in the product development pathway: 
basic research, applied research and commercialization (Georgis, 2002). Remarkably, strain 
selection is not mentioned. It does not reveal importance or order of research steps, nor 
criteria that could decide whether to continue with a product.  
A good example originating from the academic world is the Lubilosa project (see 
chapter 1). Here, the problem-solving approach was clearly taken. The wide use of chemical 
insecticides had so many negative aspects that public concern demanded an alternative 
solution, and a number of donor countries initiated the Lubilosa programme. From the 
beginning, the development of a mycoinsecticide was foreseen and all necessary steps were 
identified and executed (Lomer, 1997a; Dent, 1998). The scheme (chapter 1, figure 1.1) used 
in the Lubilosa project (Dent, 1998) illustrates all the steps in the project. 
Most scientists and biocontrol companies, however, seem to develop their products 
without a well-described plan. As observed in chapter 1, there is a need for a general 
procedure, for a systematic and structured roadmap that guides biocontrol developers through 
the complex process of developing a new biocontrol agent. A model for the product 
development of a MPCA based on 25 years of experience in the biocontrol industry will be 
presented in this study.  
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Critical steps and factors in the selection process of a microbial pest control agent 
 
In the development of a BCA into a commercial product, project management is an 
indispensible tool in order to plan, budget and conduct every step in the right sequence, so 
that no time and money will be wasted in this complex process. Project management includes 
a plan with goals and objectives, specifying tasks and timelines and how to achieve all the 
goals. It is a team effort, and proper management to stick to the “critical path” is essential. 
The sequence of the relevant steps in a selection programme of a MPCA is presented. The 
steps are the description of the problem, scouting for a solution, the collection of the MPCA, 
and the selection of the best species and strain based on well-defined selection criteria. These 
will be discussed in detail. Finally, the decisive steps and factors in the selection of a MPCA 
are defined. 
 
The description of the problem 
A new product will be developed to solve a problem or to grasp an opportunity. To justify the 
input in terms of money and time, it needs to be clear from the outset why the project will be 
started and what the ultimate goal is. In this phase, the deliverable is the project letter that 
includes the project justification, the project definition, the project plan including the project 
team, a rough estimate of the budget (resources and costs) and the time frame. When possible, 
the new product should be described in general terms, so it is clear in which direction the 
project is heading. It should also address the value of the project for the company, for the 
strategic and the operational goals, and mission. The reason for the project letter is to clarify 
to all stakeholders what the investment will be and why this investment is made. Commitment 
from all the decision-makers (board, share-holders) is crucial, especially for later stages when 
it may need more time or money. Of course this depends on the size of the project and is a 
case by case situation. 
In this exploratory phase, it is essential to make a detailed characterization of the 
problem or opportunity. What exactly is the problem and what is the scale of the problem? 
For pest control in greenhouse crops we need answers to the following questions: which 
arthropod pest is it; in which crops does it occur; in what country/region; at what time of year; 
is the problem expected to increase or decrease in the near future; what are the short term 
solutions, either available or being developed by other biocontrol companies or the chemical 
industry, or even by the seed-producing industry (are there new tolerant or resistant cultivars); 
what are the acceptable costs for a solution for the grower; will it become an affordable 
product. Finally, an impression of the potential market should be developed. If possible the 
expected solutions should be described briefly so it is understood where the project is going. 
The project plan should also include evaluation and decision moments, i.e. points of ‘go/no 
go’. All these aspects will make the overall picture clearer on which a decision can be based 
and commitment is assured. 
 
Scouting and finding a potential solution 
Where can we find information on biocontrol agents that can possibly control the pest? Or 
where can we find information on other ways, methods or products to control the problem. 
There are different areas to look at and these are usually checked in the following order: 
1) literature: screen the literature, including old literature, for possible answers. Nowadays 
that also includes searching via the internet. The first step is to make a thorough 
literature search of the natural enemies of the target pest and on related pests, followed 
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by a literature search of the natural enemies which are found in nature on the target 
species (especially for MPCAs with a broad host range). Maintain a library with all the 
information found and a knowledge management system to store knowledge and 
experiences from people in different areas; 
2)   academic research: is or was there any research related to the topic conducted at a 
university or at a research institute, anywhere in the world? What kind of research has 
been done on the pest or even on related (pest) species in the past or recently? Is 
somebody already working on a solution? Government funded and organized classical 
biocontrol projects are also sources of beneficial organisms for augmentation biocontrol 
(e.g. the 5 year Bemisia project from USDA); 
3) industrial research: is any company working on the problem or does a company have a 
product on the market, including a chemical or biological pesticide, resistant cultivars, 
supporting measures, monitoring systems, pheromones, physical means (screens, 
disinfection methods, etc.) that could contribute to a solution? In the biocontrol industry 
only a few companies really develop new products, so it is relatively easy to know what 
is going on. Although patents in the world of biocontrol are scarce (since living 
organisms per se cannot be patented) a patent search could be considered also; 
4) network: not everything is (yet) published, so it is useful to create and to have a network 
of contacts and to know who is working on what, in research, in industry, anywhere in 
the world; informing your network about the problem and that you are seeking a 
solution is useful too. This can be done quickly and widely now through internet, e.g. 
via list servers such as “Goodbugs” and “Thripnet” or through direct contact. Often 
research that did not lead to a solution has not been published. It can be useful to know 
what natural enemies or entomopathogens have been studied and which ones were 
discarded as a potential candidate and why this was decided; 
5) nature: what is around in nature? And where to search for it? What kind of solution is 
conceivable: a microbial or macrobial agent, or other measures (pheromones, natural 
products) or combinations thereof? Collections could be done in the area of origin of the 
crop, in the area of origin of the pest or in areas where the pests already occurs (e.g. as 
in the 5-year Bemisia project by Kirk and Lacey (1996)). An efficient way has been to 
collect in (unsprayed) crops in different locations and during different times of the year. 
In this way many natural enemies, especially arthropods, have been found (Dacnusa 
sibirica, Opius pallipes, Diglyphus isaea, Macrolophus caliginosus, Orius laevigatus, 
Amblyseius calfornicus, Chrysonotomyia formosa, but also Verticillium lecanii)) 
(Enkegaard and Brødsgaard, 2006). Another method is to put out trapping plants with 
the target pest, outside in different biotopes or to check the same plant species or related 
plant species in nature, or even to look on wild plants which are a host of the pest.  
 
Collection of a microbial pest control agent  
When specimens of microbial agents are being collected for further research the following 
aspects need to be taken into consideration: identification, the quantity of genetic variation, 
and purity. In the case of micro-organisms care has to be taken to make a pure culture from 
the collected material, while secondary micro-organisms may also often colonize the dead 
insect. It is crucial to have the primary pathogen in hand. This needs to be tested then by 
satisfying Koch’s postulates. 
How to recognize and collect the various types of pathogens is well described in the 
comprehensive Manual of Techniques in Insect Pathology by Lacey (1997). Collection can be 
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carried out in nature or in crops, as with arthropods. Various pathogens can be found and 
further research is needed to identify pathogenicity and virulence to the target insects.  
In micro-organisms every isolate can be different and as many as possible isolates should be 
looked for to study in further screening programmes. The isolates need to be purified and 
stored properly. Identification on strain level will be necessary later in order to be able to 
recognize it and for regulatory reasons. 
For isolates of fungi, bacteria and viruses there are several culture collections (such as 
the ATCC (USA), CABI (UK), CBS (the Netherlands), DSMZ (Germany)) where pure 
isolates can be ordered. There is no public culture collection of EPNs. 
 
Selection of species and strain for the development of a bio-insecticide  
The first selection level regarding the selection of the optimal micro-organism in order to 
control a pest is the “type of organism” level. Is a fungus the most suitable candidate versus a 
bacteria or an entomopathogenic nematode? This depends largely on the pest, its biology and 
on features such as feeding behaviour, mobility and habitat. The second level is the 
species/strain selection, once the decision on the level one “type of organism” has been made: 
which isolate is the most pathogenic and virulent one? 
When a microbial agent is considered, there are five groups of organisms from which a 
selection can be made: bacteria, viruses, fungi, protozoa and entomopathogenic nematodes 
(EPNs). Many products have been developed for augmentative biocontrol as biopesticides 
based on these organisms, although products based on protozoa (mainly microsporidia) are 
the least common and successful. Depending on the pest insect and the knowledge on its 
pathogens (or of related insects) a first selection can be made, considering also the biology of 
the pest and the pathogen. The possibilities are different for leaf-feeding insects than for 
sucking insects, or for foliar insects or soil insects, or boring insects in a hidden habitat. 
Federici (1999a) summarized the utility of the different types of organisms against different 
types of insect pests. This is, of course, a theoretical exercise based on the biology of both 
organisms: the pest and the pathogen. Many other factors influence the best choice of a 
biocontrol agent for a given pest and these will be dealt with later in this study. Burges 
(1981a) divided the insect groups in: feeders on plant surfaces, sucking insects, boring insects, 
soil insects and aquatic insects. Next, he tried to assess the efficacy of pathogens against these 
different pest groups. 
The possibilities for use of a pathogen on the dominating pest groups in protected crops 
are given in table 2.1. This is an attempt to assess the likelihood of successful control based 
on the biological characteristics of both pest and pathogen, not on production and 
toxicological aspects.  
The reasons for the given indications in table 2.1 are the following: 
• mites: few bacteria are known to infest mites (De Kogel and Ravensberg, 2006); some 
fungi are known to cause diseases in tetranychid mites (van der Geest, 1985) and in 
eriophyoid mites (McCoy, 1996), but many of these fungi are from the group of 
Entomophthorales and cannot be cultured; only few viruses are known of tetranychid 
mites (van der Geest, 1985); and EPNs are too large to enter and kill mites and are not 
very effective against foliar pests; 
• aphids, whiteflies and scales: these phloem feeders are not likely to ingest bacteria; 
many fungi are known to infest aphids, but many of them are Entomophthorales (Latgé 
and Papierok, 1988); whiteflies and scales can both be infested by many fungi (Fransen, 
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1990; Evans and Hywel-Jones, 1997); viruses are rare; EPNs can hardly penetrate them 
and are difficult to use for foliar pests; 
• leafminers: few pathogens are known to infest them. The eggs and larvae are hidden in 
the leaf tissue, the pupae are well protected and pathogens of the adults are unknown. 
EPNs have been used with reasonable effects (Williams and Walters, 2000); 
• thrips: few bacteria are known, although they can be infested by them; they are known 
to be killed by various fungal species (Brownbridge, 1995); pathogenic viruses are not 
known, EPNs can kill them (Wardlow et al., 2001) and also parasitic nematodes are 
known to regulate populations (Mason and Heinz, 1999); 
• caterpillars: susceptible to Bt and can be controlled depending on their biology and the 
chance that they ingest the pathogen; the same holds for baculoviruses, although only a 
few are known. A number of entomopathogenic fungi are known (Inglis et al., 2001) 
and EPNs can be used, especially in cryptic or soil habitats (Van Tol and Raupp, 2005); 
• true bugs; these active phloem feeders are hard to infest by any of the pathogens; some 
entomopathogenic fungi are known to kill them (Liu et al., 2002). 
 
 
Table 2.1.   The potential of different kinds of pathogens to control greenhouse pests 
 
Pest group Bacteria Fungi Viruses EPNs 
Mites + ++ - - 
Aphids, whiteflies, scales - +++ - - 
Leaf miners + - - + 
Thrips  + ++ - + 
Caterpillars (defoliators) +++ + ++ + 
Caterpillars (soil, cryptic) + - - +++ 
True bugs - + - - 
-       : no chance of successful control +      : some possibility of control  
++    : reasonable possibility of control +++  : good possibility of control 
 
 
This table could help in setting up an exploration program for pathogens for a certain pest. 
When it is already well known which agent to look for or which one to use, selection level 
two becomes important. In this phase the screening and selection of the collected isolates (of 
one or more species) takes place. Differences between isolates can be large per characteristic 
or set of characteristics in all pathogens. In a screening/selection programme species and 
strains of various types of pathogens can be studied simultaneously. For instance, when a soil-
inhabiting caterpillar needs to be controlled, the efficacy of a bacteria and an EPN can be 
studied. Finally, however, isolates of one type of organism are investigated. Our research 
group has screened bacteria on thrips and spider mites and in this project several strains of 
three bacteria species were screened simultaneously for mortality and speed of kill of the 
targets.  
 
Strain selection in entomopathogenic bacteria 
The most successful microbial insecticides are based on bacteria. Worldwide, only a small 
number of bacteria species, however, has been used to develop these products, namely three 
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Bacillus species, B. thuringiensis, B. sphaericus and B. popilliae and Serratia entomophila. 
Most products have been developed on the basis of strains of B. thuringiensis and a number of 
subspecies of it. Various isolates have a good activity on caterpillars (B.t. kurstaki, B.t. 
aizawai), mosquito larvae (B.t. israelensis) and beetle larvae (B.t. tenebrionis). B. sphaericus 
also kills mosquito larvae and B. popilliae and S. entomophila are pathogens of white grubs.  
B. thuringiensis is the dominant pathogen in the market in terms of field of application 
and commercial success. Natural isolates of the subspecies are used as the active ingredient 
for the products. Selection of the isolates is based on a LC 50 test. Some recent products are 
based on transconjugate bacteria. An overview of the subspecies, the products and their use is 
given by Federici (1999b). For more details on Bt development and its uses the reader is 
referred to Charles et al. (2000).  
Selection of isolates is indispensible in Bt as its activity depends on which endotoxin it 
makes. Each endotoxin has a specific mode of action and host range (Navon, 1993). Finding 
isolates and screening for activity has become a field of science where standardization of bio-
assays is important but also still a debate ((Skovmand et al., 2000). It seems that only a 
specialized company, in collaboration with scientists, can successfully develop new Bt 
products. In 1992 more than 25,000 isolates were found (Milner, 1992); less than ten years 
later estimates were about 60,000 (Glare and O’Callaghan, 2000). More-over, Bt’s are also 
used to develop transgenic plants, an even more costly development in which only large 
multinationals are active, such as Monsanto and Syngenta.  
 
Strain selection in entomopathogenic fungi 
The literature in which strain selection studies with fungal isolates on arthropod targets are 
described is vast. Few authors indicate which selection criteria they use to come to a final 
selection and few studies continue with the development of the chosen strain into a 
commercial product.  
A tiered approach of selecting efficacious strains is described by Milner (1992) for the 
selection of Metarhizium anisopliae strains for locust and termite control. In Tier 1 he tested 
pathogenicity of the strains under optimal conditions (scarab larvae rolled in moist tissue 
paper at 25 ºC for 14 days); in Tier 2 the pathogenic strains were tested quantitatively by 
dipping larvae in spore solutions and incubating them as in Tier 1. The best isolates were then 
tested in Tier 3 in a bio-assay under simulated field conditions (in soil treated with 
conidia).The best three isolates were then used for field tests, in fact a Tier 4 step. Milner 
found the three tiered assay useful for quickly assessing the efficacy of a large number of 
isolates. Most authors use a similar sort of system, but few of them have described it in such a 
methodical approach.  
The approach of Milner is a logical one for assessing the pathogenicity and the efficacy, 
but it can be shortened and made cheaper. Tier 1 and 2 can be combined and should be tested 
under more challenging conditions, for instance, at a lower humidity and for a shorter time, 
more strains would be eliminated earlier and fewer could be tested in the bio-assay (Tier 3).  
Gillespie and Moorhouse (1990) listed nine characters for consideration when selecting 
fungal isolates for control of pests. Among these are pathogenicity and feasibility of 
production, obviously relevant characteristics, but also disease spread and fungicide 
resistance, of which I fail to see the relevance. The authors did not discuss the importance of 
these nine characteristics in any detail. On the other hand they considered that strain selection 
“cannot be over-emphasized as many characters can vary greatly between strains”. This is 
well recognized nowadays with most pathogens. 
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As described above Fransen (1987) and Meekes (2001) investigated A. aleyrodis as a 
potential MPCA and selection criteria for strains were defined. The salient criteria were high 
spore production and virulence (Meekes, 2001) which I also consider two of three of the most 
important characteristics on which a decision for development has to be based (see below). 
Posada and Vega (2005) described a new screening method based on six parameters. 
They investigated the interaction between 50 strains of B. bassiana and the coffee berry borer. 
A scoring method with a minimum value for each parameter was developed to rate the 
potential of the studied strains. The parameters they used seem to be appropriate for the 
studied case, but they may not always be key features. For instance, the speed and quantity of 
spore production on cadavers to initiate an epizootic effect is often not relevant for 
commercial biocontrol products used in greenhouses. Generally, greenhouse crops do not 
generate the necessary high relative humidity conditions. Nevertheless, the scoring system is 
an interesting way of evaluating different features for selecting the most promising biocontrol 
agents. 
 
Strain selection in baculoviruses 
A small number of baculoviruses out of the approximately 700 known species (Moscardi, 
1999) are used as microbial insecticides. Two types of occluded baculoviruses, 
nucleopolyhedroviruses and granuloviruses, cause epizootics in insects. They cause diseases 
in caterpillars and in some Hymenoptera (sawflies) and some Diptera, and kill their hosts in a 
number of days. They have a narrow host range and are safe to most other organisms. These 
attributes make them suitable for the development of a bio-insecticide.  
Among isolates of a baculovirus large differences may exist in virulence. Natural 
populations are often heterogeneous and contain many isolates and an isolate often contains a 
number of genotypically distinct variants (Murillo et al., 2006). Isolates can show a 50-fold 
difference in activity (Shapiro and Ignoffo, 1970). 
Selection of the most virulent isolate is done in a bio-assay on the host insect(s). 
Attention needs to be paid to using a standardized set up with a dose range and a suitable 
larval stage. The best isolates should then be tested under conditions that closely mimic the 
field conditions. However, few isolates have been found and producers have a low number of 
isolates available to select from, or sometimes only one, as in the case of the codling moth 
granulovirus (J. Huber, pers. comm.). Only five strains were available for the selection 
process in the development of the biological insecticide for control of Spodoptera exigua 
(Smits and Vlak, 1988a). 
At the same time, these isolates need to be checked for production of infective particles 
on the host insect to select for a good isolate for the mass production, which, up to now, needs 
to be done in vivo. Producers of baculovirus products consider efficacy and yield of infective 
particles as the selection criteria (M. Andermatt, pers. comm.). Smits and Vlak (1988a) 
selected the best strain on the basis of efficacy, speed of kill, and on host specificity, as this 
would facilitate registration. In products based on baculoviruses producers choose an isolate 
which consists of a mixture of genotypes in the production and in the final product. The 
reason for this is an increased virulence and to avoid development of resistance (M. 
Andermatt, pers. comm.). 
 
Strain selection in entomopathogenic nematodes  
Among researchers on EPNs selection of virulent strains is considered imperative, because 
large variations exist between nematodes species and strains (Bedding et al, 1983; Grewal et 
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al, 2005b; Van Tol and Raupp, 2005). In the selection process of EPNs authors often compare 
a relatively low number of species and strains in bio-assays. This selection is usually directed 
towards infectivity, mortality, and the determination of a lethal dose, sometimes in 
combination with environmental factors such as soil temperature, soil texture or moisture 
content (Van Tol, 1993; Westerman and van Zeeland, 1989). These studies are often 
relatively short studies by academic scientists and are not a part of a development process as 
is needed to come to a commercial product.  
To facilitate strain selection Bedding et al. (1983) proposed a predictive approach 
whereby not all available strains need to be tested. He eliminated on 1) the basis of 
knowledge of the biology of the nematode (temperature demand, behaviour, penetration 
mechanisms) and the host (movement, defence mechanism) and 2) the temperature 
requirement of the host’s environment and a simple lab mortality test with 100 nematodes per 
pest insect; he called this a preliminary scan. The remaining species/strains need to be tested 
further in field trials. However, how to continue then was not described and they did not 
provide a hierarchy for the above-mentioned aspects or for testing. Nevertheless this approach 
is a process of strain elimination and seems valuable, quick and time- and money-saving. 
Strain selection is complex since two organisms are involved, the nematode and the 
symbiotic bacterium. The nematode’s features are crucial for successful finding and invasion 
of the host insect, the bacterium determines the pathogenicity towards the host. A workshop 
was held among EPN researchers on strain selection and a number of authors described their 
methodology in selecting an effective strain, including selective breeding through many 
generations (Simões et al., 1998). The workshop did not get any further then a case by case 
description. A general methodology for a selection process was not developed. Generally, 
three different kinds of foraging behaviour are recognized within EPNs: ambush foragers (S. 
carpocapsae), cruise foragers (Heterorhabditis spp.) and those with an intermediate foraging 
strategy (S. feltiae). This behaviour, however, does not give a high predictive value in 
screening as the ‘ambusher’ S. carpocapsae showed to be the best candidate for control of a 
sedentary pest, the large pine weevil Hylobius abietis (Dillon et al., 2006). This illustrates the 
complexity of a screening programme. Researchers have not as yet developed a good system 
for selecting the optimal strain. Currently there is no consensus on a clear set of criteria for 
selecting strains for commercial development (R.-U. Ehlers, pers. comm.). 
According to Georgis and Gaugler (1991) most work within the field of applied 
entomopathogenic nematology has been by trial and error and has not been based on any 
predictive screening. The authors analysed 380 treatments with nematodes and concluded that 
there was a high risk of failure when selection of the optimal strain under the prevailing soil 
conditions was not performed or not sufficiently performed. They recommended screening for 
better isolates (for instance low-temperature active strains), and also close examination of the 
environmental factors that hamper success of the nematode treatment. This last aspect should 
be tested not only in the lab, but under real field conditions. I can only stress this last 
conclusion. The problem herewith is that it is time-consuming and therefore expensive.  
The number of nematode species and strains (isolates), however, is limited compared to 
those in fungi and bacteria. And only a limited number of species/strain can be produced by a 
commercial company due to practical and economic reasons. It is just too expensive to 
maintain and produce a large number of strains. As a group, EPN companies produce a 
limited number of species: five Steinernema and five Heterorhabditis species and two others 
(Grewal et al, 2005c: p. 480, table 28.1) and only one strain per species. In a number of cases 
they even produce the same strain. These strains usually have been selected by academic 
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researchers and then handed over to a particular company. Biosys (Georgis, 2002) did not 
conduct strain selection by themselves, but acquired licenses to strains from several 
universities in the USA.  
For many uses it is better to optimize the application method and conditions of the target 
site to favour the nematode’s behaviour, then to search for a new, more effective strain. This 
search would cost time and money and may not provide a better candidate. Moreover, 10% - 
20% increased mortality in small scale field trials by a better strain is often not recognized in 
commercial field applications due to the many variables. Therefore, it is more economical and 
practical to focus on the whole range of aspects around the application and to optimize those 
than to search for a new strain. It is recognized that soil moisture is the most relevant physical 
factor and this could be manipulated before and after treatment and contribute to increasing 
the effect of the nematodes and their persistence. Application technology needs more research 
and innovations in this area can stimulate a broader use of nematodes (Shapiro-Ilan et al., 
2006). 
In nematodes the most infective strain is not necessarily the strain which was found on 
its natural host, better control might be achieved by another species or strain (Bedding et al., 
1983). This means that in screening all combinations need to be investigated: local strains for 
a native pest and for an introduced pest, as well as non-local strains for both pests. This has 
also been found for fungi in biocontrol (Gillespie and Moorhouse, 1990), as well as in 
biocontrol of insects (van Lenteren and Tommasini, 1999). 
This poses the question of how valuable all the academic research on new strains is. It 
confuses the companies in further development of new products and new applications. 
Nevertheless, it is still essential to choose the correct species in accordance with the biology 
of the target insects. Strain selection is a crucial part of the EPN development, but its 
relevance should be evaluated against all other aspects of the development of an EPN product. 
It should not be overestimated in relation to the ecological and behavioural characteristics. 
The temperature range over which the nematode shows a good activity, however, is an key 
trait, as is tolerance to desiccation, which is needed in order to formulate the nematodes and 
have a good shelf-life. In the end, the most relevant points for a company are production 
efficiency in a liquid fermentation system, including formulation, and efficacy in the field, so 
strain selection should focus on these aspects. 
 
 
Selection criteria for a microbial pest control agent 
 
The most important selection criteria 
Which criteria are the most important in a screening study of a microbial pest control agent? 
In order to be able to answer this question, it is necessary to have in mind the foreseen 
application of the pathogen. Here we are selecting for a biocontrol agent that will be used in 
an inundative approach, an application, usually by spraying, that is meant to give a high 
mortality of the pest. It would be different when we want to apply a pathogen for long term 
control, as in classical biological control or for one seasonal application leading to an 
epizootic in the field. The decisive criteria for a pathogen that will be developed into a 
commercial bio-insecticide and that will be used for inundative release are: 
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1)  mortality:  
-  dose rate   
-  mode of action 
-  speed of kill 
-  host range 
-  sensitivity to abiotic factors  
-  persistence  
2)  production efficiency 
  -  yield 
  -  costs 
3)  safety:  
-  toxicological aspects 
-  non-target effects  
It is hard to put these features in order of importance: many of them cannot be seen as a single 
factor, but must be seen as a set of parameters that together will ultimately lead to a go or a 
no-go decision. But mortality and production efficiency are clearly the decisive factors. With 
a low mortality or an almost impossible to produce organism further development into a 
commercial product is useless. With other factors a compromise can be accepted, for instance, 
a high mortality with a slow kill still can be accepted in many cases. Ecological factors, such 
as host plant effects, effects on natural enemies, etc., are often studied in great detail by 
researchers. These are, of course, necessary in order to better understand the relationships 
between the pathogen, the target and its ecology and could improve the efficacy if we are able 
to incorporate these ecological factors into the application of the pathogen. This is not always 
possible and therefore these studies are not pivotal for the decision whether or not to develop 
a strain or species into a biopesticide. Further they are often complicated, long, and expensive 
and it is not always realistic for a company to investigate this in an early stage of the product 
development. 
 
Mortality 
It is evident that a high mortality is a highly preferred feature. The goal of the use of the 
pathogen is a quick and good control of the pest. The optimum would be that all stages of the 
pest quickly be killed, but this is rarely the case. Often only one stage of the cycle is sensitive 
to the pathogen which implies one or more treatments at some point in time to break through 
the cycle of the insect. For instance, the egg stage is often not susceptible to any of the 
pathogens. Bacteria, viruses and EPNs need to be ingested, or to get inside the insects, thus 
they are not effective on eggs. Only fungi can penetrate the cuticle into the insect, but in most 
cases not into the egg. Microsporidia can be transferred vertically within the egg, but usually 
do not give any mortality at this stage. The larval stages are often the most susceptible stage: 
through feeding they become infested with pathogens or in the case of fungi through 
penetration of the germ tube through the cuticle. Pupal stages are quite well protected in most 
cases, adults can be killed, but often they are also less susceptible or they do not pick up the 
pathogen (different feeding behaviour, living in another habitat, etc). Consequently, often the 
larval stage is the preferred stage that is being tested in bio-assays and field studies, and in 
many cases the larval stage is the eventual target stage for the biopesticide.  
Mortality is caused by the pathogenicity and virulence of the pathogen, is dose-
dependent, and dependent on the quality of the administered inoculum. In literature many 
different types of testing methods are described, often bio-assays, for the various pathogens 
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and all kind of different target pests. For overviews and critical considerations regarding the 
use of bio-assays I refer to Robertson et al. (1995), Lacey (1997), Navon and Ascher (2000), 
and Hatting and Wraight (2007). It is beyond the scope of this study to analyse all the 
different types of methods, however, the goal of the testing should be clearly defined 
beforehand and an attempt is being made here. To do this one has to look at the final goal of 
the product: to control the pest effectively. In practice this means for a grower that a high 
percentage of the pest be killed within a short time after he has applied the product and at 
affordable costs. In other words the two crucial parameters are efficacy and economy. These 
parameters are the same for all pest control methods, including chemical pesticides. This is 
the point of departure in the screening programme. The isolate that gives the highest 
mortality, and preferably quickly, at the lowest possible dose (= costs) is the most preferred 
isolate for further development.  
 
Dose rate 
Mortality is dose related. The susceptibility of an insect or mite is dependent of the dose of 
the pathogen. The dose-mortality relationship is usually the principal component in bio-assay 
testing. Virulence between species and strains is measured by LD 50, LC 50 and LT 50 
values. The LC50 is the concentration of a given entomopathogen required to kill 50% of the 
insect population within a given time period. Similarly, the LD50 is the dose required to kill 
50% of a population. Beside this value, the LT50, the time required to kill 50% of a 
population at a given dose or concentration of a pathogen, is indicative for the “speed of kill” 
of a pathogen and is valuable in the selection process. A dose-mortality curve should be made 
by testing a number of dosages and the slope of the curve gives useful information when 
comparing isolates. A flat curve indicates that the insect’s susceptibility is less dependent on 
the dose, and that the pathogen strain is more virulent then a strain that gives a steeper sloped 
curve. The above is generally the case for all pathogens and is important in selecting the best 
strain. Obviously, the lower the dose, the better the chance that a product can become 
economically produced. 
  
Mode of action  
Preferably the mode of action of the pathogen is known, but is not absolutely necessary to 
know it in detail for the development of a final product. Similarly, for many chemical 
pesticides the exact mode of action is not always precisely known. Understanding the mode of 
action of the pathogen can be helpful and is also needed for registration, although rather 
superficial descriptions have been accepted. Whether or not toxins are involved is more 
important to know, and if toxins are involved pesticide regulators want to know more before 
an approval for usage is given. More details on this will be discussed in chapter 5.  
In the case of pathogens the mode of action is often complex and several processes may 
be involved in the insect’s death. For instance, an infection sequence of an entomopathogenic 
fungus may consist of the following steps: adherence to the insects’ cuticle, host recognition 
and germination, appressorium formation, penetration of the cuticle by making a penetration 
peg and cuticle degrading enzymes, growth inside the insect and overcoming its immune 
system, possibly by release of toxins, and further development in the insect and finally killing 
the insect. This can be followed by sporulation outside the insect and spread of the spores for 
a new infestation cycle (Butt, 2002).  
In the commercial development of a bio-insecticide there are two reasons to have 
detailed information on the mode of action of the micro-organism:  
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1) the first is related to the virulence of the pathogen and whether virulence can be affected 
by the storage of the inoculum material (does the strain attenuate during storage?) and/or 
during the mass production (is virulence kept during production in artificial media?). 
Depending on the mass production system, that is whether a fungus is produced by 
liquid fermentation or by solid substrate fermentation, it may or may not produce a 
certain metabolite, and perhaps a toxin, which is part of in the mode of action process. 
In this case knowledge on the toxin and a method to measure its quantity in production 
will be useful; 
2) the second is the registration of the pathogen as an active ingredient for a biopesticide. 
When mortality is caused by a toxin or partly caused by a toxin, pesticide regulators 
want to have information on the toxin: which compound it is and in what quantity it is 
produced. Information will also be required on persistence on food and in the 
environment and on the risk for the applicator and workers. To generate knowledge on 
the toxin will be costly. If we can choose a strain that is efficacious without the 
production of a toxin, it is obvious that that is the preferred one.  
 
Speed of kill 
The trait “speed of kill” is also useful. The following example illustrates this: when leaf-
eating caterpillars are present in an ornamental crop economic damage is obviously increasing 
with time; a grower will choose a pesticide that can stop this. If he uses a Bt product, 
caterpillars will quickly stop feeding due to the early disease symptoms that paralyse its jaws, 
so the damage is not increasing. When a virus is used, the caterpillars will only die in 3-7 
days, depending on the pest species and the larval stage. When a grower has the choice 
between a virus and a bacterium based insecticide, he will not choose a bio-insecticide based 
on a virus since caterpillars will only stop feeding after a number of days and then die. 
Differences in speed of kill are present between species of pathogens, but can also be present 
between strains within one species. Screening for the best available isolate should also take 
this intra-specific variation into account.  
 
Host range 
Biocontrol scientists often search for a pathogen that is selective to a narrow host range 
and at the same time safe to non-target organisms. A more selective and specialized species or 
strain is often better adapted and as a consequence more virulent to its host(s). Selectivity is 
must be known for both the registration process and for use in IPM systems with natural 
enemies and pollinators. The trade-off is that this allows only a small market for the 
biopesticide which may make it difficult to have an economic product at the end. Eventually, 
the market size determines whether a product will be successful, so selectivity is conflicting 
with market size. In the case a pest is serious enough and its market large enough to justify 
the investment in the development of a biopesticide, than we can allow selectivity to weigh 
more. But of course, it is clear that when a larger number of pest species can be controlled by 
the same product, the development costs of this product can be justified and the product will 
be more profitable (see box 2.3).  
In the case of fungi and nematodes selectivity needs to be considered carefully since 
they can have a broad host range, while baculoviruses and Bacillus thuringiensis are specific 
and non-target effects are less likely to occur. Selectivity in relation to non-target organisms 
and the registration will be discussed more extensively in chapter 5.  
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Screening on selectivity should be focussing on two levels: 1) more in general to safety 
to humans, mammals and the environment and 2) more specific to effects on the pest species 
and other exposed organisms in the direct application area of the pathogen, such as target 
plants, natural enemies and pollinators. First of all, the desired pathogen should not have any 
harmful effects on humans, so broad opportunistic pathogen cannot be used. Secondly, it 
should be effective on a small group of insects with minimal effects on the non-target 
organisms occurring concurrently in the habitat of the area of application.  
 
 
BOX 2.3.   The importance of a broad host range for the market size of a microbial insecticide 
 
The product Vertalec has been developed for control of aphids, but in the field it only is effective 
against Aphis gossypii, the cotton aphid and on the peach aphid Myzus persicae, pests in cucumber and 
sweet pepper and in chrysanthemum greenhouse crops. Other aphids are less effectively controlled or 
not controlled at all; this is partly due to the limited host range of the Vertalec strain, partly due to the 
high humidity requirement of the strain. In a widely-grown crop as tomato it cannot be used 
effectively for aphid control.  
The strain does not kill whitefly and therefore Mycotal was developed. Mycotal has a good 
effect on whitefly, both on Trialeurodes vaporariorum and Bemisia tabaci and its strain is less 
dependent on a high relative humidity. Mycotal can be used in cucumber, sweet pepper and tomato 
and in many ornamental crops. As a consequence the market for Vertalec is much smaller than for 
Mycotal. Vertalec is only registered in the U.K., Switzerland, Norway, Finland and Japan. Mycotal is 
registered in The Netherlands, Denmark, Finland, France, Japan, Switzerland, Turkey, UK and 
approval is pending in Greece, Spain and Italy. Over the years 2003-2006 the sales of Mycotal were 
ten times higher than those of Vertalec. Due to its small market Koppert decided not to re-register 
Vertalec, which actually concerns its active ingredient Lecanicillium longisporum, strain Ve2. The 
high costs of updating the dossier to the current requirements and of the evaluation by the authorities 
do not justify to investment related to the expected future sales of the product Vertalec in the EU.  
Mycotal also kills thrips (Thrips tabaci, Frankliniella occidentalis) and gives reasonable control, 
to about 60% after three consecutive applications (Ravensberg et al., 1990a) in an IPM system. Some 
approvals allow the label to say “Mycotal has a side-effect on thrips” and this opens the possibility for 
more sales. In cucumber, whitefly and thrips almost always occur simultaneously and Mycotal will 
contribute to the control of both pests. So a broader host range leads to a more successful product.  
 
 
Sensitivity to abiotic factors  
Abiotic factors, such as temperature, relative humidity (RH), light (UV) and rain need to be 
considered in the screening process. For all pathogenic organisms, the temperature range of 
the pathogen and the optimal temperature in relation to the target pest’s biology and 
occurrence are determinative. In greenhouse crops temperature can be regulated within limits, 
the lower temperature by heating, and to a lesser extent the higher temperature by cooling. 
Usually, pathogens survive low temperatures, although they may not be active then, while 
high temperatures can be lethal. In screening for species or strains, the optimal temperature 
for the pathogen for infectivity and growth needs to be considered, together with the 
prevailing temperatures for the pest species and the crop in seasons in which the pest is the 
most problematic in the crop. This means that a rather large range should be looked at and 
strains with a large temperature range would be more desirable. In fungi and EPNs this is 
more important than in viruses and bacteria. The activity of the first two organisms is strongly 
influenced by temperature: germination in fungi and searching behaviour and penetration in 
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EPNs. Baculoviruses and Bt’s are more passive pathogens, they need to be ingested by the 
insect and only become active once inside the insect.  
Soil moisture is crucial for EPNs, without a water film they cannot move and find a 
host. This aspect is not considered important in strain selection since variability between 
strains is expected to be low and it has not been taken into account. 
Relative humidity (RH) is a determining factor for fungi, but much less so for viruses 
and bacteria. In the case of screening strains of fungi, it certainly needs to be considered, as 
RH requirements may determine success or failure (see box 2.3). Therefore, it is vital to 
screen fungal species / strains in a bio-assay system where the RH can be set. Many authors 
have tested infectivity of fungi at a 100% RH to find the most virulent strain. At lower RH 
conditions the selected strain may perform less well. Screening at 100% RH is useless and 
often gives the wrong outcome. A certain strain may be effective at 100% RH, but fail to give 
good results at RH conditions that prevail in the target crop. Screening should take place at 
the RH that is most prevalent in the foreseen crops.  
Light and UV can have negative effects on the pathogen and its survival, especially in 
baculoviruses (Ignoffo, 1992), but strain differences do not usually help in overcoming this 
problem. This is something to investigate with the product formulation (chapter 3). Rainfall 
and washing-off of pathogen particles are generally irrelevant in greenhouses as overhead 
sprinkling is done in a few crops only. Formulation should take this aspect into account when 
necessary.  
 
Persistence 
The longer the inoculum survives on the leaves or in the soil the greater the chance that the 
pest comes into contact with the pathogen. When the pathogen is applied on the foliar parts of 
the plant contact between pest and pathogen may be immediate due to spraying, or the pest 
may contact or eat the pathogen later in time, even days or weeks later. The longer the 
inoculum is infective, the better the control, even though direct control is desired. In EPNs 
persistence in the soil can enhance the effects in outdoor applications. When used in 
greenhouses this is usually less relevant.  
Persistence is also influenced by many other factors (ecological, host plant effects, 
target effects) which cannot be studied in the screening process. This requires fundamental 
and detailed research. It is interesting, but too expensive and too time-consuming. Screening 
for persistence is less crucial than for virulence, host range and abiotic factors. It can be 
improved by formulation techniques and then can be a helpful trait of the product, but it is not 
an essential one.  
 
Production efficiency 
A prerequisite for a pathogen to be developed as a biopesticide is that it can be easily and 
economically mass-produced. This should be taken into account from the very beginning. In 
general, it is nowadays known whether a certain pathogen can be economically mass-
produced or not. Bacteria usually are relatively easily to produce, certainly Bacillus spp. 
Fungi are more difficult, but the main ones used in biocontrol can be produced relatively well. 
Viruses still need to be produced on an insect host. EPNs can be produced in liquid 
fermentation or in vivo. More information on production of pathogens is given in chapter 3. 
New candidate strains must be checked for their ability to be mass-produced with a high 
yield of infective propagules. In this phase it can still be a global check; further optimization 
will take place once mass production is really investigated. For bacteria, this screening step 
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should focus on the ability to produce spores and/or crystals in high numbers and in a short 
time. For fungi this should also focus on spore production, either in solid or in liquid 
fermentation. For viruses it is important to obtain an overall idea on the production on the 
host and of the host itself and whether this is the target pest or a related species that is easier 
to produce. Whether or not caterpillars show cannibalistic behaviour and consequently need 
to be produced separately or in groups will have an impact on production costs. EPNs can be 
produced in the target insects or alternative hosts such as Galleria mellonella, but scaling up 
will be expensive because of labour costs. Usually, EPNs are produced in liquid fermentation 
and this possibility needs to be investigated early in the process.  
Differences between strains can be large. Strains that showed a high mortality of the 
pest in bio-assays but are difficult to produce should be discarded early in the selection 
process. A good example of this is given by Meekes (2001) in the screening of Aschersonia 
strains, where on the basis of global spore production strains were discarded in the first step 
of the screening process, even before assessing their virulence in a bio-assay.  
 
Safety profile  
Two areas need to be considered for harmful effects, on humans and on the environment. 
Considering the human aspect, there are two reasons that ask for an early survey on the 
toxicology of the pathogens that are under research. The first is to make sure that persons who 
are doing the research with the pathogens are not exposed to harmful organisms and that 
standard laboratory safety precautions are sufficient to protect them. The second is the 
registration of the pathogen as an active ingredient of a biocontrol product. Products based on 
fungi, bacteria and baculoviruses need to be registered in the EU as pesticides according to 
the EU Directive EU 91/414 (EC, 1991a). A great number of questions have to be answered 
or studied to fulfil the requirements for the approval of the active ingredient. EPNs are exempt 
from registration in the EU, although some countries require a registration or an import permit 
(see chapter 5).  
In the case of fungi and bacteria the mode of action could be (partly) based on 
metabolites. This should be investigated in literature and/or by testing of a culture filtrate on 
various organisms for biological activity. In the case that mortality is caused by a toxin, 
further research should first focus on this in relation to the registration requirements and costs. 
It could become too expensive to generate all data related to the toxin. Consultation with the 
competent authorities is needed before continuation of the development the MPCA. If the 
pathogen is a potential human pathogen or closely related to one, consultation with the 
authorities should also follow before further time and money is invested. It could be useful to 
do an acute animal testing package first in order to be able to make the right decision. See 
Box 2.4. for an example on the possible harmful effects of a pathogen. 
Considering negative environmental effects, several groups of organisms need to be 
looked at such as aquatic organisms (fish, daphnia’s and algae), and soil organisms such as 
earthworms, soil micro-flora and non-target organisms in the crops, like natural enemies and 
pollinators. Literature and information on the mode of action, the host range and persistence 
can give indications as to whether or not there are any risks for these types of organisms. 
Further tests may be necessary when there are doubts on environmental effects. 
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BOX 2.4.   Possible harmful toxicological effects of a pathogen and the consequences 
 
In a research project carried out by Plant Research International, Wageningen and Koppert BV, 
several bacteria were investigated as possible biocontrol agents for control of thrips, mites and 
whitefly in greenhouse crops. The bacteria were found as endophytes and some showed promising 
effects on these pests. Several species and strains were further tested in bio-assays and one bacterium 
gave good results on thrips. Mortality was 100% in only a few days on thrips (Frankliniella 
occidentalis) and spider mites (Tetranychus urticae) in a broad range of relative humidity and 
temperature. Also production of this strain appeared to be easy.  
 Identification showed that it was a strain of Serratia marcescens, an opportunistic human 
pathogen. Although this pathogen was found as an endophyte, we contacted a toxicological consultant 
and the helpdesk of the Ctgb (Dutch Board for Authorization of Pesticides) for their opinion on this 
bacterium in regards to filing an application as a biopesticide. The Ctgb reported that it will not be 
possible to get approval for this pathogen because it is an opportunistic human pathogen and a 
producer of a range of toxins. Even without specific information on this strain and its mode of action, 
the conclusion was not to proceed with its development. Unfortunately other strains were not found 
with a similar virulence on these greenhouse pests and the project did not lead to the development of a 
new bio-insecticide due to their toxicological aspects (De Kogel and Ravensberg, 2006). 
 
 
Conclusions and recommendations 
 
Considerations leading to a ‘go/no go’- decision  
In the development of a MPCA into a microbial insecticide the finding and selection of the 
isolate is a crucial component. Further research based on this isolate will follow on mass 
production, formulation, shelf-life, field trials, etc. The building of a dossier for registration 
will also be based on that isolate and this should start from the moment of the selection of the 
isolate. From this point on, costs and labour investments will be larger and more substantial. 
The decision whether to continue with the MPCA development, based on the initial findings, 
has a great impact. At this point a project can still be stopped without having lost a lot of time 
and money. If it is decided to go ahead, investments in time and money will become 
substantially larger. At the same time it is then implicitly decided (in most cases anyway) not 
to spend the budget and time on finding other solutions. This should be realized. Therefore a 
‘go/no go’-decision at this stage is the most important decision taken in the development of a 
microbial pesticide. The generation of the information on which the decision is based needs to 
be done with great care and always with its purpose in mind. The information used to make 
the decision to develop an agent has to give good insight into the efficacy and the costs of the 
MPCP.  
Efficacy is usually defined as high mortality, preferably with a fast “speed of kill”, and 
comparable to mortality caused by other competing control methods, usually chemical 
pesticides. Costs relate to costs of production, or to costs of a unit of the final product, and to 
registration costs. The first are easier to estimate based on some initial production tests than 
the latter. Registration costs are often difficult to estimate and depend, among others, on the 
company’s experience in this area. High costs of registration can be foreseen if metabolites 
need to be identified, studied and tested on animals. If many toxicological questions are 
expected, it is best to consult an expert in this area for an initial cost estimate of generating all 
necessary data for the registration dossier. The focus should be on human toxicology since 
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authorities are mainly concerned on applicator and worker exposure (see box 2.4.). If the 
investment looks to be very high this could lead to the decision to stop working with this 
strain or even species.  
I consider the initial information on efficacy, production costs and registration costs 
absolutely crucial in order to make the ‘go/no go’-decision on the continuation of the 
development of the biopesticide. Once the prospects of these aspects look positive, a company 
can decide whether to continue the development and to invest in the next research steps. Other 
aspects such as speed of kill, mode of action, host range and persistence influence the 
decision and depending on the case, they can be of greater or lesser importance. Whether a 
MPCA is affected by abiotic factors and how dependent its efficacy is on these abiotic factors 
is important, but not crucial.  
In the literature few examples are found in which similar considerations are taken into 
account and where studies are done on the three main traits efficacy, production and 
registration costs. In the Lubilosa project it was recognized early in the process that the key 
factors for strain selection were good production features and good field performance (Prior, 
1992). Roberts et al. (1991), when describing the ideal microbial pesticide, list five traits 
which a product must meet to become successful: good efficacy, economical production and 
good shelf life, safety and a potential market. This is similar to my conclusion, that 
effectiveness, costs and the toxicological profile are the decisive factors. Academic 
researchers understand the requirements for a biopesticide. Efficacy is studied, but costs and 
safety, however, are often neglected in their research.  
 
Importance of parameters in the selection process 
Above I have described how crucial the selection the MPCA is and what the main 
considerations should be. But which parameters should weigh the most for which pathogen? I 
will indicate the importance of the parameters for the different pathogens in table 2.2 and 
explain briefly why that is. Three areas are considered, the first concerns efficacy, the second 
production efficiency and the third safety (figure 2.1).  
The traits related to efficacy are: 
• dose-mortality response; the dose is critical in fungi, EPNs and viruses since these 
organisms are difficult to produce and therefore expensive. Bacteria are relatively easy 
to produce and, thus, the dose is less critical;  
• host range; in baculoviruses the host range is narrow, so apart from screening isolates on 
the target pest, investigations to find out what the host range is are not really useful. For 
the other pathogens, this is relevant and it could be useful to know other potential targets 
and markets; 
• survival and persistence; survival of EPNs in soil is usually limited and therefore can 
play a lesser role in screening tests. It is laborious and expensive to test. In bacteria, 
baculoviruses and fungi, and at foliar applications where 100% targeting is usually 
impossible, persistence of infective propagules adds to the total mortality. A long 
persistence increases the chance of contact or ingestion by a target insect. Few studies, 
however, have reported on the importance of this fact and personally I do not consider it 
a key trait. Persistence usually ranges between a few days and a week, and is also 
dependent on the formulation. In glasshouses, rain and UV, usually factors that reduce 
persistence, are not relevant;  
• abiotic factors; mainly temperature and relative humidity (RH) can limit the activity of 
the MPCAs. Bacteria and baculoviruses have to be ingested and only become active 
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inside the insect. In this case, temperature affects the insect host activity more than the 
MPCA and selection for a certain temperature range is accordingly less relevant. For 
EPNs, however, it is very important to know their temperature range. If it is too cold, 
the nematode is not active, does not search or cannot penetrate the host, at high 
temperature the same happens or the EPNs even die. In fungi, the RH is the main abiotic 
factor taken into account as fungi need a high RH for germination and this should be 
studied in the selection assays.  
 
Production-related considerations are: 
• for use of a pathogen as a biopesticide it is necessary to have infective propagules that 
can be applied to a crop. These are usually spores for bacteria and fungi (bacterial cells 
and mycelial parts are also possible), occlusion bodies for baculoviruses and infective 
juveniles or dauer larvae (L3) for EPNs. Spore-producing bacteria are generally easy to 
produce and formulate, while fungi are more difficult and more expensive to produce. 
Baculoviruses are produced in vivo and production is both laborious and expensive. 
EPNs can be produced in vivo and in vitro; production is both complicated and 
expensive. For all pathogens it is important to investigate how easy or difficult it is to 
produce them. This is especially true for the production of infective propagules. In 
addition to ease of production, a long shelf-life is highly desirable. For example, 
whether a bacterium can make spores or not influences the selection because spores are 
stable and can be stored for a long time. 
 
 Safety-related considerations are: 
• toxicological characteristics; the different types of pathogens vary in potential for 
harmful effects towards humans and the environment. In registration, safety to the 
applicator and worker in the crop are the main concern. Regarding bacteria this is 
critical, because many of them make metabolites and many of the ones used for 
biopesticides are closely related to harmful bacteria such as Bacillus and Serratia 
species. B.t is closely related to B. cereus, a food poisoning bacterium for humans. For 
fungi this is generally less important, although many of them make metabolites. 
Baculoviruses and EPNs, including their symbiotic bacteria, are specific, and safety to 
humans needs little attention in the selection process; 
• environmental effects; the potential of harmful effects of the pathogens on non-target 
organisms are usually relatively small. Bt’s and baculoviruses have a narrow host range 
and are quite specific. Fungi and EPNs can have a broader host range and that needs to 
be studied further. Effects on natural enemies need to be known too, not only for the 
registration dossier, but also for use in IPM programmes. Depending on the organism 
and its mode of action (metabolites) there may be concern for aquatic organisms, 
although serious effects are not known with the current approved biopesticides. 
 
In table 2.2 I have estimated the importance of the described traits in the selection process. A 
trait that is critical for the success of the pathogen needs to be studied with great care, such as 
relative humidity requirements (abiotic factors) for a fungus. A similar table with 
characteristics of the different types of pathogens is given by Federici (1999a: p.543, table 7), 
but I added the importance of the various traits in a selection process for the development of a 
biopesticide. I included the importance of toxicological aspects.  
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Figure 2.1.   Schematic, simplified process of sieving strains on criteria resulting in a small 
          number of strains for further research and development 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2.   Importance of traits in screening MPCAs for biopesticide development 
 
Trait Mortality Production Toxicology 
MPCA Dose Host 
range 
Survival Abiotic 
factors 
Propagules Effects on 
humans 
Non-target 
effects 
Bacteria ++ ++ +/- +/- ++ +++ + 
Fungi +++ +++ + +++ +++ ++ ++ 
Viruses +++ + + + +++ - - 
EPNs +++ +++ ++ +++ +++ -/+ + 
-       : unimportant   +      : slightly important 
++    : moderately important +++  : very important 
 
 
Recommendations for bio-assays 
Bio-assays are too often done under optimal conditions for the pathogen, such as high 
dosages, high relative humidity, absence of UV light, optimal administering techniques 
(immersion, diet incorporation, direct deposition, forced feeding) to find the optimal strain. 
Also, target insects or mites are often kept under unnatural and stressful conditions which 
could lead to susceptible animals. This kind of bio-assay set-up is not discriminating enough 
and could lead to false positives. Bio-assays should therefore be done under conditions that 
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mimic the natural situation as closely as possible, only then useful data can be generated. 
With abiotic factors this can be easily done, more care needs to be given to biotic conditions. 
 Standardization of the bio-assay is imperative in order to obtain reliable results. Natural 
variation in bio-assays is a complicating factor and can only be tackled by repeated testing 
with sufficient replicates and a tightly standardized assay (Robertson et al., 1995; Hatting and 
Wraight, 2007). Attention should be paid to possible attenuation of the pathogen strain 
(depending on culturing method, storage, etc), the culture of the target organism, even to the 
host plant on which tests are done. Even in well-conditioned climatic rooms seasonal effects 
are present and susceptibility and natural mortality may fluctuate throughout the seasons. This 
should be realized at all times when not only bio-assays but also semi-field tests are 
conducted. 
 
Final conclusions and recommendations 
In table 2.3 I summarize the most important steps in the selection process of a suitable 
candidate isolate for further development into a commercial product. Objective 4 and 5 will 
be treated in the following chapters. All these steps should be seen as a general approach and 
emphasis on selection criteria may shift a little depending on the organism and its specific 
characteristics and the pest problem that needs to be solved. Commercial considerations 
should always play a key role from the beginning. 
 
 
Table 2.3.   Recommended steps in the selection of an isolate for a microbial pest control 
 product 
 
   Objective Procedure 
1. Collection of isolates From culture collections, field collections, baits, crops, 
etc; make pure culture and test on Koch’s postulates 
2. Initial laboratory  
    screen to assess  
    efficacy 
Test a large number of isolates in a bio-assay against the 
target species at conditions close to the application 
conditions. Selection is a process of strain elimination 
3. Initial laboratory  
    assessment on  
    production efficiency 
Determine growth parameters and the production 
efficiency of infective propagules in laboratory scale 
process close to the foreseen mass production conditions 
4. Assessment of mode of 
    action and toxicological  
    properties 
Determine whether mode of action is (partly) based on 
metabolites and study toxicological properties of the 
microorganism and /or its metabolites 
5. Evaluation of efficacy 
    of selected isolates in  
    small glasshouse trials   
Determine optimal dose (LD 90), application method on 
target species and target host plant(s) at conditions as 
close as possible to the grower’s conditions 
6. Evaluation of efficacy 
    under commercial 
    conditions 
Determine efficacy of mass-produced propagules and 
with a formulated product at grower’s field 
(modified after Kerry, 2001: p.162, table 5.2) 
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Finally, after the selection and evaluation phase a ‘go/no go’-decision has to be taken 
based on the gathered information as described above, on efficacy, production efficiency and 
toxicological traits that were generated as much as possible under conditions that mimic the 
conditions in later phases in the development. It should be taken into account that a decision 
is always a compromise between finding the best strain and the best solution for the pest 
problem. Do not search endlessly to find the perfect isolate, but accept a good one or perhaps 
two or three for further research, and optimize one in formulation, application, etc. as far as 
possible. The best strain is the one that gives the best compromise between economics and 
good efficacy. In a commercial setting, economical considerations will be the leading ones in 
the decision. Consider criteria and results on a case by case study and relate constantly the 
economical aspects and aspects of the final field of use. Once the “go decision” has been 
taken for the selected strain or strains, further investments and research steps in the 
development process have to be taken and many of them will be addressed in the following 
chapters. 
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Chapter 3 
 
 
Mass production and product development of a microbial pest control agent  
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Abstract 
The feasibility of economic mass production of the selected strain and the development of a 
stable product are key factors to a successful microbial pest control product. Two phases are 
distinguished, the first is the development of the production process, including downstream 
processing, the second is the development of the product, including formulation, packaging 
and field testing. Registration requirements and commercialization considerations 
continuously need to be checked during the development of production and product. The 
critical technical and economic factors are identified and evaluated for the four types of 
pathogens. These factors as well as the biology of the pathogen are determinative for the 
choice of the production system. Preferably, it will be an in vitro process because that offers 
more control than an in vivo process. Bacteria, fungi and entomopathogenic nematodes are 
generally produced in vitro. Baculoviruses must be produced in vivo; production in insect 
cell-lines is not yet economically and technically feasible. The production system also 
determines costs of medium composition and the method of downstream processing. 
Advantages and disadvantages in terms of costs, manageability and versatility are provided 
for each production system. Recommendations are provided for medium optimization and for 
the choice of mass production and downstream equipment. The ultimate goal is to produce the 
greatest number of infective propagules for the lowest cost. Stabile inoculum is a prerequisite 
for maintaining strain characteristics and a high quality product. The development of a stable 
product that is able to deliver effective pest control requires a formulation. The four main 
objectives in formulating the infective propagules are: to stabilize the propagules for reasons 
of packaging, shelf-life and shipping; to make a user-friendly product that can be effectively 
delivered to the target; to protect the propagule, once applied, to improve its persistence at the 
target site; and to minimize risks of exposure to the applicator. Formulation is specific to a 
certain type of pathogen and determined by the characteristics of that pathogen and its 
specific use. Formulation considerations are presented per formulation function as well as per 
type of pathogen. Pivotal elements are reviewed per pathogen. Formulation requirements are 
particularly difficult for foliar applications of entomopathogenic nematodes and fungi. Oil-
based formulations for fungi improve their performance. Protection from UV is the greatest 
concern for baculoviruses; research is ongoing. The use of tank-mixed adjuvants is an option 
to improve the biological activity of pathogen-based products. Biological and economic 
aspects are evaluated. Technological advancements such as encapsulation, controlled release 
systems, and new surfactants may enhance field efficacy. Product packaging is an important 
factor in shelf-life, and innovative technologies should be investigated as they may improve 
shelf-life, handling and economics. Field testing is a key phase in the product development 
which links all steps in the developmental process. It provides information on the efficacy of 
the selected strain, on the quality of the produced propagules, on the formulation, on the 
optimal application strategy, on efficacy that is necessary for registration, on compatibility, on 
the implementation of the product in an IPM system, and on the marketability of the final 
product. Obviously, the method of field testing is crucial and should reflect ‘real world’ 
conditions. Results from field tests provide a continuous circle of feedback that allows 
improvement of each of the steps of the entire developmental process. Product specifications 
are briefly presented as the basis for product quality control. A cost price model for 
biopesticides is provided with cost factors involved from production to product, and from 
product to market. The first part of the model  presents fixed costs for the production facility 
and general overhead, and variable production costs. The second part outlines indirect 
overhead and sales costs as well as direct sales costs. The market price requires a profit 
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margin for producer and distributor. The model provides a perspective on the makeup of the 
end-user’s price and all the costs that must be considered to achieve a profitable business. 
Recommendations for an economic analysis of a biopesticide production from literature are 
reviewed, and relevant considerations for a producer are provided. In the conclusion, 
production and formulation considerations and recommendations for a economically feasible 
production are presented. Economy of scale, full use of the production capacity, and capacity 
planning are essential factors to keep the costs low. Production economics and final product 
costs need be to analysed on a case by case situation and depend on the type of product, the 
company, and the market. Formulation research is imperative for microbial pest control 
products. It can improve limiting features such as shelf-life, targeting of the pest, and user-
friendliness. Formulation also adds value to the product. Key elements to successful 
biopesticides are both production efficiency and product efficacy. 
 
 
Introduction 
 
A key factor in the success of a MPCA is cost-efficient production and development of a 
product that will be stable and able to deliver effective pest control. In the phase of mass 
production and product development, decisions will have to be taken on the choice of 
production system, on downstream and formulation equipment, often even on building a 
production plant with the entire infrastructure. A company needs to make large investments, 
although the start can be done on a pilot-plant scale, but eventually it will be followed by a 
full scale commercial production facility. In the case that production equipment is already 
available, this can be used first, before new equipment is bought. Nevertheless, the research 
and development of the production system and of the final product is the main process in 
terms of money and budget and needs the full commitment of the company. This also 
underlines the importance of the initial phase described in chapter 2, i.e. the definition of the 
problem and the selection of the potential microbial control agent as the solution for the pest. 
After the selection of a microbial agent, two phases can be distinguished in the development 
of a microbial control product: 
1) the development of the production process: a cost-efficient and reliable method of 
production must be developed which gives predictable yields of infective propagules 
(spores, bacteria, etc) in a large quantity and of a high quality within a given period of 
time. This includes the choice of the equipment to be used for production, for harvesting 
and processing of the propagules (drying, centrifuging, sieving, etc.): the downstream 
process. The process further includes development of a method for storage of a stable 
inoculum (known as the stock culture, or ‘mother’ culture), preparation of inoculum for 
subsequent steps in the production process (from small bioreactors to large ones), 
medium development, research on determinative process parameters and how to adjust 
these parameters during the production process, process quality control, harvesting and 
storage methods including methods for stabilizing the yield into a “technical product”. 
The whole process must be focussed on obtaining the optimal yield quantitatively and 
qualitatively against the lowest possible costs;  
2) the development of the product: a final product must be developed which is stable, has a 
long shelf-life, and which will give the required control results when applied in the field 
with an appropriate delivery system at the lowest effective dose. The formulation must 
be developed taking into account the specific purpose of the product and the delivery 
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system. The most efficient dose must be established in semi-field and field tests under 
commercial conditions. Product specifications and quality control methods need to be 
developed to safeguard this. The final formulation needs to be packaged appropriately.  
Both phases cannot be seen as independent processes, they are complex and interconnected. 
The ultimate goal is to develop an affordable product that is user-friendly and will 
consistently produce good results. During the development of the product, registration aspects 
also need to be kept in mind. Registration authorities require more or less the same as the 
producing company and the end-user: a stable and safe product that gives a certain predictable 
efficacy when used according to label recommendations. It is beyond this thesis to describe in 
detail mass-production systems, production manuals, formulation methods and formulation 
recipes. Many researchers from academia and the biocontrol industry have published details 
of production methods and formulation of MPCAs (Ignoffo, 1973; Bedding, 1981, 1984; 
Smits, 1987; Bartlett and Jaronski, 1988; Jackson et al., 1997; Burges, 1998; Couch, 2000; 
Wraight et al., 2001; Ehlers and Shapiro-Ilan, 2005).  
In this chapter I will identify the critical aspects of production and formulation that need 
to be considered in the developmental process of a MPCP (table 3.1). These factors are of a 
technical and economic nature, and are vital to the success of a company. Recommendations 
on how to consider these factors will be given, because few papers have addressed this topic 
in this way. Notable exceptions are Lisansky (1985) and Jackson et al. (1992). Lisansky 
briefly described the whole process that leads to commercialization of a pathogen. He 
highlighted the decisive aspects of the process and product development. His paper is 
predominantly based on his work with entomopathogenic fungi. It is a complete listing that is 
still appropriate and useful more then twenty years later for all types of pathogens. Jackson et 
al. (1992) briefly described the development of a bacterium for grub control and concluded 
that the process is not a neat, stepwise linear programme, rather a step by step spiralling 
process. I am sure that many researchers and companies have similar experiences, and by 
identifying the conclusive factors in the production and product development I will try to give 
guidelines that will result in a more predictable pathway and outcome. 
 
 
Table 3.1.   Steps in the development of the production process and the product development 
       of a microbial control agent  
 
          Production process            Product development 
• Production method and equipment 
• Downstream method and 
equipment  
• Medium development  
• Inoculum quality 
• Process parameters control  
• Process quality control  
• Production costs 
• Formulation 
• Dose 
• Application method and delivery system 
• Packaging  
• Product specifications 
• Product quality control 
• Product cost price  
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Process development 
 
Mass production and downstream processing 
The production and the downstream method should deliver a yield of infective propagules, 
called the technical product, which can be further formulated into a final product. The 
production method is the phase in which the pathogens are mass-produced, and includes the 
bioreactor type and the medium. Once infective propagules are produced, these will be 
collected by the downstream process: any large-scale processing of the ferment or solid state 
matrix to recover and purify the propagules until making of the technical product. “The 
technical” usually consists of pure propagules, sometimes with medium remnants and/or with 
produced metabolites. It may also include components that are added during the downstream 
process as a protectant. This intermediate product will be formulated further with co-
formulants to make the final product. 
Depending on the pathogen, processes and production systems or bioreactors may vary 
greatly. A company can choose a highly sophisticated technical approach or a low-budget 
approach with simple production systems: the production of a fungus can, for example, take 
place in a computer-steered bioreactor or in autoclavable plastic bags. These approaches are 
also referred to as the capital-intensive model and the labour-intensive model (Swanson, 
1997). Often investment costs versus labour costs will determine this choice, but the scale of 
the production and the eventual market price also need to be considered. Many production 
systems have been studied and developed for the pathogens discussed in this study and many 
researchers have reported their findings in handbooks and papers. The research generally 
concerns laboratory scale production, but these studies often provide valuable information 
that can be used in developing a mass production process. Scaling up is the challenge for the 
many biocontrol companies that are producing MPCAs. Information on details is usually 
proprietary. Production methods, however, of a certain pathogen whether performed by in 
vitro solid or liquid state fermentation or in vivo (table 3.2), are generally known. 
 
 
Table 3.2.   Economic feasibility of mass-production methods for microbial pest control 
       agents (SSF = solid state fermentation; LSF = liquid state fermentation) 
 
MPCA \ production method In vivo In vitro SSF In vitro LSF 
     Bacteria  +/– + +++ 
     Fungi + ++ +++ 
     Baculoviruses  +++ – –x 
     EPNs ++ ++ +++ 
–  : not possible (x :  insect cell culture) +/–:  possible, in some cases the only method 
+ :  possible, but not or hardly economical ++:   economical method 
+++ :  most economical method  
 
 
Below I will review the current status, type of system and kind of information needed to 
develop a mass-production system for the four groups of pathogens: bacteria, fungi, 
baculoviruses and entomopathogenic nematodes. A pivotal element is production costs in 
large scale productions. This is largely unreported in the literature. I will present a cost model 
that can be used to estimate the costs of each step in the overall product development and that 
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provides insight into the cost factors. I have experienced many times that researchers quote 
production costs, but often it is unclear which costs are meant, from what type of scale they 
are calculated and what the end-user’s price will finally be. The cost model will take into 
account all contributing factors so that estimations can be made on turnover, profit, and return 
on investment.                        
 
Mass production of entomopathogenic bacteria  
Entomopathogenic bacteria can be easily produced in in vitro systems, although one species, 
B. popilliae, used for the control of the Japanese beetle, can only be produced in its natural 
host. It is effective against this beetle, which is a problem in outdoor crops in the USA. In 
New Zealand, a product called Invade has been developed on the basis of Serratia 
entomophila for control of grubs in grasslands. Production of bacterial cells is carried out in 
vitro by liquid batch fermentation (Johnson et al., 2001). These examples will not be 
discussed further since they are not used in greenhouses. 
Bacillus thuringiensis is the most successful biopesticide and this is largely due to its 
economical production (Federici, 2007). Three subspecies are produced, and commercial 
products have been developed on the basis of these subspecies: B.t. kurstaki against 
caterpillars, B.t. israelensis against mosquito larvae and B.t. tenebrionis against larvae of the 
Colorado potato beetle. B. sphaericus is also produced and used against mosquito larvae. 
Production for all of these bacteria is similar and they can be easily produced in large 
fermentors in liquid culture. Research on Bt as a biopesticide is almost 100 years old and 
hundreds of researchers have published on it, including papers on mass production. Bt can be 
produced by (semi-)solid state fermentation, but industrial production is performed by liquid 
state fermentation. Semi-solid and solid state fermentation is done on a small scale in 
developing countries for local use (Bernard and Utz, 1993; Vimala Devi et al., 2005; El-
Bandary, 2006). I have seen in 2006, however, that even in Cuba submerged fermentation is 
taking over with fermentors of a few thousand litres. Semi-solid and solid state fermentation 
is difficult because is takes a long time, and parameters cannot be adjusted. Liquid 
fermentation is therefore the preferred process in industry. Only when production takes place 
in vessels of over 30.000 litres does Couch (2000) consider it mass production, which 
indicates today’s scale of production. Hundreds of products have been developed by tens of 
companies. In the USA about 125 Bt products are registered (http://www.epa.gov/pesticides/ 
biopesticides/product_lists/microbial_prods_by_ai.pdf). 
Details of the production of Bt are given by Lisansky et al. (1993), Bernhard and Utz 
(1993), Couch (2000) and El-Bandary (2006). An excellent overview of “Bt in biological 
control” on its biology, mode of action, commercial development and on Bt transgenic crops 
is given by Federici (1999). The Bt development has always been dominated by large 
companies (Solvay, Abbott, Novo Nordisk), including chemical pesticide companies 
(Syngenta, formerly Novartis, resp. Ciba Geigy and Sandoz). American venture capital 
companies joined this area in the late eighties (Mycogen, Ecogen). They focused on 
genetically improved strains, but never marketed Bt products on a large scale. They have sold 
their strains and technology to companies which are focussing on transgenic plant 
development with Bt genes (Monsanto, Syngenta). Currently two companies dominate the 
world’s Bt market, Certis USA and Valent Biosciences. Typically, production is conducted in 
fermentors of 40,000 to 120,000 litres (Federici, 2007). Many small companies produce Bt 
products, but apparently the market has become very competitive so that only two companies 
have large sales. The large scale productions definitely are profiting from the economy of 
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scale and most likely that is the only way to be profitable. Downstream processes have 
become an integral part of Bt production and large facilities are needed to accomplish drying 
of the bacteria sludge by spray-drying and/or fluidized-bed drying. Formulation is often 
included in this process. Obviously this production has become capital-intensive because of 
its size and technology and it shows that competitive biopesticides can be produced in this 
way. 
 
Mass production of entomopathogenic fungi  
Entomopathogenic fungi have been studied widely for use as a mycoinsecticide and many 
researchers have given an overview on mass production of these fungi (Quinlan & Lisansky, 
1983; Bartlett and Jaronski, 1988; Bradley et al, 1992; Goettel and Roberts, 1992; Feng et al., 
1994; Jenkins and Goettel, 1997; Wraight & Carruthers, 1999; Wraight et al., 2001). Most of 
this work has been performed on a select group of Hypocreales (formerly Deuteromycetes), 
particularly on fungi of the genera Aschersonia, Beauveria, Metarhizium, Isaria 
(Paecilomyces) and Lecanicillium (Verticillium). Two species have been the subject of most 
of the research: Beauveria bassiana and Metarhizium anisopliae. Both fungi have a broad 
host range and are relatively easy to produce. Many researchers have studied these fungi for 
control of various pests (Inglis et al., 2001), including their production and formulation. An 
extensive review has been given on production, formulation and application of B. bassiana by 
Feng et al. (1994). This fungus has been and is still produced on a large scale in many 
countries by solid state fermentation (SSF), liquid state fermentation (LSF) and di-phasic 
fermentation (Ferron, 1981; Bartlett and Jaronski, 1988; Bradley et al., 1992; Feng et al., 
1994). M. anisopliae, (including the acridid-strains, formerly called M. flavoviride,) is usually 
produced by solid state fermentation (Mendonca, 1992; Cherry et al., 1999; Milner and 
Hunter, 2001), but the production of blastospores by submerged production (LSF) has also 
been studied (Kleespies and Zimmermann, 1992). Most products are based on conidiospores, 
and some on conidia and hyphae on a granular substrate. There is no blastospore-based 
product on the market. The majority of the mycoinsecticidal products have been developed 
with these two fungi: 58 based on B. bassiana and 61 based on M. anisopliae out of 171 
mycoinsecticides and mycoacaricides (De Faria and Wraight, 2007).  
Entomophthoralean fungi have successfully been used in classical biological control in 
two cases, with Entomophthora maimaiga against gypsy moth in the USA and with 
Zoophthora radicans against the spotted alfalfa aphid in Australia), but they are not used in 
inundative programmes. Their potential is reviewed by Pell et al. (2002), but unfortunately 
they cannot be mass-produced in vitro and they are not further discussed here. Fungi used for 
control of plant diseases, plant pathogenic nematodes and weeds are often mass-produced in 
similar ways as entomopathogenic fungi. For an overview of fungal species products, see Butt 
et al. (2001b: p. 2-4). Relevant aspects of mass production considered in this chapter relate 
also to these fungi, regardless of their field use. 
Fungi can be mass-produced by solid state fermentation, also called solid substrate 
fermentation, and by liquid state fermentation (LSF), also called submerged culture 
fermentation. A third method is an intermediate system, called a di-phasic fermentation, 
where both phases are involved: mycelium, produced in liquid culture, is allowed to sporulate 
in shallow trays (Feng et al., 1994; Jenkins and Goettel, 1997). The choice of how to produce 
a fungus is generally led by the ability of an organism to produce a high yield of spores of a 
high quality in a certain system. Conidiospores are preferred over blastospores or hyphae 
because of their better survival in downstream processes and during storage, and for their 
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superior persistence after application. Most fungi produce conidiospores only when produced 
by solid state fermentation, still, some do produce conidiospores in submerged fermentation, 
like B. bassiana and Trichoderma harzianum. Other fungi like I. fumosorosea and L. 
longisporum (V. lecanii) are produced by liquid state fermentation and form blastospores.  
Production by solid state fermentation can be conducted by a simple method, e.g. 
growing on a carrier – often enriched cereal grains or parts thereof – in plastic autoclavable 
bags or in trays. This is often seen in developing countries or in situations where labour is 
relatively cheap or investments low. Well-established biocontrol companies use this method, 
as well as small local “cottage-industry” like organizations as the CREEs (Centros de 
Reproducción de Entomofágos y Entomopatogénos) in Cuba (Nicholls et al., 2002) and in 
Central America (Grimm, 2001) and South America (Mendonça, 1992). The start-up costs are 
low, the technology used relatively simple and the labour input is high. Nevertheless, it can be 
successful as proven by the Lubilosa project (Jenkins et al., 1998) and by BCP’s production 
of M. anisopliae var. acrididum for locust control (www.biocontrol.co.za). 
More sophisticated bioreactors are used for solid state fermentation by a number of 
companies such as Koppert (unpublished data, see figure 3.1), Laverlam (the former 
Mycotech facility) (Bradley et al., 1992), NPP (Guillon, 1997a) and Prophyta (Kiewnick, 
2001). In these reactors environmental conditions can be regulated much better than in bags 
or trays, for instance by means of conditioned airflow, heating or cooling. Investments are 
rather high, labour input is medium. Some examples of products with conidiospores produced 
by solid state fermentation are: Mycotal, based on L. muscarium and produced by Koppert; 
Botanigard, based on B. bassiana and produced by Laverlam; Naturalis, based on B. bassiana 
and produced by Intrachem (formerly by Troy Biosciences); Bio1020 and Met52, based on M. 
anisopliae and produced by Novozyme (formerly Earth Bioscience, resp. Taensa and Bayer).  
LSF has also been studied for entomopathogenic fungi such as B. bassiana (Hegedus et 
al., 1990), Hirsutella thompsonii (McCoy et al., 1975), M. anisopliae (Kleespies and 
Zimmermann, 1992; Andersch, 1992), I. fumosorosea (Jackson et al., 2003) and 
Lecanicillium spp. (Hall, 1981a; Feng et al., 2000 and 2002). In submerged cultures, fungi 
may produce blastospores (thin-walled, single-celled hyphal bodies) and/or submerged 
conidia and/or mycelial parts or pellets. This depends on the species, the strain and the 
production medium and parameters. Most of the research on submerged fermentation is aimed 
at blastospore production. In the case of H. thompsonii, McCoy et al. (1975) studied the mass 
production of mycelial parts as propagules. They assumed this would be the easiest and 
cheapest method, but the product Mycar developed by Abbott on this basis gave variable 
results and poor stability in storage. Later, a conidia formulation was developed with good 
storability (McCoy, 1981). Still, poor field efficacy resulted in withdrawal from the market in 
1985 (Mccoy, 1996). Rombach et al (1988) investigated the production and formulation of 
mycelium parts of B. bassiana as infective material because it seemed the simplest, thus 
cheapest fermentation process.  Another approach was taken by Andersch (1992) who 
produced mycelial pellets of M. anisopliae as the active parts of the product Bio1020. Bayer 
chose for the production of pellets as the foreseen formulation was a granule that could be 
mixed with growing substrates for plants (Reinecke et al., 1990). An other reason to choose 
for submerged fermentation was Bayer’s perception that solid state fermentation cannot be 
scaled up to an industrial production method. This idea, however, did not succeed and the 
product with this formulation was never launched since production costs were too high. 
Bio1020 is currently registered as a formulation based on rice kernels with conidiospores 
(www.ctb-wageningen.nl). Some examples of products based on blastospores are Preferal, 
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based on I. fumosorosea and produced by Certis USA (formerly Grace & Co, resp. Thermo 
Trilogy). Production costs and scaling-up considerations determined that LSF be used to 
produce this product (K. Bolckmans, pers. comm.). Vertalec, based on L. longisporum 
(formerly V. lecanii) is produced by Koppert by LSF since spore yields by solid state 
fermentation are low with this strain. 
Generally LSF is investigated for reasons of scale and costs, or because the yield of 
conidiospores is too low when using solid state fermentation. Spore type and production costs 
generally drive the choice on how to produce a fungus, see Box 3.1 for an example. 
Economical mass production of stable propagules is essential for the commercial 
development of a mycopesticide.    
 
Mass production of baculoviruses 
Baculoviruses can be produced in vitro and in vivo. The commercial development of 
baculoviruses as viral insecticides started in the 1960’s in the USA, based on in vivo 
production of the Heliothis NPV virus (Ignoffo, 1973). About 20 years later, interest in virus 
products in Europe increased and even then in vitro production was investigated and 
compared with in vivo production because of cost concerns (Gröner, 1987). Today, mass 
production of baculoviruses for biopesticide products still occurs in vivo, in most cases on the 
original host, sometimes on a factitious host. In vitro production is performed in research and 
for purposes such as protein production, but not yet for biopesticide production. Many authors 
have reviewed the development and production of baculoviruses in general (Ignoffo, 1973; 
Granados and Federici, 1986; Huber and Miltenburger, 1986; Shieh, 1989; Weiss et al., 1994; 
Black et al., 1997; Hunter-Fujita et al., 1998). 
In vivo production of baculoviruses has been described in detail by Shapiro (1986). He 
identified the production of the host: moths, eggs and larvae (labour, medium, containers and 
facility costs) as the chief cost factor. Automation and optimization of the artificial media 
(simplification) for caterpillars are areas for improvement. Production costs are higher where 
caterpillars are cannibalistic and need to be reared singly in contrast to in groups. Finding an 
alternate host that is not cannibalistic is in some cases a possibility for reducing costs. In virus 
production, inoculation and harvest mechanization could lead to further cost reduction. 
Essential aspects in the production are the optimal inoculation dose and larval stage and the 
optimal harvesting time, giving the highest yield of infectious occlusion bodies (OBs) or 
polyhedral inclusion bodies (PIBs) per larva. A difficulty with in vivo production is 
contamination with micro-organisms, mainly bacteria, and degeneration of the virus (Black et 
al., 1997). Using inoculum from a well-defined mother stock can overcome this risk of loss of 
activity by mutations, and companies are usually using this method. A general problem is that 
process control of in vivo production of viruses is limited and therefore many authors suggest 
that production in vitro would be much better. The possibility for this method is discussed 
below. Many authors have given detailed descriptions of in vivo production methods of 
various baculoviruses in different insects (e.g. Ignoffo and Couch, 1981; Lewis, 1981; Smits, 
1987; Shieh, 1989; Cherry et al, 1997; Grzywacz et al., 1998; van Beek and Davis, 2007)).  
An advantage of the production of baculoviruses and their hosts is that it can be started 
in a simple set-up without high initial investments. This gives a company the possibility of a 
step by step approach, implementing improvements continuously over the years. Likewise, 
production systems in developing countries also rely on relatively simple technology. 
Techniques have been developed for high-density rearing of various caterpillars (Wood & 
Hughes, 1996). Besides, produced virus can be stored frozen for many years without loss of 
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activity, allowing the producer to produce all year round and to build up stock. Failures in 
production are therefore not as problematic as with EPNs or fungi. The large scale production 
of the insect host is pivotal. Optimization and automation can reduce costs. Other problems 
such as diseases and premature virus infection can be devastating. Quality control parameters 
should be developed to detect problems, like virus degeneration, in an early phase. Production 
in vivo is not a sterile process and it is not as controllable as production in vitro. Microbial 
contamination can be a problem (Hunter-Fujita et al., 1998), leading to variable yields and 
discarding of batches. Generally, registration requirements do not allow high bacterial 
contamination levels, and for this reason too, contamination needs to be kept under control. 
Guillon (1995) considers quality control the main cost factor, which underlines the 
importance of this aspect in baculovirus production. Downstream processes such as 
harvesting dead larvae and virus purification can be laborious, but are relatively easy in terms 
of technology. Product can be stored easily, unformulated as well as formulated. For high 
value crops this in vivo technology has proven to be feasible in the western world. In low 
value crops baculoviruses are also used, even on a scale of over two million hectares in soy. 
Production, however, is too expensive for these crops, therefore diseased larvae are collected 
in the field and virus is extracted from these caterpillars and prepared for application 
(Moscardi, 1999). This is called field production of baculoviruses. 
The number of baculovirus biopesticides is about 35, based on 15 different virus species 
(Copping, 2009). Baculoviruses are used to control lepidopteran pests and dipteran pests 
(mainly sawflies in forests, the latter are not discussed further here). Production systems have 
been developed for codling moth, fruit tortrix, and gypsy moth and for Heliothis spp., and 
various virus products have been registered and are marketed. Examples are Carpovirusine, 
Granupom, Madex, CYD-X and Virosoft for control of codling moth, Capex for control of the 
fruit tortrix, Gemstar for control of Heliothis species and Gypscheck and Disparvirus for 
control of the gypsy moth Lymantria dispar in North American forests (Copping and Menn, 
2000). There are two products used for a greenhouse pest, Spod-X, produced by Certis USA, 
and Virex, produced by Biocolor, Spain, both against the beet army worm Spodoptera exigua. 
Virus products are able to compete in the market with chemical pesticides, for example in the 
case of codling moth in apples and pears in Europe. The amount of active ingredient needed 
per ha is a significant factor. For codling moth the dose is 3 x 1012 OB/ha, for the beet army 
worm the dose is 3 x 1011 PIB/ha (polyhedral inclusion bodies). Recently, a baculovirus has 
been found of Chrysodeixis chalcites, the tomato looper (Van Oers et al., 2005). This 
caterpillar is the predominant lepidopteran pest in Dutch greenhouses and this virus may be 
developed into a product.  
 
In vitro production of baculoviruses 
In vitro mass production of baculoviruses for biocontrol purposes has been studied for 
decades by academic researchers (Stockdale and Priston, 1981; Weiss and Vaughn, 1986; 
Black et al., 1991; Shuler et al., 1995; Wood and Hughes, 1996; Szewczyk et al., 2006) and 
by industry, by chemical companies such as Hoechst (Gröner, 1987), American Cyanamid 
(Gard, 1997), Dupont and Zeneca (Harris, 1997), as well as by biocontrol companies such as 
Biosys (Weiss et al, 1994). For two important reasons, in vitro production of baculoviruses 
could be advantageous over in vivo production:  
1) economy of scale. As described above, in vivo production is economically feasible up to 
a certain scale of use of a virus product or, when labour is not expensive. If there were a 
large demand, say over several 100,000’s ha, scaling up would give production in 
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fermentors the advantages of economy of scale. Product costs for growers could become 
lower and products more competitive with traditional chemicals; 
2) baculoviruses kill their host relatively slowly. This is a drawback of the products. The 
possibilities of improvement by genetic modification of strains aiming at an accelerated 
speed of kill are reviewed by Inceoglu et al. (2001). Recombinant strains, in which the 
‘speed of kill’ trait is improved, for instance in toxin-expressing recombinant 
baculoviruses, however, give much lower virus yield per larvae than the wild-type. 
Larvae infected with improved baculoviruses die quicker and the production of 
occlusion bodies is therefore too low. Yields can decrease from 20% to even 95% (Sun 
et al. 2005; Burden et al., 2000) depending on the virus species and the recombinant 
virus. This will render in vivo production no longer economically feasible.  
Production in cell lines may not have this disadvantage and may be the solution for the 
production for genetically improved strains. The lower yield problem may be overcome by 
production in insect cell lines. Many authors (e.g. Wood and Hughes, 1996; Inceoglu et al., 
2001; Szewczyk et al., 2006) believe that in the near future these strains will be used as pest 
control products and that cell line cultures will become the appropriate production method.  
The production of insect cells has been studied extensively and an overview of this 
research is given by Vlak et al. (1996). Many authors have been optimistic about the potential 
of baculovirus production in insect cell lines by submerged fermentation. A variety of 
baculoviruses can be produced on selected Lepidoptera cell lines, and the formation of 
occlusion bodies (OBs) in high titres is possible (Goodman et al., 2001). Baculovirus 
production in cell cultures is well studied for pharmaceutical purposes. The baculovirus 
expression vector system is able to produce proteins efficiently in insect cells and this could 
be used to develop a method for large scale production of biologically active proteins for 
human therapeutic and vaccine use (Ikonomou et al., 2003). Much progress has been made in 
this area and some companies are able to produce insect cell lines in 600 litre fermentors. 
They claim that scaling up to 30,000 litres is feasible and that they have overcome the 
challenges with oxygen and nutrient supply and high shear forces, and can produce high titres 
of viruses on serum-free medium (Cox, 2004). Nevertheless this technology is complicated 
and demands highly skilled biotechnology experts. Moreover, there were in 2003 already over 
5000 patents on insect cells or baculovirus production. This complicates production and could 
make it expensive due to license fees (Cox, 2004). 
 Another problem is the instability of the recombinant virus in such a production 
process. Deletions in the virus genome often occur and after a number of passages through 
cell lines in the cascaded process of scaling up, production of occlusion bodies per cell 
decreases. The quality of the final yield may be completely unsuitable for the control of the 
pest because of the loss of biological activity caused by this “passage effect” (Pijlman et al., 
2001). Recently a patent (WO 2005/045014) has been published suggesting a method to 
overcome this problem. A two step method was developed by which the initial inoculum is 
produced in insects, and the second step is using this inoculum for the production in cell lines 
with only a limited amount of passages. The inventors claim to be able to produce infectious 
OBs of the Heliothis armigera SNPV in a 10,000 litre fermentor with about 2,5x1011 OBs/l 
and that this method can be used to develop a formulated product. The use of this technology 
is theoretically possible for agricultural use, but more research is needed on the stability of the 
recombinant baculoviruses. The prospects of the future use of recombinant baculoviruses are 
reviewed by Szewczyk et al. (2006). Technically, much progress has been made and many 
examples show that an accelerated speed of kill can be reached. The safety of these 
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recombinant viruses still needs to be investigated, although it is not believed to be a great 
concern. Registration and use of such strains, however, will be much more difficult or even 
impossible in some countries due to the political or societal attitude towards genetically 
modified organisms.  
Production costs are not considered by Szewczyk et al. (2006) in their future outlook, 
but from a commercial point of view this seems to be the major factor that will not allow for 
in vitro production of baculoviruses for the near future. The scale on which in vitro 
production is currently possible is too small, and it is too expensive due to high costs of 
specialized reactors, media and patent license fees. An economic analysis of baculovirus 
production in vitro has been made by Rhodes (1996). He concludes that it is economically 
feasible, but due to high investments, mainly in bioreactors, it can only be profitable if the 
market is over 1 million hectares. Such a large area would most likely apply to a low value 
crop where only low prices can be afforded for pesticides. This makes it a highly unlikely 
scenario and means that in vitro production is still far away as a commercial production 
system for viral insecticides. In two EU projects (AIR1-CT92-0386 and FAIR-CT96-3222, 
see www.biomatnet.org) the large scale production of baculoviruses in insect cell cultures was 
studied, but due to the instability of the virus through a number of passages and due to the fact 
that available cell lines do not produce high enough titres, commercial production is still not 
possible and not much progress has been made in this field for the last 10 years (J. Vlak, pers. 
comm.). Biocontrol companies keep an eye on the trends but are not actively engaged in 
research of in vitro technology. Andermatt Biocontrol AG does not expect in vitro production 
in the next ten years (M. Andermatt, pers. comm.). Despite the optimistic views of many 
researchers and the industry, including major agrochemical companies, over the last twenty 
years, in vitro production of baculoviruses for viral insecticides seems still far away. 
Commercial development of genetically engineered baculoviruses and production thereof in 
insect cell lines is even further away from successful commercial use (Summers, 2006). 
 
Mass production of entomopathogenic nematodes 
There are three methods by which EPNs can be commercially mass-produced: in vivo or in 
vitro either in solid or in liquid culture. Each method has its advantages and disadvantages 
relative to costs of production, investments, technical expertise, economy of scale and quality 
of nematodes. An overview of the three production methods is given by Gaugler and Han 
(2002) and by Shapiro-Ilan and Gaugler (2002). 
For research purposes EPNs are usually produced in larvae of the greater wax moth 
Galleria mellonella. Most nematode species reproduce well in this insect. In vivo production 
has been studied in many different nematode species on many different host insects: G. 
mellonella, Tenebrio molitor and many other lepidopteran and coleopteran larvae. 
Inconsistency of infection of hosts, variable yields, costs of the insects and labour make mass 
production in insects not attractive for an industrial production (Shapiro-Ilan and Gaugler, 
2002). Still, some companies used in vivo mass production in the past and the odd one may 
still use this method. It requires little capital investment, but it is labour-intensive. Scaling-up 
is difficult due to labour-intensive, space- and time-consuming production and harvesting 
methods (Gaugler and Han, 2002). Attempts have been made to improve in vivo production 
on G. mellonella by automation of the production and the harvesting technology (Gaugler et 
al., 2002). This system could be used in places where labour is less expensive and capital 
investment limited and for small business companies in niche markets. Also, in vivo 
production is suitable for production of nematode species or strains that cannot be produced in 
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vitro, or for research purposes where large numbers of nematodes are needed for field trials. 
For large volume production though, in vivo mass production is not suitable, mainly due to 
the lack of economy of scale.  
Production of nematodes without a host insect became possible after Bedding (1981, 
1984) developed a low cost solid-phase system using animal offal homogenate as a medium 
in a three-dimensional inert carrier in plastic bags. This was a major breakthrough and opened 
the door for economically commercial mass production.  A number of companies (Biotech 
Australia, De Groene Vlieg and Koppert Biological Systems, both from the Netherlands, and 
Bionema, Sweden) started to produce and sell EPNs for soil pests, mainly in greenhouses 
(Ehlers, 2001a). These nematodes were Steinernema feltiae and Heterorhabditis megidis 
against larvae of Sciaridae and larvae of the black vine weevil Otiorhynchus sulcatus. In vitro 
solid culture does not require high technology inputs and large investments, but is labour-
intensive and the system lacks economy of scale. Stability of the production process is also a 
problem, as well as the variable quality of the animal offal used as medium and, consequently, 
yields. Koppert stopped solid culture mass production of H. megidis and S. feltiae after about 
seven years of commercial production. The main reasons were the inconsistency of the 
cultures, production runs were long (2.5-3 weeks) and contaminations often occurred. Further, 
scaling up did not lead to substantially lower cost prices. Labour costs for preparation of the 
bags, inoculation and harvesting were the most limiting factors. Foam and waste removal 
were other relevant costs that did not profit from economy of scale effects. For similar 
reasons, Biotech Australia, later taken over by Ecogen-Australia, stopped their production 
(Gaugler and Han, 2002). For Biosys, cost prices of EPN products which could not compete 
with prices of chemical insecticides were the main incentive to study in vitro liquid culture 
technology (Georgis, 2002). Few companies use the solid culture method nowadays, although 
it still has its role. Andermatt Biocontrol AG produces H. megidis in this way since 
production of this species in liquid culture is not cost-effective due to low yields. BioLogic 
USA uses this method and it is also used in developing countries (Gwynn, 2006).  
In vitro production in liquid culture was developed step by step by several researchers 
(Ehlers, 2001b). It is a complex rearing process which demands medium development, 
understanding of the biology of the nematode and the bacterium, and bioreactor development, 
including understanding and control of the process parameters. Two excellent overviews of 
the history of these developments are given by Ehlers (2001b) and by Gaugler and Han 
(2002). Collaboration between public researchers and research within companies contributed 
largely to further developments. Biosys, a venture capital company founded in 1983 in the 
USA, had a large research group and they were able to produce three species of nematodes in 
large fermentors of 15,000 litres in 1989. Some years later, production even succeeded in 
80,000 litre fermentors. Biosys patented their liquid production technology (1989; WO 
04602). An overview of these developments within Biosys is given by Georgis (2002). A 
similar situation was seen with Ecogen where many researchers studied this process; a brief 
historical overview on this within Ecogen is given by Ehlers (2007). The large amount of 
capital spent on research by both venture capital companies contributed enormously to the 
progress in liquid culture production. EPNs could now be produced for lower prices and for 
bigger markets, although still there is no comparison with the prices of chemicals pesticides. 
Many authors have reported on the production technology in liquid culture of EPNs over time 
and research is still being continued. For more details the reader is referred to Ehlers (1996; 
2001b, 2007), Ehlers and Shapiro-Ilan (2005), Shapiro-Ilan and Gaugler (2002) and De la 
Torre (2003).  
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Gaugler and Han (2002: p. 293, table 14.1) compared the different production systems 
in terms of investment, direct costs, R&D efforts, waste and space requirements and 
concluded that there is a place for all three systems. But in order to expand the use of 
nematodes and to compete with chemical pesticides, the only way to produce them is in large 
bioreactors where overall production costs will be the lowest (Ehlers, 2001b; Ehlers and 
Shapiro-Ilan, 2005). This is shown by the production of EPNs by Becker Underwood, 
formerly Microbio Ltd, currently the largest producer in the world, which uses liquid culture 
systems up to a scale of 30,000 litre fermentors. Prices in the market have gone down in 
recent years, indicating that they have managed to lower their production costs. The other two 
companies currently producing in liquid culture are Enema and Koppert Biological Systems, 
ranking below Becker Underwood in scale of production. These three companies are the 
world’s leading EPN producers, indicating that liquid culture is successful and that the other 
productions systems are not economically feasible for large scale production. Apparently, 
economy of scale determines the method used, although for liquid culture production 
investments are quite high and great technological expertise is needed within the company. A 
number of EPN species can be produced in liquid culture such as Steinernema carpocapsae, 
S. feltiae, S. glaseri, S. kraussei, S. riobravis, S. scapterisci, and Heterorhabditus 
bacteriophora, H. indica and H. megidis, although with different yields/ml. Some of these 
species, like H. megidis, cannot be produced (yet) economically in liquid culture due to the 
variability in recovery and yields (Ehlers et al., 1998). H. marelatus was produced by solid 
state production by BioControl Systems Inc, USA, until 2007. Production of S. scarabaei is 
not yet possible; this could be a valuable species for control of white grubs (Koppenhöfer and 
Fuzy, 2003). There are still many challenges in the mass production of the various EPN 
species and research will need to continue in order to make production more reliable and 
economical (Ehlers and Shapiro-Ilan, 2005). More research is particularly needed on the 
process parameters (Ehlers, 2001b; De la Torre, 2003) that influence the bacteria as well as 
the nematodes in liquid cultures. Expertise from other disciplines like biotechnology, 
fermentation technology, and from large-scale production of bacteria could be helpful. 
Another significant factor is phase variation of the symbiotic bacteria, shifting from primary 
to secondary forms, which leads to unpredictable yields. More fundamental research is needed 
to be able to control phase variation in these bacteria (Ehlers, 2001b).  
Eventually, the goal is to achieve a predictable and stable production method. Process 
quality control and insight into biotic and abiotic variables is required. Further, we need to 
know more about the relationship between production and shelf-life, and between production 
and field performance. Producing high yields of low quality nematodes is futile when their 
shelf-life is short and their field performance variable. To improve acceptance of EPNs as 
alternative pest control solutions, we need to be able to ensure better efficacy. It is not 
understood why only a part of the applied nematodes are active or pathogenic in the field and 
others are inactive or show delayed activity (Grewal and Georgis, 1994). Costs could go down 
due to improved production. The continuous scale up of bioreactor volumes will further 
reduce production costs when accompanied by improved process stability and downstream 
processing (Ehlers, 2001b). If the numbers applied in the field could be decreased and good 
results could still be obtained this would create even more market opportunities for EPNs. 
Further research is needed on these intertwined aspects of production and field performance. 
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Other important aspects in mass production  
An efficient and low-cost medium for the production is an essential part of the process. Each 
organism needs a medium tailored to its demands and the growing conditions, and research is 
needed to develop such a medium. The choice of equipment is determinative. This depends on 
how an organism will be produced, a chief part of the cost factor of a product. Below the 
relevant considerations for these two aspects are given. Stability and quality of the inoculum 
used in the mass production over a certain period is an absolute necessity in order to have 
good production and an effective final product. Relevant considerations are briefly presented. 
Quality control related to the production process will be discussed in chapter 4. Production 
process parameters need to be established and routinely checked. Depending on the system 
and the pathogen, a production run may take a few days up to more than two weeks, as in the 
case of nematode production. Any fault, deviation or contamination that may lead to an 
unsuccessful yield or to discarding of the batch should be detected as early as possible. This 
will save time and money. Knowing the system in detail is of paramount importance. In the 
design of a bioreactor and a production process, possibilities for parameter control and sample 
taking needs to built in. A production manual which includes parameter behaviour and checks 
needs to be established and a logbook be kept reporting all the events. In the end, gained 
experience and knowledge on the production process and the predictability of the yield, 
quantitatively and qualitatively, are extremely valuable. Analysing failures will give useful 
information and could improve the understanding of the system and help preventing future 
failures. A stable production process is indispensible. 
 
Medium development and optimization 
The production efficiency of an organism greatly depends on the nutrients that are available to 
it and whether they can be utilized by that organism. When production takes place in in vivo 
systems, the producer can only have a limited influence on the nutritional value of the hosts. 
Insects used as hosts should be of good quality, and by means of medium composition this 
can be influenced. Relationships between host propagation and pathogen production are both 
direct and indirect and optimization is more an art than science. This is seen in the production 
of baculoviruses in insect larvae. Medium composition is optimized in order to get large and 
healthy caterpillars, but the relationship between the medium and the virus production is 
hardly studied and largely unknown. 
In in vitro production systems the relationship is more direct, and can be studied in 
detail. In fungi and bacteria this has been studied by many researchers. Methods are available, 
for instance, to find the optimal C : N ratio. The necessity of other minor nutrients can also be 
studied experimentally. In case of defined artificial media for LSF of fungi, bacteria and 
EPNs, medium optimization is possible. Still, this is a complex matter since there are 
generally two phases in the production, a vegetative phase and a generative phase which 
should lead to the production of spores or other propagules. In EPN production two organisms 
are produced more or less simultaneously in the same medium that makes optimization 
complex. The amount of propagules produced per millilitre as well as their quality is 
important, and whether they are suitable for surviving the downstream process and the 
formulation process. Further, do they have a long shelf-life and a good virulence in the field? 
Media components and production conditions are known to influence all of those factors.  
An overview of effects that can be obtained by manipulation of the medium for various 
fungi is given by Magan (2001). Fungal spore survival under harsh conditions can be 
improved by adding certain sugars in the medium. For instance, trehalose and glycerol 
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improve germination in B. bassiana and M. anisopliae at low water activities (aw  value = 
proportion of unbound water)(Magan, 2001). Additives to standard media could give higher 
yields of blastospores in M. anisopliae, as demonstrated by Kleespies and Zimmermann 
(1998), but at the same time, spore resistance to high temperatures and low humidity 
decreased, as did virulence. Carbon-nitrogen ratios may influence yield, germination rate and 
survival rate in I. fumosorosea (Jackson et al., 1997) and virulence in M. anisopliae (Shah et 
al., 2005). Nutrient rich media may cause attenuation in many entomopathogenic fungi (Butt 
et al., 2006). Improvement of one trait does not necessarily mean improvement of another 
trait and the effects of production changes should be studied on all relevant traits with great 
care. In the production of Bt’s, medium composition should support both the vegetative 
growth phase and the production of spores. Medium optimization has to be carried out for 
each strain. The salient criterion for an efficient production process is the amount of 
endotoxins that are produced. Exotoxins may be produced depending on the medium and 
culture conditions, but exotoxins are a serious concern to regulatory authorities. Medium and 
production parameters need to be standardized in order to prevent production of these 
metabolic toxins (Glare and O’Callaghan, 2000). 
For solid state fermentation of fungi, an inert carrier or an organic solid substrate, often 
a cereal product, is used. The latter is also defined as solid substrate fermentation. When an 
inert carrier is used, conditions come close to LSF production. Media components can be 
added according to the demands of the fungus. Various inert carriers can be used such as clay, 
perlite, glass beads, or synthetic material like polyurethane foam. When an organic carrier, 
such as cereal grains or bran, rice, hemp, wood chips, or bagasse is used, it fulfils two roles at 
the same time, both as a nutrient source and simultaneously as a carrier. The carrier function 
is to create three-dimensional structure that allows gas and heat transfer and it is important for 
the needs of a fungus related to spore formation. For instance, in Aschersonia spores are 
formed in pycnidia on the surface of the carrier and not inside the material. Creating a large 
surface with the help of the structure of the carrier improves the production efficiency. In 
Lecanicillium sporulation takes place wherever mycelium is able to grow, but it needs space 
since this fungus makes conidiophores. An open structure of the carrier improves the 
efficiency. Sporulation does not take place inside a cereal grain, but on the outer surface only. 
Fragmented cereal or rice kernels or bran are better in this case. In some uses of fungi, spore 
production takes place in the field and production is aimed at high production of fungal mass, 
in this case whole cereal kernels are used. An example is the use of Beauveria brongniartii, 
where mycelium overgrown barley kernels are applied into the soil (Keller, 2000). Examples 
of products that have been developed on this base are Melocont-Pilzgerste from Kwizda 
Agro, Austria, and Beaupro from Andermatt BioControl. 
Medium optimization for production of EPNs is complex since a bacterium and a 
nematode are produced on the same medium, subsequently. In LSF, the medium is 
predominantly developed for the bacterium, while the bacterium reverses the medium for the 
nematode. The medium composition is important, but according to Ehlers (2001b) it should 
not be overestimated. Process stability and mean yields are more meaningful parameters. 
Medium optimization and growth kinetics of the organism in a particular medium/ 
carrier matrix should be evaluated in the production of pathogens because they determine 
production efficiency in terms of production time, yield of propagules, quality of propagules 
and costs. Even shelf-life and field efficacy can be influenced by it. The methods that can be 
used in the downstream process, and the formulation type depend on propagules’ properties to 
some extent. Accordingly, it is necessary to profoundly study this aspect of the mass 
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production: primarily, considering production efficiency, and secondarily, considering 
medium costs. Advantages and disadvantages of media composition in mass-production 
systems are given in table 3.3. PhD studies are devoted to this subject of optimization, but in 
the biocontrol industry this is too expensive and takes too long. During the development of a 
MPCP, collaboration with a university would give the opportunity to study the fundamental 
requirements of the production of a certain pathogen. Eventually, medium composition will 
be a compromise between production efficiency and medium costs. 
 
 
Table 3.3.   Advantages and disadvantages of medium type and composition in mass- 
       production systems (SSF = solid state fermentation;  LSF = liquid state  
       fermentation) 
 
Production system        Advantage        Disadvantage 
In vivo • On natural host or 
(closely) related 
host 
• No attenuation 
• Limited influence on composition 
• Non-sterile, contamination risk 
• Downstream complicated 
• Quality and yields variable  
In vitro: SSF 
- Inert carrier 
 
 
- Cereal (like) carrier
 
• Sterile 
• Defined artificial 
medium  
• Some influence on 
medium 
• Semi-sterile to 
sterile 
 
• Downstream easy - complicated 
• Attenuation possible  
 
• Variable quality 
• Downstream complicated 
In vitro: LSF  • Sterile  
• Defined artificial 
medium  
• Downstream easy  
• Can be expensive  
• Risk for attenuation  
• Unnatural  
 
 
Mass-production equipment  
The fundamental question to be asked at the start of product development is which type of 
bioreactor should be used for the mass production of a pathogen. Many factors play a role and 
it depends on the possibilities of production of the organisms (table 3.2), but decisive is the 
expected scale of the production for the coming years in relation to investment costs. A well-
performed marketing study will give estimates of the expected market size, but nothing more 
than an estimate. Looking ahead for more than five years is difficult and investments should 
not be based on long term projections. It is wiser to choose a system that can be extended or 
scaled up once the market demand increases. It should also be kept in mind that registration 
requires detailed information on production and product and that, when scaling up, no major 
changes occur that would need additional registration information to be submitted and 
evaluated.  
It is beyond the scope of this thesis to elaborate in detail on the various types of 
bioreactors and to consider which one to choose for which organism. It is a case by case study 
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depending on the organism, the required propagule for the final product and the scale of 
production. For solid state fermentation, non-sterile or sterile reactors could be used, non-
stirred or stirred or rotating. For LSF sterile reactors are needed. Solid state fermentation is 
used for many purposes, such as for production of enzymes, metabolites and for the 
production of (Asian) foods like soy and tofu. To some extent it is also used for the 
production of entomopathogenic fungi. Many different types of bioreactors have been 
designed. An overview of techniques and bioreactors is given by Roussos et al. (1997). The 
literature on solid state fermentation is vast, including on production of entomopathogenic 
fungi and on nematodes. A careful study of this literature is useful before a new production 
system is built. Scale and costs and the biology of the pathogen are decisive. It is essential to 
study the organism in detail in order to know its nutritional and environmental requirements 
and to adapt the production system to meet these requirements. Process control and 
management of the all parameters are vital. There is no standard recipe for the production 
method of an entomopathogenic fungus, bacterium or nematode. Each case needs its own 
approach, although much can be learned from other cases. Fine-tuning is always needed and 
must be continued over the years.  
What companies use is also strongly influenced by their expertise and available 
equipment. Experience tells us that, particularly in the case of solid state fermentation 
reactors, many companies develop their own equipment, focusing on their first and main 
microbial organism. Koppert built their own solid state fermentation reactors, with a tray 
system, for production of A. aleyrodis and Lecanicillium muscarium. The former one needs 
light to sporulate which made it necessary to build “windows” in the reactor, making it more 
vulnerable to contamination (see figure 3.1). Other companies have built and even patented 
their equipment and technology, like Mycotech (now part of Laverlam) (1995: WO 95/10598) 
and Prophyta (2004: EP 1502946). Mycotech developed a packed bed reactor for the 
production of B. bassiana (1995: WO 95/10598); Prophyta produces a biofungicide based on 
conidiospores of Coniothyrium minitans (Kiewnick, 2001). NPP (now part of Arysta 
LifeSciences Europe) used a packed bed, non-sterile reactor, designed and patented (WO 
94/18306) by INRA Dijon (Durand et al., 1997), for the production of B. beauveria for corn 
borer control. Another reason for these in-house developed bioreactors is that solid state 
fermentation reactors for pathogen production are hardly available on the market, in contrast 
to various types of LSF reactors which are standard in the biotechnical and pharmaceutical 
industry. Sterility, removal of metabolic heat, maintaining water content, and transfer of gases 
must all be carefully managed in the production of pathogens in SSF reactors. This is similar 
for LSF reactors, and additional critical aspects are the shear forces. When developing or 
buying equipment, care should be taken that these parameters can be controlled. 
Recovery of the propagules from the mass production system is an intrinsic part of the 
process. In most cases propagules need to be separated form the medium and this process 
should not negatively influence the quality of the spores, dauer juveniles, etc. The percentage 
recovery should, of course, be as great as possible. Harvesting often means a sudden change 
in conditions and care should be taken to avoid potential damage to propagules by osmotic 
shock, low or high temperatures, desiccation, shear forces or high pressure. Harvesting 
methods depend on the production system whether from submerged or solid fermentation. 
Downstream equipment is usually not a standard type of equipment available to the biocontrol 
industry and needs to be developed in-house or bought from other industries. Typical 
apparatuses are centrifuges, separators, sieving and milling equipment, and machinery to dry 
spores or medium/carrier with spores or mycelium, such as a spray-dryer, a fluidized-bed 
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dryer, a freeze-dryer or a simpler forced-air blower. This equipment is needed to concentrate 
progagules from the production phase, and in the formulation process. Biocontrol companies 
have to investigate which equipment is suitable for their processes and develop the 
appropriate protocols. This is a case by case study. Advantages and disadvantages of various 
production systems is given in table 3.4. Mass production is a multi-disciplinary process. On 
an industry scale both advanced biological and technical knowledge and skills are necessary. 
 
 
Figure 3.1.   Mass-production equipment (left: 1000 litre fermentor for liquid state  
 fermentation; right: 1.3 m3 bioreactor for solid state fermentation) 
 
                
  
 
Inoculum stability 
The first aspect in producing a micro-organism is storing the strain in a way that it keeps its 
relevant characteristics, mainly its virulence. It is well known that repeated sub-culturing 
could lead to a reduced virulence or loss of other properties, such as reduced sporulation (Butt 
et al., 2006) and a decrease in production of cuticle-degrading enzymes (Nahar et al., 2008). 
Further there is a risk of contamination. Every production batch should lead to yielding 
propagules of the same quality and obviously the inoculum for the production is the basis for 
this. Loss of virulence can often be restored by passing it over the target host again, but in a 
mass-production system this is cumbersome and costly. The solution is to make a master 
stock from which many sub-cultures are made, also called working seed stock that can be 
stored for a long period at the appropriate conditions. This is often at low temperatures, deep-
frozen or by cryo-preservation. A strain should also be properly identified and deposited in a 
public collection culture as a back up. This is also a registration requirement. Every 
production batch can now be started using one of the stored samples. Depending on the 
organism, a new master stock needs to be made every two to three years. A newly made 
master stock needs to be rigorously checked on identity, on virulence via a bio-assay and on 
microbial contaminants. Re-identification of the culture by a specialized laboratory further 
ensures the identity and that the quality of the stock material is still maintained. This makes 
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the whole procedure of keeping stable inoculum relatively easy and cheap. Further, the 
number of culturing steps in producing inoculum for scaling up to the final mass production 
should be kept as low as possible to minimize the risk of any loss of characteristics. Any new 
batch needs to start with inoculum from the original master stock. 
 
 
BOX 3.1   Production of Lecanicillium muscarium in SSF and LSF 
 
In 1989 Koppert started to mass-produce Verticillium lecanii strain Ve6 (renamed as Lecanicillium 
muscarium) for Mycotal, in SSF home-built bioreactors. In the past, Tate & Lyle produced it in LSF 
as they did with the V. lecanii strain Ve2 (renamed as L. longisporum) for Vertalec (Quinlan, 1988). 
Tate & Lyle’s biopesticide department became independent as Microbial Resources Ltd in 1984. In 
1986 all registrations and technical know-how of Microbial Resources were acquired by Novo 
Industria AS of Denmark (S. Lisansky, pers. comm.). In 1988 Koppert bought the IP rights of these 
products and started to produce them. Koppert choose for SSF in order to improve the products and 
their efficacy. Tate & Lyle produced Mycotal in LSF, the main reason for this was the scale-up 
possibility which was considered too difficult with SSF technology. LSF was a “second choice” 
based on spore quality: conidiospores have a better shelf-life and field persistence; on the other hand 
economy of scale is much better with LSF (S. Lisansky, pers. comm.). Koppert wanted to produce 
conidiospores in order to have a better shelf-life and better efficacy and persistence in the field. At the 
same time, there was SSF production equipment available as well as experience with the production 
of Aschersonia aleyrodis. The bioreactors were designed with a tray-system. The fermentors had a 
surface of 28 m2 (52 trays of x 0.55 m2) and each held 100 kg dry medium. Koppert built 12 
fermentors in 1990 and had drying and sieving-milling equipment built. The fermentors were 
equipped with an inoculation system of ultrasonic nozzles on each tray, and with internal cooling 
systems. Pre-conditioned air can be lead through the reactors in order to keep the RH high and for 
supply of oxygen and transfer of CO2 and metabolic heat. Everything was built to keep the system 
sterile. A large autoclave was designed and built in which one reactor, equipped with wheels, could 
be sterilized, including the medium. Investment for the reactors was around €120,000 in 1990. A 
production run (including medium preparation, autoclaving and downstream processing) takes 10 
days and mean yields are about 8.10E14 spores/reactor. Annual full capacity is about 25 runs with 10 
reactors per run, giving 2.10E17 spores (approx. 20,000 kg Mycotal (10E13 spores/kg)). 
In 2005 our group started to investigate again the LSF technology for Mycotal. The production of 
blastospores reaches 2.10E10 spores/ml in a 120 l fermentor, and scaling up to 1000 l fermentors 
gave a similar yield per ml. A complete production run takes 7 days. To have the same capacity on an 
annual basis, a LSF fermentor capacity of 1000 l only needs 10 runs (2.10E16 spores/fermentor). This 
would only occupy a quarter of its annual capacity. A new set of SSF bioreactors, including autoclave 
and downstream equipment, would cost around €750,000 in 2007, a 1000 l fermentor around 
€300,000, including all equipment. This clearly shows the economy of scale, the difference is about a 
factor 10: 2.5 times the price, and 4 times the capacity. If variable costs are considered, SSF demands 
about 10 times more labour to produce 20,000 kg Mycotal. This example shows that the costs for a 
yearly supply of Mycotal for SSF are much higher than for LSF when investment and running costs 
are considered (see table 3.5). Thus, LSF has a considerable advantage over SSF in terms of economy 
of scale. The decision on how to produce a pathogen, however, is also influenced by quality of spores 
(see Feng et al., 2002), shelf-life, efficacy, production of metabolites, contaminants, and registration 
issues. A final decision on whether to produce by SSF or LSF can only be made based on all aspects. 
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Table 3.4.   Advantages and disadvantages of various mass-production methods (SSF = solid  
       state fermentation;  LSF = liquid state fermentation) 
 
Method        Advantage        Disadvantage 
In vivo • Only economic method for 
baculovirus production 
• Exceptionally used for bacteria (B. 
popilliae) 
• Low start-up costs 
• No high technical expertise 
required 
• Low developmental costs 
• Easy to scale up when labour costs 
are low  
• Labour-intensive 
• High risk for contamination 
• No effect of economy of scale  
• Host and baculovirus 
production must be kept 
separate 
• Little influence on “medium” 
In vitro 
SSF:  
bioreactors 
• Can be used for many fungi and 
bacteria 
• Medium to high start-up costs 
• Technical expertise required 
• Sterile technology 
• Control of parameters possible  
• Start-up costs medium to high 
• Labour requirements medium 
• Effect of economy of scale 
limited 
• Production facility of medium 
technology required  
• Limited influence on medium 
composition 
• Limited homogeneity 
In vitro 
SSF: bags 
• For fungi and EPNs 
• Low start-up costs  
• Low technical expertise required  
• Cheap to scale up to mid-range 
level 
• Low quality facility will suffice 
• Labour-intensive 
• Risk for contamination, 
particularly in drying steps 
• Labour-intensive downstream 
methods 
• No effect of economy of scale 
In vitro 
LSF  
• Versatile; fermentors can be used 
for fungi, bacteria and EPNs 
(viruses in cell cultures)  
• Sterile technology 
• Homogeneous process 
• Large effect of economy of scale  
• Labour requirement low  
• Good ability to control conditions  
• Medium optimization possible to 
high degree 
• High start-up costs 
• Great technical expertise 
required 
• High quality equipment and 
facility needed 
• Fungi may not produce conidia  
• Large scientific input required, 
particularly in virus / cell line 
production 
         (modified after Lisansky, 1993) 
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Table 3.5.   Parameters of the production of L. muscarium spores in SSF and LSF  
       (SSF = solid state fermentation;  LSF = liquid state fermentation) 
 
 
     Production parameters SSF LSF 
Run time 10 days 7 days 
Runs per year 25 x 10 = 250 40 
Total spore yield 8 x 10E14 / unit 2 x 10E16 / 1000 L 
Investment (reactor, incl. 
downstream equipment)  
€750,000 / set of 10 units €300,000 / 1000 L 
Spores per ml or gr 1 x 10E10 sp/gr 2 x 10E10 sp/ml 
Medium costs €0.06 / gr €0.16 / ml 
Fermentor labour  4 hrs / unit 2 hrs / 1000L 
Downstream labour  4 hrs / unit 8 hrs / 1000 L 
Annual capacity  250 x 8.10E14 =  
2 x 10E17 conidiospores 
40 x 2.10E16= 
8 x 10E17 blastospores 
 
 
Product development 
 
Formulation  
As a general rule, pesticides are formulated products containing an active ingredient or active 
ingredients and co-formulants or additives, components with specialized characteristics that 
are needed to make and keep the pesticide efficient in many aspects. Biopesticides are no 
exception to this rule and formulation may even be more consequential as they contain living 
organisms, and as a result, small particles, in contrast to chemical pesticides which contain 
molecules. There are many different types of formulations depending on the active 
ingredient(s), the production process, the target(s) and the application method. This is true for 
biopesticides as well. In the chemical industry, formulation technology has a long history and 
many different types of formulations have been developed. Most information is, however, 
proprietary and confidential. The knowledge of formulating chemical pesticides is not 
available to biocontrol workers, but neither is it very appropriate. Of course, there is some 
similarity in requirements for both types of products, and in biocontrol we could learn from 
the chemists, but mostly, formulation is a new research area for biopesticides and there are no 
“off the shelf” solutions available. New technologies have to be developed for each of the 
different pathogens. First and foremost we need to ask the question “why do we need 
formulation?” The four main objectives in formulating a micro-organism, virus or nematode 
are:  
1) to stabilize the propagules that are collected from the production process by means of 
the downstream process so that they ultimately can be packaged, stored and shipped to 
the end-user; 
2) to make a user-friendly product that can be applied economically by the end-user and 
can be effectively delivered to the target; 
3) to protect the propagule, once applied, against harmful environmental influences, 
thereby maintaining and even improving its persistence at the target site; 
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4) to minimize the risks of exposure to the applicator during loading, mixing and applying 
the product as well as to the worker in the crop, and to the consumer in the case of food 
crops.  
The solutions for these four objectives are not always compatible and the final formulation is 
a compromise between all these demands. The different types of pathogens vary in their 
formulation demands concerning storage and application aspects; some may be the same for 
some pathogens, while others may be very different. Formulation is specific to a certain 
pathogen and determined by the features of that pathogen and its specific use: it demands a 
case by case approach. The mode of action is the most essential feature that determines the 
formulation requirements. Further, the type of the propagules, and whether they are used for a 
foliar or a soil application, will influence formulation choices. Formulations for foliar 
applications demand different considerations than formulations for soil applications. 
Formulations for the latter application can be simpler. In table 3.6 the most significant 
formulation considerations are given per type of pathogen.  
 
  
Table 3.6.   Formulation considerations per type of pathogen 
 
1.     Stability  Bacteria Fungi Baculo- 
viruses 
EPN 
• Maintain virulence  
• Standardization of potency or content  
• Maintain physical stability  
• Maintain chemical stability  
• Minimize number and growth of contaminants
• Packaging 
++ 
+++ 
+ 
-- 
++ 
++ 
++++ 
++ 
++ 
-- 
--- 
+++ 
++ 
++++ 
++ 
+ 
++ 
++ 
++++ 
+ 
+++ 
+++ 
-- 
++++ 
2.    Efficacy and user-friendliness     
• Spray characteristics 
• Application method and equipment  
• Efficient targeting 
• Convenience of use 
• Enhancement of propagule activity  
+++ 
++ 
+++ 
+ 
++ 
++++ 
++++ 
++++ 
+++ 
++++ 
+++ 
++ 
+++ 
+ 
+++ 
--- 
++ 
- 
++ 
-- 
3.    Persistence       
• Protection  
• Stimulation of growth of propagules  
+++ 
--- 
++++ 
+++ 
++++ 
--- 
-- 
--- 
4.    Registration and safety     
• Minimize exposure 
• Minimize microbial contaminants 
++++ 
+++ 
++++ 
+++ 
+ 
+++ 
--- 
--- 
+  to  +++++:  increasing amount of attention needed during formulation;    - : not relevant 
 
 
First function of formulation: stability 
The first function of the formulation is to keep the propagules in a state of low metabolic 
activity or non-metabolic activity and, at the same time, maintain the infective propagules 
viable and virulent for as long as possible during storage in the final product package: this is 
called shelf-life. The protection of propagules could already be necessary during the 
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downstream process, especially when drying is a part of that process. Thus formulation 
considerations can start even before the infective propagules have been collected, and before 
formulants are mixed with them. Storability features too can be influenced during production 
by the composition of the medium and culture conditions. This has been shown for fungi such 
as M. anisopliae, B. bassiana and P. farinosus (Hallsworth and Magan, 1994) and T. 
harzianum (Agosin et al., 1997). Virulence can be influenced by the nutrients in the 
production as was demonstrated in M. anisopliae by Shah et al. (2005) and by repeated sub-
culturing in vitro (Nahar et al., 2008). Degeneration of entomogenous fungi on nutrient rich 
media has been described for many species (Butt et al., 2006) and needs to be monitored in 
commercial productions. The lipid content in dauer juveniles (DJs) can be influenced by the 
production medium and eventually this may have an effect on shelf-life and infectivity (Patel 
et al., 1997). These examples demonstrate that formulation is not merely adding components 
to the propagules once they have been collected from the production. Ultimately, formulation 
considerations start from the beginning of the production process and formulation features can 
be influenced by medium components and culture conditions.  
Formulation can also be part of the downstream process. Protectants and other 
compounds may be added before or during drying. This depends on the method used and on 
the type of formulation. For instance, when granules are made by spray-drying, protectants 
may be added in the drying process, as well as formulants with other functions that play a role 
in spraying characteristics or in enhancing persistence. Standardization must be realized in 
formulation. Each product batch must contain similar numbers of viable propagules within a 
narrow range. This often requires counting, germination tests and/or bio-assays whose results 
are used to set the standard content or potency of the active ingredient. A difficult issue in 
setting the standard is whether over-formulation can be done to compensate for loss of viable 
propagules over time. An example: if a shelf-life of one year is aimed for, but survival of 
propagules is only 80%, over-formulation can be done to 125% so that after one year 100% is 
still viable, which is in absolute numbers the required amount. Registration generally 
demands stability over the shelf-life period within a narrow range, but the possibility of over-
formulation is not well laid down in the regulations. Death of 20% of the propagules is likely 
to be accompanied by a quality decrease in the still viable ones. This is an aspect that has 
hardly been studied in pathogens. Apart from the quality concerns, costs also play a role. 
Generally, 10% over-formulation seems acceptable, but there is no information available on 
what companies actually do in this respect.  
The formulation needs to be physically stable, i.e. no clump-forming in wettable 
powders or irreversible sedimentation of propagules in suspensions should occur, nor 
separation of carriers in the case of emulsions. Besides protecting the active ingredients from 
degradation, formulation also serves to inhibit growth of possible contaminants. Other 
unwanted micro-organisms may be present in low numbers and need to be killed or limited in 
their presence and growth as much as possible. Not only could they harm the active ingredient 
during storage, they could interfere with the biological activity once applied, or pose a risk to 
the applicator and consumer. Also registration requirements reply to product stability with 
regard to physical-chemical stability as well as to biological stability. 
 
Second function of formulation: efficacy and user-friendliness 
The second function of the formulation is related to its use in the field, where the formulation 
should enhance the desired effect on the target pest. Pests can acquire pathogens by direct 
contact and by secondary pick-up from the spray deposit via contact or per oral. Another 
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possible route is pick-up after a primary growth cycle on the leaf or secondary growth after 
cycling through a dead insect. The latter is not influenced by formulation. A primary 
consideration is the spray characteristics in case of a foliar application that is aimed at an 
optimal coverage of the target pest and/or the target’s host plant. Next, good contact with the 
target insect should be aimed for, as well as enhancement of the activity of the organism such 
as germination and growth on the insect and on the foliage. Stimulants could also be added to 
the formulation to enhance oral uptake or to modify the insect’s behaviour through which 
more propagules may be picked up. In the case of a soil application, an even distribution 
matters more than spray characteristics. Spray characteristics are a well-studied area in 
chemical products, but this is an almost neglected area in biopesticides. Droplet size spectrum 
and droplet behaviour during spraying (evaporation and drift) and when droplets hit the plant 
surface (bouncing off, spreading and drying) can be manipulated by the formulation and the 
spraying equipment. Propagules should be easily dissolvable and well dispersed in the spray 
solution and be evenly distributed over the droplets, and to the plants and targets. These spray 
characteristics can be influenced by additives such as surfactants, spreaders, stickers, 
humectants, etc. The list of compounds for these functions is huge. Finding the right additives 
requires an extensive range of investigations on the target and target crops. Few papers refer 
to these parameters as part of a biopesticide formulation, but they are a relevant part of 
successful targeting the pest. Bateman and Alves (2000, figure 1) illustrated where spray 
application effects can be manipulated by the formulation of biopesticides. Co-formulants can 
influence propagule distribution in the spray droplet spectrum, evaporation of the spray 
solution during atomization, and effects on the deposit on the leaves. The latter can be 
retention, spreading, drying, survival and availability of active ingredients for the target 
insect. Particularly persistence, adherence, protection, propagule growth and feeding 
stimulants are important for mycoinsecticides (see figure 3.2). Evans (1999a) reviewed the 
principles of dose acquisition and transfer of pathogens. He emphasized the connection 
between the biology of the microbial agent and the biology of the target, as well as the 
delivery system. Bateman and Alves (2000) studied the effects of equipment type in relation 
to the numbers of spores per droplet and the impact on delivery to the target. Their work 
underlines the role of these factors for biopesticides. A formulation should be appropriate for 
a variety of crops and field conditions.  
Other aspects are convenience of use and compatibility with the end-users’ equipment 
and practices. The formulation should be an acceptable quantity with regard to logistics, 
storage, handling, and to measuring the desired quantity for an application. An unmanageable 
quantity that needs cold storage is a big disadvantage that will cause failure of the product in 
the market. An example from my own experience in the mid 1980’s is R350, a fungal 
nematicide based on Arthrobotrys irregularis: it needed cold storage and the rate of 
application was 1000 kg/ha. Further, the formulation consisted of mycelium-overgrown cereal 
kernels that formed one big mass that needed to be separated manually into small pieces that 
could be spread over the soil. Besides efficacy problems and costs, the difficulties with the 
formulation and with logistics caused this product to fail in the early days of biopesticides. 
 
Third function of formulation: protection and persistence  
The third function of formulation is to protect the propagule from harmful environmental 
effects and increase its persistence on the target site. Protection is needed against desiccation, 
high temperatures, de-activation by sunlight, and washing off by irrigation or rain, 
particularly when used outside the greenhouse. Good persistence increases the chance of 
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secondary pick-up and pick-up after a growth cycle of the pathogen on the leaf. The addition 
of growth stimulants to the formulation may give rise to the formation of new propagules 
which increase the chance of secondary pick-up. This is particularly useful with fungi as 
illustrated by the following example. Additives in the formulation of Mycotal allow the 
fungus L. muscarium to grow on the leaf surface and form new conidia. These conidia are 
formed in clusters and covered with a sticky slime that prevents desiccation and improves 
adherence to insects. This slime dissolves in water and as a result is not present anymore on 
spores that have been sprayed onto the plant. Newly formed spore clusters are produced in 
slime heads and enhance secondary pick-up by passing insects such as thrips (Hall, 1980).  
 
 
Figure 3.2.   Spray application, deposit and pick-up processes of the active ingredient. The 
shaded box represents effects which can be manipulated by the formulation and 
which are particularly important for mycoinsecticides. The dark box represents 
effects only relevant in mycoinsecticides (modified after Bateman and Alves, 
2000) 
 
 
 
 
Fourth function of formulation: registration and safety 
The fourth function of formulation relates to registration demands and concerns possible 
harmful effects of the formulation on, especially, the applicator. In the toxicological risk 
assessment of the product, exposure to the micro-organisms is a concern during loading, 
mixing and spraying. Especially dusty formulations may pose a hazard to the person 
measuring the needed amount and during pouring this into the spray liquid. Therefore, the 
trend in agrochemicals is to change from powder formulations to liquids and granules. Most  
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biopesticides are formulated as a powder, and small particles as spores can easily can be 
inhaled and thus pose a possible risk. This may cause sensitization by or allergenicity to the 
micro-organism. Liquid formulations are difficult to make with micro-organisms, because 
water activity has to be low to keep the propagules inactive and to prevent contaminants from 
developing. However, currently an increasing number of oil suspension formulations is being 
developed, which minimize inhalation risks during loading and mixing. The aspect of 
microbial impurities is also a concern in registration and needs attention during formulation. 
 
Formulation in academic research 
Many authors have recognized the importance of a good formulation (Couch and Ignoffo, 
1981; Rhodes, 1990; Guillon, 1993; Hofstein and Fridlender, 1994; Jones et al., 1997; Jones 
and Burges, 1997; Couch, 2000; Boyetchko et al., 1999; Brar et al., 2006; Jackson et al., 
2010) and many aspects of formulation have been studied by scientists and by the biocontrol 
industry. A comprehensive overview of formulation of microbial pesticides is given by 
Burges (1998). This book covers formulation of beneficial micro-organisms and EPNs, 
including usages as insecticides, herbicides, fungicides and seed treatments. It discusses the 
principles of formulation and specific features per group of micro-organisms. This review is 
very helpful for any product developer. Jones and Burges (1998) recognized four basic 
functions of formulations; Couch (2000) listed six criteria for Bt’s that need to be satisfied for 
commercial formulations. All criteria are similar to the first three described above. These 
authors, however, do not mention the aspects related to registration, but these are surely 
relevant and need to be considered seriously. For an overview of the different types of 
formulations, such as dry products (wettable powder, granules, etc) and liquid suspensions 
(water or oil-based, emulsions, etc.), I refer to Jones and Burges (1998). They also included 
the advantages and disadvantages of equipment that can be used for various specific 
application methods for each group of entomopathogens. A more recent overview is given by 
Lisansky (CPL, 2006a) with a specific focus on commercial formulations. He also provided a 
number of tables with the advantages and disadvantages of wettable powders, flowable 
concentrates, granules and high-potency formulations. 
In academic research, formulation has received much attention. Often, investigations 
have focused on a specific aspect of the formulation. Rarely are all aspects covered. In Burges 
(1998) the state of the art for the mid 1990’s is presented for the insect pathogens covered in 
this thesis. I will review developments since then per type of micro-organism and relevant to 
bio-insecticides for greenhouse applications, particularly for foliar applications. The details of 
formulated commercial products, however, are rarely published or patented and in most cases 
details are kept as trade secrets. I will also discuss possibilities to improve efficacy of 
biopesticides by using adjuvants, by other enhancing agents, and new developments in 
formulation.  
  
Formulation of entomopathogenic bacteria 
Standardization, spray characteristics and protection from environmental factors must be 
considered in formulations of bacteria. The formulation of bacteria seems to be the least 
demanding when the four pathogen types are compared, at least when it concerns bacterial 
spores and proteineous substances, as in Bacillus species. Spores formed by these bacteria are 
long-lived and resistant to heat and desiccation. There is a big difference between these 
dormant stages versus metabolically active stages. For bacterial cells as in the case of Serratia 
spp. and Pseudomonas spp., formulation is much more complicated. As only Bt’s are used in 
Chapter 3 
___________________________________________________________________________ 
 72 
greenhouses, these will be considered here. The good stability and easy handling of Bt 
formulations surely are part of their success. Shelf-life is generally 2 years at room 
temperature. Points of attention here are the concentration of the spores, the drying 
technology, and the determination of the potency standard (Skovmand et al., 2000). Most 
formulations are wettable powders or water dispersible granules, some are oil-based or water- 
based or mixtures thereof; detailed information is given by Burges and Jones (1998a) and 
Couch (2000). Every conceivable type of formulation has been developed with Bt. Brar et al. 
(2006) review recent advances in formulations of Bt’s. They summarize screening factors for 
which additives need to be chosen and they give a list of different types of additives and their 
function that are used in microbial formulations. Formulation requirements and formulation 
types are different depending on the usage of a Bt product, in agriculture, forestry or in 
aquatic habitats. 
Advances in formulation technology like encapsulation and controlled release 
formulations offer possibilities to improve efficacy. Brar et al. (2006) also review possibilities 
to better protect Bt’s from harmful factors such as sunlight, rainfall, dew, extremes in 
temperature, pH and foliage effects. They recommend studying the whole process from 
fermentation to formulation since many factors are interconnected. The large Bt producing 
companies have developed successful and convenient formulations, but details of commercial 
formulations are proprietary. Improvements are always possible and new formulations appear 
on the market. In most Bt products the potency has been doubled in recent years in order to 
make the products more cost-effective and to comply with the trend to reduce spray volumes. 
To increase the effect of Bt’s, feeding stimulants have been studied, but satisfactory 
improvements have not been found and feeding stimulants are generally not included in 
formulations nor added as tank-mixes (D. Avé, pers. comm.).  
 
Formulation of entomopathogenic fungi  
Formulation of fungal propagules is the most challenging among the four types of pathogens 
discussed in this study. This is related to their mode of action which is primarily by adhesion 
to the outer parts of an insect and penetration through the cuticle. This infection process is 
described in detail by Butt (2002). The infection process is complicated compared to bacteria 
and baculoviruses with which infection takes place after take-up per oral, or compared to the 
active search and penetration behaviour of EPNs as part of the infection process. Formulation 
of fungi poses challenges related to targeting, persistence, protection against harmful 
environmental factors, growth stimulation and enhancing agents. Generally, formulations of 
fungal products contain spores, either conidiospores or blastospores, sometimes mycelial 
particles.  
The literature on formulation of fungal spores is vast. Burges (1998) reviewed the 
developments in formulation of mycoinsecticides and provided an excellent overview of the 
various formulations and additives that stabilize and protect the propagules and enhance the 
biological activity. Vega compiled a bibliography called “references dealing with 
formulations of fungal entomopathogens”, see the website http://www.sipweb.org/fungi.htm. 
There are about 150 references, updated to 1999. Most products are based on aerial conidia, 
some on conidia and hyphae on a granular substrate, and some on blastospores (De Faria and 
Wraight, 2007). Most entomopathogenic fungi produce large amounts of aerial conidia which 
are responsible for dispersal and infection. These spores are thick-walled and relatively stable. 
In solid state production these spores are also formed in high numbers. These characteristics 
make them the preferred propagule for formulating final products. Some fungi are difficult to 
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produce efficiently on solid media and submerged produced blastospores are used for 
formulation. Blastospores may also be more infectious as is shown in I. fumosorosea against 
Bemisia argentifolii (Jackson et al., 1997) and in M. anisopliae against Locusta migratoria 
(Kleespies and Zimmermann, 1994). Wraight et al. (2001) reviewed stabilization and 
formulation in relation to production of the different kind of propagules of entomopathogenic 
and herbicidal fungi. Feng et al. (1994) reviewed formulations of B. bassiana based on 
conidiospores, blastospores and mycelium. Jackson et al. (2010) reviewed the ecological 
considerations in producing and formulating fungal entomopathogens with emphasis on 
interactions between the propagule and the insect cuticle, and the role of a surfactant. 
Formulation-related aspects can be improved during production and this area has 
received considerable attention in entomopathogenic fungi. Hallsworth and Magan (1994) 
demonstrated that inoculum quality (in this case virulence and shelf-life) can be improved by 
the culture conditions (low water activity) and nutrient composition in conidia of B. bassiana, 
M. anisopliae and P. farinosus. Jackson et al. (2003) studied blastospore production in I. 
fumosorosea and showed that blastospore tolerance to desiccation can be positively affected 
by supplementing certain medium components. Ypsilos and Magan (2005) showed that 
modifications in physico-chemical culture conditions such as water stress, and washing 
treatments of blastospores of M. anisopliae have the potential to improve spore quality in 
terms of drying–resistance and storage stability. Tolerance to desiccation is an integral factor 
in the process of drying blastospores and for long shelf-life and this should be considered 
early on in the production. Many features are influenced in the production and this needs to be 
studied and used in the product development. Formulation additives are another tool to 
improve the propagules’ stability and activity. Tolerance to desiccation can be further 
improved by formulation additives. Blastospores of I. fumosorosea mixed with starch-oil 
mixtures improved survival of spores during freeze-drying and improved storage stability 
(Jackson et al., 2006).  
Oil-based formulations have been developed for conidiospores of M. anisopliae var. 
acridum for locust control. This proved to be a major breakthrough, enabling the usage of this 
fungus in hot and dry environments with ULV applications (Bateman et al., 1993). This 
formulation technology has several advantages that made it so successful: shelf-life is quite 
long for a mycoinsecticide (> 18 months at 17° C); good persistence in the field; enhanced 
biological activity; and usage by conventional equipment at ultra low volumes (Bateman, 
1997). The precise role of the oil in the infection process is not well understood. Bateman 
(2000) suggests that secondary pick-up from plants plays a greater role than direct impaction 
of spray droplets in the case of locusts. This would mean that persistence of spores was 
improved by the oil as well as the pick-up and adherence to insects. These aspects relate to 
efficacy, user-friendliness, and costs, and resemble the use of a chemical, making acceptance 
of this product easy. This technology was developed in the Lubilosa Programme 
(www.lubilosa.org) and the product Green Muscle, based on M. anisopliae var. acridum, is 
formulated in mineral oil. 
Oil formulations have been developed with mycoinsecticides (Botanigard ES, Naturalis, 
Green Muscle) based on mineral and paraffin oils. It is believed that oil formulations increase 
spore adherence to insects because they improve contact between spores and the hydrophobic 
cuticle of insects. In oil-based formulations sprayed with water as a carrier, the assumed mode 
of action is that the mixture once sprayed with a pressure of 10-15 bar forms an emulsion with 
fine oil droplets. Under high pressure and considerable shear forces an inverted emulsion may 
be formed with oil droplets that contain water and spores. These oil droplets may enhance 
Chapter 3 
___________________________________________________________________________ 
 74 
adherence to insects once the water has evaporated. In these droplets the spores may 
germinate and grow out of the droplet and infect an insect. In this way, spore germination and 
adherence are enhanced, resulting in greater insect mortality and reduced dependency on a 
high relative humidity and the availability of free water. Where an invert emulsion does not 
occur, the result might be protection of spores from dehydration under a thin film of oil (Auld, 
1993) and a better adherence to insects, still resulting in improved efficacy. These effects 
were seen using a vegetable oil-based adjuvant with Mycotal, which contains hydrophilic 
conidia of L. muscarium, for control of thrips (Van der Pas et al., 1998). Many other studies 
indicate that oil formulations improve the efficacy of mycoinsecticides; a review is given by 
Inglis et al. (2002). On the other hand, Ugine et al. (2004) showed that there was no increased 
secondary acquisition of conidia of B. bassiana by Frankliniella occidentalis adults and 
larvae between unformulated conidia and two formulations with conidia. These were the WP 
and the ES (emulsifiable suspension) formulations of Botanigard. It was tested, however, 
under optimal conditions for the fungus, at 25°C and a 100% RH. Formulations are developed 
to enhance product efficacy under sub-optimal conditions, e.g. lower RH conditions. Testing 
under optimal conditions is not likely to show enhancement of efficacy by a formulation. It 
also may explain why the oil-based formulation (ES) did not increase conidia acquisition. B. 
beauveria spores posses a hydrophobic cell wall (Inglis et al., 2002), so any adherence effect 
of oil is much less relevant, even under optimal conditions for the fungus. 
Vegetable oil formulations could also be developed to improve shelf-life of vulnerable 
fungal material. This has been studied with mycelium of Lagenidium giganteum in water-in-
oil emulsions, together with prevention of sedimentation of cells (Vandergheynst et al., 2007). 
Oil thickeners based on silica nanoparticles proved to be effective in preventing sedimentation 
to a large extent in the formulation as well as in the mixture with water. The authors assume 
that shelf-life was improved by protecting propagules from desiccation in the water-in-oil 
matrix. In biocontrol of weeds with pathogenic fungi various kind of oil formulations have 
been tested, including invert emulsions, oil suspension emulsions, and many adjuvants. An 
overview is given by Green et al. (1998).  
Many compounds have been shown to protect spores and to enhance biological activity. 
This area of research offers interesting ideas that could be useful in developing formulations 
with entomopathogenic fungi. Other non-agricultural areas where micro-organisms are used 
for pest control should also be considered. Examples are the control of mosquitoes and weeds 
in aquatic environments, insect control in forestry where specialized formulations, often oil-
based, have been developed for low volume aerial applications, and control of termites, ants 
or cockroaches in domestic usages. 
Some formulations consist of the production substrate including the spores. These are 
usually fungi grown on rice or cereal kernels where the spores are not separated from the 
production substrate and where fungus-overgrown granules are applied to soil. Examples are 
Melocont from Kwizda (Austria) and Engerlingspilz form Andermatt Biocontrol AG for 
control of white grubs in meadows, lawns and orchards.  The production matrix is here the 
final formulation and these products are not formulated with any additives.  
A small number of products have been formulated with mycelium. The product Laginex 
AS (Agraquest, USA) for control of mosquitoes, based on the fungus L. giganteum, is 
formulated as an aqueous suspension with mycelial parts since production of oospores gives 
uneconomic yields (Vandergheynst et al., 2007). The product is no longer on the market due 
to an unstable formulation with a short shelf-life and a limited market (D. Edgecomb, 
AgraQuest; pers. comm.). A formulation of M. anisopliae, based on mycelial pellets, was 
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developed by Bayer, but it was never marketed due to economical constraints (Zimmermann, 
2005). The product Mycar, based on mycelium of H. thompsonii was put on the market, but it 
was withdrawn because results were insufficient (McCoy et al., 1975). In mycoherbicides 
mycelial formulations are also used. An example is the fungal herbicide Chontrol Paste, from 
MycoLogic Inc., Canada, which contains mycelium of Chondrostereum purpureum for 
inhibition of re-sprouting of tree stumps (www.epa.gov.). A definition of formulation types 
and an overview of mycoinsecticides and mycoacaricides, including the type of the 
commercial formulation, are provided by De Faria and Wraight (2007). 
 
Formulation of baculoviruses 
Key aspects in the formulation of baculoviruses are standardization, microbial contamination, 
protection against harmful environmental factors, improvement of the speed of kill by faster 
and greater uptake of viruses, as well as enhancement of the pathogenicity of the virus. Shelf-
life is of minor importance because products can be stored for many years when kept at 
approximately -20°C, or one year at refrigerated temperatures, and even for a few weeks at 
room temperature. Products can also be re-stored from one temperature to the other to some 
extent. Spray characteristics should ensure an even distribution on foliage for optimal oral 
uptake by caterpillars. 
A main issue in virus formulations is microbial contaminants. Purification of the crude 
technical product is needed for product stability and registration requirements, and various 
methods can be used (Huber and Miltenburger, 1986). On the other hand, it is well known 
that remainders of the dead insects enhance stability of the virus during storage and that these 
particles also aid in the protection against UV radiation (Huber, 2005). This creates a 
formulation challenge for producers who will have to find a compromise between these two 
aspects. At the same time, the formulation needs to be set at certain potency, and counting 
occlusion bodies (OBs) or polyhedral inclusion bodies (PIBs) is difficult and unreliable. 
Particles in the formulation can be hard to distinguish from the OBs or PIBs and inactive ones 
are also counted. Bio-assays are needed to standardize the product.  
Many researchers have focused on formulation improvements such as adding feeding 
stimulants, stickers for rain-fastness, and protectors against UV. It is generally accepted that 
exposure to sunlight rapidly inactivates baculoviruses. Accordingly, most formulation studies 
focus on protection from harmful wavelengths. Overviews of formulation methods and 
research are given by Burges and Jones (1998a) and by Hunter-Fujita et al. (1998); both 
papers include extensive lists of wetting agents, stickers, phagostimulants and UV protectors. 
Encouraging results have been obtained in apple using CpGV with various additives against 
the codling moth (Ballard et al., 2000). The use of these compounds (molasses, sorbitol, ά-
farnesene) led to less codling moth damage, although the exact mechanism was not clear. 
Phagostimulants, built into a granular formulation of SfMNPV, increased infection rate in 
Spodoptera frugiperda in maize and improved persistence on crop foliage compared to an 
aqueous spray application (Castillejos et al., 2002). Sunscreens to block damaging UV 
wavelengths have been studied widely (Burges and Jones, 1998a). Optical brighteners can 
give protection against UV radiation and at the same time enhance baculovirus activity 
(Dougherty et al., 1996)). The results, however, are considered insufficiently effective for 
open field applications. The use of adjuvants based on lignin and particle films were studied 
as putative solar protectants, but showed no significant improvement in field trials (Arthurs et 
al., 2008). The situation for feeding stimulants and stickers is similar and the use of these 
compounds is not recommended in practice (M. Andermatt, pers. comm.). On the other hand, 
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Lasa et al. (2007) showed that the use of an optical brightener, i.e. a UV blocker, in the 
formulation increased mortality in greenhouse trials with SeMNPV against larvae of 
Spodoptera exigua in Spain. Mortality increased in late instars larvae, whereas persistence 
was not improved by the additive. The effect on mortality was most likely due to an increased 
rate of virus acquisition, suggesting that the optical brightener leucophor AP increases 
pathogenicity of this virus and/or acts as a feeding stimulant. The effect as a UV blocker was 
not seen. Apparently, UV radiation is much less harmful in a plastic-covered greenhouse than 
in the field. 
The formulation ingredients of current baculovirus products are not known as the 
information is proprietary. Formerly, virus products were often formulated as wettable 
powders, particularly those used in forestry (Young and Yearian, 1986). Oil formulations 
have been studied, but oils are often repellent or act as an anti-feedant to the target pests 
(Cherry et al., 1994). Nowadays, most formulations are aqueous suspensions that are 
developed for spray applications in orchards and greenhouses and are user-friendly.  
 
Formulation of entomopathogenic nematodes 
Nematodes require formulation for similar reasons as do micro-organisms, although they 
present unique features. Shelf-life and user-friendliness are integral to an optimal nematode 
formulation. Persistence in the soil cannot be influenced by adding formulation ingredients, 
and registration is not an issue of great importance. The DJs are relatively large survival 
stages that are able to move actively. They also present challenges to oxygen and moisture 
requirements and to temperature conditions during storage, and are more sensitive in this 
respect than the micro-organisms. Generally, nematodes are applied to the soil which poses 
less formulation considerations then when pathogens are applied onto foliage where spray 
characteristics and protection from environmental factors are necessary. On the other hand, 
when nematodes are applied through irrigation systems, blocking of filters and small drippers, 
either by the DJs itself or formulation lumps, needs to be avoided. DJs can be stored in 
refrigerated and aerated water to supply sufficient oxygen and to prevent settling. For storage 
and transport of products, formulation is needed. The main goal is maintenance of quality for 
as long as possible. In formulation, the stage of DJs of nematodes is used in which they 
become metabolically inactive and can withstand a relatively high degree of desiccation and 
low temperatures. Further, the growth of contaminants must be prevented. Species, and even 
strains, differ in their biology, and storage and formulation needs to be studied case by case 
(Strauch et al., 2000). Temperature should be kept as low as possible to ensure a long shelf-
life. Once temperature allows activity and mobility, DJs use up oxygen and their energy 
resources, which will negatively influence shelf-life and ultimately quality and efficacy, 
although it can vary depending on the species (Patel et al., 1997). Once DJs have moved 
inside the package, the formulation ingredients protect them less efficiently and quality 
rapidly decreases, even when the temperature is restored to a level where they can not move 
anymore. In this respect nematodes are much more sensitive than non-moving propagules of 
pathogens. High temperature can be lethal. The moisture content of the formulation demands 
a balance between the level that keeps the DJ’s from desiccation and the level that prevents 
them from moving. Moisture content should also be low to prevent contaminants from 
developing.  
Formulations need to be tailored towards the species and the type of formulation, and 
requires studying the physiological chemistry of a nematode and its ecology and behaviour. A 
historical overview of formulation with EPNs is given by Georgis and Kaya (1998). The 
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authors also identified significant steps in the process of formulation (table 9.6, page 298). A 
more recent overview of the various types of formulations is presented by Grewal (2002). 
Many types of commercial formulations have been developed and marketed, including water-
dispersible granules. This last formulation was not successful and was taken from the market 
(Georgis, 2002). The dominant and successful formulations are clay powder formulations and 
gel formulations.  
Liquid formulations may have several advantages over solid matrix formulations. The 
latter have a relatively short shelf-life of about three months, are difficult to handle, and the 
entire package needs to be used up at once because of the non-homogeneous nature of the 
package contents. High temperature effects are irreversible due to the change of the EPN-
matrix mixture when DJs have crawled out of the carrier. On top of that, active nematodes 
produce heat and gases and contaminants may start to develop, resulting in negative spiral 
effect with regard to product quality. Aqueous formulations, however, have the disadvantage 
of sinking of EPNs and lack of oxygen. Wilson and Ivanova (2004) investigated neutral 
density liquid formulations based on colloidal silica suspensions which could overcome these 
problems. Survival and virulence with H. megidis and S. feltiae DJs was improved compared 
to nematodes stored in aerated water solutions with Ringer’s solution at 4°C and at 15° C for 
S. feltiae. Still they found a decline over time of surviving DJs. This is not acceptable in 
commercial formulations. The number of DJ/ml was at maximum 10.000 per millilitre which 
would mean a 5 litre volume for a 50 million nematode package which is generally about 200 
ml with clay formulations. Both aspects are not acceptable for a commercial formulation and 
efforts to improve these points were not sufficient (unpublished data of our group). Although 
a liquid formulation has advantages such as easy measuring off the desired quantity, less or no 
visible residue on plants, and no blockage of nozzles, this idea has not been developed into a 
commercial formulation due the disadvantages mentioned above. 
 
Foliar applications of entomopathogenic nematodes   
There is an increasing interest in using EPNs for control of foliar insect pests such as 
leafminers, thrips and caterpillars. To be successful, DJs need sufficient time to find and 
penetrate the target insect. They are only able to move in a water layer and desiccation within 
a short period of time after application limits their effect. Formulations are mainly developed 
to have a long shelf-life. For enhancement of EPNs’ effectiveness on foliage through good 
mobility and survival, formulation requirements are different. This formulation should aim at 
maintaining the presence of the water layer long enough for the nematodes to find and 
penetrate the host, usually a matter of a few hours. This can be reached by tank-mixing an 
adjuvant or by developing a new formulation.  
Piggott et al. (2000) studied the formulation of DJs in a polyacrylamide polymer and its 
effect on leafminers. This formulation improved survival of DJs on leaves because of slower 
drying of droplets compared to water and gave a significant increase of pest mortality, 
compared to DJs in water, and water plus a wetting agent. This formulation is marketed by 
Becker Underwood as Nemasys F for use against thrips and leafminer. The exact formulation 
is proprietary and not known, however. Enema and Koppert developed similar gel 
formulations. These formulations have a similar shelf-life as the clay formulations, and can be 
used for foliar as well as for soil applications. The gel formulations also have the advantage 
that there is no visible residue on plants, unlike the clay formulations. 
The use of formulation additives to enhance EPNs effectiveness on foliage has been 
studied by Schroer et al. (2005a) against diamondback moth larvae. Many different 
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compounds such as polymers, surfactants, oils, waxes, and mixtures thereof were tested in 
combination with S. carpocapsae DJs in bio-assays on cabbage leaf discs. The authors found 
that a mixture of a surfactant and a polymer gave the best results, suggesting that a good 
deposition and distribution of DJs over the foliage is important as well as a prolonged DJ 
survival. In leaf bio-assays Schroer and Ehlers (2005) demonstrated that the effect of the 
surfactant-polymer formulation is mainly due to support of the DJ’s performance on the leaf 
surface rather then to improving DJ survival. Survival was prolonged, but diamondback moth 
larvae mortality did not increase over time. The results indicate that insect penetration by the 
nematode on the leaf occurs within the first hour after application. Field trials under tropical 
conditions did not show any additional effect of the polymer-surfactant or surfactant 
formulation. This was attributed to humid, rainy conditions during the trial (Schroer et al., 
2005b). The authors conclude that the use of anti-desiccants only slightly improves the 
effectiveness of EPNs on foliage and they recommend not using them due to higher costs and 
the small additional effect.  
Studies in our group confirm that the most significant factor in foliar use of nematodes 
is contact between target and nematode, and that conditions in the first hours are 
determinative. Prolonged survival by means of anti-desiccants does not seem to be very 
useful. The above-mentioned gel formulations have an anti-desiccant effect and give 
reasonable control of foliar pests. The use of a spreading agent may improve spray 
characteristics and contact between DJ’s and target insects. Using a separate adjuvant seems 
to be the most practical. This is because EPN products generally are used for soil applications 
and do not need this kind of formulation features, so building in features for foliar 
applications would be unnecessary. The use of adjuvants with EPNs offers a potential 
improvement in the use of EPNs against foliage-feedings insect pests and needs to be further 
studied in field trials focusing on initial contact between nematode and host. 
The application method for foliar treatments with nematodes needs careful 
investigation. As DJs are large particles, the suitability of equipment (pressure, nozzle size), 
droplet size, survival, distribution and canopy structure are determinative. These aspects have 
been studied by several authors, including the use of adjuvants, but optimal application 
methods have not yet been developed (Lello et al., 1996; Shapiro-Ilan et al., 2006). 
 
Entomopathogens and adjuvants 
Efficacy of entomopathogens can be enhanced by certain additives in the formulation or by 
tank-mixing adjuvants. Additives are defined as compounds incorporated into a formulation 
and their role has been mentioned several times above. Adjuvants are defined as separate 
products that can be tank-mixed with (bio)pesticides in order to enhance their efficacy. 
Adjuvants are increasingly used to improve the biological activity of pesticides. An overview 
of why, where and what kind of adjuvants are used with chemical pesticides is given by Stock 
(1997). The main reasons are spray characteristics such as atomization, foliar retention, foliar 
coverage, foliar penetration and enhancement of the mode of action of the active ingredient. 
Adjuvants should have no biological activity on their own. This is also a requirement related 
to regulations of adjuvants. Adjuvants are needed because there are limitations to the amount 
of additives that can be built-in into one pack-formulations (products) and some additives are 
not compatible with the active ingredient and can only be tank-mixed. Another reason is that 
an additive may not be compatible with all the foreseen usages of the product; they could be 
phytotoxic to some crops, but useful in some other crops. There is a limit to a multi-purpose 
formulation.  
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The considerations for developing and using adjuvants with biopesticides are given in 
table 3.7. The range of adjuvants is increasing; the adjuvant industry is growing, with their 
own newsletters (e.g. Adjuvant Newsletter) and conferences (the 8th International Symposium 
on Adjuvants for Agrochemicals was held in 2007) and specific adjuvant market reports. 
Specialized consultants are active in this field, such as Alan Knowles (Form-AK, UK) and 
Hans de Ruiter (Surfaplus, the Netherlands). The market of adjuvants is estimated to be about 
US$1.5 billion in 2005 (Knowles, 2006). In biopesticides, similar considerations for the use 
of adjuvants play a role and adjuvants may enhance the biological activity of pathogen or 
improve their persistence on the target site.  
Adjuvants are sometimes recommended in combination with biopesticides. An example 
is Nu-Film-17 (Nufarm) that was tank-mixed with Madex as a UV protectant and sticker. 
Results were disappointing and Nufilm is no longer recommended (M. Andermatt, pers. 
comm.). Examples with fungi are AddQ, added to AQ10, a mycofungicide based on 
Ampelomyces quisqualis to control powdery mildew (Kiss et al, 2004), which improved 
efficacy. And, NuFilm added to Naturalis (B. beauveria) brought the level of control of 
whiteflies up to the chemical standard level (Mayoral et al., 2006).  
Some adjuvants are specifically developed for usage with biopesticides. Our group 
developed a vegetable oil-based adjuvant Addit to improve the activity and persistence of 
Mycotal (Van der Pas et al., 1998). Initially, we attempted to develop an oil formulation with 
the spores of L. muscarium in order to increase the efficacy and persistence on the foliage. 
Due to technical problems such as sedimentation and clogging of the spores over time, we 
abandoned this idea. Another reason was the need to register a new formulation, while 
launching an adjuvant only needs a limited registration or none at all in some countries. The 
product Addit is recommended to be tank-mixed with Mycotal at a dose of 2.5 ml/l of the 
spray liquid. It increases the mortality of whitefly and particularly of thrips (figure 3.3). It 
shows mycosis earlier and more pronounced than in the control, so that mortality is easier to 
assess by the grower and most importantly, its activity is less dependent on a high relative 
humidity. The main effect of the oil is the improved secondary pick-up of spores resulting in a 
quicker death and a higher mortality overall (Van der Pas et al., 1998).  
 
 
Figure 3.3.   Mortality of Mycotal and Mycotal + Addit on whitefly nymphs (Trialeurodes 
vaporariorum) (left graph) and thrips larvae (Frankliniella occidentalis) (right 
graph) 7 days after 2nd application on cucumber (RH 55-80%)   
 (Van der Pas and Ravensberg, unpublished data, 1995) 
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As a result of the development of Addit, the usage of Mycotal has increased, 
demonstrating the value of an adjuvant. The addition of arachid oil also improved the efficacy 
of V. lecanii against powdery mildew on cucumber and reduced the humidity dependence 
(Verhaar et al., 1999). Curtis et al. (2003) studied the effect of nutrient and non-nutrient 
additives to conidiospores of an Australian V. lecanii strain (FI40) derived from an aphid. 
They found that nutrient additives in the spray solution, such as whole egg powder and 
glycerol, increase growth on leaves and infection in aphids. A period of over15 hours of high 
humidity was still needed to get high mortality. Oil-based additives did not improve mortality 
rates. Our group found that an oil adjuvant did not improve the efficacy of Vertalec 
(blastospores), in contrast to Mycotal (conidiospores). Whether this is related to the spore 
type, the target insect or to strain differences is yet unclear. With Bt, the use of cotton oil as a 
tank-mix improved the efficacy in sweet corn on three lepidopteran pest species considerably, 
although the mechanism is not fully understood (Hazzard et al., 2003). The use of adjuvants 
for foliar applications of EPNs is discussed above. 
The quantity and the cost are the issues in using adjuvants. Often, improvements on 
efficacy can be realized by tank-mixing an adjuvant, but in many studies the quantity required 
is prohibitive. A typical example is the study of Ballard et al. (2000). They found that adding 
10% (v/v) cane molasses or 10% (w/v) sorbitol or 0.08% ά-farnesene to CpGV treatments 
with 250 l/ha in an apple orchard significantly improved levels of codling moth control. 
Damage reduction was 41% with pure CpGV and 74% with pure CpGV plus molasses. In this 
case, 10 % molasses is 25 litres, costing about €25 (purchase price (in 2007), without any 
sales margins. Adding sorbitol gave a significant increase of control, but it would mean using 
25 kg/ha, costing about €200 (purchase price, in 2007). Efficacy was also improved by adding 
ά-farnesene in a quantity of 200 ml, but the additional cost is about €55 (purchase price in 
2007). One treatment with a CpGV product costs a grower about €60/ha in 2007 in the 
Netherlands. From a practical point of view, this renders the use of these compounds as 
adjuvants in terms of logistics and costs impossible. If the price of an adjuvant increases the 
cost of the overall treatment considerably, a grower chooses another product. An adjuvant 
must be cheap and easy to use.  
Undesired effects of adjuvants need also to be taken into account. Molasses may 
stimulate growth of sooty moulds. Oils may cause phytotoxic effects. Optical brighteners and 
other compounds may cause visible residues which can be a problem on ornamentals and on 
shiny fruits like eggplant and sweet pepper. Besides, harmful effects on natural enemies may 
occur. All these aspects need to be considered and studied. 
The use of biopesticides is often criticized for its lack of reliable efficacy. Adjuvants 
offer a potential improvement, and more research should be dedicated to investigating the 
combination of biopesticides with both available and new adjuvants. This is a relatively quick 
and affordable approach by which efficacy of microbial products can be improved. Adjuvants 
are regulated in most countries, but dossier requirements for registration are much less than 
those of biopesticides. 
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Table 3.7.   Considerations when using tank-mixed adjuvants with biopesticides 
 
Adjuvant aspect Features that need to be considered 
Formulation functions  Improve spray characteristics, enhance mode of action, increase 
persistence, improve secondary pick-up, etc. 
Efficacy Should not have direct efficacy on its own 
Costs Additional end-user’s costs should be acceptable 
Quantity Logistics, storage, handling 
User-friendliness Easy to mix (dilution, emulsion) and apply 
Undesired effects Phytotoxicity, growth of sooty moulds, visible residue; harmful 
effects on natural enemies, etc. 
Registration Often needed, sometimes exempt; often easier than a new 
formulation registration 
 
  
New formulation technologies 
Formulation technology offers a promising field for improvements in terms of efficacy and 
user-friendliness. This will improve the uptake of biopesticides in the market. New research, 
new knowledge and new products open ways to develop more sophisticated formulations. The 
agrochemical industry is constantly trying to improve their formulations and new 
developments are taking place that could be interesting for the biocontrol industry. The latest 
are micro-encapsulated formulations, granular formulations and replacement of harmful 
solvents agents by vegetable oil or water. Some examples: Syngenta and Zeneca are looking 
at micro-encapsulation techniques (Anonymus, 2004; Perrin, 2000), Bayer is developing 
vegetable oil/additives dispersion formulations to optimize coverage and penetration and to 
improve spray characteristics and rain fastness (Anonymus, 2006) and Dow AgroSciences is 
developing small droplet sized water-based formulations (Anonymus, 2007). Incentives are 
the wish to create more user-friendly products, using less active substances and less to no 
organic solvents, better efficacy, reduced exposure and safer formulations for human and the 
environment. Formulation research for biopesticides can learn from these developments as 
these are going towards safer compounds and formulation concepts that may be useful for 
biopesticides. There are some examples with biopesticides: granular formulations such as dry 
flowables and water dispersible granules have been developed for Bt products. Aqueous 
suspensions have been developed for organic use: Serenade ASO and Madex. 
Many new products and new concepts have been developed by the additive and 
adjuvant industry. Better understanding of the role of surfactants, dispersants, emulsifiers, 
spreaders, and other additives is resulting in new and safer formulations. These new concepts 
are used for built-in formulations as well as for tank-mixed adjuvants (Knowles, 2006). In the 
past, adjuvants were mainly studied for use with herbicides, while current studies include 
usage with insecticides and fungicides. Since many of these developments are focusing on 
safer additives for humans and the environment, they may also be useful for formulating 
living propagules for biopesticides.  Some examples of new co-formulants that can be used in 
biopesticides are compounds such as natural and modified alcohols, fatty acids, starches, 
sugars, polymers, vegetable oils, waxes, etc. Examples of companies involved in the 
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production of these compounds are Akzo Nobel, Clariant, Degussa, Helena, Seppic, Croda 
and Uniqema.  
 
Enhancement of entomopathogens through formulation 
Improvements can be made by manipulating biological characteristics of a pathogen and 
technical aspects of the formulation. Biological improvements can be made in various ways. 
A review of potential improvements through biological features is given by Charnley et al. 
(1997), but few of these have been incorporated in products. A better understanding of 
production aspects related to virulence and quality of propagules and a longer shelf-life is 
needed. This requires more fundamental research. Nutrition can influence virulence and 
quality of propagules (Butt et al., 2006). Fungi produce cuticle-degrading enzymes and 
bioactive secondary metabolites (Butt, 2002) and a better understanding of when and which 
ones are produced and what their role is in the infection process could help improve fungal 
products. We also need to know more about these enzymes and metabolites and how to 
exploit them better in the production process and in the formulation. Once more fundamental 
knowledge becomes available, it will be possible to devise strategies to improve strains. If 
features such as a broader host range, improved speed of kill, reduced dosages, and increased 
resistance to harmful environmental factors could be improved, biopesticides may become 
better. Other possibilities to improve strains are somatic hybridization and genetic 
modification, but the latter is not accepted in Europe.  
A novel approach for getting better results is to search for organisms or strains of 
organisms that are able to grow and reproduce on foliage or roots. Koike et al. (2004) found 
that strains of L. muscarium with an epiphytic character are able to colonize the leaf surface 
and give a higher mortality of whitefly over time than strains without this characteristic. This 
feature could be improved by designing a formulation that stimulates epiphytic growth. 
Similar examples are epiphytic bacteria like Pseudomonas syringae that colonize the leaf 
surface and thereby give an effective protection from frost injury (Hirano and Upper, 2000), 
and root colonizing antagonistic fungi that are able to protect plant roots from pathogenic 
fungal diseases as demonstrated with T. harzianum (Harman, 2006). 
Further, there is a wide range of recent technological innovations that could be used to 
improve pathogen formulations. Shelf-life of biopesticides is critical and new packaging 
technology may help improve shelf-life. New materials such as oxygen absorbers, carbon 
dioxide absorbers, and water absorbing gels could stabilize the environment in the package. 
Packaging under inert gases may prevent degradation of the propagules and result in a longer 
shelf-life. Additives with a certain function could be used to improve efficacy. These could be 
compounds that enhance virulence (enzymes such as chitinases, proteases and lipases, or 
stimulators such as chitin and activity enhancers) or that increase survival (UV blockers, etc). 
Other additives could be used as growth stimulants or compounds that improve secondary 
pick-up of spores. The latter may be achieved by compounds with sticky features such as oils 
and gums; by behaviour modifying substances such as attractants (sugars), repellents (garlic 
oil), alarm pheromones (β-farnesene for aphids) or by low doses of insecticides that increase 
insect movement and thereby increase the chance for pick-up of spores. This approach proved 
to be effective when 1% of imidacloprid, a sub-lethal dose, was used in combination with L. 
muscarium. The chemical dramatically increased aphid movement and as a result secondary 
pick-up of spores increased and led to high mortality (Roditakis et al., 2000). Similar effects 
have been reported in trials studying mortality of vine weevil larvae with M. anisopliae and 
low, sub-lethal doses of imidacloprid and fipronil (Shah et al, 2007a). New technologies, such 
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as the Exosect technology (www.Exosect.com), may improve the efficacy of biopesticides 
through an improved adherence of particles, i.e. spores, by formulating them with electrostatic 
wax powder or magnetic metallic powders. Combinations of functional additives may give 
synergistic effects. 
Technical innovations in the downstream and formulation processes offer another type 
of potential improvements. Protection of propagules by encapsulating techniques has been 
studied with bacterial cells of Pseudomonas fluorescens and mycelium of the nematophagous 
fungus Hirsutella rhossiliensis. Hydrogel capsules improved storage possibilities and efficacy 
(Patel et al., 2005). The hydrocapsule technology has been further developed by ARS, Inc., 
USA (www. ars-fla.com/hydrocapsules/html), and applications for biopesticides have been 
suggested. Propagules can be protected during formulation processes with different drying 
and coating technologies. New equipment and technologies together with new compounds 
enlarge the possibilities by methods such as spray-drying, agglomeration, fluidized-bed 
granulation, freeze-drying, encapsulation and (film-)coating. With these processes, various 
types of formulations can be made, starting with either particles or liquids, and resulting in 
dry flowables, water dispersible granules or capsules. A new formulation technique has been 
developed to coat propagules with water-soluble compounds and then to dissolve the particles 
in oil. This can be applied to the targets, such as locusts, where the formulation provides 
protection of the pathogens against heat and solar radiation (patent US 2004/0038825). 
According to Hynes and Boyetchko (2006) there is a high priority for formulation 
development with a multi-disciplinary approach to optimize biopesticide-pest interaction. 
They made a plea for a better understanding of the ecology of the interaction. This would 
certainly be a new area for investigations that may lead to better formulations. The authors 
also observed that researchers in formulation have focused on individual biopesticides rather 
than on developing general principles on groups of pathogens. This concurs with my 
experience. The ecology of the interactions should be studied more, and this should be done 
in institutional research because of its fundamental character. If pathogenicity factors could be 
elucidated further, then efficacy could be improved by better adapted formulations, and if 
application rates could be reduced, biopesticides would become more efficacious and more 
competitive with chemicals. This would be highly advantageous to both the producer and the 
user. Budgets should be made available for this kind of academic research in order to improve 
biopesticides. 
  
Product packaging  
Product packaging is usually considered from a marketing perspective only. However, it is 
intrinsic to the success of a microbiological control product. The final formulation needs to be 
packaged in an appropriate package. The packaging material needs to be compatible with the 
formulation and its shelf-life. Registration requirements demand evidence hereof by means of 
shelf-life studies in the final packaging. Other general requirements are that the packaging be 
well-designed and constructed, that its content cannot escape, that it be strong and solid and 
will safely withstand normal handling, and that opening and closing be easy. Minimizing 
product contact and creating convenience to the user are other desirable elements. The 
material of the package needs to protect the formulation in order to maintain its shelf-life. 
This is important with biological products, particularly fungi, which are less stable than 
chemical products. Biocontrol products are more vulnerable to changes in moisture content 
(clumping or desiccation), oxidation and microbial contaminants. It may be necessary to keep 
out daylight and it needs to be air-tight to maintain the formulation’s moisture level. Products 
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could be packaged in an inert atmosphere (N2 or CO2) although I have not yet seen examples 
with MPCPs. In the case of EPNs, gas exchange is required, however. 
Shelf-life, as defined by registration requirements, is the period that the product in the 
final packaging remains stable under certain conditions. Storage stability of unformulated 
technical product, often called the technical grade active ingredient (TGAI), and formulated 
product may differ, as well as the storage stability of formulated product in bulk containers 
versus in the final packaging. This will differ per pathogen, per type of propagule and per 
formulation type. Sometimes bulk storage of the TGAI or the formulated product has better 
storage stability than the end-use product. This will affect operational decisions such as 
whether, what, when, and how to store and package. In-house and distributor storage of the 
end-use product uses up part of the shelf-life period which is unfortunate for the end-user and 
this period should be kept as short as possible. Therefore, in the process of packaging, the 
timing of making the end-use product is related to the product’s shelf-life. The actual shelf-
life length determines this decision, especially when shelf-life is relatively short. For instance, 
DJs of EPNs are usually stored in aerated vessels before formulation. They are formulated 
upon demand and from this point on packaged in the commercial packaging. The shelf-life 
period starts here. In the case of some fungi our group has found that bulk storage is better 
than storage in the final package. Some formulations and pathogens have more flexibility 
considering this than others; thus, it needs to be approached on a case by case basis.  Further, 
the moment of packaging depends on the frequency of production runs and the demand of the 
market.  
Other relevant considerations to the packaging are user-friendliness, size and costs. It is 
easy to underestimate the costs of packaging, especially the labour component. Whether this 
requires manual labour or the use of costly specialized packaging machinery, these costs need 
to be anticipated. Other costs are cold room storage and stock management. Size and weight 
of the packaging should be manageable. Handling and using the package should be easy as 
well as (repeatedly) opening and closing, including measuring off partial amounts of the 
product. Marketing is an indispensible part of the game. The packaging of the product 
including the label must look professional instead of amateurish. The user’s first impression 
comes from the product’s appearance, i.e. the packaging. Here we are competing with the 
chemical industry and the image that the product produces in the customer’s mind. On the 
other hand, the biological industry wants to emphasize that it is a biological product and not a 
chemical one. Biopesticides are innovative products and creative packaging offers an 
opportunity to deliver this message. This is a challenge for the product developer and the 
marketer. Rarely is the biopesticide package employed to emphasize the innovative and 
environmentally-friendly character of the product. The biocontrol industry has largely ignored 
this element. Improvements call out to be made in this area. In the development of product 
packaging, commercial as well as biological aspects need to be considered. Product quality 
and cost of packaging are key factors. Packaging is an imperative element of overall product 
quality in terms of efficacy, handling, economics and image.  
 
Field testing 
Field testing the MPCA serves a number of purposes. After the strain has been selected in a 
bio-assay, its effectiveness needs to be studied under more natural conditions. At the same 
time, it is necessary to evaluate the quality of the propagules from the mass production and to 
develop the formulation. Further, testing is needed to determine the dose and the best 
application method and strategy. All these factors are interlinked and form a complex matrix. 
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Finally, field testing needs to deliver proof of efficacy of the final product for registration 
purposes and for marketing purposes.  
In the development of pathogens for control of greenhouse pests, testing can be done on 
small plants in a greenhouse setting, ranging from small plots to large blocks in commercial 
greenhouses, respectively from small plants to mature crops. The advantage of working in 
greenhouses is that testing can be done more or less year-round and climate conditions can be 
controlled within certain limits. There is no need for outdoor testing and thus much less need 
to consider variable climatic conditions and influence of rain and UV.  
Considerations for testing microbials against greenhouse pests are provided by Burges 
(2007), illustrated by examples with Bt and L. longisporum. He focused on experimental 
design, infestation with pests, and spraying methods. Evans (1999a) described the parameters 
involved in dose acquisition and relevant considerations needed on field dose rate 
determination, and on the importance of persistence of primary inoculum and the role of 
secondary inoculum. To evaluate the use of entomopathogens against pests, many methods 
can be used, depending on the microbial agent, the target pest and the crop and the 
environment. An excellent overview providing methods and tools for experiments with 
entomopathogens is given in the Field Manual of techniques in invertebrate pathology of 
Lacey and Kaya (2007). Several chapters focus on evaluation considerations with each of the 
pathogen groups, while others focus on the use of pathogens in specific systems, like 
greenhouse, mushrooms, nursery, lawns, etc.  Particularly useful is the chapter by Chapple et 
al. (2007) that discusses the application of MPCPs as particulate products in relation to spray 
application, equipment, and dose transfer to the crop canopy. Most of their considerations are 
theoretical. Still, product developers need to be aware of the application variables in order to 
optimize formulation and application. 
A vast amount of papers has been published on testing entomopathogens under semi-
field conditions and, to a lesser extent, under commercial conditions. Most of these focus on a 
particular aspect such as strain comparison, product comparison, determination of dose, 
formulation aspects, influence of abiotic factors, etc. The challenge for the product developer 
is to integrate in a testing programme all the aspects that need to be studied to bring about an 
economic, effective, and user-friendly product. This testing programme should not take too 
long and should be affordable in time and money. This requires a very good understanding of 
the crops, targets and the microbial product that is under development, including the delivery 
system. It is necessary for the product developer to have a good idea of what the ultimate 
product should become. Each case demands a specific approach and a good understanding of 
the relevant issues. Organisms with a  per oral mode of action, Bt’s and baculoviruses, are 
quite different from organisms with a contact mode of action (entomopathogenic fungi) and 
demand another approach. EPNs have a searching and penetration mode of action and clearly 
require different testing methods. An overview of testing methods for EPNs is given by 
Koppenhöfer (2007). Most entomopathogens are sprayed on the foliar part of the crop, but 
sometimes they are applied to the soil. EPNs in general are soil-applied. 
For all pathogens field testing is required in the development of the final product and to 
arrive at end-users’ recommendations. A list of the essential considerations is given below:  
1) to demonstrate the suitability of the selected strain(s) in a situation mimicking as closely 
as possible the commercial crop. The strain selection has taken place with the help of 
bio-assays and must be seen as an initial phase in the selection process. Ideally, all 
strains are compared under more natural conditions, but that is impossible for reasons of 
space, time and costs. Nevertheless, this should be done with the strain or a small 
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number of strains that were selected by the first selection phase. Testing on whole 
plants, or even better in a crop system, should prove that the selected strain is also 
effective under these conditions or that further selection between strains should be 
conducted. This can initially be done with propagules from laboratory cultures, but must 
be followed by mass-produced propagules and the formulated product. It is not possible 
to give detailed information on the testing methods as they vary greatly between 
entomopathogens and crop systems. Information can be found in Lacey and Kaya 
(2007), and particularly in Burges (2007) for greenhouse pests; 
2) to identify whether mass-produced propagules are effective and of good quality. Mass 
production must deliver infective propagules that are able to kill the target. Production 
on artificial media or in artificial systems may influence the effectiveness of the 
propagules. In the process of optimizing the mass production, many variables are 
studied, usually focussing on improving yield. Downstream processes may be hard on 
the propagules and negatively influence them. Field testing is needed to see whether the 
output still performs as is expected; 
3) to improve the formulation. As described above, the formulation should, amongst 
others, optimize application to the target and protect the pathogen after application 
(Jones and Burges, 1998). This is true for the products based on bacteria, baculoviruses 
and fungi which are foliar-applied. It plays no role in the case of soil applications of 
EPNs, but it is relevant however for formulations which are suitable for foliar use of 
EPNs. Testing formulations can be done in bio-assays and in field tests or in an in-
between assay, the “plant-to-tray” assay. Our group often uses this test when testing 
formulations, particularly when we are looking at field persistence, thus at the protecting 
abilities of the formulation. The formulation is then sprayed on the plant and after a 
variable number of days leaf discs are taken and put in the bio-assay trays on water-
agar. Insects are then transferred onto the leaf discs and efficacy is assessed after the 
appropriate amount of time. In this way deposit of the formulated product ages under 
natural conditions on the plants and many tests can be done with the same deposit over 
time. The plant does not have to be infested with insects, only the bio-assayed leaf discs. 
This proves to be a simple and easy assay. But it is also important to test the formulation 
on plant or crop level, assessed by mortality. First, to test direct effects of the 
formulation such as coverage, and targeting. Second, to test protection of the 
propagules, and field persistence. Persistence can be strongly influenced by the relative 
humidity on the plant and therefore whole-plant testing is required. There may be other 
plant-related effects such as anti-fungal compounds or micro-flora effects, but these are 
more difficult to assess and generally less relevant; 
4) to determine the optimal dose and spray volume. The most important factor determined 
by field testing is the optimal dose. The goal is to find the highest mortality with the 
lowest possible amount of formulated product using the optimal application method. 
Application equipment should be similar to equipment used by the grower. In these tests 
the optimal spray volume needed to deliver the dose in the best way should also be 
studied, and this may vary depending on the crop and how it is cultivated. Establishing 
the dose is crucial to the economics of the product and it should answer the question: 
“can a product be developed that satisfies the grower and the producer in terms of 
results, and economics?” The initial data on the dose-mortality relationship originating 
from bio-assay tests should be followed by semi-field tests and finally confirmed by 
testing in commercial greenhouses with the final formulation;  
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5) to determine the optimal application. This refers to the method of application, the timing 
of the application, the frequency of the application and intervals between applications. It 
actually concerns the application strategy for the product. The method of application is 
usually spraying with the equipment that is available to the grower. It is unlikely that 
growers will buy specific equipment for a new product; in that case he will choose for a 
conventional product. To my knowledge there is no commercial equipment specifically 
designed for the application of microbial products available on the market. Adoption of 
a MPCP will only be done if it does not require extra efforts or costs for the grower. The 
timing of the treatment is relevant with respect to the level of the pest and the age 
structure of the population and the position of the pest on the plant and leaves. Insects 
can be all over the plant or only on the growing top, on the underside of leaves only, in 
flowers, etc. This varies per pest and can be dependent on the crop. Often treatments 
have to be targeted at the most susceptible insect stages. Pathogens may have a slow 
killing activity and this may demand repeated applications with certain intervals. The 
optimal interval needs to be established as well as the number of consecutive treatments 
to control the population. This should lead to the final label recommendations; 
6) to demonstrate efficacy for registration purposes. In order to get approval for a product, 
efficacy has to be proven with a certain number of tests performed under commercial 
crop conditions and compared with a reference product. In the EU these tests are only 
accepted by the registration authorities when they are done according to accepted 
guidelines, often EPPO guidelines, and executed by GEP (good experimental practice) 
certified organizations. The testing has to be done with the final formulation and 
following label recommendations. Selectivity tests have to be performed also, showing 
that the product does not cause any phytotoxic effects to a variety of plants; 
7) to demonstrate efficacy for marketing purposes. Field tests will be used to show to 
growers, but also to distributors and sales people, that the product works in commercial 
greenhouses and that it fits in with all the other cultural practices. Actually, these are all 
demonstration trials that are not only needed to convince growers to use the product, but  
it is just as compelling for the company who developed the product to convince its own 
sales people that the product works when applied by growers on a large scale. There is 
always the unexpected and the unforeseen. Feedback from others, who have no 
experience with the product, is more than useful and can be used to improve the product 
and its application strategy before the product is definitively launched on the market.  
From the above it is clear that a good field testing method is imperative. It should be a test 
that can be performed easily, quickly, cheaply, year-round and give reliable and reproducible 
results. Our research group has found that cucumbers can be used for several pathogens and 
many pests develop well on it. It germinates easily, grows quickly in various growing 
substrates, and it does not require specific climate conditions or fertilizers. Diseases are 
usually not a problem, although powdery mildew is always a risk and resistant varieties 
should be used. Cucumber forms a big plant in a few weeks, mimicking a commercial crop. It 
needs only a little labour and can be easily pruned. It also shows an intermediate sensitivity to 
phytotoxic effects thereby proving to be useful in testing formulation types.  
Field testing consists of a series of tests, focussing on the issues that need to be studied 
step by step. It should be done in a logical order, as presented in table 3.8, although 
frequently, one will have to go back a step and adapt or change something, e.g. in the 
formulation, and repeated testing will be needed to optimize a certain aspect. After this series 
of testing the product has been developed and the label recommendations established. With 
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this in hand registration trials can be initiated. Field testing should give answers to all the 
issues mentioned above and should confirm that the final product with the right 
recommendations for use is an effective product.  
 
 
Table 3.8.   Purposes of field testing in product development  
 
• Demonstrate effectiveness of selected strain(s) 
• Demonstrate efficacy of mass-produced propagules 
• Improve the formulation and demonstrate its 
effectiveness  
• Determine the optimal dose and spraying volume 
• Determine the optimal application strategy, incl. 
equipment, timing, repeated treatments and interval 
• Prove efficacy for registration purposes 
• Demonstrate efficacy for marketing purposes 
 
 
Product specifications and quality control 
During the development of a product the product characteristics need to be established, 
ultimately resulting in product specifications. Every product batch must conform to these 
‘specs’ and product batches that do not meet the ‘specs’ must be improved or discarded. 
Products need to be routinely checked on these criteria, testing methods need to be developed 
and a quality control protocol needs to be designed. Product specification implies a number of 
aspects given in table 3.9. For every aspect a limit has to be set, including a tolerance range, 
and what measures should be taken if the limit within the range is not met. Procedures should 
comply with ISO working methods including tracing and tracking possibilities. Product 
‘specs’ need to be checked before product is sold. This is directly after packaging, but also 
after certain storage times. Product ‘specs’ need to be set in such a way that the product still 
performs at the end of the shelf-life. Quality control needs to be carried out a number of times 
during various phases of the product. “Specs’ refer to all types of intermediate products too. If 
“technical product” is produced and stored, ‘specs’ need to be developed. The same holds for 
bulk-stored formulated product and the packaged final product. Details of quality control will 
be discussed in chapter 4. 
 
 
 Table 3.9.   Product specifications and quality control aspects   
 
• Number of propagules or CFU’s per gr or ml product 
• Viability  
• Virulence (efficacy) 
• Purity (microbial contaminants) 
• Physical parameters (moisture level, particle size, etc 
depending on the type of formulation) 
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Production economics and final product costs     
 
A cost price model for biopesticides 
 Decisive for the success of a biopesticide is its price in the market where it needs to be a 
good alternative in terms of costs and efficacy. If one of these two features does not meet the 
user’s expectations, the product will not be used or used again. “Can the product be produced 
for an acceptable price in the market?” This essential question needs to be answered in an 
early stage of the developmental process. Which factors determine the costs of the product? 
And which factors are the main ones? I want to address these questions in general for the 
development of a MPCA into a biopesticide. Insight into the makeup of the end-user’s price 
of a product highlights where attention needs to focus to render it more economical, if 
possible. It is also important for decisions relating to the building of a production plant, to the 
choice of how to produce a pathogen, to registration costs, etc. In fact it is the basis of a 
business plan that will lead to a ‘go/no go’-decision. A business plan also may be necessary to 
raise money. 
 
Cost factors from production to product 
The manufacturing costs must be regarded as specifically product linked and calculations 
must be made like-wise. However, depending on the economic area and the structure of the 
manufacturer this could be evaluated in different manners. For instance, capital costs could be 
spread over various products depending on their stage in the market. For better understanding 
I will regard all costs as product-specific costs. The production costs can be divided into fixed 
and variable costs or into direct and indirect costs. These categories are not exactly the same, 
for instance, variable costs could also be sub-divided into direct and indirect costs, but for 
ease of use I will use the terms fixed and variable here. Fixed costs are usually expenditure for 
the production facility: the land, the building and the utilities, and production equipment. 
They also include overhead costs of the management of the business and of the plant. 
Production equipment includes bioreactors, downstream and formulation equipment, and 
packaging machinery. Facility and equipment costs are usually calculated by means of a 
depreciation factor, which may include a mark-up for interest and maintenance. Research and 
development costs can be seen as an investment because they are made before the product is 
launched and are therefore regarded as fixed costs. When a company has a certain permanent 
R & D staff, costs are seen as fixed, and part of them can be attributed to a certain product. 
After the product launch, research is often needed to improve the product or its use and then it 
is considered as a variable. In the case of biopesticides, registration costs may be a large cost 
factor and they can be accounted as fixed or as variable costs. Here too, they should be seen 
as an investment, thus as fixed costs. Later they may be some registration maintenance costs 
or costs for use extensions, and then they could be seen as variable. In the development phase 
I regard them as fixed costs and both R & D and registration are factored in as a depreciation 
factor. For the depreciation time a period of 5 years is taken as a generally accepted period for 
equipment, R & D, and registration, and 30-40 years for buildings. These periods are mainly 
determined by the national tax rules.  
Variable costs usually include the costs of raw materials (medium and formulation 
ingredients) energy, fuel, water, steam, production labour costs, packaging costs and 
packaging labour costs. Costs for quality control and waste removal are considered variables 
since they depend on the production level. These fixed and variable costs differ from plant to 
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plant, and are strongly influenced by the types of processes and products. Besides the above-
mentioned production costs, other aspects should be considered such as a certain mark-up for 
production failures, product left-over when not sold within the shelf-life period (together 
called production buffer), extraordinary cases, etc. A small mark-up is also needed for a profit 
margin on the production (table 3.10).  
 
 
Table 3.10.   Cost price model for a biopesticide: costs factors involved from production to 
         product 
 
        Fixed costs: facility, equipment,  
        R & D, registration, etc. 
       Fixed costs: overhead costs 
• Land and buildings  
• Utilities 
• Production equipment 
• Downstream equipment 
• Packaging equipment 
• Repair and maintenance 
• R & D 
• Registration 
• Insurances, etc 
• General management  
• Financial administration 
• Human resources 
• ICT 
• Facilities 
• Purchasing department 
• General costs (insurance, legal 
costs, etc) 
 
       Variable costs      Mark-up 
• Raw materials 
• Utilities (energy, water, steam, etc) 
• Production labour  
• Packaging costs 
• Packaging labour 
• Quality control 
• Waste removal 
• For production buffer 
• Extra-ordinary cases 
• Production profit margin 
 
 
The total of the fixed and variable production costs and these mark-up factors determine 
the full product cost price. The costs can be calculated per amount of propagules, per product 
unit or packaging unit or per hectare, depending on what is the easiest for comparisons. The 
costs per hectare are often used in order to estimate the competitiveness in the market.   
 
Cost factors from product to market 
The final market price further includes selling expenses and marketing costs, together called 
sales costs, and sales profit margins for producer and distributor. Sales costs generally 
comprise indirect costs, which include overhead costs, and direct costs. Indirect sales costs are 
administration and secretary costs, public relations and advertising costs. Overhead costs may 
include general administration (purchasing, financial, human resources, and ICT 
departments), general maintenance, management, office costs, insurance, etc. Direct sales 
costs are salary costs, car costs and telephone costs of sales people, travel and accommodation 
costs and shipping costs (table 3.11). All these costs can be calculated on a product-specific 
basis or, what is often done, a certain percentage is used as a sales margin on top of the full 
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product cost price as a method to cover sales and marketing costs. Finally, the full cost is 
calculated for which the product will be sold to a distributor. If the product is directly sold to 
the end-user, the sales margin charged by the producer needs to be higher to cover the 
expenses which would normally be carried out by the distributor. 
 
 
Table 3.11.   Cost price model for biopesticide: costs factors involved from product to market 
 
        Indirect sales costs          Indirect sales costs: overhead costs  
• Management   
• Administration, secretariat 
• Public relations  
• Advertising, publicity  
• Registration 
• Insurances, etc  
• Miscellaneous 
• General management  
• Financial administration 
• Human resources 
• ICT 
• Facilities 
• Purchasing department 
• General costs (insurance, legal costs, etc.) 
      Direct sales costs       Mark-up 
• Direct salaries  
• Car, telephone 
• Travel, accommodation  
• Shipping 
• Sales profit margin  
 
 
 
Often products are sold in the market by a distributor, who also makes various sales and 
marketing costs, and needs to make a profit on its activities. Distributor tasks are usually 
storage, logistics, and billing and advising the end-user. A certain sales margin is required by 
the distributor and the percentage depends on his efforts. Roughly this can vary between 20 
and 40% in the area of crop protection, calculated from the market price. The market price is 
made up of direct and indirect production costs, direct and indirect sales costs and sales 
margins for the producer and the distributor. A fictive example is given in table 3.12 based on 
our group’s experience with fungal products in a capital-intensive production system with 
solid state fermentation. The full product cost price is set at 100; this makes it easy to see the 
makeup by the various factors. From this example it can be seen that direct production costs 
(variable costs) constitute 10-15 % of the end-user’s price and that fixed costs and sales 
margins are a considerable part of the final product’s market prize. 
In research and product development generally the focus is on costs of raw materials, 
medium ingredients and equipment. However, they only constitute a low percentage of the 
market price. This model provides a perspective on the subdivision of these costs and their 
contribution to the end-price. Labour costs are generally a relatively high percentage (over 
50%) of the variable costs, while raw materials and packaging material constitute the 
remainder. The full production cost price is for a large part determined by depreciation costs, 
a factor which is often overlooked or at least the significance of it. On the other hand, once 
the plant has been built and equipped, costs can only be influenced by reducing medium and 
labour costs. 
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Table 3.12.   Example of a cost model for a biopesticide, per unit of product 
 
Production phase 
 Variable costs     30 
            Fixed costs    
  Facility, etc. costs   50 
  Overhead    10 
 Mark-up     10     
 Full product cost price 100 
Sales phase 
 Sales margin     60 
     ___       37.5 % of distributor price 
            Full cost price  160                                                                           
Distributor phase 
 Sales margin     80 
     ___           33 % of market price 
            Market price              240     
 
 
This model is only an example and depending on the kind of product and its production 
method, the importance of each cost factor may vary greatly. It also depends greatly on the 
company, on the source of capital resources and how costs are internally calculated. Costs 
may vary substantially country by country, and companies may have different views on 
profitability. Other reasons for producing biopesticides may also be involved. Nevertheless, 
this cost model may help researchers and product developers to evaluate and consider the 
importance of certain costs in the process of product development. Medium costs are often 
mentioned in publications as a limiting factor, but actually in many situations they are only a 
small percentage of the product costs. Burges and Jones (1998b) state: “There are too few 
costs analyses in research literature”. Costs of storage, marketing and application are lacking. 
Most of the information is treated as proprietary information within the biocontrol industry. 
Academic researchers sometimes report on production costs, but often it is not clear which 
factors are actually included. My experience is that they usually refer to medium costs, and 
only sometimes include labour costs. Unfortunately these cost factors only represent two of 
the factors involved and do not give a reliable basis for a complete cost calculation.  
 
Economic analyses of biopesticides in the literature 
In the literature there is a limited amount of papers presenting details on production 
economics, I will briefly review a number of useful studies that illustrate different cases. In 
the Lubilosa project, an economical analysis for the product Green Muscle, based on the 
fungus M. anisopliae, has been made by Cherry et al (1999). It concerns the mass production 
of spores by solid state fermentation in the “bag-system” in a purpose-build facility in Benin. 
The authors gave a breakdown of production costs illustrating the main factors that determine 
the costs, which are salary costs and capital deprecation (60%). Salaries are the largest single 
item, accounting for 30% of the costs. Generally, there is a concern that medium costs are a 
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constraint, but in this case rice was used as a medium and considered an expensive product in 
Africa. Still the authors found that medium costs are only 7% of total costs. Sales costs are 
not included, which is understandable since Green Muscle is not sold to individual farmers, 
but mostly to sponsors and governments. This route is different for most biopesticides which 
are sold to individual growers. 
Grimm (2001) presented a study on the economics of a small-scale production plant for 
entomopathogenic fungi in Nicaragua. He demonstrated the economic feasibility of the 
proposed plant over a ten year period, with calculations including all the cost factors, when 
products are produced for 20,000 ha/yr. Makeup of product costs showed that overhead costs 
and labour costs are the main cost factors in the production of mycoinsecticides. 
An interesting and detailed desk study is presented by Swanson (1997) who compares 
the economic feasibility of two production systems for a mycoinsecticide against locusts in 
Madagascar. He compared the capital-intensive production model with the labour-intensive 
production model. The first one is usually exploited by biocontrol companies in the 
industrialized countries, the second one in developing countries where labour is relatively 
cheap. Swanson used data from actual operating production facilities, the Mycotech facility as 
the capital-intensive model and the IITA in Benin production site as the labour-intensive 
model. He demonstrated that economic feasibility over a ten year period depends on the 
production capacity and the product price per hectare, and that at a higher capacity the capital-
intensive model is profitable, even in Madagascar where labour is cheap. This publication is 
the only one where two different production methods are compared on their economic 
feasibility and therefore presents a valuable study for biopesticide developers. Swanson 
recognized a number of caveats that may affect his analysis such as irregular demand, 
insufficient performance, calculating with predetermined quantity of output, and the static 
nature of technology. These challenges, however, are unavoidable in such an economic 
analysis and pose a certain risk that entrepreneurs face when developing a MPCP. 
The three cases above describe low-tech production of fungi in developing countries.  
Total investment to build the plants was US$96,000 in Benin, US$264,000 in Nicaragua and 
US$650,000 in Madagascar. An economic analysis of a large high-tech plant for the 
production of Bacillus thuringiensis-based bioinsecticides was given by Rowe and Margaritis 
(2004). Here the investment was approximately US$13 Million. The assumed output of the 
facility is about 7% of the world’s Bt market. The authors gave a detailed overview of 
installed equipment and total capital costs and a breakdown of the operating costs. They 
illustrated how profitability depends on production scale and sale price for various 
fermentation systems. Rowe and Margaritas concluded that it is essential to have a reliable 
estimate of the selling price in order to calculate the potential profitability of a production 
facility.  
In EPN production only one author reported on a breakdown of costs for the production 
of H. bacteriophora in a 300 litre fermentor (Gaugler and Han, 2002, fig. 14.2). Media costs 
were 8%, while formulation and packaging were 16% and 2%, labour 22% and toll 
manufacturing 40%, additional costs 12%. Friedman (1990) provided a detailed review of 
commercial and technology development in EPNs. He illustrated the effects of economy of 
scale of in vivo and in vitro solid and liquid production of nematodes and showed that liquid 
production is the best for large scale production when analysed from the perspective of scale-
related costs. 
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Relevant considerations for an economic analysis 
The reviewed papers are valuable examples of economic analyses of biopesticides 
developments and will help to estimate feasibility and profitability in new cases. This can be 
done together with the model above which is an attempt to illustrate the cost makeup of a 
biopesticide and to give perspective on the importance of cost factors involved. The model 
can be used for both the capital-intensive and labour-intensive models. In a feasibility study, a 
sensitivity analysis should be made to identify the main cost factors. In a capital-intensive 
model this is often the capacity ratio. If the production capacity is not fully used, this has a 
large effect on the fixed costs, particularly, because depreciation is calculated over much less 
output, making the full product cost price considerably higher. This is especially relevant for 
products with a short shelf-life and with a strongly variable or seasonal demand. Capacity 
planning is very important to have an optimal capacity usage and to keep costs down. In a 
labour-intensive model the reciprocal factor is labour, more precisely productivity per man 
hour. Other factors that could influence the sensitivity analysis are medium costs, certainly 
once a plant is running at full capacity. Registration costs are often regarded as a decisive 
factor. The main problem is that they are hard to estimate beforehand; nevertheless they 
should not be underestimated to prevent great miscalculations. 
To review and compare economics of the various biopesticides, based on fungi, 
bacteria, baculoviruses and EPNs is extremely difficult and probably impossible, given the 
wide range of production systems, yields, application rates and crop values. Even within one 
group of pathogens this would be difficult. The examples from literature provided above 
demonstrate this also. Nevertheless, the model helps to indicate the main cost factors and to 
consider where attempts to decrease costs can be made. From the model a rough estimate can 
be made from direct production costs to end-user’s price. In an early phase of the research, 
variable costs can often be estimated based on labour input and medium costs. Then one could 
assume a factor 7-8 for the market price, or a factor 3, based on the total of the fixed and 
variable costs. This assumption could be used as a rough indication. When it is known what 
end-user’s price is acceptable in the market, profitability can be analysed. This should be seen 
as the starting point for a feasibility study. Depending on what level of profitability and over 
what period of time this can be reached, a company can decide whether to develop the product 
or not. Clearly, production economics and final product costs need be to analysed on a case by 
case situation and depend on the type of product, the company and the market.  
 
 
Conclusions and recommendations 
 
Production considerations and recommendations 
A challenge in the process development is the extrapolation and realization from laboratory 
scale techniques to commercial and large scale technology. Investigators often assume that 
laboratory production parameters are valid on production scale. This miscalculation is often 
made. Scaling-up always presents new problems and unforeseen deviations that need to be 
tackled. For instance, experimental production in shaking flasks may give misleading data.  
Production research should be started as early as possible in the foreseen bioreactors. 
Optimization of each parameter also needs to be investigated at the production scale. The 
production process needs to be tailored to the specific pathogen and its biology. Several 
companies have patented their bioreactors and/or production processes (medium, carrier). Up 
to 2000, about 215 patents had been filed on the general topic of biopesticides (Montesinos, 
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2003), but how many are related to mass production is not mentioned. The costs of filing a 
patent are high and the relevance is limited. Minor changes may avoid breach of the patent 
and, more importantly, checking on patent breach is also difficult. Keeping production details 
confidential should usually suffice with regard to concerns about competitors.  
Economy of scale could provide a way to decrease costs in three areas: capital, labour 
and materials. Improvements in production technology should be a continuous research 
objective as well as reducing production costs. In designing a production plant and a 
production process, the possibilities and advantages of scaling-up should be part of the 
business plan in case the market demand increases. In in vitro production of nematodes, 
capital costs (depreciation, interest) are the main cost factors and may account for over 60% 
of the total costs, and they should, therefore, be the focus for cost savings, according to 
Gaugler and Han (2002). Production costs are a function of scale and they illustrate this 
(fig.14.4, p. 306) by the production of H. bacteriophora: a 10 times larger fermentor reduces 
the production costs more then 4 times. Changing from low technology to high technology 
may give a more controlled technology with low fault equipment and more fault tolerant 
processes. This will also result in better control over process parameters and more predictable 
yields. A high investment is then the trade-off. In the Lubilosa project, “after much debate”, 
the capital-intensive approach with high technology of large scale SSF was chosen over a 
cottage-type industry production because of product quality and unit production costs 
(Douthwaite et al., 2001). 
The developments of a mass-production system and of a formulated product are 
complicated and expensive processes. Production efficiency and cost-effectiveness are the 
key-factors. It is obvious that only a competitive product can become successful in the market 
and that companies will survive and be profitable when their costs are covered by selling 
enough products. The mass-production system is the engine that drives everything. Capital is 
needed to build it, and once running, it needs to run efficiently and at low cost. In Lisansky’s 
words “any biopesticide company planning to remain in the business should be actively 
addressing its process technology and production facilities as a matter of high priority” 
(Lisansky, 1993). The production should be reliable and failure-free; instability will cause 
many problems and increase product costs.  
Comparisons between the production systems of the four different types of pathogens 
are challenging to make due to all the different biology and technology. The production of 
pathogens of the same group is comparable to some extent and systems may be quite similar, 
as for instance for EPNs. The use of deep tank fermentors seems the most versatile in 
production of biopesticides. Comparisons between SSF and LSF are difficult to make, but 
may be necessary to make cost estimates for a certain pathogen and to decide in which system 
it could be produced most efficiently. Federici (1999) attempted to compare the different 
types of pathogens based on product characteristics, such as mass production and cost-
effectiveness, but for a commercial evaluation this is insufficient and not very useful. Only 
general requirements for an economical mass production therefore can be given (table 3.13). 
A mass production of a certain pathogen needs to be approached and studied on a case by 
case basis.  
 
 
 
 
 
Chapter 3 
___________________________________________________________________________ 
 96 
 
Table 3.13.   Considerations and requirements for an economical mass production 
 
• Technology level: in vivo, in vitro: SSF or LSF 
• Production equipment: availability and versatility 
• Possibility for economy of scale for capital, labour and  
materials  
• Ability to control process parameters; fault tolerance of the 
process 
• Length of the production cycle, the shorter the better 
• Reproduction factor and yield 
• Medium composition and costs: defined or a natural source 
• Downstream equipment: availability and versatility  
• Virulence and storability of the propagules: technical product 
 
 
Formulation considerations and recommendations 
Shelf-life is often mentioned as a weak point of biopesticides. The agrochemical industry 
requires a shelf-life of a minimum of two up to even four years for a product to be able to go 
through the whole supply chain, at ambient temperatures, with a range from zero °C up to 
over 40°C for extended periods in tropical countries (Rhodes, 1990). In biopesticides, some 
companies require a long shelf-life too, but if this objective is rigidly strived for, this could 
mean a failure in developing a product. Jaronski (1986) stated that an 18-month period at 
room temperatures is a valid goal for mycoinsecticides and that this has been achieved with 
formulations of B. bassiana and M. anisopliae. Biosys’ aim was a shelf-life of two years at 
room temperature with EPN products. They did not achieve this goal. Jones and Burges 
(1997) reviewed the requirements of biopesticides regarding product stability and shelf-life 
and they gave suggestions on how to improve this through strain selection, production, 
downstream methods and additives. They rightfully concluded to start investigating this 
aspect early in the product development.  
In the greenhouse industry distributors and growers are accustomed to handling short 
shelf-life products like predatory mites and parasitoids. Biopesticides with a shelf-life of six 
months at refrigerated storage are acceptable. A short shelf-life is also less of a problem when 
the application period is known in advance and to which production can be adapted. In EPNs 
this is often the case, for instance, for control of larvae of the black vine weevil or white 
grubs. In EPNs, shelf-life is usually three months at refrigerated storage and the producing 
companies and distributors are coping well with this shelf-life period. Ideally, companies 
would like biopesticides to have a shelf-life of two years at room temperature. This would 
improve their position when compared with chemical pesticides on user-friendliness. Much 
research is still needed to achieve this.  
Direct contact is often required in order to target the pathogen and this demands careful 
spraying with well-adjusted equipment. Biopesticides do not profit from extra features such as 
systemic and trans-laminar distribution of the active ingredients which is the case with many 
chemicals. An improvement in targeting biopesticides with more appropriate equipment is 
also an area where general principles need to be generated by institutional organizations. 
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User-friendliness is also a fundamental aspect which should not be underestimated. If 
there are extra requirements to what a grower is used to with chemicals, adoption of the 
biological will be less easy. An example from Mycotal: previously, users had to pre-soak the 
product for at least two hours before spraying and they complained often about it. This 
requires planning of the application early in the morning or late in the afternoon (as 
recommended since the relative humidity is higher then) and this was too complicated. Once 
this was no longer necessary due to a small formulation change, product acceptance was 
improved. Further, spraying early or late in the day makes it more inconvenient for the grower 
and this can be a disadvantage for a microbial product. These aspects may seem irrelevant, but 
in practice they should be avoided as much as possible. 
 The formulation of entomopathogens is an absolute prerequisite for a commercial 
product. Hofstein and Fridlender (1994) considered formulation as the critical stage in 
product development. A formulation may offer a unique selling point and add value to the 
final product. The development of a formulated product, including the application 
recommendations, is a complex process, intertwined with aspects of the production and the 
downstream processes. Formulation research needs to look at production, storage stability, 
efficacy, user-friendliness and costs, and to consider their importance continuously during the 
product development. A multi-disciplinary approach is needed and knowledge and products 
be included from other industries such as the adjuvant industry, packaging industry, coating 
industry and others. Cooperation with academic research may provide insight in the 
fundamental aspects and may study more generic principles that could improve formulation. 
Formulation needs a case by case approach and it can influence the products’ success to a 
great extent. In industry, hands-on experiences and know-how are valuable in order to 
improve formulations for new products.   
Therefore formulation studies are essential through the whole process of production and 
product development. Registration considerations should be included too in designing a 
formulation. Lisansky (2005) recommended that formulation staff be involved in process 
development and product design from the end of fermentation to the final product (unlike in 
chemical industries). I recommend including involvement early in the mass production and in 
registration. In the biopesticide companies this is usually in the hands of a small team 
anyway, but they should be aware of all these aspects. On the other hand, the product 
developer needs to decide what an efficient formulation is within a certain timeframe and 
budget. Research in this area should be pragmatic focussing on key demands. The challenge is 
to find the balance between what is acceptable and what may give real improvements. Based 
on knowledge, experience and considerations of the four main functions of a formulation, the 
formulation expert must make a decision. The complex interactions and the demands of the 
formulation mean that the selection of the best formulation will ultimately be a pragmatic 
compromise with a main focus on efficacy, ease of use and costs. 
 
Final conclusions 
In optimization of production there is a maximum to the yield of propagules per ml. In many 
cases substantial improvements are hard to make even after 20-30 years of research in this 
area since one is confronted with the biological limits of the organism. Another factor that 
influences product costs strongly is the application rate. In many pathogens, the slope of the 
dose-mortality regression curve is not steep indicating that higher application rates do not 
contribute significantly to a higher mortality. A small factor matters less in efficacy, but 
matters more in production. Even a factor of two can be pivotal. This relationship between 
Chapter 3 
___________________________________________________________________________ 
 98 
production and application rate needs careful study. Formulation is part of this relationship 
and an area of improving the product’s performance and reducing its costs. These areas are all 
interconnected and offer potential for improvements and lowering costs for the end-user. 
 
 
Table 3.14.   Key factors determining a successful economical mass production and  
          formulated product 
 
• Investments 
• Economy of scale 
• Stability of production process 
• Production yield and application dose 
• Capacity usage 
• Product shelf-life 
• Level of efficacy  
• User-friendliness 
• Full product cost price and end-user price 
• Turnover, profitability and return of investment 
 
 
In addition to the technical issues of the development of the mass production and of the final 
formulated product, a key issue is the upfront investment and the market price for the end-
user. Further, R & D costs, and registration investments contribute largely to the final cost 
price. Depreciation is a large part of the costs. The size of the market and the potential 
turnover determines the market price too, since costs and depreciation can be divided over 
more products. Once production is running, the focus should be on variable costs, stability of 
the process, and optimal capacity usage.  
A sharp business plan is indispensible to the decision-making process. The development 
of a mass production and a formulated product are interconnected and technical and 
economical issues should be leading. The entire process is multi-factorial and multi-
disciplinary and scientists and industry should work together from an early phase on. Many 
different aspects need to be investigated and specialists are required. These developments 
need the commitment of all involved, including the commitment for financial resources. The 
technical issues of the development of the mass production, the final formulation, and the 
application strategies must follow the commercial aspects. For the product to remain 
competitive, improvements in these areas are a never-ending process. To be successful with 
biopesticides, both production efficiency and product efficacy are the keys.  
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Abstract 
Quality control can de divided in production control, process control, and product control. 
The first two refer to internal quality control with regards to the production of a microbial pest 
control product, and ensure a stable production process with a minimum of failures. Product 
control refers to the quality of the final product that leaves the factory and which needs to 
perform according to registration and customer satisfaction requirements. Products must meet 
product specifications set by the manufacturer. Parameters checked per batch are the number 
of effective propagules, microbial purity, presence of toxins, technical properties and efficacy. 
Proper identification of the biocontrol agent is part of process control. Product specifications 
must be met until the end of the claimed shelf-life. Each type of pathogen presents a different 
set of difficulties for the final product’s quality control assessment. The methodology to 
establish the number of active propagules and efficacy vary per type of pathogen and its mode 
of action, and demand a specific approach. Well-standardized bio-assays, tailored per 
pathogen and target pest, are necessary to determine efficacy. A reference standard is required 
to confirm bio-assay results. Checks on microbial purity and technical properties are similar 
for all types of pathogens. Registration requires well-described quality control protocols and 
real data for validation. It demands product quality control procedures for all batches before 
sale. Producers submit their own methods and data. Officially recognized standard methods 
and criteria are lacking, submitted data are evaluated by the competent authority. This is 
difficult for producers since various requirements and interpretations of data between 
countries exist. Label information is only required for the number of active propagules, not 
for efficacy statements. Post-registration checks by authorities are seldom performed. One 
Danish study illustrated that regulators also face the lack of standard criteria, and that 
guidance documents need to be developed. Other regulations that impact product quality, 
particularly microbial purity, are HACCP protocols for growers, maximum residue 
requirements, and product accountability. Practical difficulties in conducting quality control 
are the establishment of protocols, sampling methods, and test procedures. Each producer 
establishes its own product specifications and tolerance ranges. Product ‘specs’ generally are 
the number of active propagules, the germination rate, an efficacy level, levels of accepted 
microbial contaminants, and some technical properties. Natural variation makes efficacy 
testing via bio-assays difficult, and setting a standard is only possible once a large data set has 
been generated from which true deviations, in the case of poor quality batches, can be 
distinguished. Post-shipment product quality control is particularly warranted for nematode-
based products. The establishment of standardization of efficacy for all microbial pesticides is 
not recommended since this has not succeeded for Bt’s after thirty years of research, 
comparative testing and discussions. I recommend that the tolerance range for the number of 
active propagules be ±25%. Quality control must ensure that end-users receive high quality 
products. Total quality control covers all aspects of quality, including the field use of a 
biopesticides. Biocontrol companies should ensure that the whole chain is well aware of 
quality issues and that those involved act accordingly. A list of benefits of quality control is 
provided which illustrates that both the biocontrol industry and its customers benefit from 
proper quality control.  
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Introduction  
 
Biopesticides are often criticized for their variable performance and lack of reliability. Quality 
control (QC) is therefore of paramount importance in order to ensure that products are 
delivered that comply with pre-determined specifications and deliver the efficacy within the 
prescribed conditions for use. Quality control does not only refer to the final end-use product, 
but also to the production and the production processes. In general, quality control objectives 
are to ensure that: 
1) properties of incoming raw materials comply with the manufacturer’s specifications;  
2) there is consistency between production runs and products;  
3) end-use products meet criteria set by registration authorities; and that 
4) product performance meets the end-user’s perception of quality in relation to price, and 
leads to repeat purchases of the product.  
Quality control is performed in all manufacturing fields, but interpreted differently. Thus, 
each industry must define quality control precisely. In biocontrol, quality control has received 
much attention in the field of sterile insect technology and in arthropod natural enemies. For 
an overview of quality control matters regarding mass-reared sterile insects I refer the reader 
to Boller and Chambers (1977), and for arthropod natural enemies to Van Lenteren (2003). A 
brief historical overview on the development of quality control for beneficial insects is 
provided by Leppla (2008). In quality control of natural enemies, Leppla (2003) distinguished 
three functions: production, process and product control. In the field of microbial pesticides, 
however, clear definitions are lacking. Few authors extensively treat quality control in its 
entirety. Most papers dealing with quality control focus their comments to end-use product 
control, while aspects of process control are frequently included. Definitions of quality 
control used for microbials will preferably be similar to the ones used for natural enemies and 
other beneficial biocontrol agents, for the sake of convenience. I will use the separation of 
functions as given by Leppla (2003) and use the following slightly modified definitions:  
1)  production control is a procedure intended to ensure that incoming raw materials 
comply with defined specifications, and that production equipment be properly 
maintained, and that all inputs needed to run the production (materials, labour, energy, 
etc.) be available at the right time; 
2) process control is a procedure intended to ensure that a manufacturing process runs 
according to previously determined process parameter profiles so that expected yields 
and formulated products be delivered; 
3) product quality control is a procedure intended to ensure that a manufactured end-use 
product adheres to the product specifications, a previously defined set of quality 
standards, in order to meet the efficacy norms within described conditions for use, and 
to meet criteria set by registration authorities.  
To determine the process parameters and the specifications of incoming raw production 
materials and formulation ingredients, and the outgoing end-use products, research is needed 
to establish the appropriate standards and to develop methods to measure these standards. A 
company can decide itself on specific standards, although for the final product some of these 
are requirements of registration authorities. As a result, standard operating procedures (SOPs) 
should be developed. This research is imperative and is a considerable amount of work. It 
should be conducted within the developmental phase of the production and of the final 
product. The results are the basis for a consistent manufacturing process once products are 
routinely made and quality control is implemented. 
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The term quality assurance is often used in this context; it covers all activities from 
designing and developing quality control and the implementation of it during all phases, 
including reacting to deviations and improving processes and procedures to ensure good 
quality of the end-use product. It can be described as the continuing process of ensuring good 
quality. International standards have been developed for manufacturing activities and models 
are described and certified under ISO 9000 series. Implementation of such a quality 
management system can ensure consistent production and high quality products. Furthermore, 
a producer may choose to comply with Good Manufacturing Practices (GMP), although this 
has been developed for the pharmaceutical industry for which it is more appropriate. ISO and 
GMP are, however, rarely implemented in the biocontrol industry. The biopesticide 
companies Andermatt Biocontrol, Futureco and Prophyta are ISO 9001-2000 certified. The 
Bio-Fly plant, a subsidiary of Bio-Bee, Israel, operates in compliance with the ISO 9001-2000 
quality standards in the production of sterile flies of the Mediterranean fruit fly. Bio-Fly is the 
only company in the field of mass production of arthropods which works with this certified 
quality system. Generally, companies find these systems too complicated and too expensive.  
The production of MPCAs is a complex system that involves living organisms. This 
calls for the monitoring of crucial aspects in the whole line of processes, from production to 
the use of the end-use products. Quality control and feedback from deviations should be an 
integral part of the development and the use of biocontrol products within all biocontrol 
companies. This overall process is called Total Quality Control (TQC). An elaborate view on 
TQC for natural enemies is given by Leppla (2003); the relevant aspects of TQC apply to 
microbial control agents as well. Quality control systems for MPCPs are much more 
comprehensive and specialized than those used for chemical pesticides, where relatively 
simple analytical techniques can be used. MPCPs contain living organisms, which are 
inherently variable in performance, and as a result the products will never be as stable as 
technical products. This variability demands a rigorous quality control system in order to 
ensure that biological products are delivered within specifications. Manufacturers are required 
to develop their own systems and regulatory procedures are not harmonized, nor are any 
standards aivalable. As a result, quality control in biopesticides is neither transparent nor 
standardized. I will discuss the critical aspects of quality control in the commercial 
development of biopesticides, focussing on product quality control, and provide 
recommendations for a more standardized quality control.  
 
 
History of quality control in microbial pest control products 
 
The market of MPCPs is characterized by the frequent appearance and disappearance of 
products as well as companies (Lisansky, 1997). For this, many different explanations have 
been put forward, including poor performance of products. The lack of effective quality 
control is often cited as a possible reason for the failure of a product. Some examples are 
given in the literature for baculovirus products produced in Egypt respectively India 
(Grzywack et al., 1997; Battu et al., 2002). Likewise, quality control of EPN products by 
independent scientists has revealed inconsistent quality. Gaugler et al. (2000) investigated 
mail-ordered H. bacteriophora and S. carpocapsae products from cottage industry in the USA 
and found only 60% of the number of nematodes stated on the label, on average. Also, 
reduced pathogenicity was often found. Few resources are dedicated to quality control, whose 
importance is often underestimated in the biocontrol industry. Small companies may not have 
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the knowledge or the facilities for proper quality control checks. To be fair, proper testing 
methods were lacking in the past.  
Registration does require well-described quality control procedures and quality control 
data, but quality control is seldom enforced following approval. Some countries do not 
require registrations, or products are sold without formal approvals, and quality control may 
well be lacking in such situations. I have seen many unregistered MPCPs on the market which 
did not comply with the label claims. On most of the occasions this concerned the number of 
infective propagules, which was too low, and sometimes, even infective propagules were 
lacking. More complicated features such as performance and purity were not checked, but 
were bound to deliver inferior results. These products damage the image of biocontrol. This 
underscores the importance of a good quality control programme.  
In the field of natural enemies, similar situations have occurred, leading to failures in 
biocontrol and the disappearance of some companies (Van Lenteren, 2003). The biocontrol 
industry together with scientists did develop quality control criteria and test guidelines for 
most natural enemies (Van Lenteren et al., 2003a), and now most of the larger companies do 
conduct quality control according to these tests and criteria (Bolckmans, 2003).  
In the field of microorganisms, an attempt was made in 2001 to initiate a similar 
collaboration between industry and scientists. Scientists of CABI and the International 
Biocontrol Manufacturers Association (IBMA) initiated a working group on quality control 
and standards of MPCPs. A joint IBMA – COST 830 workshop was held in 2001 to try to set 
appropriate standards for microbial products (Migheli and Ruiz Sainz, 2003). As a result of a 
lack of funding, this laudable initiative did not produce many tangible results and the IBMA 
Working Group is no longer active. Today, there is no mutually agreed set of testing methods 
and criteria for MPCPs, unlike for natural enemies. Registration procedures for MPCPs 
generally require quality control methods and data, but standardized guidelines and clear 
criteria are lacking, even within the EU Directive 91/414 (EC, 1991a) on registration of plant 
protection products. Every company is allowed to develop its own methods and to set its own 
standards with which products should comply. Jenkins and Grzywacz (2003) recognized the 
lack of standardization and they have suggested a minimum set of parameters for quality 
control for fungi and baculoviruses.  
In the field of EPNs, quality control was first discussed between industry and scientists 
at the eighth workshop of the IOBC Working Group on “Quality control of mass-reared 
arthropods” in 1995. All companies agreed that QC criteria needed to be developed for 
nematodes as with beneficial arthropods (Mason et al., 2002). Ultimately, successful 
collaboration between scientists and the industry in the EU COST Action 819 led to the 
development and publication of QC criteria and testing protocols (Grunder, 2005). Clear 
standards, as determined and accepted for natural enemies, however, are still lacking for most 
quality control parameters for EPNs. 
 
 
Production quality control and process quality control 
 
Quality control of production concerns internal procedures for checking whether inputs 
(purchased raw materials: medium ingredients, formulation compounds and packaging 
materials) comply with their specifications, whether standard operating procedures (SOPs) are 
well set-up and followed, and whether production and downstream equipment is maintained 
properly and operating as expected. Warrior (2000) emphasized that the quality of raw 
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materials contributes to a large extent to the quality of the final products and that 
specifications of raw materials must be checked before release for production purposes. He 
referred mainly to the large scale production of Bacillus thuringiensis (Bt).  
Quality control of production processes relates to monitoring vital process parameters, 
and whether they run according to expected profiles. Conducting these procedures should 
result in minimum production failures, and in expected yields of good quality. Continuous 
feedback and improvements should also lead to production stability with minimal extra costs, 
and to products that match planning. As production systems and processes vary greatly for 
MPCAs and between companies, details cannot be given here. Nevertheless, quality control is 
important and should be an integral part of the mass production. Process parameters can be 
relatively simple such as room temperature and percentage relative humidity in a rearing room 
for insects in in vivo production of, for example, a baculovirus. On the other hand, it can be a 
complicated set of parameters that influence each other in liquid production of EPNs. In this 
case, variables such as pO2, pCO2, pH, temperature, foaming and hydrostatic pressure need 
to be monitored and adjusted where necessary. Some variables can be adjusted in various 
ways, as for example oxygen pressure, which can be adjusted by aeration, stirrer speed, 
temperature and by vessel pressure. This illustrates the complexity of such production 
processes and computer steered programmes are needed to regulate the process. Process 
control also includes downstream and formulation processes, packaging and storage. At 
various steps in the processes, parameters must be monitored and checked. Data should be 
gathered during all processes and should be used to improve the production on a continuous 
basis. Production control and process control are often combined in SOPs and performed by 
production personnel. Production and process control have the greatest effects on the quality 
of the resulting product and therefore should be taken very seriously within a company.  
 Quality control on inoculum stability is crucial. A procedure for storage and use of 
inoculum material for the production is described in chapter 3 where the chief goal is 
maintaining inoculum stability. The inoculum needs to be monitored for phenotypic and 
genotypic changes and for contaminants. When genetic stability is an issue, specialists may 
need to be consulted to make sure the inoculum quality is still as desired. Examples of quality 
problems are loss of plasmids in bacteria, and mutations in baculoviruses. If the original 
inoculum is no longer of good quality, the strain needs to be recovered anew from a culture 
collection or from a stored product. Starting with a new isolate is a delicate decision and 
requires very detailed checking of the strain and its properties before it should replace the 
older strain and be taken into production. Companies prefer to avoid this as it costs time and 
money. Long term storage of stable inoculum is the preferred option; if this is not possible 
new inoculum must be made and tested rigorously. In the case of the production of Green 
Muscle (Metarhizium anisopliae var. acridum), the standard isolate is passaged through the 
desert locust every six months to avoid loss of virulence (Cherry et al., 1999). Inoculum 
storage should be taken extremely seriously and measures should be taken to avoid any 
problems with the stored material as much as possible. For instance, it is wise to keep 
inoculum in two different places to spread risks and to have an alarm system on the storage 
facility or deep freezer. 
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Product quality control of microbial pest control products 
 
Quality control generally refers to product control, i.e. to the final formulated product. In 
manufacturing, however, there may be several in-between products, like the “technical grade 
active ingredient” (TGAI), that need to be checked. Material from succeeding production 
batches may be stored to be formulated together. Checks on propagule numbers, microbial 
contaminants are needed and some batches may be discarded or handled differently, stored 
longer or shorter. During formulation, propagule numbers may be set to the specification of 
the final product, thus propagule counts are needed before final formulation. The final 
formulated product is subject to quality control and the product needs to conform to 
previously determined product specifications (‘specs’). These specifications are usually 
determined with regard to product performance in the field in a broad sense and to registration 
requirements. Product performance relates to efficacy, obviously, but also to applications 
characteristics (particle size, emulsion separation, sedimentation in the package) and to shelf-
life parameters (moisture content, microbial purity).  
The ‘external’ objective of quality control is to deliver a product to the end-user that 
complies with the specifications at the moment of use. It should also deliver the expected 
results. This objective focuses at satisfying customers and on complying with registration 
criteria. Each batch has to be tested prior to sale in order to prevent release of products that do 
not meet the ’specs’. The ‘internal’ objective of quality control is to highlight any problem 
areas which should then be subject to corrective action. This should lead to improved 
production of products with fewer and fewer discarded batches, and to stability of the 
production and the products. 
A number of papers refer to the overall issue of quality control of MPCAs. Burges 
(1981b) recognized two main aspects of quality control: identity of the pathogen and level of 
contaminants. In addition he discussed activity, physical features, and safety to vertebrates in 
an example treating baculoviruses. Jenkins and Grzywacz (2000) reviewed the need for 
quality control procedures in fungal and viral biocontrol agents in the production as well as 
for the final products. Product specifications should be determined with regard to physical 
properties, microbial contaminants, efficacy and storage. They illustrated this by providing 
recommendations for specifications for fungal and viral products. Lisansky (1985; CPL, 
2006b) listed five aspects that should be subject to QC: efficacy, microbiological purity, 
absence of mammalian toxicity, physical characteristics and shelf-life. Quality control 
methods and specifications are discussed and given in detail for Green Muscle (Jenkins et al., 
1998). The need for quality assurance in the industrial production of biopesticides is briefly 
discussed for bacterial, fungal and viral products by Guillon (1997b). One company, Verdera, 
Finland, has disclosed some information on their chosen quality criteria for biofungicides. 
Specifically, they refer to QC during production and to end-use product criteria. Assessed 
product criteria are viability and efficacy tests, related to storage stability (Palin-Holmberg et 
al., 2003). In the literature, product quality control generally comprises the features named 
below.  
 
Identity of the microbial pest control agent  
The organism needs to be properly identified at strain level using the most appropriate 
scientific techniques. Molecular techniques are needed to do this. The area of taxonomic 
identification is still developing and species and strain concepts are changing with the 
development of new technologies. Identification is a difficult topic, but very important with 
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regard to a proper risk assessment. Therefore, the Biopesticide Steering Group (BPSG) of the 
OECD is developing a guidance document that should help regulators and the industry in 
assessing the taxonomic identification. Most companies lack the expertise to do this in-house 
and external laboratories are asked to conduct the identification. The OECD recommends that 
two laboratories identify the strain to ascertain the identification (OECD, 2007). Typically, 
this identification is done at the beginning of a product development and not as part of the 
quality control procedure of every batch. Once a master stock culture has been made of the 
properly identified inoculum, production is started with a specimen of that stock, and batch-
wise identification is superfluous. When a new master stock is made, re-identification of the 
organism should be conducted. Nevertheless, cultures should always be checked visually for 
deformations or other deviations (genetic or phenotypic changes) to make sure the organism 
still shows its usual features. At the slightest suspicion, re-identification should be conducted. 
I consider this aspect to be part of the process control rather than of product control. It cannot 
be done for every batch, and furthermore, there is no need for it. I recommend re-identifying 
the inoculum every three to four years by a specialist. Then, a recent identity confirmation is 
available for registration purposes and liability.   
 
Number of infective propagules 
A product contains a certain number of infective or virulent propagules. This needs to be 
specified on the label. This number of infective propagules, when applied according to the 
recommended methods of application and under the right conditions of use, should achieve 
the claimed level of control of the pest. Counting of propagules can be done, but is often 
difficult in technical grade products as well as in formulated products in which remnants of 
the production medium and/or carrier and particles of formulation ingredients may be difficult 
to distinguish from spores or virus particles. The number of propagules, however, does not 
necessarily reflect virulence directly. Accordingly, the actual activity needs to be determined 
by germination tests or by establishing the number of colony forming units (cfu). This method 
is used in the case of bacteria and fungi. The active ingredients in Bt’s are spores and 
endotoxins (crystallized proteins), the latter can be measured by analytical techniques. But 
virulence of the product needs to be assessed in bio-assays. Baculoviruses cannot be counted, 
usually, because they are hard to distinguish from formulation particles or insect remnants. 
Even if they can be counted, viable and non-viable particles cannot be distinguished. Since 
they are obligate parasites that can only replicate in insect cells, a bio-assay is needed to 
assess the product’s virulence. EPNs can usually be counted and living and dead dauer 
juveniles (DJs) can be distinguished under the microscope. Since yields may vary per batch, 
counts of infective units needs to be carried out to be able to adjust the number during the 
formulation process to reach the total number in the end-use product as specified. Next, 
packaging samples need to be counted again to confirm the ‘specs’. Checking the product on 
the number of infective propagules is a basic element of product control. 
 
Microbial purity  
The total number or percentage of microbial contaminants in a MPCP should be limited. 
These contaminants may negatively influence product quality in terms of shelf-life, efficacy 
and even physical characteristics. Furthermore, contaminants may pose a risk to the applicator 
and the consumer. Registration criteria therefore only accept low numbers of contaminants 
and require absence or near-absence of human pathogens. The total number of contaminating 
organisms should not exceed a certain number, or, it should not exceed a certain percentage of 
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the number of the active ingredient. The standard depends on what the company decides or on 
what the registration requirements demand. The standard is often set at 0.1% of the number of 
infective propagules and is just a pragmatic amount chosen by many companies. There are, 
however, no obligatory standards within the EU, EPA, OECD and national regulations for 
MPCPs. For more details, see below at registration requirements. Determination of the level 
of contaminating organisms, usually bacteria and fungi, is done by cfu testing on microbe-
specific media and at certain temperatures. A total count of mesophiles (fungi, bacteria and 
yeasts) is often conducted and counts of bacteria, specifically human and mammalian 
pathogens, by selective tests. Some countries demand animal toxicity tests for Bt products and 
baculoviruses with every batch to exclude human pathogens. Determination of the level of 
contaminants needs to be part of process control as well as of product control. 
 
Presence of toxins 
Presence of toxic metabolites is a concern of regulatory bodies and information needs to be 
presented to the authorities for each specific MPCA where this is considered relevant. The 
issue of toxins is not well regulated and a discussion between the industry and regulators is 
ongoing. Clear and appropriate requirements still need to be defined. This topic is dealt with 
in chapter 5 in more detail. Standard criteria are not defined and a case by case approach is 
taken. Harmful effects should be minimal. In the production of some fungi and bacteria, 
metabolites may be formed and this may depend on the conditions of the production process. 
Deviations in the process may lead to a higher production of metabolites, and metabolite 
levels may need to be checked. Toxins are difficult to monitor and biochemical analytical 
techniques have to be developed to identify them and to monitor them. Routinely monitoring 
of toxins in the production is only required in some cases following risk assessments by the 
evaluating authority. An example is the fungus Isaria fumosorosea (=Paecilomyces 
fumosoroseus) where absence of secondary metabolites must be checked in each fermentation 
batch. This has subsequently been decided and documented by the EC (EC, 2002a). When 
toxins are found, the batch has to be discarded.  
 
Physical, chemical and technical characteristics 
Registration requirements demand product stability with regard to physical and chemical 
stability, and information on technical properties. The formulation needs to be physically 
stable during the shelf-life period. This means no clump-forming in wettable powders should 
occur, nor should irreversible sedimentation of propagules in suspensions or separation of 
carriers in the case of emulsions take place. Chemical stability (like pH) also needs to be 
considered and checked according to registration requirements, but in reality this is of lesser 
importance. Each type of formulation has its particular characteristics that need to be checked. 
These are referred to as technical properties. Examples are wettability, suspensibility, and 
particle size distribution in wettable powders and water dispersible granulates. For emulsions 
it is emulsifiability and stability, for suspensions pourability, etc. These properties have to be 
tested according to recognized CIPAC methods, which have been developed for chemical 
pesticides, and comply with standard criteria. 
 
Efficacy 
Efficacy is the most significant parameter in quality control. The product’s field performance 
is the most valuable aspect; not only for registration, but also for the company’s revenues 
from the product. If batches of the product do not perform up to expectations, repeated sales 
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will decline. Therefore, every batch should be tested prior to release. This can only be done 
quickly and in a cost-effective way by using bio-assays. These should reflect the product’s 
performance in the field as much as possible. The relationship between bio-assay results and 
field results needs to be established from the outset. This study should include batches with 
poor quality in order to see whether the bio-assay really distinguishes good batches from poor 
batches. This is often not done and then the test is useless. Bio-assays must be developed in 
such a way that they give a reliable prediction of how a product will work in the field. 
Obviously, field studies cannot be conducted for each batch because of time and costs issues. 
Bio-assays differ per pathogen and per target. The same bio-assay that was developed 
for strain selection can also be used in QC tests. There are numerous tests available, see 
chapter 2 for more information. Registration requirements demand a description of a QC 
efficacy test, but specific guidance is not available. Every company is allowed to use its own 
method as long as it gives reliable data. Bio-assays must be standardized and must be done 
correctly, otherwise they are meaningless. A major problem in using bio-assays in quality 
control testing is accuracy and reproducibility. Variations due to insect-rearing fluctuations, 
assay conditions and insect stage can influence the insect’s response to the pathogen. As a 
result, it is desirable to include a standard product as a reference in the test and to compare the 
results of the sample with the results of the standard. This is possible in bacteria and 
baculoviruses where material can be stored for years without a change of properties. In fungi 
this is more difficult. In EPNs this is almost impossible due to difficulties in storing material 
for along time. Testing for efficacy is clearly the most important aspect of product control. 
 
Quality control and shelf-life 
A product has to comply with its set QC criteria up to the end of its shelf-life period. Usage of 
a product at the end of its shelf-life should give similar results as does usage of a fresh 
product. As a consequence, the length of the shelf-life period is determined by the QC criteria 
and product specifications which it still has to meet at the end of the shelf-life period. For 
example, if spore germination rate in a fungal product has a minimum set criterion of 80% 
and after six months the germination rate drops under this level, the shelf-life period is 
determined at six months, even when other criteria are still above their minimum criteria. If 
one parameter does not comply to ’specs’ anymore, the batch has to be discarded.  
There are no clear registration requirements for storage stability for biopesticides in the 
EU. The company determines the product’s shelf-life period in combination with the storage 
temperature. For instance, a mycoinsecticide has a shelf-life of six months when stored 
between 5 and 10°C. Evidence of product stability should be presented in the registration 
dossier and then this will be accepted by the authorities. For registration tests, QC parameters 
need to be tested at initiation and at termination of the storage period. Tolerance levels are, 
however, only specified for chemical pesticides, and those are not appropriate for 
biopesticides. Currently, the OECD BPSG (Biopesticide Product Steering Group) and the 
IBMA are in discussion regarding the establishment of specific testing procedures and 
tolerance limits for storage stability of MPCPs (OECD, 2007). I will discuss this more in 
detail in chapter 5. Product quality parameters need to be checked at regular intervals during 
the shelf-life period to investigate whether product characteristics are stable. This will ensure 
confidence in the determined specifications. Where deviations are found, corrective measurers 
need to be taken in the preceding processes. If, in the end, improvements are not possible, the 
length of the shelf-life period must be reconsidered. 
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Quality control parameters for end-use products 
Product quality control needs to be carried out on the formulated product. It may also be done 
on bulk material just before packaging if this process is known not to influence quality. 
Testing should require as little time as possible so that no valuable storage time is lost. 
Parameters subject to testing at this point in time are:  
1) number of infective propagules; 
2) physical-chemical properties; 
3) microbial contaminants; 
4) efficacy. 
Once results are conform ‘specs’, the batch can be released for sale. If one of the parameters 
does not comply with its specification, the batch has to be discarded or send back to 
production in order to be improved, if possible. Batches where human pathogens or harmful 
toxins have been detected are to be discarded early in the production process. An identity 
check is not part of product control. 
 
 
Critical aspects of product quality control with the various types of pathogens  
 
Product quality control is an integral part of manufacturing biopesticides to ensure sale of 
high quality products. I believe that today this concept is well recognized in the biocontrol 
industry and that QC has become a routine procedure. In addition, registration requires 
detailed description of QC procedures, accompanied by real data to illustrate that products do 
meet previously determined specifications. Entomopathogenic fungi and bacteria, and 
baculoviruses are subject to registration, EPNs generally not. Registration requirements with 
regard to product control of biopesticides are discussed below. In many papers, quality 
control of MPCPs is discussed. Researchers acknowledge the importance of quality control, 
but few papers treat this subject systematically and in-depth. I will review the specific aspects 
of each type of pathogen related to product control. Each type of pathogen and each type of 
product requires monitoring of specific characteristics related to the number of infective 
propagules, the formulated product, and its field of application. On the other hand, all 
products require monitoring of similar parameters that are relevant to all of them such as 
microbial purity and technical properties. The most determinative parameters are the number 
of infective propagules, the biological activity of the product, microbial purity, and technical 
properties. Counting propagules is difficult in bacterial and viral products and generally it 
does not give reliable information on efficacy. A bio-assay must be conducted to obtain useful 
information on efficacy. In fungal products, the germination rate and bio-assays produce 
reliable information on virulence. In nematode-based products counts of dauer juveniles and 
bio-assays need to be conducted to measure quality.  
In bio-assays, standardization of the methods is crucial, as is comparison with a 
reference standard. This reference ideally is a stored reference standard of the product; if this 
is not available, then the reference can be a chemical insecticide, or a specific mortality rate. 
A standard should be developed in the developmental phase of the product and should have a 
predictable relationship with field efficacy. This must have been established by concurrent 
testing of the product in the field and in bio-assays. In bacteria and baculoviruses, a reference 
product can be stored for many years. This is not the case in fungi and nematodes; there a set 
mortality rate can be the ‘standard’. 
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Standardization has been investigated and discussed within each group of pathogens. 
This is, however, still ongoing and appears to be a complex matter. As of today, little 
standardization has been agreed upon and it is hardly implemented in the industry except for 
Bt’s. For fungal and viral products, standardization of quality control has been proposed by 
Jenkins and Grzywacz (2003). The authors recommended minimum quality control 
parameters and methods for each type of product. Research has delivered a good 
understanding of the critical quality aspects in each type of pathogen. Further investigations 
are still needed to improve quality control testing methods and to make testing easier and 
cheaper. 
 
Entomopathogenic bacteria 
In bacterial insecticides, the essential parameters subject to quality control are the same as for 
fungal products: the number of active propagules, the biological activity, and the microbial 
purity. Most of the literature discussing QC in bacterial products refers to Bt products. 
Warrior (2000) listed five parameters for QC as used by a major producer (Valent 
Biosciences, formerly Abbott) of Bt products: strain identity, metabolite profile, spore count, 
biological stability, and physical properties. Potency and physical specifications are the main 
QC parameters according to Couch (2000). The insecticidal activity of Bt is based on spores 
and toxins. There are many strains and types of toxins available, each with its specific 
biological activity. Pathogenicity of Bt’s is often primarily due to δ-endotoxins (crystallized 
proteins). Accordingly, spore counts do not correlate well with the biological activity, and 
hence a bio-assay is a prerequisite for quality product control. Standardization of the bio-
assay, the use of a reference standard Bt, and which test insect to use have been the focus of 
many studies and debates. Detailed bio-assay protocols are needed. Otherwise, reproducibility 
is poor as was demonstrated by Skovmand et al. (1998) when a B. thuringiensis var. 
israelensis (Bti) preparation was tested in different laboratories. Factors such as age, stage 
and strain of larvae used, amount and type of food used and rearing conditions influence bio-
assay results. Also the method and duration of sample homogenization may strongly influence 
results, as well as the method of administration. Analytical biochemical techniques (HPLC 
and electrophoresis) can be used to determine the concentration of the δ-endotoxins and this 
could make QC easier (Bernhard, 1992). Within Valent BioSciences this is used in 
combination with bio-assays (D. Avé, pers. comm.). If the analytical method is reliable and 
shows a strong correlation with efficacy, bio-assays may no longer be necessary. This would 
give quicker and cheaper QC results, but today bio-assays are still required. 
Another problem is the lack of standardization when expressing the active ingredients. 
This can be done in spores/g, but in Bt’s this is meaningless in most cases. Endotoxin levels 
can be expressed in dry weight, but this often includes fermentation products as it is difficult 
to measure only the crystal proteins, and because other metabolites may also be involved in 
the pathogenicity process. As a result, standardization in Bt has been a subject of discussion 
for a long period of time. For two reasons: first, industrial standardization which refers to the 
need of a producer when checking his product’s quality, and second, there is a need for an 
international standardization to be able to compare products with different strains, and from 
different producers (Burgerjon and Dulmage, 1977). The latter is desirable for scientists, 
regulators and users. The discussion has resulted in the acceptance of an international 
reference standard for Bt’s where the biological activity is measured in a bio-assay on a single 
insect species and compared to a reference Bt strain. The biological activity of products, often 
called potency in Bt’s, is expressed in International Units (IU) /mg based on a comparative 
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bio-assay with the product and the standard, assessed against a particular insect. Generally, 
Trichoplusia ni or Ephestia kühniella are used as reference insects. Sometimes diamondback 
moth and Spodoptera units are used. This way of expressing potency of products in order to 
make them comparable is unique to Bt’s within the field of biopesticides. Still, some 
problems occur with standardization such as the lack of available standard Bt, and the need 
for more detailed bio-assay and sample preparation protocols (Skovmand et al., 2000). The 
increasing number of discovered Bt toxins as well as the number of products warrant 
suggestions for improvements for bio-assays and internationally accepted standard reference 
material as given by Skovmand et al. (2000). They suggested the use of three test insect 
species in the bio-assays because of the differing susceptibilities of lepidopteran species to 
various endotoxins, and the establishment of a standard based on three Bt strains containing a 
mix of toxins. Further on, they suggested the combination of bio-assay testing with 
quantitative protein analysis. Finally, they called for an international podium to further 
develop and acknowledge the standardization, as was carried out earlier by the USDA and the 
WHO. A historical overview on the progress in this area over the last 50 years and on the still 
existing problems is given by Asano (2006). 
The above paragraphs are relevant for lepidopteran Bt’s. Bti products for mosquito 
control all contain the same endotoxin which makes comparisons easier. For Bt tenebrionis, 
for control of Coleoptera, international standards have not been developed (Skovmand et al., 
2000). For Bti products, the FAO and WHO have jointly developed specifications for the 
active ingredient (identity and biological activity), relevant impurities, bacterial contaminants, 
physical properties and storage stability (FAO/WHO, 2006). The document includes detailed 
physical and biological testing methods. These specifications could be used as a reference for 
all Bt formulations.  
Standardization as discussed above refers to a QC parameter for product efficacy. It 
does not include other QC parameters such as microbial purity, physical properties and safety. 
Registration requires monitoring of these parameters also. Concerning microbial purity, 
Couch (2000) gave a list with acceptable levels of various contaminants based on 
internationally recognized levels for animal feed. Generally, this is similar for all 
entomopathogen-based products that need to follow registration requirements. Below these 
requirements will be discussed in detail. In a Danish post-registration survey on specifications 
of biopesticides, Bt products were found to be free of contaminants (Winding, 2005). For 
safety reasons, each batch should be tested on toxicity to mice according to Couch (2000). 
When Bt products were first commercialized, there was concern that possible contamination 
with B. anthracis would not be detected with conventional testing for contaminants. 
Therefore, a mouse toxicity test has been required by the EPA in the USA for each batch and 
companies still perform this test on a regular basis (CPL, 2006a).  
Specifications for physical properties for Bt products should be developed by a producer 
and checked for in every batch. The properties depend on the type of formulation. Protocols 
and specifications as for chemical pesticides should be used as a reference.  
Quality control in Bt’s has been intensely investigated by many researchers and 
companies and quality control is well developed. Many organizations and regulatory 
authorities agree on the methods and reference standards. As a result, Bt products are of high 
quality and are the most reliable products in the MPCP market. 
In a non-Bt product, Invade, based on Serratia entomophila, the quality control system 
QC has been described by Pearson and Jackson (1995). QC parameters are cell density, 
purity, virulence and longevity. Purity is defined as confirmation of the production strain by 
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cell growth characteristics on a specific agar plate and the expected phages pattern. Microbial 
contaminants are not separately tested. Virulence is checked by visualization of plasmids and 
by a bio-assay confirming pathogenicity on the target insect, i.e. grass grubs. In the longevity 
test, the decline of cell viability is periodically checked. The authors do not give product 
criteria or tolerance limits. This demonstrates that QC in bacterial products varies per product 
and per species and depends on the active ingredient, the mode of action and the target 
insect(s).  
 
Entomopathogenic fungi 
In general, biopesticides based on entomopathogenic fungi need to be registered and a 
detailed description of quality procedures as well as real data from tests are required to 
illustrate that the product complies with pre-determined specifications. In fungal products, the 
essential parameters subject to quality control are the number of active propagules, the 
biological activity and the microbial purity. Fungal biocontrol products cover a range of 
species and applications such as antagonists, mycoinsecticides, plant growth enhancers, and 
weed control products. Production of these fungi generally is in vitro and it is well-known that 
several passages on artificial medium can influence their virulence. For all these products, 
there is a need to check QC parameters to guarantee an effective and safe product in the 
market. Jenkins and Grzywacz (2003) gave recommendations for minimum quality control for 
fungal products, including aspects of process control as well as product control. To test the 
product quality the following should be checked: the level of microbial contaminants, 
viability, virulence, moisture content and particle-size distribution. Specifications and 
methods were given for microbial purity, viability and particle-size distribution. The difficulty 
of setting up a system to check virulence was discussed.   
Counting the number of active ingredients is relatively easy in fungal preparations. The 
infective propagules can be conidiospores, blastospores or mycelial particles, which can be 
plated out on artificial medium and counted to assess the percentage viability. There is no 
standard accepted viability rate. Jenkins and Grzywacz (2000) originally recommended 85% 
for fungal products, up to the advised expiry date when kept at recommended temperature. 
But they later reduced it to 80% (Jenkins and Grzywacz, 2003) without explanation. Speed of 
germination is a quality factor too and can be assessed under the microscope in water or on an 
artificial medium.  
In entomopathogenic fungi, virulence is a complex process in which many factors such 
as cuticle degrading enzyme production, spore binding factors to the cuticle, and metabolite 
production play a role (Pernfuss et al., 2004). The loss of any of these factors, a process called 
attenuation (Butt et al., 2006), may have a detrimental effect on the product’s performance. 
This phenomenon has been observed in many fungi where it affected virulence, but it also can 
lead to phenotypic changes such as alterations in growth and reduced spore production. 
Therefore a QC check on biological activity in bio-assays is essential. Bio-assays can be 
conducted in many ways, depending on the product and on the target insect. Guidance on bio-
assays for entomopathogenic fungi can be found in Lacey (1997) and in many other papers. 
The vital factor in bio-assays is that they be standardized in terms of target insect instar, 
insect-rearing method, and inoculum. Ideally, batches should be compared with a reference 
product, a standard, but since stability in long time storage of fungal material is uncertain, this 
cannot be done. The alternative is to test the recommended label dose and to set a certain 
percentage mortality as a specification. This needs to correlate with the desired efficacy in the 
field. This correlation has to be studied first before a specification can be determined.  
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Every producer develops its own methodology and sets its own specifications, 
depending on the product and the registration requirements. Because of the lack of general 
accepted protocols, a standardized laboratory bio-assay method was developed by Landa et al. 
(1994) for entomogenous fungi against whitefly. They described a method using fourth instar 
nymphs of whitefly and placing them in a droplet of a conidial suspension on a microscope 
glass slide. Assessments were made on fungal growth rate and mortality. This bio-assay does 
not need any plant material and can easily be standardized. Several entomopathogenic 
whitefly fungi were compared in this test. Many variables can be tested in this way such as 
dosage, temperature, relative humidity, effects of adjuvants and chemical pesticides. The 
authors believe that they have developed a sensitive and rapid assay for fungal insecticides 
that could be used as QC tool. The assay certainly seems quick and cheap and easier to 
standardize than a bio-assay involving plant material and populations of insects. Whether 
there is a good correlation with field efficacy, however, has not been studied and this could be 
a weak point. This is essential for product QC. Thus far this method has not been 
implemented within the industry or accepted as a testing method by regulatory authorities. 
 Bio-assays are time-consuming and laborious and they may give variable results. 
Loesch et al. (2007) have made an attempt to develop a quick screening technique. They tried 
to correlate strain attenuation with carbon utilization profiles in Beauveria brongniartii. This 
was studied in a microtiter plate test-system with 128 different media and assessed for 
germination rate and speed. Correlation with bio-assays still needs to be done. This could 
prove to be an easier and cheaper virulence testing method once tested and shown to be 
reliable in several fungi. 
Microbial contamination in fungal products needs to be examined as part of a QC 
procedure. It involves the assessment of the total level of contaminants and checking for the 
presence of human pathogens and of other opportunistic bacteria. The total level should not 
exceed a certain number, and human and mammalian pathogens should not be present at all or 
at very low levels. Jenkins and Grzywacz (2003) stated that the acceptable level of 
contaminants will be product-specific and that higher levels are acceptable depending on the 
nature of the contaminants. This may be true when only technical aspects of the product are 
taken into account, such as storability and efficacy. When safety and product liability are 
taken into account, however, the total level of contaminants is not just product-specific. This 
depends on general standards, and registration requirements that should apply regardless of 
the product concerned. The risk that these contaminants pose depends on their nature and 
their number. Assessing the total number of mesophiles is rather easy, but identification of 
pathogens is more difficult. Various methods can be used by plating samples on selective and 
differential media and at different temperatures, including 37°C. Most of these are standard 
methods for assessing bacterial contamination in food; they can be done by the producer itself 
or it can be out-contracted to a specialized laboratory. These standard tests to monitor 
microbial purity can be used for all pathogen products. Safety testing can be required by the 
regulatory authority when metabolites are produced by the fungus. An example is described 
above concerning I. fumosorosea (P. fumosoroseus).  
Physical properties like moisture content and particle size distribution are important and 
need to be checked too. Moisture may affect storage stability, while particle size may 
influence the proper application of the product. The properties that need to be checked depend 
on the formulation type. The above-mentioned refer to wettable powders, which is the most 
common formulation with mycoinsecticides. 
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Standardization for mycoinsecticides has been proposed by Jenkins and Grzywacz 
(2003) for products with similar activity. They recommended that product performance be 
compared with that of a standard and that tolerance limits be set. Establishing such a set of 
agreed criteria for should be done between manufacturers and researchers and regulators to 
cover the needs of all stakeholders. This initiative, however, has not been followed up yet. 
 
Baculoviruses 
In baculovirus products, the essential parameters in the quality control procedure are the 
assessment of the number of propagules, the biological activity and the microbial purity 
(Shapiro, 1986; Smits, 1987; Shieh, 1989; Guillon, 1997b). Counting of occlusion bodies 
(OBs) or polyhedral inclusion bodies (PIBs) is difficult in formulated products due to their 
small sizes and due to insect remnants from the production as well as particles of formulation 
ingredients. PIBs of nucleopolyhedroviruses (NPV) are bigger than OBs of granuloviruses 
(GV) and can be counted under a light microscope; GVs are more difficult to count because 
they are smaller than 0.5 μm. Analysis of the protein concentration in a suspension is another 
method of assessing the concentration of GVs. Details of various methods is given by Hunter-
Fajita et al. (1998). The actual number of OBs or PIBs does not necessarily reflect the 
product’s biological activity since active and non-active viral particles can not be 
distinguished. Hence a bio-assay is needed. Bio-assays can be conducted in many ways 
depending on the product and the target insect. Guidance on bio-assays for baculoviruses can 
be found in Smits (1987), Lacey (1997), Hunter-Fajita et al. (1998) and Jones (2000). The 
significant factor in bio-assays is that they be standardized in terms of target insect instar, 
insect rearing method and inoculum. If this is not the case, the results are meaningless. A 
virus reference standard sample can be tested simultaneously with the produced batch and 
results can be compared. This is possible because a standard stock of virus can be stored for a 
long period without any loss of activity.   
Microbial purity is a critical parameter in baculovirus products due to the production in 
vivo. Details for monitoring contaminants in baculovirus products are given by Hunter-Fajita 
et al. (1998) for determination of various groups of bacteria. Human pathogens are normally 
not present in baculovirus samples. Smits and Vlak (1988b) did not find any in produced 
batches of SeMNPV; neither did Lasa (2007). Smits and Vlak (1988b) did find a relatively 
high rate of contaminants, about 1-10 bacteria per 100 polyhedra. A formulated viral product 
typically contains 1012 to1013 PIBs or OBs per litre which would mean > 107-109 
contaminants/ml. Lasa (2007) found similar ratios. The upper part of this range of 
contaminants is generally considered to be too high. In that case purification is needed or 
other methods to control the level of microbes, such as the use of antibiotics or other 
antimicrobial products. These results, however, originate from research projects in which 
production was relatively small scale. There are no recent reports publicly available from 
samples of commercial mass production and end-use products. The above indicates that 
microbial purity in baculovirus products is a critical quality control aspect that needs 
considerable attention, not only in the final product, but surely also during production where 
preventative measures should reduce the level of contamination as much as possible. 
There are no quality standards for baculovirus products that are internationally accepted, 
either by the industry or by regulatory bodies. The lack of standards was recognized by 
researchers in Eastern Europe and an attempt was made within the IOBC/EPS region in the 
late 1980s to establish the main criteria with regard to quality control of viral insecticides 
(Ciuhrii, 1996). A draft proposal was set up in which it is recommended to determine the 
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following QC parameters: the pathogen concentration indicated by the normal amount of 
nucleocapsides, identification of the strain based on the number of virions, nucleocapsides 
and envelopes, and the microbial contaminants. The methods described are too academic and 
too difficult for industry since an electron microscope is needed. This draft proposal was more 
about methods then about setting standards. It was never broadly adopted and further details 
have not been published on this issue. 
Registration of baculoviruses requires product specifications, but again there are no 
standards and no tolerance limits. The producer determines the product specifications. The 
number of propagules, as decided by the producer, must be mentioned on the label, but as 
discussed above, this is only of limited value. Other product specifications are not mentioned 
on the label, it is also generally not required to do so. Biological activity should be measured 
in a standard way against a company’s internal standard and it should be consistent for all 
batches. The specification is usually set by the manufacturer. Jenkins and Grzywacz (2003) 
recommend testing product virulence “in a standardized bio-assay on final product, using 
defined instars of a laboratory reared strain of the target pest. Results should confirm that the 
potency ratio is within defined limits specified for the product and determined during product 
development or > 0.5 of a standard virus preparation”. The maximum level of microbial 
contaminants can be set by the company itself, provided that the number is acceptable in 
terms of safety and in terms of the product’s shelf-life and performance. This level is then 
documented, including the assessment methods, in the registration dossier and the authority 
may accept that level. Some regulatory authorities, though, have set an acceptable limit for 
the total number of contaminants. According to Guillon (1997a) the legal maximum is 106 
cfu/ml for baculoviruses, but it is not specified in which country. Jenkins and Grzywacz 
(2003) recommend that “formulated products should not exceed a maximum of non-pathogen 
contaminants of 1x108 cfu/ml in for liquid formulations with an activity of 1x109 OBs or 
PIBs/ml and 5x108 cfu/gr for dry powder formulations”. The rationale here is that bacteria that 
develop in in vivo production on insect cadavers are usually associated with dying insects and 
do not pose a risk to humans.  
According to Guillon (1997a) B. cereus is the most common contaminant in insect guts 
and it represents 99% of the contaminants. This is a ubiquitous bacterium in many 
environments and not considered very hazardous. In the REBECA project, a maximum level 
of 107 per ml product is recommended as the acceptable level for this species (REBECA, 
2008). Nevertheless, human pathogens should be absent or at very low levels. Safety to 
mammals is also mentioned as a QC parameter (Burges, 1981; Shapiro, 1986; Smits, 1987). 
The EPA demands a mouse intraperitoneal (IP) test for harmful effects with the TGAI before 
release of a production batch for formulation and selling (OECD, 2009). The rationale in this 
case is the monitoring for human pathogens. I believe this is not needed as a routine QC check 
on every batch when other parameters are within specifications and human pathogens are 
absent. This can be tested on microbe-specific media. Only in specific cases, animal testing 
should be included as a standard requirement. It is costly, time-consuming, and requires 
unnecessary use of testing animals.  
Physical and chemical parameters are required for registration by the EPA (Shieh, 
1989), but are of minor concern and hardly relevant as a routine check of product QC. 
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Entomopathogenic nematodes 
In most countries, EPNs are not considered a biopesticide in terms of registration and strict 
registration criteria, including quality control criteria, do not apply to EPN products. In that 
respect they are similar to natural enemies, but unfortunately, EPNs were not considered in 
the IOBC/EC project with beneficial arthropods in which testing methods and standard 
criteria were developed (Van Lenteren, 2003). Consequently, quality criteria are set by the 
producers themselves. With the use of EPNs, field performance can be quite variable and as a 
result the quality of the product frequently is a point of discussion. Many authors, from 
research institutes as well as from industry, have recognized the importance of QC and a 
range of testing methods have been developed to assess various aspects of quality. In EPN 
based products, quality control parameters are viability, i.e. the percentage of viable 
nematodes and the minimum total number of viable nematodes per unit of product, virulence, 
age (shelf-life), morphological and physiological characteristics, and field performance 
(Miller, 2002). Grewal (2000) considered maintenance of high viability and virulence as the 
backbone of an effective quality control strategy. Testing virulence in bio-assays, however, 
can be set up in many different ways. Grewal proposed a sand-well bio-assay with parameters 
for seven nematode species and strains as a standard tool for assessing virulence. The 
parameters are the Galleria larvae-nematode ratio to be tested and the temperature, and he 
determined the expected mortality after 72 hours as a specification. This was a worthy attempt 
to standardize testing virulence in nematodes. Peters (2000) proposed another type of bio-
assay for three nematode species as a standard test, although without determining 
specifications. These standard tests, however, are not widely accepted and have not been 
adopted by the industry. Later, Grewal and Peters (2005) defined nematode product quality 
broader, including packaging, instructions for use, ease of transport, etc. In my opinion these 
are not product QC parameters strictly speaking, rather aspects of total quality management. 
This indicates the importance of defining quality control and product quality control as 
mentioned above.  
The easiest parameter to assess is viability, the ratio of live to dead nematodes, and the 
total number of viable DJs per unit of product. Although in some cases it may be difficult to 
see whether a DJ is alive or not, especially for a non-trained end-user or distributor, this can 
be overcome by providing the right technique to assess viability. The number of living DJs 
should meet the number as stated on the label, up to the end of the shelf-life period. Still 
unresolved topics for stakeholders are the percentage of viable DJs that is the minimum 
acceptable amount and whether over-packing compensates for low viability. This depends on 
the origin of the death of the DJs. If it is caused by mechanical factors, there is little concern. 
If it is caused by a slow decrease in quality, for instance through a long storage period, the 
surviving specimens are most likely also of lower quality and then there is a reason for 
concern. However, an end-user is not likely to accept a high percentage of dead larvae, even 
when the living DJs are still of good quality. In this case quality determination becomes 
highly subjective. No more than ten percent dead DJs in a product seems an acceptable limit 
in the market. This is also dependent on product quality of similar products in the market. 
When one product out-performs the others in this respect, users will demand a higher quality.  
Viability assessment should go along with the testing of virulence or biological activity. 
Many different types of bio-assays have been developed for testing biological efficacy. A 
number of variables can be tested in these assays. These can be abiotic factors such as 
temperature, soil type, moisture content, time period, depth of target in a soil column, as well 
as biotic factors like the nematode species or strain, the number of DJs, age of DJs, the target 
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species and its developmental stage. These tests are often used to screen species and strains 
for suitability against a certain insect, and for quality control purposes; numerous papers 
describe such testing. Tests should be done under sub-optimal conditions and conditions 
should mimic field conditions as much as possible. Positive results in laboratory bio-assays do 
not automatically correlate with good field efficacy, as was demonstrated with H. 
bacteriophora products from different production systems (Gaugler and Georgis, 1991). 
Testing under optimal conditions is likely to mask lower quality and is therefore meaningless.  
Despite more than thirty years of research and production of EPNs it is still not clear 
which parameters can be best used to monitor QC in relation to field performance. Many 
different intrinsic QC parameters have been studied in Heterorhabditis species by Jung 
(1999), such as mortality, body contents, presence of secondary cuticle, wave-like movements 
per time unit, body length, lipid and glycogen contents, number of bacteria carried within a 
DJ, movement in sand or agar, penetration capacity in wax moth larvae and infectivity. These 
factors were studied in relation to storage temperature, storage period, formulation type (with 
differences in osmotic value, pH, and carrier material). A semi-field test with strawberry 
plants infested with vine weevil larvae was performed to correlate the parameters with 
efficacy. Jung found that energy reserves and migration ability correlated best with efficacy, 
although it varied between species and isolates. She recommended that each laboratory test 
for the determination of quality be validated by successful control in the field. This example 
shows that energy reserves and migration ability may be used as QC parameters, but also that 
they should be tested and validated for each strain. The validation of bio-assay data with field 
data is highly desirable, but this is extremely difficult since efficacy in the field depends on 
many factors and is therefore highly variable.  
Energy reserves in relation to quality have been studied by many scientists (e.g. Patel 
and Wright, 1997; Patel et al., 1997) and it is generally concluded that this is a useful 
laboratory tool for quality assessments. The determination of lipid content was a standard 
procedure in Biosys to monitor the quality of its products (Georgis, 2002). Grewal and 
Georgis (1999) also stated that differences in lipid content between species do not always 
reflect proportionate differences in storage stability and field efficacy. This indicates that 
quality control is a complex matter where various factors interact, and that species behave 
differently. More research is needed to find out which parameters need to be assessed in 
relation to QC. It is apparent that there is no single parameter that can be used as a QC 
parameter, and certainly not for all different taxonomic groups (Jung, 1999). If quality 
assessments of commercial products are done by independent organizations, the lack of 
accepted protocols and criteria becomes apparent. Quality may then be judged on a limited set 
of criteria and, although all QC parameters should meet their set criteria, concerns may be 
raised based on too limited testing. An example is Caamano et al. (2008) where only viability 
in commercial products was assessed and biological activity was not. 
Scientists, extension workers and the biocontrol industry collaborated for many years 
developing standardization of quality control tests for EPNs and defining standards. This 
work was done within the EU COST Actions 819 and COST 850. It resulted in the 
publication of a handbook on quality control of EPNs (Grunder, 2005) describing protocols 
for testing biochemical, physical and behavioural characteristics related to quality, and 
protocols for bio-assays and field testing. The book presents commonly accepted protocols for 
quality testing in relation to field efficacy, but only a few standards have been given and were 
accepted among all involved. It further recognized the need for a common database for some 
commonly used nematodes so that companies and scientists can share their experiences and 
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results with the accepted protocols. This would be a first step in developing and agreeing on 
standard criteria and to a widely acceptable self-regulated product quality control with EPNs. 
The remaining difficulty is that there is no reference stock that can be tested simultaneously 
with the tested batch. This is due to the difficulty of having a stable stock as a comparison 
(Peters, 2000). Furthermore, there is no culture collection of EPNs which could store such a 
reference stock, as in the case of Bt where the Pasteur Institute keeps the reference material. 
Still, a simple and quick test should be developed for and be accepted by the industry. I 
suggest to take the work of Grewal (2000) as a starting point. He measured virulence in a 
sand-well bio-assay with a pre-determined host: nematode ratio and compared it with an 
expected mortality rate as a standard. According to the research of Grewal this method is 
sensitive to ‘impaired‘ nematodes, and therefore capable of distinguishing good quality 
batches from poor quality batches. 
 
Product quality parameters 
In general, the quality parameters for MPCPs of the four types of pathogens are similar. 
Particular aspects of quality control, however, need more attention then others due to the 
production system of the pathogen and due to the nature of the product. In table 4.1 an 
overview summarizes this point. In all products the number of propagules and the viability are 
essential parameters. Virulence is the most critical factor for obvious reasons. Microbial 
contaminants in EPN products are not a serious problem when production takes place in 
sterile fermentors; it does need a lot of attention when nematodes are produced on animal 
offal. For bacteria and fungi produced under sterile conditions, the presence of contaminants 
is less critical than for baculoviruses produced in vivo. Safety is connected with possible 
production of metabolites and this plays a role in bacteria and fungi. Technical properties are 
a minor concern for all products. Shelf-life, on the other hand, is challenging in EPNs while 
bacterial spores and baculoviruses are the most stable products stored when under appropriate 
conditions. These observations are a result of the production system and the biology of a 
pathogen. This is also the basis for the registration requirements where a case by case 
approach is taken.  
 
 
Table 4.1.  Importance of product quality control parameters per type of pathogen 
 
Parameter\pathogen Bacteria Fungi Baculo-
viruses 
EPN 
Number of propagules ++++ ++++ ++++ ++++ 
Viability +++ +++ +++ ++++ 
Virulence ++++ ++++ ++++ ++++ 
Microbial contaminants +++ +++ ++++ ++ 
Safety ++ ++ + - 
Physical stability + + + + 
Chemical stability + + + - 
Shelf-life ++ +++ ++ ++++ 
+  to  ++++:  increasing amount of attention needed during quality control;  -: not relevant 
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Registration and quality control  
 
Registration requirements related to quality control 
Registration requires description of both the production process and the product, and 
mandates quality control procedures. The EU Directive 91/414 sets out the general 
requirements for active substances for placing plant protection products on the EU market. 
EU Directive 2001/36 Part B (EC, 2001) lays down detailed requirements for those active 
substances consisting of microorganisms, and plant protection products based on 
microorganisms. Quality control requirements regarding production of the active substance 
are given in a descriptive way only: “quality control assurance criteria for the production 
should be submitted. The techniques to ensure a uniform product and the assay methods for 
its standardization and purity of the microorganism must be described”. For the plant 
protection product as well “quality criteria for the product should be submitted.” Further, 
analytical methods must be provided for the analysis of the product. This information is 
required for post-registration control.  
In EU 2005/25/EC (EC, 2005a) Uniform Principles are laid down to ensure an 
equivalent evaluation by EU member states. The Uniform Principles stipulate that an 
authorization can only be granted if full information is provided on the continuous quality 
control of the production method, production process and the plant protection product. There 
should be emphasis in the evaluation on occurrence of changes in characteristics of the 
microorganism and on contaminating organisms. This directive, however, only states that 
“proposed quality criteria must be evaluated.” The three directives, thus, do not stipulate 
obligatory standards with which products should comply. Quality criteria are left open for 
evaluation by the competent authority to which a dossier is submitted. This still leads to 
various interpretations of the requirements and to differences in acceptance of data by EU 
Member States.  
Producers need to set their own criteria and develop their own methods to demonstrate 
that products comply with these criteria. Only with regard to contaminants does the Directive 
state that “it is desirable to have a plant protection product without contaminants, if possible. 
The acceptable amount should be judged by the competent authority.” OECD Guidance 
documents also do not provide standard criteria (OECD, 2003a, 2004a, b). The FAO and 
WHO have developed specifications for pesticides in order to “….provide an international 
point of reference against which the quality of products can be judged, either for regulatory 
purposes or in commercial dealings…” (FAO/WHO, 2006). A chapter on “Specification 
guidelines for microbial pesticides” is included. The chapter content lists bacterial, viral and 
fungal pesticides, but details are only given for bacterial larvicides (Bt’s) for mosquito 
control. The document is clearly not yet finished. Testing methods are described in detail 
regarding bio-assays for potency determination and physical and chemical properties. Some 
criteria are given for these properties. Maximum acceptable levels of microbial contaminants 
have not yet been determined. 
For biopesticides, the lack of official criteria refers particularly to the number of viable 
propagules and its tolerance range, and to the level of contaminants in products. For a 
producer it is hard to estimate which data are acceptable. My experience is that acceptance of 
the total level of microbial contaminants varies per country. This is further complicated since 
acceptance has shown changes over time. An example of the USA illustrates my point. When 
the USDA Forest Service registered the gypsy moth virus in the 1970s, they set the maximum 
level of aerobic bacteria at 109/g. Later, when Elcar (Heliothis NPV) was registered, the EPA 
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had set the level at 107/g (Battu et al., 2002). Currently the EPA has not defined maximum 
levels, at least not in their guidelines for registrants. Only when a dossier is being evaluated, 
does an applicant learn whether his proposed levels are accepted. 
Only for chemical and physical properties such as acidity, viscosity and technical 
properties of a formulation such as wettability, dry sieve test, emulsifiability, etc., testing 
must be done according to recognized CIPAC or OECD methods designed for chemicals. 
These do contain set criteria to which products must comply.  
Regarding human pathogens, the Uniform Principles state that an authorization for a 
microorganism is not granted if it appears that it is pathogenic to humans under the conditions 
of use. This is not necessarily the same as a complete absence of human pathogens in the 
product. The EPA (Environmental Protection Agency) in the USA has similar requirements: 
“human and non-target animal pathogens must not be present at hazardous levels in the 
product before formulation”. They require a toxicity test on mice with an intraperitoneal 
injection of > 106 cfu before formulation for bacterial and viral products. Canada’s Pest 
Management Regulatory Agency (PMRA) asks for an assessment of potential microbial 
hazards, using criteria and methods that are consistent with international standards for food. 
The language used by authorities attempts to be clear, nevertheless it is ambiguous. Presence 
of human pathogens is accepted so long as they do not reach hazardous levels. For a producer 
this is to difficult to work with, so I recommend that absence of human pathogens must be the 
goal for the producer. A proposal has been developed within the OECD to clarify this issue on 
acceptable maximum levels of contaminants, and particularly of human pathogens (OECD, 
unpublished). This is still under discussion within the authorities (see below for more details). 
Industry, regulators and scientists have discussed these omissions in the regulations 
within the REBECA project, an EU policy support action with the goal to propose alternative, 
less bureaucratic and more efficient regulation procedures maintaining the same level of 
safety for human health and the environment while at the same time accelerating market 
access and lowering registration costs. Results of this project will be discussed in detail in 
chapter 5. 
 
Regulation concerning label information 
Label information related to product quality control parameters, as required by registration in 
the EU, only concerns the content of active ingredients such as number of spores, cfu’s or 
viral particles, per unit weight or volume of product. Neither infectivity nor biological activity 
is required on the label, except for Bt’s where potency (units/mg) is indicated on the label. 
Label information of chemical pesticides only indicates the content of active substances. 
Some authors plea for standardization so that activity quantification can be accomplished and 
put on the label. This will offer the ability to compare different formulations of the same 
pathogen or different pathogens on biological activity. Guillon (1997b) reported that the 
IBMA strongly expressed the need for harmonization and that the organization wanted to 
develop this together with organizations like the IOBC and the European Committee for 
Standardization (ECS). This has not been done, however. Would this be a useful exercise? 
Chemicals can not directly be compared with each other on the basis of activity quantification 
on the label. 
An activity indication would refer to a certain target insect, but this does not mean that 
activity towards another target can be deduced from that. It may be very different. This is seen 
in Bt products where potency is determined on a standard insect. This allows comparison 
between products, but does not give information on the efficacy on other insects. Skovmand 
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et al. (2000) recommend the use of three different reference insects, but does this really 
improve the situation? Even after thirty years of experience with Bt’s there is lack of 
consensus on standardization for Bt’s. For other biopesticides standard methods for 
determining potency have not yet been developed. As a result there is no label information 
required. 
 
Post-registration product inspection by authorities 
Plant protection products are subject to post-registration checks on compliance with the 
regulations in a broad sense. For MPCPs, aspects eligible for control are the identity of the 
microorganism, the number of active propagules, the microbial purity and physical-chemical 
properties, and compliance with obligatory label information. Assessed data will then be 
compared to what has initially been provided by the registrant in the registration dossier. 
Authorities seldom perform these checks and in more than 25 years working with 
biopesticides I have only once experienced such a control. This was conducted by several 
Danish institutes under the auspices of the Danish EPA in 2004 on all microbial products that 
were on the market in Denmark (Winding, 2005). Thirteen products were checked, three Bt 
products, the others mycoinsecticides and mycofungicides. The objectives were the identity of 
the microbial agent, the number of propagules and the number of contaminants, and to 
compare this with information provided earlier by the producer. Deviations in quantity as well 
as identity were found for some MPCPs. In some the occurrence of contaminating 
microorganisms was higher than specified by the producers. Earlier investigations in 
Denmark on seven MPCPs revealed similar results (Løschenkohl et al., 2003).  
The report also mentioned that a query among nine EU countries was performed on 
checks on MPCPs and the quantity of microorganisms in them. It did not give information on 
tolerance levels and apparently these checks were not being performed in any country as a 
routine inspection. In a postscript in the report, the Danish EPA comments on the maximum 
level of deviation of content of active ingredients. In chemical pesticides these are fixed in the 
EU Directives, but this is not the case for microbial pesticides. For MPCPs the EU directive 
asks for information on the nominal content and the maximum and minimum, but criteria are 
lacking. The Danish EPA suggests a margin of maximum five-fold be acceptable. Further, the 
amount of acceptable contaminants is also not regulated and the Danish EPA suggests 
initiating discussions on these two topics within the EU to establish agreed levels of 
deviations in MPCPs. This topic has been further taken up within the REBECA project; see 
for more details on this project chapter 5. The most interesting topic in this report is that 
authorities seem to accept a five-fold deviation in the level of propagules in products on the 
market until the expiry date. This is nowhere to be found in any guideline and offers 
producers insight into what level is acceptable to authorities. Acceptance between countries, 
however, is likely to vary considerably until levels of acceptable deviations are officially 
established within the EU. Whether such a deviation is acceptable for the product’s efficacy is 
a matter that a producer has to decide himself. 
 
Other regulations that have an impact on product quality 
Food crops are increasingly produced taking into account HACCP (hazard analysis and 
critical control points; EU Regulation 2073/2005/EC (EC, 2005b)) protocols. This is to 
prevent introduction of microorganisms in quantities that present an unacceptable risk for 
human health. Supermarkets impose this on growers of food crops because of growing 
concerns of public health. It is obvious that MPCPs should not have any contaminants that 
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may be a potential food pathogen. The EU data requirements even refer to HACCP in respect 
to microbial purity of a plant protection product. For a biopesticide producer, the use of 
HACCP protocols is another good reason to strive for absence of human pathogens and other 
opportunistic bacteria in MPCPs.  
Residue levels on food crops are regulated and maximum residue levels (MRL) are 
generally set for plant protection products. Microorganisms are exempt of a MRL unless 
secondary metabolites pose a health concern. Both HACCP protocols and MRL regulation 
relate to food safety, a growing concern in our society. 
Obviously, product accountability is a concern of every manufacturer. The producer or 
the importer of a product into the EU is responsible for the quality of a product and any 
harmful events or damage that may arise from the use of the product. Liability claims may be 
filed against a producer if gross negligence and irresponsible behaviour with the product can 
be shown.  
 
 
Practical aspects of product quality control 
 
Protocols, sampling and testing 
Methods and protocols have to be developed in order to monitor the quality parameters of 
products. This needs research and validation of the methods on their predictive value related 
to the performance of the product in the field. Specifications must be established. Methods 
may be available from a screening programme or from the literature. Developing this quality 
control programme takes a lot of research and should not be underestimated. Facilities, insect 
rearing and production of product are needed. It will take time and money and contributes to 
the costs of the product. Such a testing programme needs to be established during the 
developmental phase of a product. It also needs to generate methods and real data for 
registration purposes. 
Sampling is an important part of a quality control programme and many questions have 
to be answered. Some examples are: how many samples need to be tested, what sample size is 
required, what is the number of replicates per sample, what tolerance is acceptable for the 
various parameters, how frequently are samples tested during the shelf-period and even 
afterwards. Unformulated as well as formulated material needs to be tested. If a batch has to 
be discarded, preferably this is determined before formulation and/or before packaging. 
Production batches are not necessarily the same as product batches. Several production 
batches may be formulated together. TGAI may be stored first before formulation is 
conducted, and formulated product may be stored before packaging. Where is a need to 
monitor quality? Some of these procedures are process control. Finally, product control must 
be conducted. The line between process control and product control is not always that clear. 
Batch numbers are given to material because of traceability needs. Material must be treated in 
a uniform way in order to be called a batch, otherwise material must receive different batch 
numbers and they must be tested separately. Each batch that is to be tested must be sampled 
separately. 
A guideline for sampling for quality control of bulk technical grade active ingredients 
(TGAI) and formulated products is given by the FAO/WHO for pesticides (FAO/WHO, 
2006). The FAO/WHO guideline can be used for biopesticides too. Other regulatory 
authorities do not provide any guidance on this topic. Companies determine themselves 
sampling methods, frequency and number of samples tested for quality control purposes. 
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Statistical methods should be followed in order to have reliable results that will be acceptable 
for official regulatory purposes.  
Other aspects of quality control are monitoring properties of packages. Packages must 
be filled with the correct volume of material and within the tolerance limits, or each package 
must contain a minimum of material. Packages must be sealed and labelled correctly.   
Still another aspect is who will be conducting the tests. It is usually done within a 
company, but parts of the quality control can be outsourced to independent laboratories. 
Testing is preferably done by a quality control or an R& D department rather than by the 
production people themselves. This guarantees independent results and independent 
interpretation of the results. In small companies this may be a problem. It is difficult to 
discard a batch on a minor deviation from the standards when people have worked hard to 
produce that batch. If possible, testing methods should be tested by an independent third party 
laboratory to confirm their reproducibility. A critical part of QC is determination of microbial 
contaminants, particularly the presence of human pathogens. One may consider having this 
conducted by an independent laboratory.  
In the case of Invade, the producer outsources QC to the research laboratory 
AgResearch. Once, a batch was sold that contained non-pathogenic bacteria. This may have 
been a reason to have the QC carried out by the research laboratory, but this was not 
explained in the paper (Pearson and Jackson, 1995). Perhaps some methods cannot be done by 
the producer due to complexity of the tests or availability of certain expensive equipment. 
Using an independent organization for QC may give more accurate data. At Koppert, we also 
use an independent accredited laboratory for an extra check of Mycotal and Vertalec on 
microbial contaminants. The reason here is not the difficulty of the tests as we do test 
ourselves for contaminants. Rather, we want an independent confirmation of the quality of the 
product with regard to contaminants and human pathogens. Since our products are used in 
food crops up to the day of harvest, this item ranks as the most critical risk with regard to any 
harmful effects and serious complaints.  
 
Determination of the standards and tolerance ranges 
Each manufacturer has to establish product specifications and tolerance ranges. There is 
hardly any guidance to this from regulatory bodies, except in the case of Bt’s. For Bt’s, 
standards have been developed as is discussed above. A producer needs to know what will be 
acceptable for the authorities, however. This is not an easy exercise, but relevant. 
Communication may be sought with the authority in order the obtain clarity on this subject. 
Decisions on specifications and on tolerance levels should take into account biological and 
ecological factors in the field, and even in the bio-assay. Biological variability may 
overshadow set criteria and therefore broad tolerance levels may be needed. The tough 
question is what a realistic and relevant tolerance range is. Each situation demands its own 
research. Generally, there are normal batch to batch variations, as well as variations within the 
testing methods. A company has to tackle this problem in a pragmatic way and decide by 
what limits they still feel confident in selling the product, simultaneously taking registration 
requirements into account.  
In Bti bio-assays with strict protocols for measuring bio-potency results may vary to ± 
25% from the average (FAO/WHO, 2006). Still, FAO/WHO recommends the following 
minimum standard to be met: no more than 10% loss in bio-potency below the labelled 
potency value when stored at 5ºC for 2 years. This example illustrates the complexity of 
determining specifications and tolerance limits. In bio-assay testing of Mycotal we have seen 
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a similar variation in mortality and germination levels between batches. These two parameters 
show a significant correlation (linear regression analysis, P< 0.001) (figure 4.1, unpublished 
data, Koppert). Nevertheless, batches that comply with the germination rate do not necessarily 
comply with the specification for mortality (R-Sq is only 54.1%), so the germination rate is 
not a reliable predictor for the mortality. Both parameters need to be tested independently, 
unfortunately. At Koppert, we have set the standard for germination > 85% and for virulence 
at > 70% mortality at a critical relative humidity (see Box 4.1). Jenkins and Grzywacz (2003) 
recommended for baculoviruses that potency be >0.5 of a standard virus preparation. For 
fungal products they did not recommend a specification due to difficulties in establishing it. 
These examples illustrate that each case needs it own research and considerations before 
a specification for virulence can be established. For parameters such as microbial 
contaminants, safety tests, and technical properties, generally minimum or maximum 
standards are established which makes decisions easier to take. Generally, a batch can only be 
released for sale once all the QC checks have been performed and the outcome approved. 
When one of the ‘specs’ is not met, a batch should be discarded. If possible, a batch could be 
returned to production to improve it.   
 
 
Figure 4.1.   Mycotal: relationship between germination and whitefly mortality in bio-assays 
          (-------: standard for germination rate; – – – – – – : standard for mortality rate) 
               
 
 
 
Virulence testing and determination of the specifications 
Efficacy of the product is the all-important quality trait. Bio-assays are needed to test this, but 
they are time-consuming and costly; they may not be timely and may not allow deadlines to 
be met. Scientists often suggest checking LD50 values as a product QC parameter (Jenkins  
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and Grzywacz, 2003; FAO/WHO, 2006; CPL, 2006b). This implies testing various dosages 
above and below the expected LD50 dose in bio-assays which makes testing laborious and 
expensive. I recommend testing just the label dosage in a bio-assay. This keeps the test easier 
and less costly. Batches should be run against a reference standard preparation, if available. 
This makes testing more reliable. If a reference standard is not available which is usually the 
case in nematodes and fungi, the outcome can be compared with the untreated. The corrected 
activity should then be compared with the specification that has been set for the bio-assay test 
in previously conducted research. Preferably, in bioinsecticides, the label dose gives 80-90% 
mortality in the bio-assay and this can be used as the specification for bio-assay activity for 
each batch. Correlation with good field efficacy must be studied in order to know what the 
bio-assay specification means under field conditions.  
Few authors discuss setting a specification for virulence. In Elcar, the baculovirus 
product for control of Heliothis spp., potency was determined by bio-assays developed for Bt 
products. As a reference, material was used that had shown good results in the field in earlier 
years (Shieh, 1989). In product control of Green Muscle, Jenkins et al. (1998) used a standard 
stock culture of the fungus for comparison. Virulence expressed as average survival time 
should be within 0.5 days of that obtained with the reference in a bio-assay with the desert 
locust. The FAO/WHO has set a minimum standard of 90 % mortality for Bti in the 
standardized bio-assay (FAO/WHO, 2006). 
Bio-assays must be highly standardized in order to get accurate and reproducible results 
year-round. Insects used in bio-assays should be reared under standard conditions so that 
testing results are comparable over a period of time. Stressed insects are more susceptible to 
disease, and this may give higher mortalities and unreliable outcomes of bio-assays. 
Untreated should be tested in all cases. The result indicates whether the standardized bio-
assay performed as expected, and whether the test has been conducted properly. Only a 
certain percentage of mortality in the control treatment should be allowed. If this is too high, 
the bio-assay should be assessed as invalid. Seasonal effects are known to influence natural 
mortality as well as bio-assay outcomes, even in well-standardized testing methods.  
Robertson et al. (1995) investigated the effect of natural variation when performing bio-
assays with one chemical and two microbial insecticides. They analysed the variations in bio-
assay responses of three insect species. They concluded that when results of bio-assays are 
used to determine resistance, treatment efficacy or product quality, the range of natural 
variations should have been assessed first by collecting a large data set. With this information 
other phenomena can be separated from natural variations. For quality control purposes they 
recommended, first, to production managers to be aware that LC values are estimates, not 
constants, and second, to establish whether test results of a new batch fall within the 95% 
confidence limits of the existing large data set. Only then significant differences can be 
determined. This study shows the complexity of making decisions on quality control 
standards and tolerance ranges, not only for manufacturers, but also for regulators. Still, bio-
assays are the only pragmatic tool for quality control checks. They must be performed with 
great care, and although they take up considerable resources, they are indispensable for 
product quality control.  
 
Examples of product specifications 
Details of product control are generally kept confidential or are just not published. An 
exception is the mycoinsecticide Green Muscle where details of product control are presented 
by Jenkins et al. (1998). The authors gave the specifications to which the product must 
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comply and briefly described the testing methods. Tolerance limits were not given. 
Specifications for a baculovirus product, Elcar, were given by Shieh (1989). Besides bio-
assay potency and a polyhedral count, biochemical methods were given which were used to 
characterize the product and to compare it with stored standard material. The company 
Verdera disclosed some information on their chosen quality criteria for biofungicides (Palin-
Holmberg et al., 2003). Specifications for Mycotal used at Koppert BV are presented in Box 
4.1. Product specifications can also be found in publicly available reviews of registration 
dossiers by regulatory authorities. Examples are the Dutch Ctgb (Board for Authorisation of 
Plant Protection Products and Biocides) which publishes evaluation reports on their database 
on internet, and the EC which discloses review reports of new active substances including 
specifications and methods on http://ec.europa.eu/food/plant/protection/evaluation/newactive. 
 
Post-shipment quality control 
Taking into account the vulnerability of biological products during shipping, sampling should 
also regularly be carried out along the distribution chain in order to check quality. Sampling 
may be carried out at any point in the distribution chain, from the producer to the end-user. 
Usually it is carried out at the factory only. If quality shows a decrease in the distribution 
chain, corrective measurers have to be taken to improve shipping and storing conditions. Post-
shipment quality control has shown that quality loss during this process is occurring and that 
it needs appropriate attention, particularly in nematodes (Gaugler et al., 2000; Caamano et al., 
2008). Enema and Koppert have developed protocols for end-users to check aspects of quality 
of EPN products (Ricci and van der Pas, 2005; Peters et al., 2003). Post-shipment QC is part 
of total quality control and essential to guarantee delivery of high-quality products to 
customers.  
 
Costs of quality control 
Bio-assay testing calls for laboratory facilities, insect rearing, host plants, and labour. 
Facilities may need to be separate from the production location because of the risk of 
contamination and different staff members should be involved. Lisansky (CPL, 2006b) 
estimated that costs are about $60,000 annually per insect species and recommends planning 
budgets for QC. Guillon (1995) considered QC as the main cost factor in the production of 
baculoviruses. I have not found any other reference to this topic. At Koppert, it is hard to 
estimate costs since we rear most of the pest insects anyway for production of natural 
enemies. Labour costs involved in the QC of Mycotal are approximately €5,000 on an annual 
base. On top of this, overhead costs should be calculated. From this figure and the estimated 
insect rearing costs, QC costs are likely to be between €10,000 and € 20,000 for a 
bioinsecticide depending on the pest insect, the product and the activities of a company. QC is 
a considerable expense that must be attributed to the full product cost price. 
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BOX 4.1.   Product Quality Control for Mycotal: specifications and methods used at 
       Koppert Biological Systems 
 
Every batch is tested before sale, after three months and at the end of the shelf-life period of six months. 
Microbial purity, moisture content and solubility are only checked before sale. The product must comply 
with all standards. 
Number of propagules: 
 
Standard: 1 ± 0.15 x 1010 spores 
per gram of product 
 
Method: a diluted spore solution is prepared (spreading agent and anti-
foam added) by stirring for 60 minutes. Counting spores is done with a 
Bürker-Türk counting chamber under the microscope. Two samples of 50 
gram are taken from one end-use product package. From each sample four 
sub-samples are counted. The average number is compared to the standard. 
Germination rate and speed of 
germination: 
 
Standard: ≥ 85% within 16 hours 
at 21° C 
Method: prepare spore solution as above. Samples are incubated on a slide 
with SDA medium. The slides are stained after 16 hours with lactophenol, 
followed by counting germinated and non-germinated spores at 1000 x 
under the light microscope. Germinated is defined as having a germination 
peg at least as long as the diameter of the spore. One sample of 50 gram is 
taken from one end-use product package. From this sample three sub-
samples are counted. The average number is compared to the standard. 
Efficacy: 
 
Standard: ≥ 70% mortality 8 days 
after treatment and incubated at 
RH 75% and 21° C 
 
Method: one sample of five gram from a product package is tested. Bio-
assay leaf discs containing young instars (L2 and L3) of Trialeurodes 
vaporariorum, embedded on water-agar, are sprayed by a Potter-tower 
with the label rate. Surviving and dead larvae are counted under the 
binocular microscope. Five leaf discs are counted and about 100 larvae per 
disc are assessed. Average mortality is compared to the standard. 
Microbial contaminants: 
 
Standard: < 50,000 cfu/gram of 
product at 30°C and at 37°C;  
 
 
Standard for external testing by 
accredited laboratory: 
- Total aerobic plate count 
   at 37°C:     < 50,000 cfu/g  
- Yeasts and moulds 
  at 37°C:                   < 10 /g 
- Coliforms:              < 50 /g 
- Staphyloc. aureus:  < 50 /g 
- Fecal streptococci:  < 50 /g 
- Salmonella.: absent in 25 g 
Method for internal testing: one sample of 50 gram is taken from one end-
use product package and prepared as in germination test. Four sub-samples 
in two dilutions are plated on two specific agar media: eight CLED plates 
for bacteria and eight MEA plates for moulds and yeasts. Incubation takes 
place for two days at 30° C and 37° C for bacteria, for three days at 30° C 
for moulds and yeasts.  
 
Method for external testing: one sample of 250 g from an end-use product 
package is tested according to standard testing methods. 
Technical properties: 
1) moisture content: 
 
Standard: between 5 and 9% 
 
2) wet sieve test/solubility: 
 
Standard:  < 2% residue on 75 μm 
sieve 
 
Method: one sample of 1 gram is dried at 100 ° C in an IR moisture 
analyser. The weight difference before and after drying is loss of water.  
 
 
Method: the solubility of the product is tested by the wet sieve test. A 
sample of 5 gram is diluted in 5 liter (=label rate) and stirred for 30 
minutes. The solution is poured over a 75 μm sieve; the remnants are dried 
and weighed. The percentage left on the sieve is determined and compared 
to the standard. 
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Conclusions and recommendations 
 
The need for quality control 
Every batch should be subject to all quality control tests. Essential parameters that need to be 
checked are listed in table 4.1. Too many poor quality products have been put on the market 
in the past and this still occurs today. Poor quality leads to inadequate efficacy, and could 
even be a risk to human health and the environment. This is unfavourable for the producer 
and the users; ultimately it is bad for biocontrol in general. Product control should only be 
needed to confirm that the end-use product is of good quality. If production and formulation 
are done properly they should deliver products of high and consistent quality. This is an ideal 
situation. If product control finds deviations from the specifications, batches should be 
discarded. Improvement of those batches is rarely possible. Feedback from product control 
must be used to improve processes at an earlier point in the production line. This is one 
pivotal aspect of product control for the producer. QC is also a process that ensures that 
remedial efforts, if necessary, have produced satisfactory results and that detects recurrences 
or new instances of quality problems. Ultimately, quality control must ensure that end-users 
consistently receive high quality products. 
 
Standardization of biological activity 
Standardization for measuring efficacy has been developed for Bt’s, but not for other 
biopesticides. Standardization of biological activity of Bt’s allows scientists and regulators to 
compare products, although there are still difficulties (Skovmand et al., 1998; 2000). In 
addition to standardization in Bt’s, a number of authors have expressed a desire for commonly 
accepted standard methods and criteria in other biopesticides as well (Burges, 1981; Guillon, 
1997b; Glazer and Lewis, 1998; Jenkins and Grzywacz, 2003). I presume standardization of 
Bt’s was initiated by researchers because demonstration of efficacy is not required for product 
approval in the USA. In the EU efficacy requirements are strict and in order to get approval a 
considerable amount of efficacy data has to be generated. Users can be confident that label 
claims of an approved product have been evaluated by the authorities. In this respect, 
biopesticides are treated similarly as chemical pesticides. Therefore, I believe that 
standardization of biological activity is not necessary and that efforts should not be spent on 
this activity as was carried out with Bt’s over the last five decades. This would require a 
considerable amount of research in co-operative programmes between industry and academia 
and would need considerable resources.  
For EPNs, on the other hand, it is desirable to establish a standardization of activity 
since they are generally not registered and efficacy data are not required. I recommend 
following the same approach as with beneficial arthropods. Here a pragmatic approach was 
chosen whereby it was determined whether mass-reared organisms were of an acceptable 
quality rather than of an optimal quality (Van Lenteren, 2003). Quality was considered in 
terms of whether a natural enemy is in a condition to properly control the pest instead of 
quality in strictly scientific terms. This was tested under relevant laboratory conditions. As I 
suggested above, the research of Grewal (2000) can be used as a starting point. In my opinion 
this effort should be made by the industry itself, with the help of scientists, and a very 
pragmatic approach should be taken. 
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Recommendation for tolerance range of the number of active ingredients 
Registration requirements do not give any guidance on acceptable tolerance levels of active 
propagules in products during their shelf-life period. The Danish EPA suggests accepting a 
five-fold deviation in the level of propagules in products on the market until the expiry date. 
This means that on the lower side only 20% of the set specification is acceptable and at the 
upper side 500% of the amount over the specification. Both the upper and lower ranges seems 
unrealistic to me. A product will generally not achieve its field performance with only 20% of 
its active ingredients. This renders dose-mortality research and determination of the most 
efficacious dose meaningless. A producer will not over-formulate its product by a factor of 
five, simply due to economics. The suggested range is nowhere to be found in any guideline 
and offers producers insight into what level is acceptable to authorities. Acceptance between 
countries, however, is likely to vary considerably until levels of acceptable deviations are 
officially established within the EU.  
When comparing acceptable ranges of active ingredients (a.i.) in chemical pesticides the 
largest accepted deviation (tolerance ranges depend on the amount of a.i. per kg product) is 
±15 % of the declared content in homogeneous formulations when the a.i. is ≤ 25 gram per 
kg. For heterogeneous formulations the accepted range is ±25% (FAO/WHO, 2006). Looking 
at dose-mortality relationship and economics, this seems an acceptable tolerance range for all 
biopesticides to me. At Koppert, specifications of Mycotal and Vertalec were set with a 
maximum deviation of 15%, and this has been workable and achievable for many years 
without jeopardizing the products’ performance. There is a strong need to determine the 
permissible tolerance range for active propagules in biopesticides with which they must 
comply during the shelf-life period. The competent authorities should make clear 
requirements for the industry and harmonize regulation on this point. I recommend allowing a 
tolerance range of ± 25%. This seems to be a workable range for most biopesticides and this 
range is accepted in chemical pesticides for heterogeneous formulations. I consider 
biopesticides similar to heterogeneous formulations since they contain particles. In case it is 
desirable for a certain formulation to deviate from this percentage, a reasoned case should be 
acceptable.  
 
Recommendation for an acceptable level of microbial contaminants 
The amount of acceptable contaminants is also not regulated. The Danish EPA suggests 
initiating discussions on this as well as on the above topic within the EU to establish agreed 
levels of deviations in MPCPs (Winding, 2005). This topic has been further taken up within 
the OECD BPSG (OECD, 2009) and within the REBECA project. The reader is referred to 
chapter 5 for more details on this project. The OECD BPSG wrote an issue paper “Microbial 
contaminants for microbial pest control products” which was discussed with the biopesticide 
industry during a workshop in July 2009 (OECD, unpublished). The approach of the 
regulators was based on accepted levels of contaminants in food and drinking water. The 
industry argued that biopesticides cannot be compared to food products. Biopesticides are 
different products that are generally applied in highly diluted solutions (100-1000 x) onto 
crops. Moreover, microorganisms generally decrease quickly in numbers in the environment. 
The risks from contaminated biopesticides are therefore much lower than from contaminated 
food or feed products in which contaminants may reproduce rapidly. IBMA proposed limits 
for products based on baculoviruses and for bacterial and fungal products. Tests should be 
performed for a limited number of indicator species and higher levels should be accepted than 
those for food and drinking water. Further, the IBMA would like to see the general 
Chapter 4 
___________________________________________________________________________ 
 130
contaminant level (total aerobic count) set 10 times higher as proposed by the OECD 
document, to 108 cfu/gram of product. In specific cases levels may be adjusted if there are 
good reasons for it. An example is B. cereus in baculovirus products (REBECA, 2008). For 
human pathogens, the levels should be strict and clear, industry agrees with the regulators on 
this aspect of microbial purity. The toxicity test on mice, however, should only be required by 
the authorities as part of the five batch analysis in the phase of the dossier generation, and not 
as a routine batch test. The OECD BPSG is revising the issue paper and an improved version 
is due in 2010 for further discussion with regulators and the biopesticide industry.  
 
Research needs for alternatives to virulence testing 
The determination of virulence is only practical by performing laboratory bio-assays. This 
still requires considerable resources and time and may delay the release of product for sale. 
Alternatives to bio-assays have been looked for. Examples are the assessment in Bt’s by 
analysis of endotoxins (CPL, 2006 b; Oestergaard et al., 2007), or simple bio-assays without 
plant material (Landa et al, 1994) or virulence testing by measuring enzyme activity (Pernfuss 
et al., 2004; Shah et al., 2007b). 
Alternatives to bio-assays are desired that would be quicker and cheaper and would still 
give reliable results. Biochemical analyses on material could be quick and relatively simple. 
Some attempts have been made with fungi and baculoviruses. The correlation with field 
efficacy must be determined and the results of the analysis should be able to give a consistent 
and reliable predictive value. There is a need to further develop these kinds of methods that 
would make quality control testing easier. It then can be done earlier and more frequently in 
the production line, and in products. This would greatly improve testing for virulence and it 
would provide an easier way to guarantee good quality products. 
 
Total quality assurance 
Quality plays a role at producer, distributor, and extension and users level. All have a 
responsibility with regard to good storage conditions and shipment conditions. Instructions on 
labels and leaflets with directions for use should be carefully read and followed. Producers 
should indicate instructions to all links in the supply chain in a proper way. For instance, in 
Koppert, we have developed “corporate guidelines for temperature-controlled shipments for 
natural enemies and microbials” for our subsidiaries and distributors all over the world in 
order to ensure delivery of consistent high quality products. Every year these are updated with 
incorporation of lessons learned and trainings are given to all people involved.  
Post-shipment product control is pivotal for the users of natural enemies which are often 
shipped in active stages. These stages are vulnerable to harmful shipping conditions. This is 
not the case in entomopathogens which are generally shipped as dormant phases. EPNs, 
however, are more vulnerable than bacteria, baculoviruses and fungi, and do need more 
careful handling and shipping. Guidelines for checking quality have been produced for EPNs 
where it is relevant and tests can be performed within the chain. Training could be provided 
for proper quality checks. For other biopesticides this appears to be too complicated without 
relative expensive facilities and expertise. At the same time, producers have to deliver 
products and instructions for handling in such a way that quality checks are superfluous and 
that quality is guaranteed by the method of handling products.  
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The benefits of quality control 
Quality control is an essential part of a commercial production process and it is vital with 
regard to customer satisfaction and from a product liability viewpoint (CPL, 2006b). It is 
imperative because of the variable biological nature of the products and constraints 
concerning their storage life (Guillon, 1997a). In addition, registration authorities require 
solid quality control procedures and relevant standards with which products must comply. 
The responsibility for the quality of a product ultimately lies at the producer. Quality control 
starts with the production and continues until the product leaves the factory. Even after this 
point, total quality control should take the application of the product into account to guarantee 
customer satisfaction. A producer should instruct his distributors and customers properly so 
they know how to maintain a good quality once the products are in their hands.  
Sixty years after the first biopesticides were launched on the market, quality control 
must be standard in the industry and only tested batches that meet the pre-determined criteria 
should be released for selling. Manufacturers that are member of the IBMA undersign the 
Charter of Principles which implies a sound quality control programme. Members of the 
Biopesticide Industry Alliance (BPIA) of the USA subscribe to similar principles. In this way, 
the biocontrol industry attempts to self-regulate its activities. Obviously, subscribing to a code 
of conduct is not by definition a guarantee for high quality products, and many small 
companies are not member of an industry association. Therefore, these associations should try 
to broaden their membership and promote supply of high quality products only. 
Manufacturers should promote quality awareness within their companies, not only 
within the management, but on the work floor where the day to day production is executed. 
Similarly, it should penetrate to the sales people and feedback should come from all persons 
involved so that a process of continuous improvement becomes an automatism within the 
whole company. Irrespective of official regulations, quality control must become a natural 
striving for improvement of processes and products. Quality control is not a burden, but a 
benefit for all stakeholders (table 4.2). Product quality control should be used to assure users 
that they are buying and using high quality products. Where there is transparency in product 
specifications and in what a product should achieve, confidence in the product is improved. 
Proper quality control will be a benefit both to the biocontrol industry and its customers. 
 
 
Table 4.2.   Benefits of quality control  
 
• Keeps production personnel alert and aware of quality demands, and 
rewards them for improvements in quality of produced agents 
• Detects problems and deviations in the production and in the product  
• Ensures proper production and production processes 
• Checks results of corrective efforts and recurrences of problems 
• Ensures consistent delivery of high quality products 
• Gives confidence in products to sales personnel and distributors 
• Gives satisfaction to users and guarantees repeated sales 
• Guarantees safe products that comply with registration requirements 
• Benefits all stakeholders in biocontrol 
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Chapter 5 
 
 
Registration of microbial pest control agents and products and other 
related regulations  
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Abstract 
Several regulations apply to the handling and the use of microbial pest control agents. 
Microorganisms, except nematodes, need to be registered as plant protection products for crop 
protection. The history of the development of data requirements for entomopathogens started 
in the 1960-1970’s in the USA, a little later in Europe, first for baculoviruses, then for 
bacteria, followed later for fungi. During many decades, both academic scientists and the 
biopesticide industry have tried to improve these requirements to fit microorganisms. The 
regulatory framework for the EU, USA and Canada is presented. In the EU separate 
procedures apply to the active substance and the product while it is one procedure in the USA 
and in Canada. For a registration dossier, data waivers, statements, and experimental studies 
can be used to fulfil the data requirements. Useful information from the literature is provided 
for bacteria, fungi and viruses. Evaluating authorities publish risk assessment reports and 
conclusions that provide applicants valuable insight in critical registration issues. Several data 
requirements are unclear or ambiguous, and guidance documents are needed to improve this 
situation. This relates predominantly to issues on taxonomy, metabolites, stability and 
genotoxicity. The registration process in the EU is presented. It is recommended to choose the 
Rapporteur Member State based on their experience with microorganisms, and the ability of 
good communication, and of having pre-submission meetings. National product 
authorizations are hampered by inefficient organizations and procedures. Initiatives for 
improvement in the UK, Belgium and the Netherlands have been successful in improving 
procedures and have led to the launch of new products. Canada and the USA have similar 
separate procedures for biopesticides. In Europe, a project was initiated to develop and 
propose improved and more efficient regulatory procedures (REBECA). The project provided 
recommendations for improvement of procedures as well for data requirements. The OECD 
BioPesticides Steering Group continues this work and is developing guidance for several data 
requirements issues. The microorganisms registered in the EU are presented and the ones 
pending evaluation, in total twenty-two entomopathogens. A general estimate of costs for the 
generation of an Annex II dossier is about €300,000 for bacteria, €500,000 for fungi, and 
€200,000 for baculoviruses. This does not include administrative fees. Fees for a RMS and for 
national authorizations vary greatly, and are difficult to estimate.  
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Entomopathogenic nematodes are subject to different regulations, they are not covered by the 
legislation of plant protection products in the EU. Several countries, however, have a 
registration for macroorganisms in place. Costs for registration of nematodes may accumulate 
to €20,000, like in Austria where efficacy data are required. Regulations for import and for 
export, and for release of macroorganisms have become complex and an administrative 
burden for biocontrol companies. The current situation in the Netherlands is highlighted as an 
example. Harmonization of legislation is necessary to facilitate the use of invertebrate 
biocontrol agents. The project REBECA developed recommendations for a harmonized 
legislation concerning nematodes and other macroorganisms for biocontrol. Companies want 
to see an independent approval system per applicant. Biodiversity acts and regulations on 
exotic species apply to both microorganisms and nematodes and are briefly discussed as well 
as legislation covering safe handling and transport of microorganisms. 
Intellectual property rights can be a valuable asset for a biopesticide company, particularly a 
patent. The patentability of an entomopathogen is discussed as well as the criteria for granting 
a patent: novelty, inventive step, and industrial applicability. Costs and other considerations 
whether to apply for a patent are provided for a biopesticide. In conclusion, the greatest 
obstacles in the registration process are discussed and suggestions for improvements are 
provided. The issues relate to inappropriate data requirements, lack of guidance for applicants 
and regulators, testing methods for microbials, lack of experience in regulators, national 
registration procedures, and the inexperienced small biopesticide companies. The main hurdle 
is the variety of national procedures which are lengthy and not transparent. Recommendations 
for improvements are presented for data requirements and for regulatory procedures. 
Regulations with regard to nematodes also require harmonization and recommendations are 
provided. EPPO and IOBC should act together and regulate the use of nematodes, so that 
national rules can be avoided. New regulations concerning plant protection products have 
been adopted in the EU in 2009, and implementation is due in June 2011. It is believed that 
this new legislation will facilitate registration and promote the use of biological products. 
Still, law enforcement is needed to prevent marketing of illegal microbials which is of no 
interest for anyone. The IBMA continues to lobby for a more appropriate registration 
procedure for biopesticides in general. Regulatory progress is slow, but the future outlook 
looks promising. 
 
 
Introduction  
 
Various regulations apply to microbial pest control agents (MPCAs) and products (MPCPs). 
The person responsible for handling these organisms in any way and particularly who releases 
them into the environment is accountable for possible adverse effects. Compliance with the 
many different legislative requirements is integral to sustainable use of those organisms and 
to sustainable business activities of a biopesticide manufacturer. In order to bring a MPCP on 
the market it must be registered as a plant protection product. Entomopathogenic nematodes 
are often treated separately from microorganisms and in most cases other regulations apply. 
Regulations for both groups of organisms will be discussed in this chapter. Legislation is 
established in directives and guidelines and a large data package has to be generated to fulfil 
the data requirements. A registration dossier is submitted to the competent authority for a risk 
assessment. After the evaluation, they decide whether a product can be released to the market 
and what precautions are necessary for safe use. This procedure was designed for chemical 
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plant protection products and has been in place for many decades. For MPCAs/MPCPs this 
procedure was more or less copied, and gradually adapted to the specific characteristics of this 
type of products. Still, many data requirements are not appropriate to living organisms and 
this raises considerable problems. Registration is reported as the greatest challenge in the 
development of MPCPs. In this chapter I will review the development of the data 
requirements for MPCAs and MPCPs and the procedures of registration with a strong 
emphasis on the situation in Europe. For reasons of comparison, reference will be made to 
regulations and procedures in the USA and other developed countries in cases where this 
illustrates differences and gives directions for improvements. 
Further, I will give recommendations for the generation of a registration dossier and the 
information that can be used to complete the data package. Attention will be given to those 
data requirements that are ambiguous and difficult to answer. Where possible I will give 
recommendations for solutions. Often though, these matters are very complex and experts 
need to work together to make the requirements more appropriate to these biocontrol agents. 
Several initiatives have been established to improve the current situation and some examples 
will be presented, as well as recommendations from the lessons learned in these projects. The 
costs of registration are often an impediment for companies, particularly due to the 
uncertainty to what amount they may accumulate. I will attempt to give an estimate of the 
registration costs for each type of entomopathogen.  
Registration for entomopathogenic nematodes is quite different from bacteria, fungi and 
baculoviruses. The situation will be reviewed, including other regulations for import and 
export. The complexity of legislation to biocontrol companies is reviewed for invertebrate 
biocontrol agents, and ideas for improvements and harmonization are presented. 
I will pay attention to the use of exotic organisms, but I will not treat regulations for 
importation and release of exotic entomopathogens for classical biological control. This topic 
is reviewed by Bigler et al. (2005), Loomans (2007), Hajek et al. (2007) and Hunt et al. 
(2008).  Regulation on transgenic organisms is also out of the scope of this thesis and they are 
not used in crop protection in Europe anyway. 
Registration procedures are complicated and expensive and they do not really encourage 
the development of new products. In contrast, governments advocate the development of non-
chemical products, but they lack appropriate regulatory procedures. The main obstacles in 
legislation for use of entomopathogens are identified, and recommendations for 
improvements will be presented, particularly from the viewpoint of the biocontrol industry, 
and based on more than twenty-five years of personal experience with registration of 
entomopathogens in Europe. New regulations may offer new possibilities for easier 
registration of MPCPs and these will be mentioned.  
Intellectual property rights are a valuable asset. The possibility of patenting a MPCA 
and/or a MPCP is an important consideration for a company in order to protect their 
investment. Aspects to consider are presented, as well as some examples where patents on 
entomopathogens have been exploited by biocontrol companies. The data package generated 
for registration is considered protection as well and I will briefly discuss this topic.  
  
  
Registration of microbial pest control agents and products 
Microbial pest control agents and microbial pest control products, also called plant protection 
products (PPPs), are subject to registration, just like chemical substances and PPPs. The 
registration process evaluates the risks of the active substance and of the products that contain 
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these microorganisms to human and animal health and to the environment in relation to the 
intended use of the products. The regulating authority performs a risk assessment based on the 
product dossier submitted by the applicant. After the evaluation of the risk assessment an 
approval may be issued including legal label recommendations and standard phrases for 
special risks and safety precautions. The fulfilment of the data requirements in a dossier forms 
a substantial part of the investment in the development of a microbial pesticide. 
Registration is undoubtedly the largest barrier for commercialization of biopesticides, 
particularly in Europe. Ever since the development of biopesticides, registration has been the 
subject of an ongoing discussion concerning data requirements, risk assessment, 
administrative procedures and costs (Summers et al., 1975, Burges, 1981c; Lisansky, 1986; 
Quinlan, 1990; Tooby, 1997; Van Lenteren, 1996; Waage,1997a; Neale, 2000; Ravensberg 
and Elad, 2002; Franceschini and Jondini, 2004; Zimmermann et al, 2004; Mensink and 
Scheepmaker, 2007; Waage, 2007; Chandler et al., 2008a). Here are the main reasons: 
• data requirements are not well-defined and often adapted from requirements for 
chemicals which are generally not appropriate for microorganisms; 
• test methods and guidance documents are set up for chemical substances and do not 
allow proper testing of microbials; 
• end-points of risk assessments are not clearly established which allows for differences in 
interpretation and often leads to more data being required;  
• regulators and risk assessors lack expertise and consequently they tend to over-ask 
information; 
• procedures are lengthy, non-transparent and costly: both the EU procedure for the active 
substance and the national procedures for product authorizations; 
• the onset of sales is unpredictable. 
Noteworthy is that Marrone (2007) does not mention registration as a barrier for biopesticides 
in the USA, but she refers to the long and expensive registration process in the EU as a reason 
for the few available products on the market. Chandler et al. (2008a) reviewed the registration 
process for biopesticides in the EU and its member states and they concluded that “the 
regulatory failure arises from the application of an inappropriate synthetic pesticides model 
and lack of regulatory innovation”. In consequence, MPCP developers and manufacturers 
face an uncertain procedure without a clear estimation of costs and timeframe before they can 
even start generating a return on the investment. Therefore, many potential MPCAs are not 
being developed, or, companies which have tried commercializing products have failed due to 
high investments and no revenues for a long period.  
 
The development of data requirements 
The first microbial pesticide was registered in 1948 in the USA (Schneider, 2006). This was 
Bacillus popilliae (=Paenibacillus popilliae) for the control of Japanese beetle. Since the 
early developments of biopesticides, registration has been a difficult issue. Appropriate data 
requirements did not exist and had to be developed. Initially, applicants for the registration of 
a biopesticide followed chemical guidelines. Through contacts with regulators, data 
requirements were gradually adapted and they became more appropriate for biopesticides.  
Interest in baculoviruses as biological insecticides goes back more then 50 years, 
particularly in the USA. The first baculovirus product was registered by the USA 
Environmental Protection Agency (EPA) in 1975 (Ignoffo and Couch, 1981). This was 
preceded by much research in the public sector in the 1960’s and the development of data 
requirements by the EPA. In this process, many safety studies on vertebrates were conducted 
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which demonstrated the safety of these viruses (Burges et al., 1980a). In a USDA-EPA 
symposium, new test methods and criteria were jointly developed with regard to safety 
aspects of viral insecticides (Summers et al., 1975). In 1983, four viral pesticides were 
registered and in the course of these evaluations the EPA also established guidelines and data 
requirements for microbial pesticides. A detailed overview of the history of registration of 
viral products in the USA is given by Betz (1986). The discussion about data requirements 
started somewhat later in Europe, mainly in Germany and the UK (Burges et al., 1980b; 
Miltenburger, 1980a, b). The first viral insecticide (Madex) was approved in 1987 in 
Switzerland. The first virus for use in greenhouse crops (Spod-X) was approved in 1993 in the 
Netherlands. Many of the data requirements were answered by means of published studies, 
and specific product data were generated via experimental studies (Smits and Vlak, 1994).  
The first bacterial product (Thuricide) was registered in 1961 in the USA. The 
development of guidelines and data requirements was initiated by members of the American 
Society for Invertebrate Pathology (SIP). A working Group on ”Safety of Microbial Control 
Agents” was founded at the annual meeting in Montpellier in 1971. This group mainly 
worked on Bt and viruses, but also on fungi, protozoa and EPNs (Laird, 1981). In Europe, 
guidelines were drafted by an IOBC study group in 1980 for bacterial pesticides (Burges et 
al., 1982). The first product (Thuricide) was approved in Europe in 1964 in Germany. In the 
Netherlands, the first Bt products (Dipel and Thuricide) were approved in 1971 for use in 
greenhouses. 
The first proposal for data requirements for entomopathogenic fungi was provided by 
Hall et al. (1982). The first registration for an entomopathogenic fungus in Europe was 
obtained in the UK in 1981 by Tate & Lyle for Vertalec, a product based on an aphid-specific 
strain of Verticillium lecanii. (= Lecanicillium longisporum). Quinlan (1990) reported on the 
data requirements in the UK at the time. He also described the difficulties with requirements 
and procedures in some other European countries. Gradually, other products appeared on the 
market e.g. Mycotal (V. lecanii (= L. muscarium)), Bio1020 (M. anisopliae), Preferal 
(Paecilomyces fumosoroseus (=Isaria fumosorosea)), and Botanigard and Naturalis (B. 
bassiana). In the USA, Mycar (Hirsutella thompsonii) was the first registered 
entomopathogenic fungus for control of citrus rust mites, and approval was granted to Abbott 
Laboratories in 1981. However, the product was never commercially successful and was 
withdrawn in 1985 (McCoy, 1996).  
In the Netherlands, the author was personally involved with the registration of Mycotal, 
which was the first fungus to be submitted for registration. A special application form for 
microbial products had been developed following more than 10 years of discussions, 
workshops, meetings and proposals. Data requirements were similar to those for chemical 
products, and only during pre- and post-submission meetings was it decided which data was 
needed to be generated and how. The first application (1982) was not approved in 1985 due to 
insufficient efficacy. With an improved formulation, approval was received in 1992. Attempts 
to register Mycotal in France and Germany in the mid 1980’s were abandoned because data 
requirements and procedure costs were unclear and the authorities over-required data in the 
eyes of Tate & Lyle.  
Despite the many proposals for data requirements for entomopathogens by scientists and 
the biocontrol industry, most countries used their own set of data requirements or used the 
ones for chemicals with some modifications. Only eight years after the implementation of 
Directive 91/414/EEC (EC, 1991a), in 2001 when 2001/36/EC (EC, 2001a) came into force, a 
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standardized set of data requirements became available for all EU countries. These were 
established within the EU without consultation with the industry and academic experts. 
It is beyond the scope of this thesis to review the historical development of these 
requirements in detail. For applicants who wish to register a product, it is more useful to 
understand the current requirements. Below, I will give recommendations on how to build a 
dossier and which sources, in addition to the guidelines, can be used to better understand what 
exactly the authorities require.  
 
The role of researchers and industry in the development of data requirements  
The process of establishing and improving data requirements has taken place independently in 
many countries over the last five decades. Scientists have documented this process and have 
often indicated the need for appropriate guidelines both for the industry and for the regulators. 
They also have conducted much research to demonstrate that entomopathogens (and other 
biocontrol agents) are safe to the environment and to human health. Methods have been 
developed to study the effects, and based on this research new and appropriate guidelines 
have been formulated and proposed. Many papers have been presented on this subject during 
conferences, followed by intensive discussions. Specific workshops (IOBC, EPPO, OECD, 
and others) have been held on this topic since the 1970’s. The following list of publications is 
a selection that presents an elaborate illustration of this debate over a long period until today: 
Hall et al., 1982; Laird et al., 1990; Garibaldi, 1995; Cook et al., 1996; EPPO/CABI, 1997; 
OECD, 1998; Strasser, 2000; Zimmermann et al., 2004; Jaronski et al., 2003; Kiewnick, 
2007; Chandler et al., 2008a. These debates at scientific conferences were often held in the 
absence of regulators and this was very unfortunate since without their understanding and 
commitment to improve requirements and guidelines, these discussions had little impact.  
The industry view on registration of bioinsecticides, bioherbicides and biofungicides has 
been given by a number of authors who all asked for specific data requirements and 
harmonization of procedures (Lisansky, 1986, 1994; Cross and Polonenko, 1996; Neale, 
1997, 2000; Panetta, 1999; Ravensberg and Elad, 2002; Franceschini and Jondini, 2004). 
Novel products faced this challenge of registration and many companies failed to get 
approval, or only received approval after a long time and with high costs. As a result, many 
companies stopped their activities with biopesticides, or put them on hold. Even today, 
applicants face difficulties in answering the questions. Still, parts of the requirements are 
“modified chemical requirements” and are not appropriate to the specific registration issues of 
microorganisms. At the same time, they make the evaluation for risk assessors difficult and 
allow for differences in interpretation and in decisions. Change in regulation is a slow and 
difficult process with many stakeholders involved. Harmonization is strongly desired, but it is 
only slowly finding its way into these regulations and procedures. Industry and scientists are 
still in discussion with regulators on improving the requirements and regulations. This is an 
ongoing process by companies when they apply for a biopesticide registration, and by 
activities of the International Biocontrol Manufacturer Association (IBMA). This association 
plays an important role as a spokesman of the industry and participates in many activities with 
authorities and other organizations.  
The EU has realized that the registration hurdle is keeping products from the market and 
that procedures need to be improved. In some countries, specific initiatives have been set up 
to facilitate product registration on a national level. Examples will be given below. 
Legislation is intermittently revised and societal and political influences play a more 
prominent role then ever. Unfortunately, the focus is still on the chemical pesticides and the 
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biopesticides are only a minor aspect, so to achieve improvements in the regulation of 
biopesticides will be an ongoing challenge for the biocontrol industry.  
 
Regulatory framework for registration of microbial pesticides     
In the EU, the placing on the market of a PPP is regulated by the Council Directive 
91/414/EEC (EC, 1991a) which came into force on 26 July 1993. The EU registers the active 
substance (term also used for microorganisms) whereas any final formulated product needs to 
be registered in each individual Member State (MS). Before 1993, any active substance and 
PPP needed to be registered on a national level. The EU Directive was an attempt to 
harmonize registration within the EU for all involved parties. Biopesticides needed to be 
registered according to this legislation, but until 2001 there were no specific data 
requirements. Only when the Commission Directive 2001/36/EC (EC, 2001a) was published 
in May 2001 as Annex II B and IIIB of 91/414/EEC were data requirements differentiated 
from chemical substances, and specified for microorganisms as active substances (Annex 
IIB), as well as for the preparations based on them (Annex IIIB). The definition of a 
microorganism applies to bacteria, fungi, protozoa, viruses and viroids. The publication of the 
specific data requirements was a major improvement. However, both the industry and the 
regulators found that while working with these requirements several questions were 
ambiguous and needed clarification.  
Once a microorganism is approved, it is included in Annex I, the list of all approved 
active substances in the EU. Annex III lists the data requirements for the PPPs. Annex IV and 
V of  91/414/EEC (Commission Directive 2003/82/EC (EC, 2003)) describe the standard 
phrases for special risks and safety precautions (labelling). Only in 2005 were the Uniform 
Principles for microorganisms laid down in Council Directive 2005/25/EC (EC, 2005a) as 
Annex VI part II of 91/414/EEC, while the Uniform Principles for chemicals originated from 
1997. Uniform Principles ensure that evaluations and decisions with regard to authorization of 
plant protection products are conducted according to these principles by Member States. It 
was only decided in 2005 by the EU that inclusion on Annex I of microbial pest control 
agents has to be done at the strain level (SANCO/10754/2005 rev.5). Further, in 2008 it was 
decided that baculoviruses will be included at the species level, although new isolates must be 
notified to the EU (SANCO/0253/2008 rev. 2). An overview of the registration process and 
the data requirements are provided by Neale and Newton (1999). 
The EU has revised this Directive and the new version has become Regulation (EC) 
No 1107/2009 (EC, 2009a) which makes it directly law in all MSs. This Regulation has been 
published on the 24th November 2009 and will apply 18 months after publication, thus from 
14 June 2011. A few changes may be helpful in getting more biopesticides in a wider market. 
These will be discussed in the conclusions of this chapter.  
In the USA, the requirements for biopesticides were recently updated as the “Pesticides; 
Data Requirements for Biochemical and Microbial Pesticides, Federal Register Notice: 
October 26, 2007 (Volume 72, Number 207), EPA 40 CFR Part 158” (EPA, 2007a). The 
definition was changed from “microbial agent” to strictly “microorganism”. Other changes 
include the requirement for more mutagenicity studies with metabolites, immunotoxicity 
studies and an additional avian study. The intra-cerebral study was removed. Details on the 
registration process and the requirements are provided by McClintock (1999). In Canada, data 
requirements are outlined in Regulatory Directive DIR 2001-02. Data requirements in the 
USA and Canada are largely similar in practice, although they differ somewhat on paper (O. 
Messerschmidt, pers. comm.). The only substantial difference is that PMRA requires a 
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complete dossier on efficacy and phytotoxicity data, and the EPA does not. A comparison on 
legislation in Europe, Canada, the USA and the regulatory processes is made by Hauschild 
and Speiser (2007). Formal data requirements are similar, the registration processes, however, 
are different whereby the process in the EU is the most complex and  lengthy. 
Further, the OECD has published three guidance documents (OECD, 2003a; 2004a, b) 
on data requirements and the evaluation thereof. These documents are a great improvement in 
terms of harmonization. A dossier should be set up according to the OECD format and this 
format facilitates the process for all stakeholders in many countries. Below I will discuss the 
actions that the OECD BioPesticides Steering Group (BPSG) is currently undertaking to 
improve registration of biopesticides. 
 
The generation of a dossier 
In the EU an Annex II dossier is required for registration of the active substance at the EU 
level, and an Annex III dossier for the product for national authorizations. An Annex II 
dossier provides all the required information for the microbial agent per se including at least 
one representative use. This is a label recommendation such as, for instance, the spraying of a 
tomato crop against whitefly in a greenhouse with a certain dose rate, frequency and intervals. 
This use is needed to establish exposure routes and to perform risk assessments for that 
particular use. The chapters in such a dossier consist of data on the microorganism: identity 
and biological properties; analytical methods; human toxicology; residue on food and feed, 
fate and behaviour in the environment, and ecotoxicology. 
An Annex III dossier contains information on the product, with all the desired label 
uses. The chapters present data on the formulated product: physical, chemical and technical 
properties; application methods and mode of action; analytical methods; efficacy; human 
toxicology;  residue; fate and behaviour; and ecotoxicology. The difference between an 
Annex II and III dossier is small when the active substance and the formulation are very 
similar, or when the formulants are considered safe.  
 In the USA and in Canada, a registration must be obtained for the active ingredient as a 
manufacturing use product (MUP) as well as for the separate end-use product (EP). The 
registration process is handled by one authority in each country. Both Canada and the USA as 
well as the EU accept a dossier in the OECD format which facilitates international exchange 
of information. 
Most of the regulations allow for answering questions in one out of three ways: 1) via a 
data waiver; 2) via a statement based on scientific literature; or 3) via an experimental study. 
This can be decided on a case by case approach and an applicant is free to choose how to 
fulfil the requirements.  
 
Data waivers 
The request for data waivers, e.g. justifications for non-submission of data, is an important 
possibility in the building of a dossier. The acceptance of waivers reduces the need to conduct 
expensive experimental studies. Non-submission of data can be justified when exposure does 
not occur or is limited given the method of application of the MPCP. A data waiver can also 
be argued for from published literature from which it can be demonstrated that adverse effects 
are unlikely to occur. Justification for data waivers should be written using sound scientific 
arguments. It is recommended to discuss the possibility of waivers during a pre-submission 
meeting with the regulatory authority.  
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The use of waivers is under discussion in the OECD BPSG (OECD, 2009) in order to 
harmonize decision taking on this subject. A guidance document on waivers is in 
development in which the focus lies on ecotoxicology, and on infectivity tests and clearance 
studies (elimination of the microorganism from the body of the test animal). Acceptance of 
waivers will depend on the type of microorganism and its level of familiarity. It will be a case 
by case approach. Data waivers are largely accepted for the group of baculoviruses. There are 
more areas where data waivers are applicable such as on genotoxicity, residue, ecotoxicology, 
environmental fate and behaviour. Another area is efficacy regarding questions on effects on 
yield, adjacent crops, succeeding crops and non-target plants.   
 
Statements 
Questions can be answered by statements based on scientific literature. There is a wealth of 
information on microorganisms and safety. Many studies demonstrate that microbial 
biocontrol agents do not cause any harmful effects. These studies often addressed non-target 
organisms and environmental fate and behaviour. Some animal toxicity, residue, and 
metabolite studies have been conducted. I will give an overview of useful information about 
bacteria, fungi and baculoviruses.  
When using generic literature it is necessary to address the topic in relation to the strain 
that is subject to registration. When it can be demonstrated that the information also refers to 
the strain used, regulators are more likely to accept the statement. When the strain used differs 
from the information in the literature, then the differences should be addressed and it should 
be made clear to what extent the data do apply to the strain used. Bridging data may still be 
needed to accept statements which are based on information of similar strains or species. The 
more convincing evidence can be given in the statement, on a solid scientific level, the more 
valuable the statement is for the risk assessment. Statements may form a considerable part of 
a dossier when the organism is well-studied. For a newly-discovered species this is not 
possible. It is recommended to use a consultant with experience in writing statements or to 
ask a specialized scientist to address the particular topic. Sometimes it is easier and cheaper to 
have a test conducted than to have a statement written by an expert or consultant.  
 
Experimental studies 
For certain requirements, experimental studies have to be performed according to official 
Good Laboratory Practice (GLP) guidelines such as OECD guidelines. Often, toxicological 
animal studies need to be performed in this way, as do environmental studies that investigate 
non-target organisms and fate in the environment, and physical-chemical property studies. 
These study protocols have been developed for chemical substances and often adaptations are 
needed to make them appropriate for testing microbials agents. These need careful and 
accurate modifications in the protocol which need to be discussed in detail with the 
contracting research organization (CRO). The product developer needs to take the lead since 
these CROs often lack experience with microorganism. If protocols deviate considerably from 
the standard protocol, it is recommended to ask the evaluating regulatory body for their 
approval of the adapted protocol to prevent difficulties later in the process. If communication 
with the regulators is difficult on this point, assure that solid scientific argumentation is 
provided to justify the protocol adaptations.  
Efficacy studies need to be conducted by CROs that are certified for conducting trials 
under Good Experimental Practice (GEP) conditions, and according to EPPO guidelines. 
These are developed for chemical pesticides and protocols often need to be modified in order 
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to properly assess the activity of a biopesticide. Consultation with the authority is strongly 
recommended again. 
  
Useful information on bacteria 
The safety of entomopathogenic spore-forming bacteria has been documented in numerous 
publications and reviews. The majority refers to Bt species, subspecies and strains and, in 
general, these organisms pose little risk to human and animal health (Glare and O’Callaghan, 
2000; Lacey and Siegel, 2000; Libman and MacIntosh, 2000; Siegel, 2001; Federici and 
Siegel, 2007) and to the environment (Meadows, 1993; Klier, 2000; Glare and O’Callaghan, 
2003; Jackson, 2003; Lacey and Merritt, 2003). Moreover, there have not been any reports of 
adverse effects on humans and the environment arising from the widespread use of Bt’s in the 
last five decades (Otvos et al., 2005). The approval of transgenic Bt crops in many countries 
and the wide-scale planting of these crops and the use of products from these crops in food 
and feed further suggest the safety of Bt to human and animal health and to the environment 
(Federici and Siegel, 2007). A review of Bale et al. (2008) indicated that Bt crops do not lead 
to any direct adverse effects on parasitoids and predators. Several OECD guidance documents 
have been published that provide valuable information for environmental risk assessments 
(OECD, 1997), and methods with regard to identification and detection of bacteria (OECD, 
2003b, 2004c). 
A concern for regulators is the close relationship between B. thuringiensis, B. cereus 
and B. anthracis. The last two are serious human pathogens. Species differentiation is difficult 
and the genetic relationship between these three bacteria is not fully known. The same holds 
for the exchange of plasmids between these three species. Nor is their role in pathogenesis 
and toxin production understood (Vilas-Bôas et al., 2007). Moreover, the toxins of Bt’s 
require careful safety testing, particularly with new strains (Glare and O’Callaghan, 2000). 
 
Useful information on fungi 
There are many papers on the safety of fungi which can be used in statements. Excellent 
reviews on safety of Beauveria bassiana. B. brongniartii and Metarhizum anisopliae to 
vertebrates and to the environment have recently been published by Zimmermann (2007a, b). 
These publications could be a useful tool in the generation of a dossier on strains of these 
fungi. In fact, they could be the basis of a generic consensus dossier on these fungi. I will 
come back to this idea in my conclusions.  
The main concerns with fungi relate to toxicology: pathogenicity and the production of 
metabolites, to allergenicity, and to environmental effects (host range). Many authors have 
addressed these issues with entomopathogenic fungi in relation to safety, particularly on non-
target organisms. In general, there are no unacceptable effects on human and animal health 
and on non-target organisms (Strasser et al., 2000; Lynch and Thomas, 2000; Goettel and 
Hajek, 2001; Goettel et al., 2001; Vestergaard et al., 2003; Jaronski et al., 2003; 
Zimmermann, 2007a, b). The impact on earthworms and Collembola was reviewed by 
Brownbridge and Glare (2007) and they concluded that applications of fungal products do not 
pose a significant risk to those non-target organisms. The effects of the application of M. 
anisopliae on soil microbiota (Kirchmair et al., 2008) and on the microbial community 
populations in growing media (Shah et al., 2009a) was also minor and transient. In a review 
on persistence data of applied entomopathogenic fungi Scheepmaker and Butt (2010) reported 
that levels of these released fungi decline over time to natural background levels, and thus do 
not pose a major risk to soil biota.    
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Useful information on baculoviruses    
The safety of baculoviruses to human and animal health and to the environment has been 
thoroughly studied and baculoviruses are generally recognized as safe (Burges et al., 1980a; 
Groner, 1986, 1990; Cory, 2003; Lacey, 2008). The OECD published a consensus document 
on information used in the environmental risk assessment of baculoviruses (OECD, 2002). 
The raison d’être for consensus documents was to deliver information that was mutually 
acceptable among OECD member countries. The document contains information on the group 
of baculoviruses such as organism characteristics, behaviour in the environment, and safety 
considerations as well as many references. This document has formed the basis of most 
baculovirus dossiers.  
Baculoviruses do not produce any metabolites or toxins, and cannot reproduce outside 
the host. This is a major difference when compared to bacteria and fungi. The generation of 
an active substance dossier for any baculovirus species is therefore relatively easy, and to 
obtain approval of a baculovirus as an active substance should not be difficult. Specific 
information is still requested for the formulated end-product. The concerns of the regulators 
are predominantly related to 1) the safety of the formulation additives, 2) microbial 
contamination, 3) the hairs of caterpillars as potential allergens, 4) stability of the product, 
and 5) efficacy. These issues should be properly addressed in the product dossier.     
 
Additional sources of useful information  
With respect to applications of new active substances in the EU, the European Food Safety 
Agency (EFSA) coordinates the peer review of the Draft Assessment Report (DAR) with all 
MS and the European Commission. EFSA publishes a public version of the DAR during the 
evaluation process in order to give the public the possibility to submit comments. 
Furthermore, the conclusion of the peer review of the risk assessment by all MS is made 
available on the internet including the conclusions, the summary, several background 
documents with comments on the DAR, comments from expert meetings, and evaluation 
tables (http://dar.efsa.europa.eu). A study of these documents in detail provides a better 
understanding of the critical aspects of a risk assessment for a certain organism or group of 
organisms.  
Some national authorities publish a report on the decision of a PPP on the internet. This 
can range from short notices on the decision and the approved uses and label to full evaluation 
reports describing all relevant risk assessments and conclusions thereof. Such a report is 
published by the Ctgb, the competent authority in the Netherlands (www.ctb-agro.nl), and the 
BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit), Germany 
(www.bvl.bund.de). Other authorities may provide them upon request (J. Meeussen, Ctgb, 
pers. comm.). 
The US EPA also publishes evaluation reports and conclusion details on PPPs, called 
Biopesticide Active Ingredient Fact Sheets and a Biopesticide Registration Action Document 
(BRAD) (www.epa.gov). In Canada, the Pest Management Regulatory Agency (PMRA) 
publishes A Proposed Regulatory Decision Document and a Evaluation Report which 
contains information on the submitted dossier and the evaluation (www.pmra-arla.gc.ca). 
 
Data requirement issues 
The generation of a dossier is a very elaborate and complex task. Clear questions, appropriate 
guidance documents, and experience are of paramount importance in order to set up a dossier 
that fulfils all the requirements. Some of these prerequisites are lacking for biopesticides. 
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Applicants have complained about the lack of appropriate data requirements while regulators 
criticize the poor quality of submitted dossiers. Both points are true to some extent. There are 
numerous items that could be improved in the data requirements and in the guidance 
documents. I will mention a few from my personal experience that seriously hamper the 
generation of a dossier. Improvements will help both industry, and regulators in their task to 
perform a proper risk assessment. This refers mainly to the procedure in the EU. 
 
Taxonomy 
In the EU, micro-organisms are included on Annex I at the strain level (SANCO/10754/2005 
rev.5). The same is true for the USA and Canada. Since the taxonomic classification of 
microorganisms is under continuous debate and new technologies are still being developed, it 
is difficult to present the proper data for identification, and authorities require different 
methods. Currently, applicants may be submitting different methods for identification of a 
strain. This renders reference to related taxa unreliable and this situation is problematic for a 
risk assessment. A guidance document on the use of taxonomy in risk assessment has been 
published by the OECD (2003b) with regard to bacteria. The OECD BPSG (OECD, 2008) is 
developing further guidance to standardize methodology and it recommends the identification 
of the strain at the highest possible level of detail.  
For baculoviruses it has been concluded that Annex I Inclusion will be on species level 
based on the view that “In other cases in which the species is known to be relatively 
homogeneous and well studied it may be decided by experts if certain questions may be 
handled on a species/subspecies rather than on a strain level.” New isolates have to be 
applied for at Member State level, and for the application of a new isolate a Guidance 
Document (SANCO/0253/2008 rev.2) has been developed.  Following annex I Inclusion of 
the new isolate, mutual recognition is possible. It is probably best to submit the new isolate 
dossier to the RMS that wrote the DAR on the original isolate, as they know all the details 
and should be capable of handling the procedure quickly and with low costs.  
 
Metabolites 
In the registration process, data are required for (relevant) metabolites. The definition of a 
relevant metabolite has been refined for chemicals (Sanco/221/2000 –rev.10). In contrast, for 
microbials a metabolite is not clearly defined. For a chemical substance, metabolites are 
defined as “all (biotic or abiotic) reaction or breakdown products of an active substance of a 
plant protection product, formed in the environment”. Under several data requirement 
sections, more precise definitions are given. For example, in a guidance document on 
groundwater, definitions are given for “relevant metabolites”, for “metabolites of no concern” 
and for “non-relevant metabolites”. A stepwise scheme is presented to determine whether a 
metabolite is relevant. For drinking water, acceptable concentration levels are provided. 
Regarding ecotoxicology, definitions are given in specific guidance documents for major and 
minor metabolites.  
For a microbial agent, metabolites are defined in 2001/36/EC as “products resulting 
from degradative and biosynthetic reactions taking place within the microorganism”. Relevant 
metabolites are defined as “metabolites that are of concern for human or animal health and/or 
the environment”. In the section on residues there is mention of substances of concern, as well 
as of impurities and relevant impurities. There are, however, no precise descriptions available 
(no guidance documents) for the determination of whether a metabolite, substance of concern, 
or impurity is relevant, and if so, what levels are acceptable. What is precisely understood as 
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“are of concern for human health”? The distinction between metabolites and impurities needs 
clarification. The definitions for metabolites and consequently for the data requirements for 
those substances are ambiguous and confusing in the case of microbial agents, in contrast to 
chemicals. 
The production of secondary metabolites is often part of the pathogenesis in 
entomopathogenic bacteria and fungi. These compounds may pose a risk to humans and 
animals when they are exposed to them. Therefore, it is pivotal to know whether a bacterium 
or a fungus, and particularly the strain that is being developed as a bioinsecticide, produces 
any metabolites that may pose a problem. I will focus on fungi since it is more complex than 
Bt, but much of the comments are true for bacterial compounds as well. For many fungal 
species it is well known whether and what kind of metabolites they produce (Strasser et al., 
2000; Vey et al., 2001) and this is essential information for a risk assessor. For each strain 
subject to registration, however, the following strain-specific information is required: ”the 
nature and structure of this substance, its presence inside or outside the cell and its stability, 
its mode of action (including external and internal factors of the micro-organism necessary to 
action) as well as its effect on humans, animals or other non-target species” (section 2.8 of 
2001/36/EC). Investigating the exact metabolite profile of a certain strain is an elaborate and 
costly research project. Developing validation methods for analytical use of each metabolite 
(a necessary tool for residue and fate questions of a metabolite) is a project in and of itself that 
could cost up to €1.2 million per compound (Seger et al., 2005a, b; Strasser et al., 2004). It is 
obvious that these data requirements could be a major barrier for further development of a 
product (Strasser and Kirchmair, 2006). Therefore, the EU RAFBCA project (Risk 
Assessment of Fungal BioControl Agents) investigated whether simpler methods could be 
developed to assess the potential risks of metabolites (for details see www.rafbca.com). 
Effects of crude extracts were compared with effects of purified metabolites.  Crude extracts 
amplify the signal for the main metabolites, and may also take into account interactions 
between compounds. The findings of RAFBCA suggest that crude extracts represent the 
“worst case scenario” (Skrobek and Butt, 2005). One of the recommendations from RAFBCA 
was that metabolites should be investigated in a tiered approach (Strasser et al., 2008). Crude 
extracts of the fungus should first be tested for harmful effects. If no harmful effects appear, 
further information and testing is not required. If negative effects do appear, further 
elucidation of metabolites could be warranted. Risk assessment of crude extracts requires less 
time and fewer resources and consequently is more cost-effective for companies wishing to 
register fungal BCAs.  
In RAFBCA, the fate and environmental effects of metabolites were studied as well as 
whether these metabolites enter the food chain. With the fungi M. anisopliae (Längle et al., 
2004), B. brongniartii (Pernfuss et al., 2007), and L. muscarium (A. Skrobek, W.J. 
Ravensberg, N. Ben El Hadj, A. Vey and T. M. Butt, unpublished data) it has been 
demonstrated that these metabolites do not pose a risk to the environment and to that they do 
not enter the food chain.  
Metabolites also pose a problem with regard to genotoxicity. The guideline states: ”if 
the micro-organisms produce exotoxins according to section 2.8 of 2001/36/EC (e.g. “If other 
strains belonging to the same microbial species as the strain subject to the application are 
known to produce metabolites (especially toxins) with unacceptable human health and/or 
environment during or after its application…”) then these toxins and any other relevant 
metabolites in the culture medium must also be tested for genotoxicity. Such tests on toxins 
and metabolites should be performed using the purified chemical if possible”. Often, 
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genotoxicity studies are required even if the organism does not relate at all to this point in 2.8 
in the sense that no unacceptable effects are known from related strains. Three studies are 
required which altogether cost a considerable amount of money. In order to conduct the 
studies with the purified chemicals, considerable quantities need to be available. Theses are 
hard to produce and thus very expensive. I propose to test on genotoxicity only when the 
organisms produce metabolites according to the questions as in 2.8, i.e. there are known 
unacceptable effects from related strains, and with a tiered approach. 
Because of the lack of a proper definition of a relevant metabolite, regulators tend to 
over-ask for data on metabolites. Only when “other strains belonging to the same microbial 
species as the strain subject to the application are known to produce metabolites (especially 
toxins) with unacceptable human health and/or environment during or after its 
application……” data on metabolites shall be provided (section 2.8 of 2001/36/EC). The 
biocontrol industry does not work with these kinds of organisms, but only with Group 1 
organisms: “unlikely to cause human disease” (EC/2000/54 (EC, 2000a)). Still, most 
regulators require detailed information on metabolites. To improve this situation the OECD 
BPSG (OECD, 2008) has initiated the development of a guidance document with regard to 
metabolites. 
 
Various other data requirement issues 
A number of other data requirements call for improvements. I will not go into detail but will 
briefly refer to them. These aspects are:  
• storage stability: there are no guidelines specific to microbials. The test methods for 
chemicals must be used. Acceptable decline levels after a certain storage period have not 
been established. Currently, 10% loss of potency is considered unacceptable while bio-
assay variability alone is often as much as 20%; 
• microbial contamination: acceptable maximum limits of contaminants are lacking, and 
especially limits for each species or group of species of contaminant; 
• genotoxicity: three tests are required and there is no tiered approach. One of the test 
methods, the Ames test which is based on mutant bacteria lacking the capability of the 
synthesis of histidine, is not appropriate for microbial pesticides because the 
microorganism may overgrow the mutagenicity-indicator bacteria on the agar plate. 
When a homogenate of the microorganism is used presence of histidine may interfere 
with the indicator bacteria which makes the test unreliable; 
• sensitization, and classification and labelling: MPCPs are classified by default as 
potential sensitizers since there are no appropriate testing methods available. As a 
consequence they are labelled Xn R42/43 with a danger symbol with the wording 
‘harmful’ and risk phrases R42/43:  “may cause sensitization by inhalation” and “may 
cause sensitization by skin contact”. However, in the peer review report on L. 
muscarium, EFSA concluded in June 2009 in the PRAPeR expert meeting M03 that 
“Classification is not relevant for microorganisms according to classification rules for 
chemicals.” The following labelling phrase was agreed: ‘Micro-organisms may have the 
potential to provoke sensitizing reactions’ (http://www.efsa.europa.eu/en/scdocs/scdoc 
/1446.htm). This conclusion still needs to be officially included in the data requirements 
for microorganisms; 
• ecotoxicology: data on earthworm toxicity are required although there are no pathogens 
known to earthworms. For this reason, it is highly unlikely that well-known 
microorganisms will affect earthworms, so testing is superfluous. Data on effects on the 
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microbial community are required while applied microorganisms fall back to 
background levels and effects are minor and transient, in general; 
• efficacy: levels of efficacy that are equivalent to efficacy of chemicals are often 
required. Biopesticides act differently and result assessments should reflect this. 
Nevertheless, test methods are designed for chemicals and chemical reference products 
must be used.  
Many of these topics have been discussed in the REBECA Action and recommendations for 
improvements have been drawn up. The OECD BPSG is planning to translate these 
recommendations into guidance documents (see below) which are expected to be accepted for 
registration procedures. 
  
Regulatory authorities and procedures in the EU 
 
The Rapporteur Member State 
For the registration of a new active substance, an applicant can choose in which EU country 
he wants to submit the dossier. The Rapporteur Member State (RMS) acts as the evaluation 
competent authority and as the contact point for the company in the EU during the evaluation 
process. The RMS performs the completeness check and writes the Draft Assessment Report 
(DAR), which is the basis for the peer review in the EU. Not every country, however, is 
willing to accept such an assignment, although legally they are obliged to accept it. For some 
applicants it has been difficult to find a country to act as a RMS for a new MPCA. Some 
countries state that they are too busy, or claim that they do not have enough experience. This 
demonstrates that an applicant is only to a certain extent free to choose a RMS. In appointing 
a country as RMS, the first consideration is the amount of the administrative fees. The fee 
between countries differs enormously, and these costs can be considerable. Another pivotal 
factor is the ability to have direct and efficient communication with the RMS, in which each 
others’ language plays a role. Further, the willingness to have a pre-submission meeting and 
possibly follow up-meetings is determinative too. The experience of a RMS with a certain 
microorganism is a relevant factor to consider. Market aspects also play a role since the first 
provisional authorization for the product it is likely to be obtained in the RMS country. The 
choice of the RMS should take these aspects into account, although it is hard to know all of 
this in advance. Often, this experience is only gained during the process.  
Only a number of MSs have gained experience with biopesticides. In the fourth stage of 
the review programme the following seven countries have acted as a RMS for a 
microorganism: Denmark, Estonia, France, Germany, Italy, Netherlands and Sweden. Most of 
the afore-mentioned also have evaluated ‘new’ active substances. Austria, Belgium, Finland 
and the UK have also experience as RMS for ‘new’ microbials. About ten EU countries now 
have experience with one up to three microorganisms as an active substance. Participating 
members of the OECD BPSG are Austria, Denmark, Germany, Netherlands, Sweden, 
Switzerland and the UK. I recommend selecting a RMS for their experience with a certain 
MPCA and for the ability of direct and open communication, and not only based on fees. The 
government-backed initiative to facilitate registration of microbials should also be weighed in 
the decision, see the paragraph on ‘national initiatives ’below. This may save costs and time 
in the long run. Krause et al. (2006) came to similar conclusions for disease-suppressive 
organisms. 
In the USA, the EPA, the regulatory authority, has set up a special division called the 
Biopesticides and Pollution Prevention Division (BPPD) that takes care of the registration of 
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biopesticides. The BPPD is active since 1995 and has gained a lot of experience in evaluating 
the risks of biopesticides. In Canada, PMRA has a separate staff that reviews microbial and 
biochemical pesticides. The experience level is not as high as in the EPA due to much less 
registered microbials. 
 
The road to Annex I Inclusion 
The procedure for a MPCA from application to Annex I inclusion is complex. The applicant 
submits a dossier with one or more representative uses to a chosen RMS. The first step is a 
completeness check by the RMS. After the evaluation of the dossier by the RMS and the 
writing of the DAR, a peer review by the European Food and Safety Authority (EFSA) 
follows. All MS are asked to comment on the DAR and they have the opportunity to raise 
questions. EFSA reviews these issues and consults experts in various meetings. Hereafter 
EFSA drafts a conclusion for a vote by all MS that decide by qualified majority. Then the 
European Commission (COM) decides on Annex I inclusion and publication hereof in the 
Official Journal makes it official. The process (fig. 5.1) should take three years (table 5.1), but 
with MPCAs it has taken more then twice as long in most cases. The new Regulation (EC) 
No. 1107/2009 provides much clearer time lines for the authorities for the various steps in the 
procedure, and this should improve the registration process considerably. 
 
 
Figure 5.1.   The EU registration procedure for a new microorganism 
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Table 5.1.   Official time lines of EU registration procedure for a new microorganism  
 
Steps in registration process time period 
(91/414/EC) 
time period 
 ((EC) 1107/2009)* 
Completeness check by RMS 6 months 4.5 months 
Preparation DAR by RMS 12 months 12 months 
Peer review by EFSA 12 months 6 months 
Decision Annex I listing 6 months 6 months 
      Total 36 months 28.5 months 
*   additional time periods and clock stop periods are provided for submission of  
     additional information and assessment thereof 
 
 
National product authorizations 
In some countries, registration is handled by an authority that is specifically established to 
evaluate and process registrations for plant protection products (and sometimes biocides). 
Examples are the Ctgb in the Netherlands, the CRD (formerly the PSD) in the UK, KEMI in 
Sweden, AFSSA in France. In other countries, registrations are handled by departments of 
Ministries, either of Agriculture, Environment or Health; sometimes even four to five 
Ministries are involved. In the case of a special authority for registration experience is built up 
over the years within the organization. It is evident that such an organization is geared up to 
process registrations in an appropriate way. Nevertheless, from personal experience I can say 
that even in such organizations the procedures are not flawless and delays are frequent.  
Where a Ministry coordinates the evaluation process of a dossier, external experts are 
hired in to evaluate sections of the dossiers. Examples are experts for human toxicology, for 
environmental effects, for efficacy, etc. This is, for instance, the case in Belgium, Italy, 
Poland and Spain. These experts could be academia or experts from research institutes. These 
scientists are often overloaded with work, including some registration dossiers waiting on 
their desk for a risk assessment before a certain deadline. Meetings are only periodically 
organized, but when the work has not been carried out, the applicant can only wait for the 
next meeting. Decisions have been on hold for many months because external experts had left 
the assignments and Ministries were unable to replace them by new experts. The applicant’s 
only resource is to lobby for solutions, but in fact is utterly powerless. The system with 
external experts is obviously an inefficient system with many problems. Each country has a 
different organization for registration, and for biopesticide companies that want to register 
their products in many different EU countries, these processes are a challenge to understand 
and to undergo. This is one of the most difficult aspects of registering a product in the EU. 
Once the active substance has been approved on a European level, it still takes many years 
and great effort to register a product in ten MSs. As an example, it took over four years to get 
a product authorization for Mycotal in Spain. This shows that this system is just not 
functioning. It is completely unpredictable when national registrations can be expected and 
what the costs are. Communication is the key word and obviously the language can be a 
barrier. Therefore, direct contact with the help of an experienced consultant is imperative for a 
timely registration.  
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National initiatives to improve product authorizations 
Most of the discussion in the international scientific community has been focused on the data 
requirements for microbial agents. National authorization of products, however, has been 
hardly considered in international workshops and in the REBECA Action. Procedures and 
fees form a serious barrier to products coming on the market in many EU countries. In the 
UK, there was concern about the lack of microbial products on the market and a pilot project 
was launched in 2003 to encourage and facilitate registration of alternative control measures 
such as pheromones, plant extracts and biological organisms (Chandler et al., 2008a). 
Reduced fees were an essential part of the project and the fee for national registration of a 
microbial organism was reduced from £60,000 to £22,500. Initial success led to the creation 
of a permanent Biopesticide Scheme in 2006. The key elements were the appointment of a 
“biopesticide champion” for all initial contacts and support, and specific guidance (pre-
submission meetings). Further, applicants were and are encouraged to contact the Pesticide 
Safety Directorate (PSD; called Chemicals Regulation Directorate (CRD) since April 2009) 
early in the product development. The reduced fee structure is kept in place too. The fee for a 
new microorganism application in the EU is as low as £7500. The Biopesticide Scheme has 
been a successful project since its foundation and has led to the registration of a moderate 
number of new biopesticides. 
In Belgium, a special procedure was launched in 2007 in the framework of the 
“programme for reduction of pesticides and biocides” to improve the availability of 
biopesticides on the market (see www.fytoweb.fgov.be). Biopesticides are defined as plant 
extracts, microorganisms, pheromones and others. The project aims to give special 
consultancy to the applicant, a separate fast-track procedure for biopesticides, lower fees, and 
improved communication. One contact person has been assigned for the communication with 
applicants. Fees for a new active have been reduced from €100,000 for a traditional pesticide 
to €10,000 for a biopesticide and €3000 for a national product authorization.  
In the Netherlands, a similar situation as in the UK occurred. Decades of discussions 
and workshops, etc., had not led to tangible improvements and few new products were 
entering the market. The project GENOEG was set up in 2001 by the Ministry of Agriculture 
and the Ctgb, and was lead by the Centre for Agriculture and Environment (CLM) (see 
www.genoeg.net; and Chandler et al., 2008a). The goal was to register more sustainable and 
low-risk products with a small dossier which would be quicker, and with lower costs. This 
should lead to the availability of sufficient non-chemical crop protection agents for the 
farmer, a policy goal of the Dutch government. The project aim was to offer consultancy to 
applicants in building a dossier and to provide financial support for the evaluation costs and 
additional required studies. There was no reduced fee for biopesticides established in the 
project as in the UK. The project ended in 2008 and achieved registration of ten new products. 
There has, however, not been a structural change in the procedure and no special contact point 
has been established for inquiries on biopesticides. The current fee structure of the Ctgb is 
complicated and based on actual expenses. For an application of a new substance for Annex I 
inclusion there is no differentiation between microorganisms and chemical substances, and 
the maximum amount is €242,720 (for 2009). When the evaluation appears to be less 
extensive, the lower fee of €164,682 will be charged. The application fee, however, is lower 
for a microorganism: €5712 versus €11,424 for a chemical substance. For a national 
registration of a product, the fee is based on the actual studies that need to be evaluated and 
since the data requirements differ between a chemical and a microbial product, this results in 
fees of approximately €200,000 respectively €40,000. An applicant will receive a quotation 
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after submission based on the size of the dossier. This makes an estimation of the costs 
beforehand almost impossible. A help-desk has been set up for general purposes, but answers 
are very formal and legal and do not really help potential biopesticide applicants in most 
cases. A more structural solution as set up in Belgium and in the UK is highly desirable. 
These initiatives have lead to real progress in the procedures by the national authority, 
and this has led to the launch of new products on the market. Pre-submission meetings, 
reduced fees, and efficient and detailed communication have been the cornerstones of this 
success. It is obvious that there is a need for such systems in most EU countries. Governments 
that take the development of alternatives for synthetic chemical pesticides seriously have to 
implement such a system to improve registration of biopesticides. 
In the USA, the IR-4 Project has been founded with the objective to provide safe and 
effective pest management solutions for specialty crop growers. A special programme for 
biopesticides has been established, and the primary objective of the IR-4 Biopesticide 
Research Program is “to further the development and registration of biopesticides for use in 
pest management systems for specialty crops or for minor uses on major crops” (Hartman and 
Markle, 1999; www.ir4.ruthers.edu). Funds are available for efficacy research. The project 
provides regulatory assistance to applicants, can submit applications itself, on behalf of 
biocontrol companies, and is in close contact with the regulators of the EPA.  
In Canada, PMRA has also introduced a program that facilitates registration of reduced 
risk pesticides, including biopesticides. As part of this initiative, the Agency offers a reduced 
fee structure, and has shortened review timelines for these products. Furthermore, the Pest 
Management Centre of the Ministry of Agriculture and Agri-Food Canada provides 
regulatory support to companies for biological pest control products that address priority pest 
management issues identified in consultations with growers (www4.agr.gc.ca). Budgets are 
available for research projects on efficacy and safety subjects.  
 
The EU Policy Support Action REBECA 
Registration of MPCAs and their products has been difficult and slow in the EU ever since the 
development of the first products. Despite more appropriate data requirements as established 
in 2001/36/EC, few biopesticides have reached the market in the EU. Registration of active 
substances was and is a lengthy process. The whole procedure from submission of the dossier 
to Annex I Inclusion took on average more than 75 months for ‘new’ microbial agents 
(Hokkanen, 2007). This period includes waiting for additional information from the applicant 
though. The details per microorganism are provided in table 5.2. By comparison, approval in 
the USA only took about 28 months. As a consequence, companies hesitate to initiate product 
development. Research results remain on the shelf of the scientists and considerable research 
resources have been wasted in this way. Despite many EU-funded research projects on the 
development of MPCAs, the situation remained the same. In contrast, many MPCAs have 
been registered in the USA: 78 in the USA (Schneider, 2006) versus 21 in the EU (Kiewnick, 
2007). And, in 2006 the number of MPCPs available on the market was 225 in the USA 
versus 57 in the EU (Fjelstedt, 2006). Scientists and the IBMA have consistently attempted to 
improve this situation by means of lobbying activities directed at regulatory authorities, 
policy makers and to politicians (see the “Position Papers” on www.ibma.ch).  
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Table 5.2.   Registration period for microorganism as new active substance from submission 
of the dossier until publication of the Annex I inclusion (Directive 91/414/EC) 
 
Microorganism and 
strain (‘…’) 
Applicant and 
product name (in 
capitals) 
RMS Submission 
date to RMS
Annex I 
inclusion:  
publ. date 
Period 
(mths)* 
Paecilomyces 
fumosoroseus  
‘PFR 97’ 
Thermo Trilogy-
Certis/(Biobest) 
PREFERAL 
BE 18-5-1994 
 
25-6-2001 85 
Pseudomonas chlororaphis 
‘MA 342’ 
BioAgri 
CEDOMON 
SE 15-12-1994 29-4-2004 113 
Ampelomyces quisqualis 
‘AQ10’ 
Ecogen-Intrachem 
AQ10 
FR 12-4-1996 22-1-2005 105 
Spodoptera exigua 
nucleopolyhedrovirus  
Biosys-Certis 
SPOD-X 
NL 12-7-1996 3-08-2007 133 
Coniothyrium minitans 
‘CON/M/91-08’ 
Prophyta 
CONTANS 
DE 10-9-1997 
 
13-8-2003 71 
Gliocladium catenulatum 
‘J1446’ 
Kemira-Verdera 
PRESTOP 
FI 19-5-1998 
 
22-1-2005 80 
Bacillus subtilis 
 ‘QST 713’ 
Agraquest 
SERENADE 
DE 19-4-2000  
 
14-2-2007 82 
Pseudomyza flocculosa 
‘PF-A22 UL’ 
Maasmond/Plant 
Products 
SPORODEX 
NL 6-3-2001 Pending > 108 
Paecilomyces lilacinus 
‘251’ 
Prophyta 
BIOACT 
BE 15-9-2002 
 
5-4-2008 
 
67 
Adoxophyes orana 
granulovirus ‘BV001’ 
Andermatt  
CAPEX 
DE 29-11-2004 Pending > 64 
Paecilomyces 
fumosoroseus ‘Fe 9901’ 
FuturEco 
NOFLY 
BE 4-2-2005 Pending > 62 
Candida oleophila ‘O’ BioNext 
NEXY 
UK 12-7-2006 pending  > 45 
Helicoverpa armigera 
nucleopolyhedrovirus 
Andermatt 
HELICOVEX 
EE 9-08-2006 Pending > 44 
Spodoptera littoralis 
nucleopolyhedrovirus 
Andermatt 
LITTOVIR 
EE 2-01-2007 Pending >39 
Pseudomonas sp. ‘DSMZ 
13134’  
Sourcon_Padena 
PRORADIX  
NL  28-07-2007  Pending > 32 
Trichoderma atroviride ‘I-
1237’ 
Agrauxine 
ESQUIVE 
FR 28-8-2007 Pending > 31 
Aureobasidium pullulans  Bio-ferm 
BLOSS.PROTECT 
AT 17-04-2008 Pending  > 23 
Trichoderma asperellum   
‘T 34’ 
Biocontrol 
Technologies; T34 
UK 22-04-2009 Pending > 11 
* (updated until 31 March 2010; see European Pesticides Database: 
http://ec.europa.eu/sanco_pesticides/public/index.cfm?event=activesubstance.selection&a=1) 
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Eventually, the EU realized that there was a large problem concerning registration of 
microbial pesticides and other alternative pesticides such as pheromones and plant extracts.  
In 2004 the EU DG RESEARCH opened a Call for Proposals regarding improvements in the 
regulation of biological control agents (BCAs) in the Sixth Framework Programme. The 
REBECA (Registration of Biological Control Agents) proposal was written by Ehlers and 
others, and granted as a Specific Support to Policy Action. The objective was to: “review 
possible risks of biocontrol agents, compare regulation in the EU and the USA and to propose 
alternative, less bureaucratic and more efficient regulation procedures maintaining the same 
level of safety for human health and the environment but accelerating market access and 
lowering registration costs” (www.rebeca-net.de). Within the project, which ran in 2006 and 
2007, many workshops were organized where research scientists, regulators and the 
biocontrol industry met and discussed critical issues related to data requirements, risk 
assessments, and procedures. This was the very first time in the EU that such a dialogue took 
place on such a scale. It did lead to a better understanding of the positions and responsibilities 
of all the parties and the difficulties each faced. There was a positive atmosphere where 
solutions were sought in order to resolve the stagnant position of biopesticide registration. 
Informal contacts and building relationships were valuable aspects for all. Unfortunately, 
there were few regulators present from southern European countries. 
The project dealt with invertebrate BCAs, microbial BCAs, botanical extracts and 
semio-chemicals. Current regulations were reviewed, and proposals were made to improve 
procedures, harmonize risk assessments, reduce costs and accelerate procedures while 
maintaining safety to workers and consumers. A wealth of information was presented and 
reviewed. Intense discussions between stakeholders then took place in an attempt to design 
appropriate data requirements and risk assessment methods. It is beyond this thesis to present 
an elaborate review of the topics and the outcome of the project. The interested reader can 
find detailed reporting of the results on the project’s website. I will briefly report the main 
recommendations for entomopathogens (cf REBECA Deliverable 10 and 22) that are 
important for product developers and applicants and that may lead to a more balanced and 
quicker registration of BCAs.  
1. Recommendations for improvement of the registration process: 
- improve communication between applicants and regulators, e.g. by a pre-submission 
meeting; a draft application form and an information package have been designed to 
facilitate and harmonize such meetings; a formal guidance document should be made. 
Applicants should also be invited for expert meetings at EU level; 
- improve communication among regulators to harmonize evaluation approaches and to 
speed up the process. An expert group for microbials should be established that would 
meet regularly. A forum for communication could also be the OECD BPSG; 
- use the lessons learned in the fourth stage of the review programme with ‘existing’ 
microbial agents to facilitate new applications; 
- lower fees substantially. Lobbying by all stakeholders at member state level is needed.  
- develop and accept a generic approach for a certain group of active substances; 
- keep to short and strict timelines for EU and national procedures which will improve 
predictability of the length of the process; 
- develop guidance on efficacy evaluation by an expert group in order to harmonize 
decisions among member states. Assessments should become flexible and lower 
efficacy accepted. 
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2. Improvement on data requirements: 
- baculoviruses are considered safe and should be registered at species level. This has 
been implemented in the meantime (see above); 
- develop threshold levels for microbial contaminants in baculovirus products and 
others. The OECD BPSG has taken this up in their work programme.; 
- develop more specific data requirements and guidance documents with respect to 
genetic stability, human infectivity studies, exposure data, sensitization, metabolites, 
persistence in the environment, and ecotoxicity and effects on non-target organisms. 
Most of these items have been taken up by the OECD BPSG for further development. 
An important document is the “Strategy for implementation of results” (Deliverable 30) that 
recommends how, by whom and when to obtain implementation of the project’s proposals 
and recommendations. The EU microbial expert group, the OECD BPSG, EFSA and national 
regulators must continue to work on these issues. Industry should be involved through the 
IBMA, and scientists through IOBC too. A crucial topic has been whether or not to remove 
BCA regulation from 91/414/EEC and to design specific legislation for BCAs. There was no 
consensus reached on this point. The opinion of DG SANCO (The Health and Consumer 
Protection Directorate General of the European Commission) is that BCAs can be handled 
within the current legislation with adaptations in data requirements and the provision of 
appropriate guidance documents. Many regulators shared this opinion. The biocontrol 
industry desires new legislation and saw opportunities for this since 91/414/EEC in 
undergoing revision. The IBMA activities with regard to this aspect are mentioned below.  
 
Harmonization efforts by the OECD BioPesticides Steering Group 
The OECD’s Pesticide Programme strives to facilitate and improve registration procedures of 
crop protection products in member countries by harmonization and work sharing (Sigman, 
2005). The OECD BioPesticides Steering Group was established by the OECD Working 
Group on Pesticides (WGP) in 1999. The aim was to help member countries harmonize the 
assessment of biopesticides. The definition of biopesticides includes microbials, invertebrate 
biocontrol agents and semio-chemicals. The first task was to review data requirements and to 
develop guidance documents, and a format for dossiers to be used in all member states 
(Richards and Kearns, 1997). This was achieved in 2004, and guidance documents have been 
developed for the industry and for regulators (OECD, 2003a, 2004a, b, c).  
Currently, the BPSG is working on several issues related to data requirements for 
microbials (Meeussen, 2007). The goal is to develop a document that will help evaluators in 
the assessment of microbial pesticides. The first set of issues under discussion concerned: 
taxonomic identification, genetic toxicity assessment, human exposure and risk assessment, 
metabolite residues in treated food crops, and efficacy evaluation. A number of meetings have 
been held with risk assessors from EU countries and from Canada and the USA. The OECD 
also invited representatives of the biocontrol industry (IBMA and the Biopesticide Industry 
Alliance (USA)) to participate in a workshop on the regulation on biopesticides in April 2008 
in Arlington, USA, and in July 2009 in Paris. The industry appreciated this inclusive approach 
of stakeholders in this debate over difficult and sometimes controversial aspects of 
microbials. Ideas and problems from both groups were discussed in an open and constructive 
manner (OECD, 2009). A “Working Document on the evaluation of microbials for pest 
control“ (OECD, 2008) has been published where these issues are treated elaborately, and 
guidance is given on how to fulfil the data requirements, both for industry and regulators. 
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The BPSG has established a working programme for 2009-2012 where remaining 
problems related to the registration of biopesticides will be resolved. These issues are data 
waivers, microbial contaminant limits, storage stability, environmental risk assessment, 
fungal metabolites, classification and labelling, and a checklist for pre-submission meetings. 
The intention is to produce guidance papers for each subject. Recommendations from 
REBECA will be taken forward and implemented where appropriate in these guidance 
documents. The same will be carried out with ‘lessons learned’ from the evaluation of the 
review programme of the EU of ‘old’ microbial agents, and with experiences from other 
countries, like the USA. The IBMA will be consulted for the exchange of information. The 
working programme of the OECD BPSG should lead to facilitation of the registration of 
biopesticides, and the shortening of the procedures through work sharing and harmonization 
between member countries. The outcome will benefit governmental evaluators as well as the 
industry if the EU and national authorities accept those guidance documents. Ultimately, one 
DAR should suffice for the whole world. 
 
Registered microbial pest control agents in the EU 
MPCAs that were on the market in Europe before 26 July 1993, the enforcement date of 
91/414/EEC, had to go through a review programme for re-registration of the active 
substances. This was called the fourth stage of the review (Reg. 2229/2004) in which, among 
others, so-called ‘existing’ microorganisms were re-evaluated. Annex II dossiers had to be 
submitted before 30 November 2005 according to the latest data requirements (2001/36/EC). 
Twenty-two species of microorganisms had been on the market in various MSs and sixteen of 
them have been defended by one or more notifiers, e.g. companies that submitted dossiers. 
The dossiers were processed by the EU-appointed Rapporteur Member States (RMS) and 
DAR’s were written and evaluated. Based on the conclusion of the RMS that for 
microorganisms for which: ”there are clear indications that it may be expected that they do 
not have any harmful effects on human or animal health or on groundwater or any 
unacceptable influence on the environment to be included in Annex I to Directive 
91/414/EEC without detailed scientific advice from the European Food Safety Authority 
(EFSA) having been sought.”, microorganisms were placed on Annex I by 1 May, 2009 
(2008/113/EC). Peer reviews by EFSA were delayed and need to be finalized by December 
31, 2012. Additional information could be required by EFSA later to keep the active 
substance on Annex I. The ‘existing’ entomopathogens placed on Annex I are four subspecies 
of Bt: aizawai, kurstaki, israelensis and tenebrionis, and B. bassiana, Cydia pomonella GV, 
Lecanicillium muscarium (formerly V. lecanii) and M. anisopliae var. anisopliae. Further, 
nine disease control agents have been included on Annex I. One or more strains have been 
included per organism. In the re-registration procedure, ten MPCAs disappeared from the 
market for various reasons. Entomopathogens that were not further supported by the industry 
were the bacterium B. sphaericus, the fungi Aschersonia aleyrodis, B. brongniartii and V. 
lecanii strain Ve2 against aphids, and the baculoviruses Agrotis segetum GV, Mamestra 
brassica NPV and Neodiprion sertifer NPV. Three disease control agents were not supported. 
Since 91/414/EEC has been implemented, only two ‘new’ entomopathogenic strains 
have been included in Annex I: Isaria fumosorosea (P. fumosoroseus) strain “Apopka 97” and 
Spodoptera exigua NPV. Six other microorganisms have been included. Entomopathogenic 
microorganisms in the process of evaluation at the time of writing (March 2010) are the 
fungus I. fumosorosea (P. fumosoroseus) strain Fe 9901 and three species of baculoviruses 
(Adoxophyes orana GV, Helicoverpa armigera NPV and Spodoptera littoralis NPV). 
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Microbial agents for control of fungi and bacteria under evaluation are one bacterium 
(Pseudomonas sp. ‘Proradix’), two fungi (Trichoderma atroviride, T. asperellum) and three 
yeasts (Pseudomyza flocculosa, Aureobasidium pullulans, Candida oleophila). There may be 
more applications filed, and due to confidentiality I cannot be sure whether the above list is 
complete. The entomopathogens registered in the EU in March 2010 (16 on strain level) and 
the ones in the process of registration are given in table 5.3 (SANCO, 2008). The number of 
entomopathogens (on strain level) registered in the USA is 37 in 2007 (EPA, 2007b). Most of 
them (22) are Bt strains. Canada has 14 registered entomopathogenic strains (PMRA, 2008). 
With regard to microorganisms which can be used in organic agriculture in  EU Member 
States, Council Regulation 2092/91 (EC, 1991b) defines that all microorganisms are allowed 
provided that they are not genetically modified. Of course PPPs based on microorganisms 
need a regular national approval too before they can be used.  
 
 
Table 5.3.   Entomopathogenic species and strains registered or under evaluation 
       in the EU in March 2010 
 (..)- number of registered strains; (p)- registration pending; P. fumosoroseus is now called Isaria fumosorosea 
 
 
Registration costs 
Costs for registration are considerable. It is, however, not possible to give a fixed cost figure 
for a microbial agent and/or product. Costs depend on the organism and its field of use, and 
on the country of submission. It is also difficult to distinguish precisely developmental costs 
from registration costs. These overlap to a certain extent. Research conducted in the process 
of product development provides valuable information for the dossier. In the literature, many 
authors mention global figures on the costs of registration, but few are concrete. Gelernter 
(2005) estimated the costs for safety tests and registration of a biocontrol product to be US 
$1-2 million. Marrone (2007) stated that the registration of Bacillus subtilis in the EU 
exceeded US$2 million. Hökeberg (2006) mentioned that regulatory expenses for a 
biofungicide amounted to €1,6 million; Andermatt (2006) estimated the registration costs of a 
baculovirus to range between €1 to €2 million. Costs in the USA are estimated to range 
between $500,000 – 1,000,000 (Evans, 2004a). Clearly, costs are much higher in the EU 
compared to the USA. Many authors have stated this fact, but few exact figures are available. 
A survey among biocontrol companies revealed that registration costs for a microbial 
pesticide in the EU are about €1,890,000 (Hokkanen, 2007). More than half of these costs are 
external costs (experimental studies, consultant costs, administrative fees) and the breakdown 
of the total costs showed that toxicological tests accounted for the largest share (43%). These 
figures refer to all types of microorganisms, and the authors do not specify the field of use nor 
the number of countries in which approval was sought. The greater the number of label uses 
requested, the greater the number of efficacy trials that will have to be conducted. The broader 
Bacteria Fungi Baculoviruses 
Bt aizawai (2) Beauveria bassiana (2) Spodoptera exigua NPV (1; 2 p) 
Bt kurstaki (5) Lecanicillium muscarium (1) Cydia pomonella GV (1) 
Bt israelensis (1) Metarhizium anisopliae (1) Adoxophyes orana GV (1 p) 
Bt tenebrionis (1) Paecilomyces fumosoroseus (1; 1 p) Helicoverpa armigera NPV (1 p) 
  Spodoptera littoralis NPV (1 p) 
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the label, the more complicated the risk assessment becomes, and all these factors contribute 
to the total costs. 
I will try to provide a more concrete figure for registration of a pathogen as an active 
substance in the EU and an authorization in one country for a limited field of use. It is 
customary to separate the costs for the active substance dossier (Annex II dossier) from the 
product dossier (Annex III dossier). The latter contains data on the product (chemical-
physical properties, product toxicology data and efficacy data). Fees differ enormously 
between countries for acting as a RMS as well as for national approvals. Fees for a RMS for 
registration of an active substance range from €5000 (Spain) and €240,000 (NL; this is the 
maximum fee, actual fee is based on cost recovery base) in 2009. Fees per product 
authorization depend on the requested uses (crops and targets) and vary between €5,000 and 
€50,000 and possibly higher, depending on the country. I presume that these costs will be on 
average €100,000-150,000 for obtaining an active substance approved in the EU and a 
product authorization with one target crop and pest in one EU member state. Below I will 
give an estimate of registration costs for a new active substance, in other words for the 
generation of an Annex II dossier, without administrative fees.  
• Bt’s are the only entomopathogenic bacteria from which experience exists. Cost 
estimates are not available in the literature. An estimate is about €300,000 to €500,000 
per new Bt strain. This amount depends very much on whether a company already 
registered a Bt strain before and has access to ample information. If a company has to 
register its first Bt strain, costs may be more than double. For a new entomopathogenic 
bacterium that is not a Bt, costs could be much higher, particularly when toxins are 
involved in the mode of action. Costs may accumulate to around 2 million Euro; 
• Entomopathogenic fungi vary considerably in their biology and this leads to differences 
in dossier costs. At the present time, strains of four species have been registered in the 
EU: B. bassiana, M. anisopliae, L. muscarium and Isaria fumosorosea (P. 
fumosoroseus). I estimate that minimal costs for a fungal insecticide are around 
€500,000. This becomes much higher when unknown metabolites need to be analysed 
and tested. Expenses may extend 2 million Euro in that case; 
• Baculoviruses are considered safe to human and animal health and to the environment in 
general. Moreover, they do not produce metabolites and cannot reproduce outside the 
host. Extrapolation from information of the baculovirus family, from which information 
is widely publicly available, can therefore be used to build up a species dossier, the 
taxonomic level that is accepted for baculovirus registration. Costs of a registration 
dossier are therefore considerably less than for fungi and bacteria. I expect that for less 
than half a million Euros a full dossier can be made. Consequently, registration fees can 
be lower since the dossier requires less time to evaluate;  
• EPNs need to be registered is some countries and a limited dossier needs to be presented 
(see below). When efficacy trials are required, this adds substantially to the costs. The 
estimate of €20,000 per country (see below) seems to be the highest reported thus far for 
an approval at species level. If approval is sought for more targets and/or crops, this may 
increase the costs for efficacy trials. I presume this will not be much higher in the future. 
Data may be used in several countries which makes the average costs for approval per 
country in the EU acceptable. 
Registration costs are often reported as the main hurdle to the development of a MPCP. 
Therefore, it is essential to have a reliable estimate of the costs beforehand. This is a very 
difficult task for a product developer and each case is different. Experience and consultation 
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with experts will help, as will contact with contract laboratories who conduct toxicological 
tests. A pre-submission meeting with the authorities may clarify which data and studies are 
required and this may improve the estimate. In many cases data requirements can be answered 
by statements. Costs may be much lower if an applicant can refer to data of a closely-related 
approved strain by means of a letter of access. For a less well-studied organism, costs may be 
much higher than indicated above. 
During the generation of the dossier new and unexpected issues may appear which 
could significantly raise the expenses. For example, toxicological studies may reveal negative 
effects, where after higher tier studies are necessary. Expenses will depend on whether the 
microorganism is well-known in the literature or whether it is a newly-discovered organism 
with limited or no available data. The latter will make the building of a registration dossier 
much more expensive and time-consuming. The generation of an Annex II and an Annex III 
dossier will cost a certain amount. In contrast, the applicant’s choice of the RMS determines 
the total administrative fees.  
The costs for a product dossier for a typical greenhouse use, for one vegetable crop and 
one target pest, amount to about €50,000-100,000, without the administrative fees. The fee 
tariffs are sometimes made up by the fees for each (risk) assessment and it is complicated to 
ascertain what the total amount of fees will be for a product authorization. Each country has 
its own fee structure and finding out what the costs will be is quite difficult. 
 
Data protection 
Reports of experimental studies as well as statements are considered data. Data protection is 
regulated in Article13 of Directive 91/414/EEC. Annex II data are protected for 10 years 
following Inclusion in Annex I. When it concerns an “existing” microbial agent, data 
protection lasts 10 years from the date of the first registration in each member state; this was 
not harmonized, and was regulated per country. For new data on an “existing” active 
ingredient under the review programme, data protection lasts five years from the decision on 
Annex I Inclusion. For Annex III data, protection lasts 10 years from the first registration for 
new products (harmonized), and for old products, 10 years from the date of the first 
registration in each country (not harmonized). In the new Regulation 1107/2009 data 
protection is regulated in article 59. It will be ten years, but for plant protection products 
based on low risk substances the period is extended to thirteen years, thus also for most 
microorganisms. Once data protection has lapsed, national authorities should, upon request, 
inform applicants which data are unprotected. Reference to unprotected studies accelerates the 
building of dossiers for new products and reduces costs considerably. In the case of microbial 
agents and products this has hardly been done, and generic products (products based on the 
same strain) are not currently found on the market, in contrast to chemicals where this is 
commonplace. Moreover, national enforcement of data protection and track records of 
protected and unprotected data are often not in place. In addition, the provisions on general 
data sharing, the data sharing of vertebrate studies due to test animal protection, and data 
compensation are not clear. The use of unprotected data for generic products may upset 
relationships in the market which could lead to fierce competition and other undesired effects. 
In the field of biopesticides this is yet not the case.  
Registration and the concomitant data package are considered protection from 
competitors in the field of MPCPs where patents are not always possible or not applied for 
(the possibility of a patent for a MPCA will be discussed below). Therefore, it is useful to 
know the data protection rules and consider them in the development of a MPCP. When the 
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development of a biopesticide is conducted in collaboration with a research institute, data 
protection should be considered from the early phases of the research.  
 
 
Entomopathogenic nematodes and regulations 
 
Entomopathogenic nematodes and safety 
The safety of nematodes to human health and to the environment has been the subject of 
many studies and publications. Overviews of this subject have been given by Bathon (1996), 
Ehlers and Hokkanen (1996), Akhurst and Smith (2002) and Ehlers (2003a, 2005, 2006). 
Much information can also be found in presentations and papers given within the COST 
Action 850 "Biocontrol Symbiosis", a European network that organized the scientific 
cooperation in the field of nematode use for biological plant protection (www.cost850.ch). 
The safety of the symbiotic bacteria of the genera Photorhabdus and Xenorhabdus was 
reviewed by Boemare et al. (1996a, b) and Boemare (2004). Various animal toxicity studies 
have been conducted with the bacteria, independently from the nematodes, and the bacteria 
did not show any pathological effects on mammalian vertebrates. An overview of these tests 
is given by Akhurst and Smith (2002). There is one reported case of allergenicity to 
Xenorhabdus, but the risk of allergenicity is considered very low (Akhurst and Smith, 2002). 
There is concern, however, about P. asymbiotica which is sometimes found in 
Heterorhabditis indica. This bacterium is an opportunistic human pathogen and can cause 
severe infections (Akhurst and Smith, 2002; Gerrard et al., 2004). Therefore, this bacterial 
species must be avoided in nematode production and an accurate identification at the start of 
research on H. indica and its symbiotic bacterium is indispensible. In general, the nematode-
bacterium complex is considered to be safe to human health and to the environment which 
allows production and use as a biocontrol agent. Nematodes have a long history of safe use 
and there are no reports of lasting harmful effects. 
 
Entomopathogenic nematodes and the EU Directive 91/414/EEC 
Nematodes are subject to various regulations which are quite different from each other in 
European countries (Ehlers, 1996, 2003, 2005; Richardson, 1996; Loomans, 2007). They are 
not covered by the European legislation on plant protection products (Directive 91/414/EEC). 
However, when the new contours of the revision of this Directive became clearer in 2005, it 
turned out that there was an attempt made by DG SANCO to include nematodes in the new 
EU Regulation (1107/2009) as active substances of plant protection products. In a draft 
amendment (SANCO/10159/2005, dated 6th April 2005) a proposal was made stating that: 
"For the purposes of this regulation, nematodes used in or as plant protection products will be 
assimilated to micro-organisms". Individual companies that produce entomopathogenic 
nematodes, the IBMA, and scientists working within COST Action 850 objected to this 
intention. The arguments used were the following: 
• EPNs are broadly regarded and accepted as macro-organisms and as such are also 
regulated in various countries in the EU and in other countries; 
• EPNs are classified by the EPPO as macro-organisms in their EPPO Standards for “Safe 
use of biological products” PM 6/1-2. EPPO also included EPNs on the “List of 
Biological Control Agents” that have been widely used and are considered to be safe 
(PM 6/3(3)) (EPPO, 2008). The EPPO list contains six species of entomopathogenic 
nematodes;  
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• The OECD considers EPNs invertebrate biocontrol agents and not micro-organisms 
(OECD, 2004d);  
• The FAO also categorizes EPNs in their guidance documents (ISPM No. 3) under 
invertebrate BCAs and not as microorganisms (biopesticides) (FAO, 2005);  
• Many countries have adopted these guidelines and EPNs are often regulated according 
to these guidelines;  
• In the USA, the EPA has exempted nematodes from any kind of registration.  
From the above it is clear that EPNs are regarded as macroorganisms by many different 
authorities and that many of these authorities consider EPNs safe. If the EU regarded EPNs as 
microorganisms within the renewed Regulation on plant protection products, these BCAs 
would fall under both European legislation and various national regulations and would 
become over-regulated. All these regulations would have made it extremely confusing and 
very difficult to obtain approval for the use of EPNs. Later that year, in 2005, the EC agreed 
to withdraw the proposal to include nematodes within the scope of the new regulation 
(Agrow, 2005). 
 
Registration and data requirements in various countries 
Several European countries have a regulation in place which requires a registration procedure 
for nematodes. Some, however, do not have any regulations for invertebrate biocontrol agents 
(IBCAs). A list of countries with requirements can be found on the website of the COST 850 
Action under the subject “Legal & safety” (www.cost850.ch). A brief overview of data 
requirements for approval of the release of nematodes is given by Ehlers (2005) for European 
and various other countries. In general, a dossier has to be presented on safety to human 
health and to the environment. Critical aspects are non-target effects, dispersal, and 
persistence. Some countries, such as Austria and Switzerland, also require efficacy data. 
Requirements for countries outside the EU are reviewed in detail by Bedding et al. (1996) for 
Australia and New Zealand, and by Rizvi et al. (1996) and Akhurst and Smith (2002) for the 
USA. Details on British legislation regulating non-indigenous nematodes were described by 
Richardson (1996). The context of the Dutch legislation for IBCAs, including nematodes, is 
explained by Loomans and Sütterlin (2005). The authors compare and contrast the Dutch 
Flora and Fauna Act that regulates releases of native and non-native animals with 
international legal frameworks. This perspective illustrates the complexity and confusion of 
the legislation around the use of IBCAs. Recommendations for regulations of nematodes and 
harmonization were already made in 1996 by researchers and the biocontrol industry (Ehlers 
and Hokkanen, 1996). It was concluded that there should be no regulation for native species. 
On the other hand, tailored regulation was recommended for non-native species. A set of data 
requirements was proposed and a harmonized approach was recommended. However, 
nematode regulation across Europe is still a country by country approach and varies 
considerably. 
At the present time, Austria has the most elaborate registration requirements for 
nematodes in Europe. They entail information on identification, mode of action, dispersal and 
establishment, application, efficacy and side-effects. Details on production, formulation, 
contaminants, toxins, human pathogenicity, storage, and waste disposal are also required as 
well as a MSDS (Strauch, 2004). Registration of an EPN species took more than two years 
and costs were over €20,000 (R.-U. Ehlers, pers. comm.). This is a considerable cost factor in 
the marketing of a biocontrol agent for a small market. Although this particular approval was 
for broad use, registration costs would be prohibitive if all countries required similar approval 
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procedures. Belgium, Finland, France, Greece, Italy, and Portugal currently do not mandate 
registration of nematodes. Denmark, Germany, Hungary, Ireland, Spain and the UK do 
require a permit for non-native species. Usually, a dossier can be generated based on public 
information. Spain has implemented a new regulation for exotic IBCAs in 2007, but data 
requirements and criteria are unclear. 
Registration of nematodes is often complicated by the fact that their release must 
comply with several different regulations, particularly for exotic species. Examples are 
wildlife acts, conservation acts, biodiversity acts, and quarantine acts, in addition to the 
regulations on release. The authorizing agency usually must ensure that their regulation 
complies with all these others, but sometimes the applicant must deal with this. This renders 
the design of procedures and decisions complicated and confusing.  
 
The struggle with regulations for import, export, and use of macrobial biocontrol agents  
I will present the Dutch situation at the end of 2009 as an example to illustrate the current 
struggle with regulations for IBCAs. Improvements and adaptations were still being carried 
out at the time of writing. The release of animals has been regulated by the Flora and Fauna 
Act since 2002. Without approval, animals cannot be released into the environment. However, 
at the time of implementation of the act, no measures were taken with regard to biocontrol 
and so from one day to the next, biocontrol was illegal, and growers were breaking the law. A 
procedure was then developed in 2005 to allow the continuation of the release of beneficial 
organisms for biocontrol. In order to release a new beneficial invertebrate organism, one 
needs to apply for derogation for release through submission of a dossier. Importation, on the 
other hand, is not regulated in this Flora and Fauna Act, but one cannot release animals 
without the approval. The dossier requires information on the identification, origin of the 
organism, and the purpose of the release. The second section asks information on the biology 
and ecology, which are the basis of a risk assessment in section three. The procedure follows 
the environmental risk assessment (ERA) developed for IBCAs (Van Lenteren et al., 2003b, 
2006). For native organisms, the effect of a mass release on flora and fauna near the point of 
release is evaluated. Generally, this is a transient and limited effect and not a concern. For 
non-natives, the focus is on potential establishment and effects on non-targets and a risk 
assessment must be presented. Costs of the procedure are €100, and the decision should made 
within eight weeks. In 2008, however, decisions were about two years overdue. The 
‘Application Form’ (REBECA, 2007a) and the ‘Guidance Document’ (REBECA, 2007b) 
developed within the REBECA project are used from 2009 onwards. The procedure is still in 
development and is not yet officially enforced by law. In 2005, six species of 
entomopathogenic nematodes obtained derogation for release based on a safe history of use 
(cf. EPPO criteria) and they were placed on a generic list.  
In addition to the approval for release, the Netherlands have implemented the 
International Standards for Phytosanitary Measures (ISPM) No.3 of the FAO (the first 
revision of the Code of conduct for the import and release of exotic biological control agents 
and thus regulates import and export (FAO, 2005). For importation into the European 
Community, veterinary certificates are needed according to the EU Act on veterinary checks 
on animals entering the Community (91/496/EEC (EC, 1991c) and 97/78/EC (EC, 1998a)). 
This act regulates border inspections of animals, regarding diseases and well-being, by a 
veterinarian. IBCAs fall under the broad category “other living animals”. In the Netherlands 
this responsibility is delegated to the Food and Consumer Product Safety Authority (“Voedsel 
en Waren Autoriteit” (VWA) in Dutch). This organization has no expertise at all in the area of 
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IBCAs. Criteria for inspection are unclear for beneficial arthropods, except for bees 
(92/65/EC (EC, 1992)). A veterinary certificate from the exporting country is necessary as 
well. Some countries only provide phytosanitary documents while others furnish veterinary 
documents only. Phytosanitary certificates are accepted too and as long as the arthropods are 
not quarantine pests (according to 2000/29/EC (EC, 2000b)), shipments will be released. An 
importation certificate should be released within 48 hours. Once these documents have been 
made, customs handles of import taxes and inspection of safety of goods, after which 
shipments are handed over to the importer. For importation from EU countries, no border 
inspections are required.  
For exportation within the EU, export certificates are sometimes required. For 
exportation outside the EU, phytosanitary and/or veterinary certificates may be required 
depending on the importing country. Veterinary certificates are provided by the VWA and 
must confirm that no animal diseases occur in the environment around the production facility 
and that the purpose of the goods is “biological control of plant pests”. Phytosanitary 
certificates must state that the shipment contains no “harmful organisms”. These certificates 
are provided by the Plant Protection Service (“Plantenziektenkundige Dienst” (PD) in Dutch). 
The main requirements are identity and purity. These need to be ascertained by production 
protocols, records of identification by experts, and QC data of the production process and the 
product. Twice a year, the production facility and the records are audited by the PD. From 
2009 onwards a production facility can be certified based on their own in-house quality 
control system. Upon approval of the production facility, certificates are given for every 
shipment. The chance is great that all these import and export procedures will become more 
and more complicated.  
Furthermore, with regard to air freight of goods the regulations on safety of civilian air 
freight require that only authorized personnel be allowed to work in the shipping department 
of the BCA producer. For export to the USA even stricter rules apply. 
 
The confusing burden of procedures 
For many countries, it seems more important that procedures be followed and the ‘paperwork’ 
be in order than that criteria be appropriate and proper inspection have taken place. There are 
few countries that really understand the matter in detail and have the expertise to evaluate the 
certificates properly. Proper inspections on the critical issues are hardly conducted due to the 
lack of expertise. As a general rule certificates are issued as long as procedures are set up and 
followed. With regard to all the required documents, shipping within the EU is the least 
complex. Exportation to many African and South American countries and Japan and South-
Korea is the most difficult. Usually, customs are also involved which often means further 
delays. The above picture illustrates how complex and bureaucratic import and export of 
IBCAs has become. Paperwork takes time and increases costs, and causes delays in transports 
and releases of shipments. Certificates are issued within two to three work days. This last 
aspect is critical with products with a shelf-life of only a few days. These procedures also 
impact EPNs, although in general there is less concern with transport of EPNs than of 
arthropods. 
The IBCA manufacturers and distributors face a number of problems that stem from 
these regulations. The administrative burden is increasing, and authorities often have no real 
expertise on this field, thus delays of shipments are common. This may jeopardize the quality 
of the products and timely releases at the users’ sites. The design of the procedures and their 
adaptation to the biocontrol industry diverts many efforts from many stakeholders, and often 
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the results are far from clear. Uncertainties and ambiguities are omnipresent and regulations 
keep changing. This has become a real burden and is difficult to manage within a small 
industry. Koppert, for example, exports EPNs to more than thirty countries, each with their 
own regulations. It is clear that there is a need for the harmonization of legislation and for the 
development of appropriate procedures and protocols, and procedures should be handled by 
one competent authority per country only. In the Netherlands the authorities responsible for 
veterinary checks and for phytosanitary checks announced in December 2008 that they will 
merge into one authority. Combining the veterinary and phytosanitary check into one 
certificate is also anticipated. This may facilitate procedures in future. 
 
The EU Policy Support Action REBECA and nematodes  
Within REBECA nematodes were considered IBCAs. A separate working group of nematode 
experts discussed whether the ERA developed for insects and mites (REBECA, 2007c) could 
be used for nematodes. The working group concluded that the same ERA could be used for 
nematodes, but data on host range, establishment and dispersal of EPNs “would not normally 
be required”. The following recommendations on data requirements for nematodes were 
drawn up (REBECA, 2007d): 
• accurate identification;  
• for H. indica, the absence of the bacterium P. asymbiotica should be ascertained;  
• no further data are needed for indigenous species;  
• non-indigenous species to be deposited in a recognized collection;  
• data on origin, distribution and host range should be provided for exotic species.  
An application form and a guidance document were developed in order to apply for approval 
for the import, shipment, rearing and release of IBCAs in European countries (REBECA 
Deliverable 22). The form refers to native and non-native organisms, and the information 
required can easily be supplied for nematodes when literature and data waivers are accepted. 
The information is required at species level, but information on a lower taxonomic level may 
be required where appropriate. Product information is requested, but the approval is given for 
the organism, not the product. So, many product formulations and product sizes may be based 
on this approval. The procedure is intended to be used in any EU country. In this way 
REBECA recommends a harmonized approach to the approval of the use of a new macrobial 
organism for biocontrol.  
 Furthermore, REBECA does not recommend developing a new and central legislation 
within the EU (REBECA, 2007e: deliverable 22). DG SANCO concurs. But in this way, 
national authorities will continue to regulate IBCAs.  In order to harmonize regulation, 
REBECA recommended that an Expert Group be established that will give advice on the 
release of new species. Adoption of the “standard procedure” as developed within REBECA 
is a highly desirable instrument to facilitate standardization. A joint EPPO-IOBC Panel has 
been created in March 2008 which adapted and modified the REBECA proposal and updated 
the procedure and criteria for updating the “positive list” (see IOBC Commission on 
“Harmonized regulation of biological control agents (CHIBCA)” at www.iobc-wprs.org). The 
adoption of the “Application Form” developed within REBECA as a standard is under 
discussion within EPPO. A species can be added to the “positive list” of EPPO when it is 
either indigenous and widespread in the EPPO region, or established and widespread in the 
EPPO region, or has been used for five years of use in at least five EPPO countries. The 
agents are listed on the basis of  an expert judgement and when there is “sufficient knowledge 
to indicate the absence of significant risks, or the availability of reliable risk management 
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measures” (EPPO, 2008). Inclusion of new species should be evaluated by the Panel on a 
yearly basis. This regulatory process is still under development. Adoption of such a regulatory 
system by individual countries would be on a voluntary basis. Most biocontrol companies 
favour this option, rather than a central EU regulation. 
 
Intellectual property rights and data protection related to nematode registration 
Protection of data is a critical issue in registration. When dossiers have to be submitted for 
evaluation by the authorities, companies want to see an independent approval system per 
applicant where R & D and registration efforts are protected. A generic approval of an 
organism after this has been cleared following the dossier evaluation of the first applicant 
leads to less R & D, unfair competition, and a loss in competitive advantage for the first 
applicant. It is often said that the registration requirement may create more difficulties for 
small companies than for larger companies, but this should be looked at on a product-specific 
basis rather than on a company-specific basis. A smaller company specialized in a certain 
BCA may have a greater market share with that particular beneficial than a larger company in 
which the product is minor. Although company strategies may vary, a product is generally 
valued on its own merits and in the end needs to be profitable. As a solution to duplication of 
efforts and evaluations, data could be shared between companies and submitted to authorities 
with a letter of access and an arrangement for data compensation. Furthermore, data 
protection legislation needs to be developed and implemented. This approach is also 
recommended by REBECA for IBCAs (REBECA, 2007c). Approval could be made general, 
for instance, by the placing the species on the “positive list” of EPPO as mentioned above. A 
period of five years should be long enough for a company to recover the initial research and 
registration costs.   
 
 
Exotic organisms and microbial pesticides 
 
Biodiversity regulations 
The collection, export and import, and the use of microorganisms (species or strains) may be 
subject to biodiversity acts. The Convention on Biological Diversity (CBD) (Rio de Janeiro, 
1992) has now been implemented by 190 countries (Bigler, 2008). Biological control agents 
are more and more an issue, also within the context of the Access and Benefit Sharing (ABS) 
guideline that has been developed in 2000 (Biber-Klemm and Martinez, 2006). In general, the 
CBD and ABS promote conservation of biodiversity and sustainable use of its components. 
At the same time, they regulate ownership and the sharing of economic benefits from genetic 
resources in a bilateral way. These regulations require researchers and companies to seek 
approval for the collection of genetic resources from the competent authorities, and to arrange 
benefit sharing from the potential use of the material. The focus is mainly on pharmaceutical 
products. The ABS, however, includes microorganisms and nematodes. Implications for 
biocontrol are not yet clear and discussions are ongoing to avoid inappropriate regulations 
from hampering or impeding biocontrol (Cock et al., 2009). Up to today research and the 
development of biopesticides has not been hindered by the CBD as far as I know. Within the 
Lubilosa project, however, a trust fund has been set up within the context of the CBD and 
royalties are shared between African countries (Lomer et al., 2001; EC, 2002b). 
The ABS procedure will become implemented by countries and may make exploration 
and exploitation of organisms complex and liable to negotiations on “fair and equitable 
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benefit sharing”. The “IOBC Global Commission on Biological Control and Access and 
Benefit Sharing” has been established that will try to clarify concepts, terms, working 
definitions and sectoral approaches with regard to scientific research and utilization (IOBC, 
2008; Cock et al., 2009). Recommendations are provided to governments and to the CBD in 
2010 for implementation of an ABS regime that ensures arrangements acceptable to all 
parties. For the moment it is difficult to predict the impact on biocontrol, but at some point in 
time the biocontrol industry will need to be involved in order to avoid an unworkable 
situation.  
 
Registration and exotic organisms 
The use of exotic species or strains of microbial entomopathogens is not specifically regulated 
within registration laws. There are no specific data requirements given in the guidelines. 
Regulators will generally require sufficient information on the host range, effects on non-
target organisms, and on fate and behaviour in the environment for a non-native organism in 
order to be able to make a reliable risk assessment. If the outcome complies with the Uniform 
Principles an approval will be given.  
With regard to nematodes, specific approval procedures need to be followed for non-
indigenous species in some countries. This is discussed above. There is, however, no 
European-wide regulation on this aspect. Responsibilities laid down in ISPM3 are also 
applicable as explained above. EPPO has published to guidelines on safe use of exotic BCAs. 
The term ‘exotic’ excludes organisms which are indigenous to the country. The first guideline 
(EPPO, 1999) describes the required information with regard to the first import for research 
under contained conditions. The second describes the procedure for import and release of 
exotic BCAs (EPPO, 2001). It provides guidance for the preparation of a dossier which will 
be evaluated by the competent authority. These procedures may be used on a voluntarily basis 
per country.  
 
Safe handling of microorganisms 
It is vital to know in detail the microorganism under study, from early discovery up to 
commercial use, since microorganisms may present challenges to health and safety of the 
people handling it. First of all, proper identification is needed, followed by an initial risk 
assessment based on the taxonomy of the organism and existing knowledge. Few studies have 
been published on exposure to MPCAs by workers and applicators. Strasser and Kirchmair 
(2006) reviewed the literature on this subject and concluded that unacceptable effects on 
human health have not been documented. Working with microorganisms is regulated by 
several legislations. National legislation for protecting workers should be followed as well as 
international legislation. Furthermore, Directive 2000/54/EC (EC, 2000a) concerning the 
protection of workers from risks related to exposure to biological agents at work, is 
applicable. Classification on the basis of hazard is the first step, and only Group 1 species 
(“unlikely to cause human disease”) should be accepted as biocontrol agents. An example 
where work with a microorganism was abandoned due to this supposition was a project where 
Serratia marcescens strains (Group 2 organism: “may cause human disease”) had 
demonstrated potential insecticidal properties (De Kogel and Ravensberg, 2006). Deliverable 
12 of the REBECA project identified a Positive list of “low risk” MPCA candidates.  
Several regulations apply to the handling of microorganisms such as collecting, 
packaging, shipping, and storage. These could be, for instance, postal and transport (by road 
and by air) regulations. An overview of these regulations and when they are applicable is 
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given by Smith (2000). It is worthwhile to take notice of these regulations. Generally, Group1 
organisms are not subject to many of these regulations. Details on laws, regulation, and 
restrictions on transport of biological material are described by Weihs and Rohde (2005). This 
mainly refers to transport in and between the USA and Europe by postal service and by air, 
including safe packaging instructions. With regard to transport by road, microbial 
biopesticides are generally exempt of ADR rules (The European Agreement concerning the 
International Carriage of Dangerous Goods by Road). Only biological products with 
microorganisms that can cause human or animal diseases are classified  as infectious 
substances and need to comply with ADR protocols (www.unece.org/trans/danger/publi/ 
adr.html). Regulations only tend to become stricter for transport and import as a result of the 
threat of bioterrorism (Foster, 2007). ISPM3 also describes responsibilities of the exporter and 
importer for proper packaging, labelling and storage during shipment, although details are not 
given on requirements.  
A material safety data sheet (MSDS) needs to be established as soon as the initial risk 
assessment has been conducted, and this should be updated once more data become available 
during the generation of the registration dossier. The MSDS is a mandatory requirement; it  
offers a synoptic overview of the most important health and safety aspects of the 
organism/product for professional users, including what to do in case of an emergency 
(2001/58/EC (EC, 2001b)). The developer of a MPCP is liable for any harmful effects 
resulting from exposure to the product and he has a duty to inform others of the potential risks 
of the product when using and handling of the product is done according to conventional 
practices.  
 
 
Intellectual property rights 
Intellectual property rights can be divided in two categories of legal property rights: 
copyrights and industrial property rights. The latter comprises patents, plant variety rights, 
industrial design rights, trade secrets and trademarks. For a biopesticide manufacturer patents 
could be interesting. Many aspects, however, need to be considered in case patent application 
is pursued. Trademarks are easily required for a product name; the product name is registered 
and this offers protection. The other intellectual property rights (IPR) are not very relevant for 
a biopesticide manufacturer and are not further discussed here. Whether biological material is 
eligible for patent protection has been the subject of many debates. The patenting of naturally 
occurring organisms as such is not possible, but the patent law distinguishes between 
discovery and invention. Inventions can be patented, whereas discoveries cannot; the legal 
definition is still under debate and evolving alongside new technologies. For more details, I 
refer to Westerlund (2002). The patent law in Europe is laid down in the Convention on the 
Grant of European Patents of 5 October 1973, commonly known as the European Patent 
Convention (EPC). This is a multilateral treaty that laid the groundwork for the European 
Patent Organisation and provides an autonomous legal system according to which European 
patents are granted. Later, the Directive 98/44/EC (EC, 1998b) of the European Parliament 
and of the Council of 6 July 1998 on the legal protection of biotechnological inventions was 
established. This Directive was meant to harmonize the laws of Member States regarding the 
patentability of biotechnological inventions. A broader overview of laws and regulations for 
the protection of biological material and its history is provided by Fitzner (2005).  
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Patentability of an entomopathogenic microorganism 
Novelty, inventive step and industrial applicability are the criteria for patentability. These 
three criteria are briefly discussed in relation to entomopathogens:  
1. Novelty. The mere discovery of an organism is not patentable. If the microorganism 
(species or strain) has been isolated and selected by a specific method for a particular 
purpose, however, and it is properly identified and characterized, and its specific 
features for the intended use are newly described, then it may be patentable. A sample of 
the organism must then be deposited in a recognized culture collection (37 authorities). 
These are listed in the 1997 Budapest Treaty on the International Recognition of the 
Deposit of Microorganisms for the Purpose of Patent Procedure (Budapest Treaty, 
1997). This treaty stipulates that only one deposit is necessary to cover protection in the 
72 contracting countries. Details on the procedure of the deposit of biological material 
are described by Weihs (2005); 
2. Inventive step. The invention must be new and non-obvious to the skilled person. Not 
only should it be new, it should have an element of innovation, a novel use. This is often 
a difficult requirement in patent evaluation. If anything of the invention has been 
disclosed, it is considered to be ‘state of the art’ and not new anymore, and therefore not 
patentable. If it is a new use with something that already exists, this may also be 
patentable. A new use of a known microorganism could thus be patentable; 
3. Industrial applicability. This criterion is usually not so hard to satisfy. It must be 
‘technically applicable’ and be made for or used in any kind of industry, including 
agriculture. 
 
Patent application 
Inventors have three options for a patent application. This can be submitted nationally, to a 
national patent office; to the European Patent Office (EPO), which comprises 34 contracting 
states, for a European patent; and as a PCT (Patent Cooperation Treaty) application which 
covers 94 countries. If the EPO grants a patent, it still must be registered in each designated 
country. A PCT application covers all participating countries, but eventually one has to 
choose the countries, and patents are applied for per country and granted per country. Patents 
are nationally granted and are essentially independent nationally-enforceable and nationally-
revocable patents. 
The date of application to the patent authority, often called the filing date, is generally 
the date for determining whether the invention is new. If a patent application is a first filing, 
the filing date is generally the same as its priority date. Until publication of the application, 
generally after 18 months, the patent is confidential. An agreement on confidentiality must 
always be signed when material and information is shared with and disclosed to other parties 
before the publication of the patent application.  
 
Patent protection period  
Patents are granted for a period of 20 years, from the priority date on. This period can only be 
extended for a maximum of five years (Regulation (EC) No 1610/96 (EC, 1996)) in the case 
of medicinal drugs and plant protection products. The patent term extension has been 
established because product development and registration procedures consume a large 
proportion of the patent period, and the protection period in the market is largely shortened by 
then. A supplementary protection certificate (SPC) can be requested on a national basis only, 
and has to be applied for within half a year following official authorization to release the 
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product on the market. Market exclusivity, however, cannot exceed 15 years. A SPC comes 
into force only after the corresponding patent expires. It is essentially an extension of the 
lifetime of a patent, giving a company a better chance on return of investment. 
 
Patents on microbial pest control agents  
A useful publication on the patenting of microbial insecticides has been produced by 
Cresswell (1997) that treats the principles of the patenting of microorganisms. He also 
mentioned the differences between applying for a patent in Europe and in the USA. Many 
patents have been granted concerning biopesticides. The subject of the patents generally is the 
method of production, formulation, or use of the product, or combinations thereof. An 
overview of patents up to 2000 in this area has been presented by Montesinos (2003). He 
studied 215 patents on strains of microorganisms with potential as a biopesticide or plant 
growth promoter. Most patents were deposited in the USA and owned by research institutes. 
The majority concerned bacteria and fungi, but few patents were granted for nematodes and 
viruses. The number of patents does not, however, reflect the number of registered products. I 
have not executed a detailed search on patents since Montesinos’ search, but the situation has 
not really changed since 2000. Companies or research institutes expect to receive benefits 
from patents, such as a competitive edge, or income from patent licenses. In few cases are 
royalties paid for isolates, however (Cherry and Gwynn, 2007). And almost none of the 
microbial control products currently on the market are protected by patents (Gelernter, 2007).  
A small number of biocontrol manufacturers do have patents on their production and/or 
formulation technology, mostly concerning fungi and nematodes.   
  
Considerations regarding the patenting of microbial pesticides  
The advantages and disadvantages of applying for a patent need careful consideration. Several 
aspects could be advantageous to a company. Patents are property and contain a certain 
financial value in the market. They may give a company a unique market position. Other 
parties are prohibited from using the protected technology or product for a long period. 
Licensing the technology to others may generate extra income. They may also strengthen a 
company’s negotiation position in several situations.  
There are also a number of disadvantages to patenting. All details of the invention must 
be fully disclosed. Competitors are able to track the inventions that are being made and what 
kind of products may be marketed in the near future. The costs of filing a patent and of 
maintaining it for 20 years can be considerable. In the first years there are high application 
costs. After the patent has been granted, yearly increasing taxes have to be paid during the full 
patent term. For one EU country the total costs amount to about €20,000; for a European 
patent this is approximately €50,000; it can accrue to over €300,000 if a world wide patent is 
pursued. Countries have their own policies in granting patents and some countries do not 
allow patents on crop protection as is the case in Poland. This makes the whole process 
complex. Infringement of the patent needs to be monitored by the patent-holder himself and 
he is responsible for bringing the violator to court. Disputes that need to be solved in court 
can be long-lasting and expensive. There are also other disadvantages that are beyond the 
scope of a single manufacturer. Concern about the freedom of research in relation to 
entomopathogens is discussed by Gelernter (2007). A related example is the debate over the 
use of neem products for crop protection (Kocken and van Roozendaal, 1997). 
A patent on a microorganism or a product formulation is enforceable, but a patent on a 
certain production technology is difficult to evaluate and check. Sometimes it is better to keep 
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production method secret, and apparently most manufacturers follow this approach. Small 
changes in processes may negate the violation of a patent, whereas full disclosure of the 
invention may give the other party valuable ideas. These are critical aspects to consider before 
a patent is applied for. Moreover, registration offers considerable protection as does a 
registered brand name. Applying for a patent needs careful consideration before any time and 
money is spent. Lisansky (CPL, 2006a) considered IPR of minor importance to the success of 
a biopesticide company and stated that “Companies should have patents on relatively few key 
aspects of their technology and should focus instead on having know-how”. Further, he 
warned that “It too, feeds expectations by giving the illusion of value”. When patents are held 
by a research institute, a license can be obtained by a biopesticide producer in exchange for a 
royalty payment arrangement. This can be an exclusive or non-exclusive license, and in this 
case careful considerations need to be made to decide whether all the arrangements and costs 
are worthwhile.    
In one case, the advantage of a patent on the nematode Phasmarhabditis hermaphrodita 
held by Becker Underwood (WO 93/00816) has clearly led to a monopoly position in the 
market. The discovery of the nematode in combination with its symbiotic bacterium and the 
novel use against slugs appeared to be patentable. For this reason other companies have 
refrained from producing and selling this nematode. To my knowledge, this is the only 
example where a patent has kept others from becoming active in a certain field, where 
alternatives have not been easy to develop. In a similar case, the University of Florida holds a 
patent on an isolate of S. scapterisci, and an exclusive license for production and marketing 
has been given to Becker Underwood.  
 
 
Table 5.4.  Considerations on when to or not to apply for a patent 
 
       Apply for a patent when:       Do not apply for a patent when: 
• Competitors can be prevented from 
using this technology or product 
• Cost are higher than benefits 
• A large market exist • A short product life cycle is foreseen 
• A long product life cycle is expected • The invention is easy to circumvent 
• It defends R & D advances • Violation is difficult to prove  
• The invention cannot be kept secret • The invention can be kept secret 
• It is key technology of  the company • The country patent system is weak 
• It delivers market position advantages • Infringement procedures are too 
expensive 
• It influences market price negotiations  • A small market and margins exists 
• It offers the potential to sell knowledge  • A head start in time is sufficient 
• It strengthens the financial position • Registration offers enough protection 
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Conclusions and recommendations 
 
Obstacles and improvements in the registration of microbial pesticides 
The implementation of 91/414/EEC was supposed to bring about a harmonized system for the 
registration of plant protection products within the EU. In reality it has not improved 
registration, at least not for MPCAs. An average time period of more than 7.5 years for the 
Inclusion on Annex I of a microbial active substance is not acceptable for any stakeholder. 
The wait for return on investment is in many cases too great a challenge for a small biocontrol 
company; they either go bankrupt or refrain from starting a registration procedure. Research 
results are not developed into products, or products are sold illegally. The procedures for 
national authorizations are also complicated, long and costly. It may take more than ten years 
from the submission of the application for approval of an active substance at EU level to the 
launch of the product on the market in a number of countries. From the outset of the 
development of the product until actual sales, the situation in the market is likely to have 
changed considerably. In the meantime the pest problem may have changed and/or other 
control products may have solved it by then. The example of Preferal for control of whitefly 
where registration took more than seven years illustrates this problem (Ravensberg and Sterk, 
2004). What is left of the market for which the product was initially developed? This is a 
great risk that is worsened by the lengthy registration period.     
 My perspective on the six greatest obstacles in the registration process and suggestions 
for improvement are summarized below. 
 
1.  Many data requirements are not appropriate for microbials 
The data requirements for metabolites form the largest hurdle. The lack of a proper definition 
of a relevant metabolite and the lack of expertise in this area leads to unnecessary concerns, 
and regulators tend to over-ask data on metabolites. According to the guideline, data on 
metabolites need only to be provided when unacceptable human health and/or environmental 
effects are likely to occur (section 2.8 of 2001/36/EC). However, the biocontrol industry does 
not work with these kinds of organisms, but only with Group 1 organisms (“unlikely to cause 
human disease”) (2000/54/EC). Still, most regulators require detailed information on 
metabolites. With the current data requirements it is hard to fulfil the analysis of metabolites. 
For a new MPCA where information on metabolites may be null, costs for a full metabolite 
analysis will be a serious limit to further development. Two EU funded research projects 
BIPESCO (ww.bipesco.com) and RAFBCA (www.rafbca.com) investigated the effects of 
metabolites of fungal biocontrol agents on residue and environmental effects. Results 
indicated that metabolites pose no risks and that the risk assessments could be simplified 
(Strasser and Bernfuss, 2005). These project results were not yet considered by DG SANCO 
or EFSA. For the assessment of metabolites, the REBECA project recommends studying 
crude extracts for the toxicological and genotoxicological assessment (Strasser et al., 2008). 
Clear definitions and standardized test protocols coupled with a guidance document need to 
be developed.  
The production of generic documents for the main groups or species of 
entomopathogens could facilitate the writing of registration dossiers and their evaluation. An 
efficient example is the OECD consensus document on the safety of baculoviruses. It should 
be accepted that core data will be provided at species level. Obviously, strain-specific 
information will still be required. At the same time, it would be helpful to all stakeholders if 
accepted waivers became public to prevent duplication of work and this would help 
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harmonization of decisions by regulators. Furthermore, a tiered system needs to be 
established. 
The REBECA project reviewed most deficiencies and ambiguities in the data 
requirements and the OECD BPSG has taken many of these items up into their work package 
for the next 4 years (OECD, 2008). This suggests a revision of 2001/36/EC (EC, 2001a) is 
necessary.  
 
2.  Guidance documents for applicants as well as regulators 
Applicants have indicated that more guidance documents are needed to address the specific 
features of microbials. Also, risk assessors have indicated that they need more tools for a 
proper risk evaluation. Mensink and Scheepmaker (2007) designed risk decision trees and 
summary tables as tools to distinguish acceptable from unacceptable risks. These tools should 
facilitate and harmonize environmental safety assessments for regulatory purposes. In the 
Dutch Policy Note on Sustainable Crop Protection (LNV, 2004) it is stated that the 
government is committed to improving the European harmonization on crop protection 
products and to developing guidance documents with regard to the evaluation of those 
products, with special reference to metabolites and plant strengtheners. This illustrates that 
governments recognize the lack of proper guidance. The OECD BPSG planned to develop 
new guidance documents and to consider including recommendation from REBECA (OECD, 
2008). Perhaps it would be better if EFSA as the evaluating authority would develop such 
documents and that these would be enforced as legal guidelines for the EU rather than OECD 
guidance documents.  
 
3.  Testing methods adapted to microbials  
The existing test protocols (OECD, EPPO and others) are developed for chemical substances. 
As an example, testing shelf-life according to the protocol for accelerated storage stability at 
54°C makes no sense for a microbial. New or properly adapted methods have to be developed 
for microbial products. This process needs to be taken up by the OECD in consultation with 
IBMA members. 
 
4.  Regulators lack experience with microbials 
Regulators have only dealt with a limited number of microbial dossiers and have not been 
able to build experience. Many are not educated or trained in this area. Often, new and young 
employees fill this position; sometimes external experts are hired for short periods. This does 
not allow the regulators to focus on microbials and to get acquainted with the specific field, 
and learning is slow in this way. In contrast, the BBPD of the EPA has regulators that only 
deal with microbials. A general European agency for evaluation of microbials could be a 
solution, within EFSA for instance. Another idea is the appointment of a few specialized MSs 
that will carry out this task for the EU, just like the appointment of two lead Rapporteurs in 
the fourth list re-registration programme for microorganism. There needs to be enough 
confidence among regulators to be able to make this work.  
 
5.  Procedures are the most serious obstacle 
The procedure for Inclusion on Annex I is complex and is too long. First, the RMS performs 
the completeness check (up to six months). Then, after the RMS has produced a DAR (one 
year), the other twenty-six MS, the EC and EFSA make comments and several experts’ 
review rounds take place (2-3 years). The applicant has the opportunity to reply to comments 
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twice. Finally, EFSA writes a conclusion and the EC makes an official decision which it 
publishes. This can take many years, deadlines are not always met, and the various steps are 
not very transparent to an applicant.  
Provisional national authorization may be given after completeness check, but many 
MS do not accept this and wait for the DAR or even until Annex I Inclusion. Many countries 
have their own administrative requirements in their language and procedures are not very 
transparent. Evaluation can take years and more data and explanations can be requested. All 
regulators face a log-jam of dossiers and biopesticides are not treated in any kind of fast-track 
system. Fees are high in most cases and differ considerably per country. Often it is hard to 
find out the amount of the fees. Fees structures should be harmonized; a reduction in fees for 
biopesticides will promote more registrations. The initiative of Belgium and the UK should be 
followed widely in the EU. An option may be to replace fees with a tax on sales.  
In my experience, the biggest hurdle to the commercialization of biopesticides is the 
process of national registrations. It takes great effort, some years, and a considerable amount 
of money to obtain approval in ten countries, for instance. I estimate that the total expenses of 
Annex I Inclusion and approval in ten countries could reach approximately €2 million. One 
starts with the registration procedure, but the timing and amount of expenses of approvals is 
unknown. This ‘black box’ system must be greatly improved. This could be done by a wide 
implementation of mutual recognition, by the establishment of zonal registrations, and by 
work-sharing between countries. In my opinion there is only one way out of this complicated 
process of national registrations and that is to create a centralized European authority that will 
evaluate registrations in an efficient way. EFSA could execute this role, for instance. National 
registrations should accordingly be a short procedure. The EPA in the Unites States is a model 
where federal approval is first given, and then state approvals are easily obtained. The EPA 
also has a special branch (the BPPD) that assesses biochemical products, including 
microorganisms. It is obvious that such a set-up allows for an accumulation of experience 
with biopesticides. As a result, risk assessors understand this field very well. From my 
personal experience working with both the EU and the USA systems, it is clear to me that 
experience with biopesticides is a key aspect of proper and timely registration. Unfortunately, 
the European system does not allow for this since the few applications over the last thirty 
years were scattered among all the countries.  
It is a political decision to change the current system and design a new system. This is a 
complicated matter and why it has failed until now has been elaborately described by 
Chandler et al. (2008a). Apparently, the young biocontrol industry lacks a strong supporting 
policy network, and therefore it has not been able to sufficiently influence decision-makers. 
Unfortunately, there does not seem to be much support for a central European agency at the 
present time. Even REBECA did not recommend a central authority given its poor prospects. 
I consider this a missed opportunity since the REBECA project was supposed to provide 
„scientific support to policies“. The project clearly concluded that the current legislation is 
severely limiting registration of new products and that data requirements need to be adjusted. 
This does, however, not improve the difficult process of national product authorizations and I 
believe that only a new legal framework can improve this.  
If the current system remains in place, the hope of the biocontrol industry is vested in 
the revision of the EU law as laid down in the new Regulation (EC) No. 1107/2009 which 
foresees improvements such as zonal registrations and mutual recognition. This must become 
a well-functioning system in order to improve the situation. Within countries, special 
divisions within the regulating authorities should be set up to assess the biopesticides in order 
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to build experience and confidence with these products. Deadlines must be met and costs 
reduced. If the system were more transparent and open to communication, this could lead to 
predictable timeframes which are essential to companies with regard to return on investment. 
With improved transparency at every step of the evaluation process, companies are more 
likely to understand the system and to accept delays and costs.  
The EU registration process took more than 5 years for chemicals as well. EFSA and 
the EC have recognized the need for improvement and in January 2009 a new body was 
established, the Pesticide Steering Committee, to manage the overall process. Improvements 
should be made in efficiency, work-sharing, communication, meeting deadlines, procedures 
and guidance documents. Unfortunately, there is no specific mention of biopesticides (EFSA, 
2008).  
 
6.  The biocontrol companies are small and inexperienced 
Companies should also become more self-critical and improve their ways of working as well 
as the quality of their dossiers. Employ people with experience in registration of 
biopesticides; when needed, hire a consultant who knows the procedures and the details and 
who has easy access to regulators. The extra expenses will pay for themselves via a quicker 
registration. Ensure that the dossier is complete, and use communication with the authorities 
as much as needed. It is unwise to start discussions on the better safety profile of biopesticides 
in comparison to chemicals; this has little impact on regulators (CPL, 2006b). On the other 
hand, regulatory authorities should reach out to the applicant and offer assistance. The 
appointment of a contact person as the CRD (PSD) has done with the ‘biopesticide champion’ 
deserves imitation by all countries. 
 
The REBECA project also identified the main obstacles in the registration process and these 
are similar to the ones I described above (REBECA, 2007f). Within the EU, the new 
registration process in accordance with 91/414/EEC and the scientific peer review of the 
evaluations prepared by MSs is considered as follows: “overall the programme has been 
extremely successful” (Fay et al., 2007). No doubt, major improvements have been made in 
terms of joint reviews, new guidance documents, harmonization and administrative support to 
the programme by the ECCO-Team. This may be true for chemicals. Only a fraction of the 
more than thousand active substances were microorganisms and the process of evaluation of 
microorganisms is still problematic, complex, and lengthy. The above illustrates that there is 
much work to be done before this programme can be called successful for microorganism. 
Full commitment from regulators, scientists and the industry is required to improve the 
registration of microbials. A new and separate registration process and more appropriate data 
requirements must be developed: innovative products require innovative regulations. 
Suggestions for improvements are listed in table 5.5. 
 
Recommendations for a new registration procedure for nematodes 
Currently, there is no uniform regulation of nematodes across EU member states; the use of 
EPNs is regulated at the level of individual member states. The variation in existing 
regulations and procedures is unworkable for the biocontrol industry. It also creates confusion 
and lack of credibility for regulation when neighbouring countries have different regulations 
in force, or even no regulations. There is a need for a harmonized registration of 
entomopathogenic and molluscidal nematodes. Proposed steps in the set-up of a new 
regulation are given in table 5.6 (see also Ravensberg, 2004). Similar conclusions were drawn 
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up by scientists and the industry during a round table discussion within the IOBC WG “Insect 
pathogens and entomopathogenic nematodes” in 2003 (Blum et al., 2003). The procedure 
should be the same for every applicant and data protection legislation needs to be in place. 
The procedure should not be expensive and decisions should be made within short time 
periods. Nor should it become a barrier for research, commercialization, and release of new 
species.  
 
Table 5.5.  Recommendations for improvements in the registration of microbial pesticides 
 
Data requirements Regulatory aspects 
• Develop appropriate data requirements: 
revision of 2001/36/EC 
• Establish a special European group of 
regulators with experience with 
microorganisms 
• Develop appropriate guidance 
documents 
• Organize training workshops for 
regulators when new developments take 
place  
• Design a tiered approach • Develop harmonized procedures  
• Establish category of low risk substances 
accompanied by relevant data 
requirements 
• Develop a harmonized fee system 
• Generate guidance documents on 
accepted data waivers and statements 
• Reduce fees  
• Generate generic dossiers of the main 
species or groups of species  
• Establish and keep to known and short 
decision periods 
• Develop specific testing methods 
adapted to microorganisms and 
microbial products 
• Improve transparency of evaluation 
process, decision periods and costs 
• Allow for tests conducted by the 
producer, non-GLP   
• Provide guidance and support system to 
applicants (‘biopesticide champion’) 
• Adapt efficacy criteria and allow for a 
broader extrapolation across crops 
• Install pre- and post-submission 
meetings with applicant 
• Establish clear defined end-points • Optimize mutual recognition system 
 • Develop harmonization worldwide via 
OECD 
 
 
The recommendations from the REBECA project are a result of discussions between 
regulators, scientists, and industry. This does, however, not mean that they are based on full 
consensus on all requirements. Whether or not these recommendations will be implemented 
on a national level or a European level, and to what extent, is uncertain at the present time. 
Were that so, it would be a voluntary system. There are currently no concrete plans for this. If 
the recommendations are accepted, it would mean that some of the requirements would have 
to be withdrawn by a number of countries such as efficacy data. It remains to be seen whether 
countries are willing to do that. 
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The IBMA and scientists, and organizations like EPPO, IOBC, OECD and the EU must 
all work together to harmonize legislation and make registration simpler and workable, within 
Europe and in other countries. Test protocols and other guidance documents need to be 
developed for data generation, for instance, by the OECD, the IOBC and the IBMA. The 
EPPO should update its “positive list” and continue to evaluate new species for placement on 
the list as recommended in deliverable 21 of REBECA. In 2008, following the REBECA 
recommendation, the Joint EPPO/IOBC Panel on Biological Control Agents has been re-
activated and the “Positive List” has been revised (EPPO, 2008). The Panel intends to 
regularly update the lists. If regulation of nematodes remains a national process, ideally some 
umbrella organization will take the lead in the procedure in order to receive commitment from 
countries that are not familiar with IBCA regulations at the present. The building of a network 
and of confidence between regulators will be helpful to the broad acceptance of this new 
approach. The approval process should be similar to the one envisaged for other IBCAs. 
  
 
Table 5.6.  Proposed steps for a simplified and harmonized regulation for 
        entomopathogenic nematodes 
 
Data requirements Regulatory aspects 
•  Establish limited set of data requirements • Develop harmonized procedures  
•  Develop simple test methods • Develop guidance documents 
•  Demand data requirement at species level 
only, not at strain level 
• Include all stakeholders 
•  No requirements at product level  • Low procedural costs  
•  Accept data waivers and statements • Known and short decision periods 
•  Exclude presence of P. asymbiotica • Each applicant must supply its own 
dossier or have a letter of access 
referring to another dossier 
•  Exclude efficacy data requirements • Develop data protection legislation  
•  Only notification for native species  • Establish zonal system and mutual 
recognition system 
•  Environmental risk assessment 
exclusively for non-native species 
• Update the EPPO “positive list” every 
five years 
•  Tests conducted by producer, non-GLP   • Harmonization worldwide via OECD 
•  Establish end-points • Import/export inspections: minimal for 
in vitro-produced nematodes 
•  Pre-submission meeting to establish 
required data package 
 
 
 
Since nematodes are different from the beneficial insects and mites, nematode experts should 
be asked to join the by REBECA proposed EPPO/IOBC Expert Group in case new nematodes 
are applied for. So far, only one nematode specialist participates in the EPPO/IOBC Panel. It 
will be beneficial to the industry if nematodes are regulated all over Europe within a 
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harmonized system of application and evaluation. Dossier development will become easier if 
one standard dossier can be used, and costs will be acceptable. Fees should be kept low and 
decision-making within short time frames. Officially approved use of nematodes will favour 
the image of biocontrol. 
Another unsolved problem is the import and export regulations and the required 
certificates for export outside the EU or Europe, and for import into the EU. When the 
REBECA approach is accepted by a broader range of countries, this will most likely facilitate 
these procedures. This requires further action from world-wide operating organizations such 
as OECD, FAO, IOBC and IBMA. All stakeholders should be included and participate 
actively. The IOBC Commission on “Harmonized regulation of biological control agents 
(CHIBCA)” has adopted as their task the periodic updating and harmonization of regulation 
beyond the two years of the REBECA project and in the whole IOBC WPRS region, 
including countries that did not participate in the EU project REBECA (Bigler, 2007). I 
recommend that this commission take the lead here, together with the IBMA. 
 
New regulations which may affect the registration and use of microbial pesticides 
The EU has revised 91/414/EEC, and replaced it with a Regulation that will regulate the 
placing of PPP on the market: Regulation (EC) No 1107/2009. The new legislation must be 
implemented by the Member States by 14 June 2011. Principal objectives of the new law are 
to maintain a high level of protection of humans, animals and the environment, to reduce 
administrative burden linked to inclusion and authorization, and to increase harmonization 
between MS. The Regulation also promotes the use of IPM and non-chemical methods in 
recital 35: “In order to ensure a high level of protection of human health and the environment, 
plant protection products should be used properly, in accordance with their authorization, 
having regard to the principles of integrated pest management and giving priority to non-
chemical and natural alternatives wherever possible”. These changes may influence the 
registration and use of MPCAs/MPCPs positively. Other aspects that may facilitate the 
process for microbials are a positive list of safeners and synergists, a negative list for co-
formulants, and simplified procedures for basic substances (‘foodstuff’) and a category of low 
risk substances and products. Further, obligatory mutual recognition of PPP authorizations 
granted by M.S. in the same zone will be implemented. There will be three ecological zones 
and a single zone of contained environments: for greenhouses and for post-harvest storage 
facilities. This will significantly reduce procedural burdens and accelerate product releases 
into a larger market. Decisions would be taken within 90 days.  
 Low risk substances and products will be defined, and their registration will be for a 
longer period (15 years instead of 10 years standard). A fast track authorization and a reduced 
dossier is proposed. Initially biopesticides would not qualify for this category due to the fact 
that they are considered sensitizing and persistent. In a later version of the proposal, however, 
the exclusion criterion referred to “sensitizing chemicals” only. It seems that the lobbying 
activities of the IBMA have paid off in this case. A provision of comparative assessment and 
substitution of products may be installed with a view to encouraging the substitution of 
dangerous substances by safer alternatives, which could stimulate biopesticides. 
 Another new EC legislation is Directive 2009/128/EC (EC, 2009b). The aim of this 
Directive is “to achieve a sustainable use of pesticides” and it covers, among others, the 
development of national action plans to reduce risks of and dependence on pesticides, and to 
promote IPM. Furthermore, biological control measures will be included in training 
programmes. This Directive is likely to promote the use of microbials and other non-chemical 
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pest control products. Member States shall bring into force the laws, regulations and 
administrative provisions necessary to comply with this Directive by 14 December 2011. 
 A new Regulation 1185/2009/EC (EC, 2009c) has been adopted on collection on 
statistics of sales and use of pesticides for assessing policies and risks related to pesticides. 
Currently, there are no official figures on the scope of use of biological plant protection 
products and this keeps politicians from making decisions in this area. The biopesticide 
industry has been reluctant to release any data because of competition. Policymakers need to 
have insight into the relevance of biocontrol in order to be able to justify support to the 
biocontrol sector. It will become obligatory to provide data to the EC on the use of 
biopesticides. This will ultimately benefit the biocontrol industry when official data 
demonstrate the need to facilitate registration and promotion of IPM. 
 
‘Snake oils’ and illegally sold microbial pesticides 
Some companies refrain from seeking official approval thanks to the difficult and lengthy 
registration procedures and start selling products without registration. In almost any country 
in Europe dozens of unregistered biopesticides are sold by a conservative estimate. Often 
these products are of low quality and efficacy may be minimal. Safety is also a concern when 
these products are used without proper advice and knowledge. As a consequence, growers 
may develop a negative attitude towards biopesticides in general, which serves no one’s 
interest. An easier registration system may encourage more companies to register their 
products and to advertise them openly. The current registration system demands an enormous 
amount of resources, while very little attention is devoted to enforcement of regulations. More 
efforts are needed in the monitoring and control of PPPs in general, but certainly of illegally 
used biopesticides also. There is a vital role for national enforcement agencies; however, all 
stakeholders should participate in this effort and fight this problem. 
 
Position and lobbying actions of IBMA  
IBMA has been very active with regard to registration issues since its foundation in 1995. In 
fact, one of the common goals of the member companies was to improve and facilitate 
registration. In the first congress of the organization in 2003 “Bringing science to practice” in 
Beziers, France, legislation was one of the main topics. The EC was represented, and it was 
recognized that registration was a major hurdle for commercialization and that methods and 
guidance needed to be developed for companies as well as regulators. However, progress in 
that direction has been very slow, hence the situation presented above. Lately, the IBMA has 
undertaken lobbying activities with regard to the proposal for the new PPP regulation. The 
main objective was to keep the option for a separate and specific regulation for BCAs open by 
changing the current text of article 2.2: “This Regulation shall apply to substances, including 
micro-organisms and viruses, having general or specific action against harmful organisms or 
on plants, parts of plants or plant products,….” with the addition: “It shall, however, cease to 
apply to microorganisms, viruses, pheromones and biological products once a specific 
regulation on biological control products has been adopted.”  Unfortunately, this has been 
unsuccessful, the new Regulation does not mention anything on a specific regulation for 
biologically-based products.  
The IBMA also asked that MPCAs be exempted from inappropriate exclusion criteria 
for low risk substances (art. 22). Two criteria, sensitizing and persistence (half life in soil > 60 
days), exclude them. MPCAs should benefit from the favourable status of low risk substances. 
The criterion “sensitizing” has been changed and is only referring to “sensitizing chemicals”, 
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but the persistence criterion remained and this may exclude some microbial control agents for 
this low risk category.  
The IBMA is also actively contacting members of Parliament, officials in DG SANCO, 
DG ENVIRONMENT and others. Contacts at member state level are approached to try to 
increase support for the position and wishes of the biocontrol industry, and to favour the 
position of BCAs in general. For instance, the IBMA UK has developed a good working 
relationship with the CRD (PSD) that helps applicants to prepare submissions (Whittaker, 
2007). Through the foundation of IBMA, a representative body of the biocontrol industry has 
been established that has become a contact for interactions and negotiations with official 
organizations, and a spokesman for the companies. This has been very helpful and IBMA 
must continue to play an active role in improving and promoting the position of biological 
control. Members should be willing to commit resources to this purpose that will benefit all 
stakeholders.  
 
Future outlook  
After more than five decades of slow progress in the adaptation of registration for microbial 
pesticides, the situation is gradually improving. The EU REBECA Action has brought 
together regulators with scientists and the biocontrol industry representatives, and a new 
dialogue has been established. All seem committed to improving the situation and ready to 
work actively on solutions. The work programme of the OECD BPSG is very promising in 
this respect (OECD, 2008). The IBMA is also actively expanding its influence on politicians 
and decision-makers. The role of farmers is still too limited and it is up to the biocontrol 
industry to engage them more and to encourage them to exert political pressure. The same is 
true for the supermarkets. With GlobalGAP, a private sector body of supermarkets that sets 
voluntary standards for the certification of agricultural products, IPM is becoming more and 
more standard procedure (www.globalgap.org). This will ultimately offer more opportunities 
for biopesticides. New regulations in the EU will put chemical pesticides in a more difficult 
position. Ideally, biopesticides will be promoted more and registration eased. All stakeholders 
must remain active in this field and continue to assign resources to this task. Changes in 
regulatory processes tend to be slow, but I believe that the future for biopesticides in terms of 
registration is promising.  
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Implementation of a microbial pest control product in an integrated pest 
management programme  
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Abstract 
The application strategy, compatibility, and knowledge transfer to the user are key factors for 
a cost-effective implementation of a microbial pest control product. This requires the design 
of a comprehensive integrated pest management programme in which the microbial pest 
control product is to be incorporated. The first element is an optimal application strategy of 
the product. Determinative parameters are dosage, spray volume, application equipment, 
application method, timing, frequency, and intervals. These parameters are influenced by the 
tritrophic plant-host-pathogen relationships, and by environmental conditions, the type of 
greenhouse, by crop and cultivation effects, and by host plant-mediated effects on the 
pathogen. The most relevant dependencies must be identified and examined. These are 
different for each type of entomopathogen, target pest(s) and cropping system. The second 
element is the incorporation of the microbial pest control product in an IPM system. For a 
successful use, the compatibility with chemical pesticides and with natural enemies and 
pollinators needs to be investigated. Mycoinsecticides are the most sensitive to chemical 
fungicides. Products based on bacteria and baculoviruses and entomopathogenic nematodes 
are, in general, easier to integrate with chemicals. Entomopathogens potentially affect 
beneficial arthropods directly or indirectly through intraguild predation. Due to the specificity 
of most entomopathogens, they pose little or no risk to natural enemies and pollinators under 
field conditions. The mode of action of entomopathogenic fungi, however, warrants concern 
and testing under conditions mimicking field conditions must be performed to understand the 
risks, and to be able to advise accordingly. Microbial pest control products and natural 
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enemies are often simultaneously used in IPM systems against the same pest to enhance 
control. Interactions may influence the natural enemies and the entomopathogen which will 
result in synergistic, additive or negative effects. Therefore, the crop must be monitored 
regularly to ensure continuous effective pest control. Alternate and simultaneous applications 
of two types of microbial pest control products are also a possibility to enhance control, but 
are rarely practiced in greenhouse crops. This strategy is considered useful when larval stages 
have a different susceptibility towards two pathogens, when speed of kill may be enhanced, 
when insect stages are in different locations on the plant, when two pathogens increase insect 
susceptibility, and when multiple pests are targeted. Costs must be considered with regard to 
the degree of additive or synergistic effects. Combinations of a microbial pest control product 
with a chemical or another pesticide offer the potential to increase control, but this is not often 
applied in practice. The use of pollinators as vectors for entomopathogens is another possible 
combination and this is under research. Field resistance to entomopathogens has been 
reported for Bt and for one baculovirus. Resistance management must be part of the 
application strategy. Biopesticides are also excellent tools in resistance management 
programmes for chemicals. Establishment of the compatibility profile requires side-effect 
testing of the microbial pest control product with chemical pesticides as well as on beneficial 
arthropods. The methodology used may influence the outcome, and the relevance for field 
conditions is often debatable. Recommendations are provided for a tiered approach that 
results in reliable data for commercial conditions. The implementation of a microbial pest 
control product in practice demands a carefully designed adoption strategy. The benefits of 
the new product need to be demonstrated to the grower. Knowledge transfer and training are 
pivotal elements. All stakeholders need to participate in this process, particularly those in the 
distribution channel. Successful implementation is an ongoing process of knowledge transfer, 
and with feedback information from the users, a continuous improvement cycle is obtained 
for the use of the biopesticide in the IPM system.  
To conclude, the introduction of a new microbial pest control product implies manifold novel 
interactions within a complex multi-component IPM programme. The importance of these 
interactions per type of pathogen is presented in a matrix table. The most essential 
requirements for successful use of a microbial pest control product are listed.  Microbial pest 
control products have a number of advantages and disadvantages, but overall they offer an 
excellent potential as complementary or stand-alone crop protection products. The 
development and continuous improvement of the implementation process adds expense for 
the manufacturer and that needs to be calculated in the cost price. Combined uses of microbial 
pest control products offer an opportunity that is underestimated. I recommend greater study 
of this option as it can deliver new ways to control pests faster and cheaper than the 
development of new products.   
 
 
Introduction  
 
In greenhouse crops, microbial pesticides are generally used as part of an integrated pest 
management programme (IPM). They are mainly used as an inundative release strategy from 
which direct effects are expected resulting in a considerable decrease of the pest population 
within a relatively short period. In greenhouse vegetable crops, the main biocontrol 
components of the IPM system are natural enemies. Microbial pest control products (MPCPs) 
are often used as selective and corrective measures, or as additional pest control tools. The 
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same can be seen in ornamental crops such as roses and chrysanthemum, but in other 
ornamental crops they are used in a more chemical oriented programme. In such a case, they 
are used as a stand-alone product against a particular pest, or as an additional control product.  
MPCPs can be used to control key pests, often in combination with other methods, or they can 
be used against secondary or minor pests. As justly stated by Hofstein and Fridlender (1994):  
“Design of a comprehensive disease control program is the main challenge of those who 
intend to introduce biological pesticides as an attractive alternative or addition to existing 
control programs”. The same is of course true for a pest control programme. The concept of 
an IPM programme is to have an optimum exploitation of all the pest control options with a 
strong emphasis on preventative measures and biological control methods. This implies a 
good understanding of all components and their interactions, in any given cropping system.  
The concept of integration of pesticides in IPM programmes in greenhouses has been 
reviewed by Blümel et al. (1999). They described the importance of selective pesticides, and 
sequential test methods on detecting side-effects on natural enemies. Furthermore, approaches 
were suggested on pesticide application methods and on how to minimize negative effects on 
beneficials. Little attention, however, was given to microbial pesticides. An introduction on 
compatibility of pesticides, including MPCPs, with biological control agents is given by 
Hassan and Van de Veire (2004). They briefly reviewed the use of pesticides, including 
microbials, in IPM systems in greenhouse crops.   
Given the entomopathogenic character of MPCPs and their use together with beneficial 
arthropods, as well as the use with other pesticides, a “two-sided” compatibility profile of a 
MPCP with these other crop protection components must be established. This is indispensable 
for successful implementation and commercialization of a MPCP. In the literature 
compatibility of entomopathogens with other methods of pest control has been studied for 
many cases. This kind of research is usually aimed at investigating whether there are any 
adverse effects of chemical pesticides on MPCPs, or whether MPCPs have any adverse 
effects on natural enemies and pollinators. An early overview of research results of 
entomopathogenic bacteria, fungi, viruses, nematodes and protozoa and compatibility with 
chemicals and beneficial arthropods is given by Jacques and Morris (1981). They also 
reviewed the combined use of entomopathogens with pesticides. Examples were given of 
enhanced as well as of reduced effects. The option to combine a MPCP with other methods 
may give improved control through additive or synergistic effects. Compatibility studies and 
combination effects have been investigated by many scientists with all four types of 
pathogens treated in this thesis. It is not possible to review all these studies. I will highlight 
the most significant publications below with the focus on greenhouse crops. 
The efficacy of entomopathogens depends on a number of factors such as environmental 
and agronomic factors. These relationships need to be studied. Some of the factors can be 
influenced so that entomopathogens can be used in a more effective way. Inglis et al. (2001) 
reviewed the importance of temperature, humidity, sunlight, soil type, rainfall, and 
interactions among these environmental factors, and their influence on the activity of fungal 
entomopathogens. Understanding these influences is vital for developing an effective IPM 
programme in various cropping systems. The authors illustrated this by examples from 
glasshouse crops (aphids) and field crops (Colorado potato beetle, European corn borer and 
whiteflies). Compatibility with chemicals as well as with beneficials is reviewed, and 
innovative strategies such as using semio-chemicals and trap crops, were discussed.  These 
factors are also relevant for entomopathogenic bacteria, nematodes and baculoviruses, and 
vary per organism, target pest and cropping system. 
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In the development of a MPCP, following product development, the first step is to 
establish the optimal application strategy under commercial conditions. The product should be 
used in such a way that its pest control features are fully exploited within the given situation. 
The application strategy needs to take into account factors such as the delivery technology, 
the biology of the pest, the crop and how it is cultivated, and the environmental conditions. 
Each factor likely to influence the entomopathogens efficacy needs to be considered and 
studied, if deemed critical, in the application strategy. Secondly, the use of the MPCP must be 
implemented in the entire pest and disease control programme. An integrated programme 
needs to be established, with optimal effects on the pests and minimal harmful effects to all 
the biological pest control agents. These two aspects are the cornerstones of a successful 
implementation of a new MPCP in commercial horticultural crops. I will discuss how to 
consider these pivotal elements in the development and integration of a MPCP in an IPM 
system. 
Furthermore, I will discuss other relevant aspects related to this topic such as the chance 
of resistance with pathogens, practical aspects of testing compatibility, the transfer of 
knowledge to the end-users, and the cost considerations concerning implementation of a 
MPCP within an IPM programme. Finally, I will provide recommendations and conclusions 
on the critical steps in the implementation of a MPCP in a multi-component pest and disease 
control system, and on the potential of combinations of control agents to enhance biological 
pest control. 
 
 
Development of an application strategy 
 
In order to achieve effective results with a MPCP against a certain pest, an optimal 
application strategy needs to be developed. For a ‘broad-spectrum’ MPCP, this may differ per 
target species. First of all, the level of the pest determines when and how to intervene. Vital 
factors therein are the application method, the frequency of applications, intervals between 
applications, the optimal dosage, the spray volume used, and appropriate equipment. 
Furthermore, the strategy is strongly influenced by the crop, the cultivation methods, the type 
of greenhouse, the climate, etc. (fig. 6.1). These parameters influence the target pest as well as 
the pathogen. The plant-host-pathogen is a tritrophic system that is influenced by a multitude 
of factors which results in complex study systems. To investigate all these relationships is 
impossible and it is obvious that the most influential factors should be determined and studied 
where they are expected to have a relevant effect on the performance of the biopesticide. In 
the literature, only few examples have been presented where the authors have investigated and 
established a complete and effective application strategy for a pathogen. Depending on the 
pathogen and its biology, particular aspects have to be considered, and I will discuss them 
below. 
Factors influencing activity and persistence of Bt and its toxins are reviewed by Glare 
and O’Callaghan (2000). The fate of Bt is only known in general terms. Persistence can be 
years in soil, but only days in the phyllosphere. Little is known from greenhouse 
environments. Ingestion of Bt by the pest organism usually follows application quickly and 
therefore environmental factors influencing survival of Bt are less critical as with fungi. 
Generally, insects become less susceptible to Bt as larvae become older. The same is known 
for entomopathogenic fungi and baculoviruses. If possible, this should be taken into account 
with regard to timing of the treatments. Examples of greenhouse application strategies with Bt 
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are hard to find in literature, most likely because Bt behaves like a chemical and is less 
influenced by crop and environmental parameters.  
 Entomopathogenic fungi may pose the greatest challenge of the pathogens treated in this 
thesis due to their mode of action. This is exemplified by a thorough study of application 
parameters on efficacy of Beauveria bassiana for control of Frankliniella occidentalis (Ugine 
et al., 2007a). The objective was to develop a spray application guideline for maximum 
efficacy of B. bassiana in a greenhouse ornamental crop. They investigated the application 
rate, the interval between applications, the water volume and the timing of the sprays during 
the full growing cycle of impatiens. Thrips population reduction was the highest when plants 
were sprayed multiple times with five-day intervals with high rate and high volume 
applications. Early treatments in the plant cycle gave larger suppressive effects than later 
treatments. But Ugine et al. (2007a) also found great variation in the population reduction 
between spray programmes. This extensive study illustrates the complexity of establishing an 
effective spray programme and the variations that may occur. Another example is the use of 
the entomopathogenic fungus M. anisopliae for thrips control in plant-growing media in 
combination with chemicals (Ansari et al., 2007). The fungus proved to be a robust biocontrol 
agent giving good control independent of the growing media, the method of application (pre-
mixing resp. drenching) and whether used alone or in combination with insecticides. Earlier 
work had shown similar results against the black vine weevil (Bruck and Donahue, 2007; 
Shah et al., 2007a).  
 
  
Figure 6.1.   Interactions that need to be considered in the development of an application 
  strategy and in the implementation of a microbial insecticide in an integrated 
  pest management system 
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The use of Spodoptera exigua NPV in ornamental crops and tomato was investigated by 
Smits et al. (1987). Reduction of feeding damage was important in ornamental crops and 
virus application timing should be directed for young caterpillars as early as possible. Sprays 
should be directed to the underside of the leaves since early instars mainly feed there. This is 
difficult in dense crop canopies as with chrysanthemum and gerbera, but feasible in tomato. 
The authors also recommended using pheromones for monitoring the population and optimal 
timing of sprays.  
Nematodes are very different from traditional pesticides as well as from microbial 
pesticides due to their size and active behaviour. It is essential to understand the attributes and 
the limitations of these biocontrol agents. An overview of the crucial application factors is 
given by Koppenhöfer (2000), Wright et al. (2005) and Shapira-Ilan et al. (2006). An 
example of developing an effective application strategy is given by Ehlers (2003b) for control 
of black vine weevil in strawberry. Their study showed that application through the drip-
irrigation system did not give an even distribution to all plants. Instead, a dipping method 
with young plants was developed and this proved successful for the control of black vine 
weevil. Other interesting examples of the development of an application strategy are the use 
of nematodes with insecticides to control leafminers in lettuce and Chinese cabbage (Head et 
al., 2002) and to control fungus gnats with nematodes in poinsettia and impatiens, grown in 
various potting media (Jagdale et al., 2004). Application strategies with nematodes for 
glasshouse pests are reviewed by Tomalak et al. (2005). 
Above examples illustrate the complexity of an application strategy and which factors 
need to be taken into account when an optimal application strategy is being developed. I will 
discuss some of these parameters more in depth.     
 
Delivery methods for microbial pest control products  
Efficient delivery of the infective propagules is crucial for a good efficacy. A number of 
authors have addressed the issue of optimal application of biopesticides (Evans, 1999; 
Matthews, 2000; Bateman et al., 2007; Chapple et al., 2007). Because of the particulate and 
living nature of biopesticides, they pose a very different challenge to efficient delivery 
through appropriate equipment than chemicals. The available delivery system, however, is 
usually the existing equipment developed for chemicals. MPCPs should be capable of 
application through standard available equipment with minimal special requirements. 
Growers will not readily change or buy equipment just to apply MPCPs. Nor will they easily 
accept a very different spray regime or more frequent applications than is normal practice. 
Only minor adjustments are possible and acceptable for growers. As an example, pre-
treatment soaking of Mycotal already turned out to be hampering adoption of this product (see 
chapter 3 under “formulation considerations and recommendations”). Taking out sieves when 
nematodes are applied or changing nozzle types for products with small particles are about the 
maximum accepted modifications.  
In protected crops, the most used type of technology for foliar treatment is the high 
pressure hydraulic nozzle system. This ranges from knapsack sprayers to handgun sprayers, 
up to automatic spraying boom systems. To some extent other equipment is used such as air-
blast sprayers, hot and cold foggers, and low volume misting systems (LVM). Biopesticides 
are generally applied by means of the hydraulic nozzle system. With these systems good 
coverage can be obtained, and nozzle position can be adjusted to cover the upper side or 
underside of leaves or even both. Foggers and LVMs are sometimes used, but the deposit 
hardly reaches the underside of the leaves, and for many pests coverage is inappropriate then 
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and good control is not achieved. Spinning discs are not used in protected crops since it is not 
possible to penetrate into the dense canopy with this technique. The methods used to deliver 
biopesticides have been reviewed by Gan-Mor and Matthews (2003), and they argued that 
often the method of application has not been adequately considered. They recommended more 
research in the area of formulation and engineering, but the challenge remains getting farmers 
to buy and use new technology. On the other hand, I have seen growers constructing their 
own spraying devices or dripping application systems when they are convinced that this will 
bring a solution to their problems. It depends on their motivation and the results they can 
achieve. In general, however, one cannot count on this from the outset of the development of 
a new product or a new programme. 
The application of nematodes differs from the application of bacteria, fungi and viruses 
because they are much bigger. For soil applications, coarse droplets can be used and this has 
been working well. Critical aspects, also for the microorganisms, but even more for 
nematodes, are sedimentation in the tank, pump pressure and the size of sieves and nozzle 
openings. Many studies have highlighted the critical factors of the application technology 
used for nematodes (Nilsson and Gripwall, 1999; Fife et al., 2003; Wright et al., 2005; 
Laczyński et al., 2006, 2007) and alternatives as spinning discs have been suggested for foliar 
treatments (Mason et al., 1999). Optimizing the parameters for application of EPNs is still a 
topic for research after thirty years of using nematodes for pest control (Brusselman et al., 
2007).    
 
Applications and timing, frequency, intervals and combinations 
The timing of an application is essential in respect to controlling the pest and/or keeping the 
damage acceptable. The biology of the pest, the level of the pest population and the mode of 
action of the pathogen must be considered, and thus well known. Often, there is a difference 
in susceptibility between the life stages of a pest and the application should be targeted at the 
most susceptible life stage. This is possible when the insect population shows distinctive 
generations, but generally generations start to overlap later in the growing season and then 
this becomes increasingly difficult. In greenhouse crops with favourable conditions for a pest 
with a short life cycle, it takes repeated treatments before the pest population starts to 
decrease considerably. This has been demonstrated with whitefly and thrips (Ravensberg et 
al., 1990b). Intervals between treatments and the frequency are determining factors then. 
Determination of the time of spraying is very important in MPCPs. The time of the 
application during the day can be determinative for the result of an application when 
environmental conditions influence the survival and activity of the pathogen. To avoid high 
levels of UV, high temperatures or low humidity, it is often advised to spray pathogens early 
in the day or late in the afternoon. It has even been suggested to spray shortly before shipping 
plants to customers in order to control insect pests (Osborne et al., 2008). Conditions during 
shipping allow the fungus Isaria fumosorosea (formerly Paecilomyces fumosoroseus) to 
infect and kill larval stages of Bemisia tabaci in poinsettia. 
Combined treatments are often carried out by growers for reasons of convenience and 
cost savings. Most of the time, these combinations (tank-mixes) consist of two chemical 
pesticides and are targeted at different problems, like aphids and powdery mildew, or 
caterpillars and whitefly. Tank-mixes are not often carried out for the control of a single pest. 
Combined treatments including a MPCP, or of two MPCPs, has not been common practice, at 
least not in the Netherlands. Alternate use of products with different mode of actions to 
control a pest is more commonly applied; including MPCPs. Resistance management is one of 
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the reasons for this. It can also be that older larval stages or adult stages of the pest require a 
different product. When a microbial pesticide is used in a tank-mix or in an alternating 
scheme, the compatibility must be known, either of direct effects or of residual effects. The 
number of combinations is endless and in order to achieve the optimal effect of an 
entomopathogenic product in an integrated programme, it requires a lot of knowledge on 
many interactions. This is discussed below. Further to using a biopesticide as a blanket 
treatment, biopesticides can also be used as a spot treatment, or as a band spraying (top or 
lower bands), creating separation in location and making it compatible in this way. For 
instance, a product may be sprayed on the top of the plants only, leaving natural enemies 
lower in the crop unharmed.  
 
Environmental effects  
Abiotic factors are salient parameters that can influence the results of MPCPs. The most 
important one is temperature; others are relative humidity or availability of free water, solar 
radiation and wind. Soil or other growing medium conditions must be considered when 
pathogens are applied to the growing medium, as with nematodes and fungi. The 
environmental conditions can be controlled to some extent in greenhouse crops by 
computerized environmental control. In temperate regions growers use advanced techniques 
and modern greenhouse structures to control the environment as much as possible. 
Completely closed greenhouses are a new trend in which climate control is fully regulated. In 
Mediterranean greenhouses, climate control is much less advanced and temperature and 
humidity ranges are large. For an overview of greenhouse structure factors influencing 
biological control, I refer to Lindquist and Short (2000). Consequently, greenhouse 
technology in a broad sense has an impact on the activity of entomopathogens. Mediterranean 
greenhouses are also much more open for reasons of cooling, and wind can have a great effect 
on relative humidity, even at the microclimate at the leaf-boundary level which is critical for 
the efficacy of fungi (Fargues et al., 2003a). UV radiation is harmful to many pathogens, but 
under glass or plastic this effect is greatly reduced. Nevertheless, UV can still be harmful and 
various types of plastics can have different effects (Costa et al., 2001). 
 Butt (2002) and Jaronski (2010) reviewed the environmental factors that influence the 
success of fungi against insects. It has been often mentioned that epizootic effects of 
pathogens are very valuable and a marked difference from chemicals. I have witnessed 
wonderful epizootic effects in cucumber and chrysanthemum with L. muscarium on whitefly 
and with L. longisporum on aphids in the 1980’s following treatments of the commercial 
products. This worked in low greenhouses with cucumbers where the RH was very high at 
certain periods of the year. A similar situation occurred under the plastic covers used for 
decreasing the day length period to induce flowering in chrysanthemum. But since these 
technologies have changed dramatically, such favourable conditions for fungi no longer 
occur. In using biopesticides, epizootics cannot be counted on, and moreover, they are 
unlikely to occur. I will come back to this later in this chapter. 
 
Crop and cultivation effects  
The cropping system, the crop structure and cultivation techniques also influence the efficacy 
of pathogens. The greenhouse climate is to some extent influenced by the spacing of the 
plants and by the density of the canopy. A grower will focus on production and decides on the 
basis of optimal yield for a certain plant density, and for growing techniques such as watering 
regime, fertilization, temperature settings, usage of screens for energy saving or for 
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temperature control. For instance, modern Dutch greenhouses differ enormously from plastic 
covered crops in the Mediterranean basin in cultivation technology and climate. Still, 
surprisingly, Fargues et al. (2003b) found no difference in efficacy of L. muscarium 
(Mycotal) on the greenhouse whitefly between a sophisticated glasshouse and a polyethylene-
covered greenhouse. Shipp et al. (2002) demonstrated that the canopy of the plant affects the 
infection levels of pest insects using B. bassiana. Whitefly and thrips infection levels were 
higher in the top of the plant than in the middle canopy, but this was less prominent for the 
cotton aphid. These differences were both found in greenhouses with a low and with a higher 
relative humidity.  
 For pathogens used against pests or life stages of a pest occurring in the growing 
medium, other aspects need to be checked such as the influence of the growing medium on 
the efficacy of the product. Shah et al. (2007c) demonstrated that both the application method 
and growing medium influenced conidial leaching when conidia of M. anisopliae were 
applied as a drench or premixed into the medium. Inoculum losses were greater following 
drench application than premixing irrespective of media type. Ansari et al. (2008a) 
demonstrated that mortality of soil-dwelling life stages of the western flower thrips with 
fungal pathogens was similar in different growing media such as peat, coir, bark and mixtures 
of these with green waste compost. Spores of the fungi M. anisopliae, B. bassiana and I. 
fumosorosea (P. fumosoroseus), either applied as a drench or incorporated as a mix, caused a 
high mortality irrespective of the growing medium and the method of application, indicating 
that these fungi can be used as effective biocontrol agents in a range of growing media. These 
examples show that factors that are expected to negatively affect efficacy are not always that 
important, illustrating that research is required to show what factors are critical. 
  
Host plant-mediated effects  
Host plants may directly or indirectly influence survival and efficacy of pathogens. Plants 
produce a wide range of phytochemical substances which may directly influence the 
pathogen’s survival on the leaf. Plants also may influence the pest’s susceptibility to the 
pathogen. These tritrophic interactions between host plants, host insects and 
entomopathogenic bacteria, fungi and viruses are reviewed by Cory and Hoover (2006), and 
by Cory and Ericsson (2010) specifically for fungal entomopathogens.. Very little is known 
about nematodes and plant-mediated effects. Plant structure, plant morphology and leaf 
characteristics (leaf size and shape, wax layer, density of hairs, number of stomata) will have 
an effect on the microclimate which will influence the conditions for survival and 
germination, and thus efficacy. Inbar and Gerling (2008) reviewed these host plant 
interactions between whiteflies and natural enemies, including entomopathogens. Most 
studies on plant-mediated effects are carried out with fungi, most likely due to their mode of 
action and their dependency on the environmental conditions.  
 It has been shown (reviewed by Navon, 1993, and by Glare and O’Callaghan, 2000) that 
host plants can strongly affect the insect’s susceptibility to Bt. Even between host plant 
cultivars and within a season, susceptibility can vary. A brief overview of these host plant 
effects in entomopathogenic fungi is given by Butt (2002). An example to illustrate the extent 
of host plant factors is a study by Ugine et al. (2005) who showed that that the susceptibility 
of western flower thrips reared and exposed on kidney beans was six times greater to B. 
bassiana than thrips reared and exposed on impatiens. The mechanism behind this effect was 
a difference in conidial acquisition between treated bean and impatiens leaves (Ugine et al., 
2007b). The underlying mechanism of differential rates of conidia pick up has not been 
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determined. Differences in susceptibility to fungal pathogens that were dependent on the host 
plant on which the insect pest was reared were also demonstrated for B. tabaci (Poprawski 
and Jones, 2001) and for Trialeurodes aleyrodis (Propawski et al., 2000) for the two fungi B. 
bassiana and I. fumosorosea, and for B. tabaci to B. bassiana (Olleka et al., 2009). Other 
studies revealed differences between host plants and persistence of spores as well as mortality 
by fungal insecticides. Survival of spores of Aschersonia aleyrodis was influenced by the host 
plant, as was mortality of whitefly larvae ((Meekes et al., 2000). Yet, Vidal et al. (1998) did 
not find significant differences in mortality of B. argentifolii by I. fumosorosea between 
cucumber, tomato, cabbage, sweet pepper, nor between three tomato cultivars. Comparative 
trials with S. feltiae or L. muscarium against Thrips palmi revealed no differences in mortality 
with either of the biocontrol agents on chrysanthemum, tomato or sweet pepper leaves in 
laboratory trials (Cuthbertson et al., 2005a). 
 The activity of baculoviruses can also be influenced by the host plant. An elaborate 
overview of theses effects is given by Cory and Myers (2003). Host plant chemicals can 
negatively influence the efficacy of baculoviruses (Hoover et al., 1998) and this can differ 
largely between plant species and even between plant parts (Ali et al., 1998). 
 
Relevant considerations for the development of an application strategy 
Developing an application strategy requires a case by case approach. The biology of the 
pathogen and its susceptibility to biotic and abiotic factors may affect its efficacy to a large 
extent. The application strategy needs to take these factors into account as much as possible 
(table 6.1). 
 Applying the product with appropriate equipment is clearly crucial. This may look like 
an open door, but too often this element is underestimated. The equipment must be well 
adjusted so that the propagules are not damaged by the application and that good coverage is 
achieved. Because of the particular nature of the products, they work by contact or digestion, 
and optimal coverage determines the results. This is more critical with microbials than with 
chemicals which often have a translaminar or systemic uptake in the plant. 
 
 
Table 6.1.   Essential factors that need to be considered in the development of  
       an application strategy of a microbial insecticide 
 
• Mode of action of the entomopathogen 
• Application method and adjustment of equipment 
• Optimal dosage and spray volume 
• Timing of application, depending on pest level and presence of 
susceptible life stages of the pest 
• Treatment frequency and intervals 
• Host plant and cropping system 
• Environmental conditions 
 
 
 It is of paramount importance to know the influence of environmental effects on the 
performance of the MPCP. Growers generally are reluctant to adapt their climate to optimize 
the activity of the products, so one need to find to best window to apply the product. 
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Conditions and time of application should be chosen in such a way that it will result in a good 
activity of the pathogen. Crop, cultivation and host plant effects cannot be avoided, so it is 
important to know that they may play a role and to find a solution in that particular case. In 
ornamentals, various plant species and cultivars may be grown concurrently, and it cannot be 
assumed that the MPCP will work equally effective on all host plants.  
 It is necessary to know to which factors a pathogen is particularly sensitive. In fungi, the 
most critical factor is germination and the dependency on the relative humidity or available 
free water. In bacteria like Bt and in baculoviruses this is much less critical due to their mode 
of action via per oral uptake. The use of nematodes requires other considerations. The most 
relevant factors should be identified in each case and studied in order to develop a successful 
application strategy.  
 
 
Development of an integrated pest management strategy 
 
The goal of an IPM programme is to bring together all possible control options in order to 
achieve an efficient, sustainable and cost-effective control of the pest, or as in most cases, a 
complex of pests and diseases. For a MPCP that will be introduced as a new element in an 
existing IPM programme, many variables and a number of multi-trophic interactions have to 
be considered and studied. It is impossible, however, to investigate all these interactions, and 
the critical topics need to be selected based on knowledge of the host and the pathogen, and 
within a certain cropping system. The relevant aspects of such a tritrophic system with regard 
to the application strategy of the product are discussed above, but in an IPM system many 
other interactions occur (table 6.2). Means of control of the same pest are often integrated, as 
well as control means against other pests and diseases in the same crop. The MPCP could 
potentially interfere with these, or the other way around. Therefore, it is required to identify 
and study these potentially interfering interactions such as the effects of chemical crop 
protection products on the MPCP, and the effects of the MPCP on natural enemies and 
pollinators. A “two-sided” compatibility profile of the MPCP needs to be determined. This is 
a large research programme. The most relevant interactions have to be identified and, initially, 
only they need to be studied. Once a MPCP is used on a larger scale, feedback from its use 
may reveal new topics of concern which then need to be studied in order to give proper advice 
to limit negative interactions. Ultimately, an IPM approach should be developed in which 
MPCPs can obtain maximum effects, without interfering with the effectiveness of other 
practices. This is an ideal scenario. In practice negative effects may occur. Intervention is 
possible, and, for instance, new releases of natural enemies can be made when necessary. 
Monitoring after applications is needed to check whether control of the target pests has been 
achieved and is maintained, and how the populations of the biocontrol agents develop. 
 To my knowledge, no studies have been published covering this topic in full for a 
specific MPCP in a greenhouse crop. Nevertheless, it is generally well understood that proper 
incorporation of a biopesticide into an IPM programme is essential. In the early days of fungal 
insecticides, when Vertalec was developed for control of aphids in chrysanthemum, 
successful integration with fungicides was the prime concern. Many practical aspects and the 
compatibility were studied. Recommendations for use were adapted from ‘lessons learned’ 
from the laboratory and the field (Quinlan, 1988). Another example is given by Lomer et al. 
(1999) who reviewed the development of a strategy of incorporation of M. anisopliae in the 
control programme of locusts. An example of integration of pest and disease control methods 
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for greenhouse tomato is given by Bardin et al. (2004) who studied control of botrytis, 
powdery mildew and whitefly, using three biological control agents. A review of IPM 
development with microbial pesticides, including interactions, combinations and mixtures is 
presented by Dent (1997). He concluded that, up to the mid 1990’s, little research had been 
performed on true integration of control measures and that farmers were left to sort it out 
themselves. Since then this has received more attention and some examples will be given. 
 
 
Table 6.2.   Important elements that need to be considered for a successful use 
       of microbial pest control products in an IPM strategy  
 
• Compatibility of chemical pesticides with MPCPs  
• Compatibility of MPCPs with natural enemies and pollinators  
• Interactions between MPCPs and natural enemies  
• Combinations of different types of MPCPs  
• Combined use of MPCPs with other pesticides  
• Combined use with other control techniques 
• Knowledge transfer and training of technical consultants, extension 
workers and growers 
• Inclusion of a MPCP in an existing IPM system 
• Costs of MPCP and its application 
 
 
Entomopathogenic fungi used for foliar pests appear to be the most difficult with regard to 
application and integrated pest management strategies. First, these organisms are, due to their 
mode of action, more dependent on environmental conditions and plant-related aspects than 
are bacteria and baculoviruses. Second, fungi potentially have a broader host range including 
non-target organisms, which requires a better understanding of the relevant interactions. 
Third, chemical fungicides are often used in these IPM systems and their effects on the 
entomopathogenic fungi can be deleterious and therefore must be investigated. Most 
examples on side-effects of pesticides on microbial agents in the literature are focussing on 
fungi. With Bt and viruses these aspects are less critical and therefore these pathogens are 
easier to integrate in a crop protection system. For nematodes the same is true. 
 Testing compatibility of entomopathogens with pesticides is required to see if adverse 
effects of any given combination are occurring, and if so, to what degree and for how long 
these persist. Knowing these adverse effects, often called side-effects, gives the opportunity to 
avoid them or to intervene and repair the situation. Many interactions occur through 
unintentional sequential or simultaneous use of various plant protection products. On the 
other hand, an obvious approach is to control a pest by combined use of two different control 
agents. This is aimed at enhancing control, at giving quicker control of the pest, or at reducing 
the damage more rapidly. Combined use requires knowledge of their interactions and to what 
extent they contribute to improve control.  
 The optimum IPM strategy using a MPCP should be studied in the developmental phase 
of a product. There are, however, numerous pest control programmes exploited which differ 
per crop, per season, per country and region, etc. These programmes continuously change due 
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to new cultivation techniques, new cultivars, new pests and diseases, and due to new 
pesticides and disappearance of pesticides. Also socio-economic aspects play a role in a pest 
control programme and these also give rise to changes. This means that initially only basic 
interactions can be studied which will help in designing an optimal pest control programme. 
Such programmes, however, need to be evaluated regularly using field experience and 
feedback from users and advisers in order to adapt them to current and new developments in a 
broad sense.  
 Interactions between MPCPs and other control methods can be studied in the laboratory. 
This often reflects a direct exposure scenario as optimal contact is achieved in bio-assays or in 
small scale greenhouse trials. In case there are no adverse side-effects in laboratory tests, it 
can be assumed that this will be the same in the field. However, negative side-effects of a 
certain combination of agents may be overestimated in such testing scenarios. Practical 
aspects of testing compatibility and combined use will be discussed below. 
 
Compatibility of chemical pesticides with microbial pest control products 
In the registration process of plant protection products, manufacturers are obliged to test their 
product for effects on non-target organisms, including natural enemies and pollinators. Data 
on compatibility with other plant protection products (chemical as well as biological) is only 
required when the use of certain tank mixtures is to be authorized and recommended on the 
label. Generally, this is not the case and side-effects of chemicals on biopesticides are thus not 
demanded by regulatory authorities, and tests are rarely conducted by the agrochemical 
companies. The same holds for the registration of biopesticides: compatibility tests with 
chemicals are not required. This leaves the task to the biopesticide manufacturer to test 
susceptibility of the product to a range of relevant chemicals so that proper advice can be 
given for use in IPM systems. The effect of biopesticides on chemical pesticides is usually not 
tested, and I do not know of an example where a biopesticide negatively influences the 
activity of a chemical pesticide. 
 In IPM programmes in greenhouse crops, chemical pesticides are often part of the 
control measures. The use of fungicides is standard in most greenhouse crops. Due to their 
mode of action, insecticides are generally less harmful to entomopathogens than fungicides. 
Compatibility of chemical fungicides needs to be investigated, particularly on fungal MPCPs. 
EPNs, Bt’s and baculoviruses are less susceptible to fungicides. Chemical bactericides are 
hardly available and are rarely used in greenhouses. Anti-viral products are not available.  
 Theoretically, MPCPs may also have negative side-effects on other MPCPs, but I do not 
know of any case where an entomopathogen directly affects the survival and activity of 
another; this is also rarely tested. But for all cases it is true that if a product shows a reduced 
activity, one must never assume that another pest control product cannot have an effect, 
always test it when there is any doubt.  
 
Side-effects of chemical pesticides on entomopathogenic fungi 
Numerous studies have focussed on the compatibility of chemical pesticides with MPCPs. For 
entomopathogenic fungi, overviews of these effects are given by Inglis et al. (2001) and Shah 
et al., 2009b). Inhibitory effects are reported, as well as additive and synergistic effects. 
Recently, Cuthbertson et al. (2005b, 2008a) investigated the compatibility of some chemical 
and natural insecticides with L. muscarium. Exposure to the chemical insecticide solution at 
the recommended rates for 24 hours decreased spore germination dramatically for 
teflubenzuron, imidacloprid and nicotine, and for some natural insecticides. Germination was 
Implementation in an IPM programme 
___________________________________________________________________________ 
 195
only moderately reduced by spiromesifen and polysaccharide/alginate, and not affected by 
buprofezin. When the fungus was applied on 24-hour dry residue of the chemical, there 
seemed to be no inhibition. Generally, fungicides have adverse effects on fungal pathogens. 
Direct as well as persistent effects may occur and could impede the activity of the 
mycoinsecticide. Often the effect is prominent on foliage. In soil and other growing media the 
effects may be less deleterious as demonstrated for Metarhizium anisopliae and a range of 
fungicides (Bruck, 2009). But all fungicides need to be tested, and depending on the outcome, 
the use of the MPCP and the fungicide must be well separated in time or space. 
 
Side-effects of chemical pesticides on entomopathogenic bacteria and baculoviruses 
Side-effects of chemicals are rarely tested on bacterial and viral insecticides. This is due to the 
nature of these organisms and their propagules which are not susceptible to chemical 
pesticides. There is no report of any problem of integration with chemical pesticides, and 
bacterial and viral insecticides are often tank-mixed with chemicals. Baculoviruses, however, 
cannot be tank-mixed with copper containing products. Further, they are inactivated at low 
and high pH values of a tank-mix (5< pH > 8.50), and by disinfectants such as hypochlorite.  
 
Side-effects of chemical pesticides on entomopathogenic nematodes 
Dauer juveniles of EPNs are relatively tolerant to many substances, including chemical 
pesticides, but they may be very susceptible to nematicides. In the IOBC Working Group 
“Pesticides and Beneficial Organisms” nematodes have been incorporated in the testing 
programmes since the early 1990’s and a laboratory method has been developed to test side-
effects of chemicals on nematodes (Vainio, 1992). Results can be found in subsequent IOBC 
bulletins of this Working Group. More results are in publications of Rovesti (1991), Vainio 
(1994), Peters and Poullot (2004), Gutiérrez et al. (2008) and in a review on compatibility of 
EPNs with chemicals by Koppenhöfer and Grewal (2005). The effects of adjuvants and 
surfactants have also been tested and they can be toxic to EPNs (Peters and Poullot, 2004). 
Natural products like neem, neem oil, cynnamaldehyde and soaps need to be tested too and 
some have shown a considerable toxicity to the dauer juveniles of EPNs (Krishnayya and 
Grewal, 2002).  
 
Compatibility of microbial pest control products with natural enemies and pollinators 
The compatibility of microbial pest control products with natural enemies often is a subject in 
academic research as part of host range and non-target effects testing. For regulatory 
requirements this aspect has achieved relatively little attention. This is in contrast to chemical 
pesticides. The compatibility of chemical pesticides with natural enemies has been 
extensively tested for regulatory purposes and for integration into IPM programmes with 
natural enemies. Testing the effects of pesticides on non-target arthropods is required for 
registration purposes in Europe according to the Council Directive 91/414/EC. It is obligatory 
to test side-effects on two model arthropods, the natural enemies Typhlodromus pyri and 
Aphelinus rhopalosiphi, and on honeybees. These natural enemies are, however, not relevant 
for greenhouse IPM programmes. In the past, agrochemical companies only performed these 
obligatory tests, but since IPM has become standard in greenhouses, the testing of important 
greenhouse natural enemies is considered more and more (Schnorbach, 2006). An example is 
the testing of side-effects of spinosad in order to develop an IPM system (Miles, 2006). 
Testing methods and evaluation procedures have been developed for chemical pesticides and 
non-target arthropods within or in conjunction with experts of the IOBC Working Group 
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“Pesticides and Beneficial Organisms” and in the ESCORT Working Group (Barrett et al., 
1994; Candolfi et al., 2000). For regulatory purposes, a tiered testing and assessment schedule 
is provided, and decision criteria and trigger values exist for both in-field and off-field 
assessment. When products are only applied in greenhouses, off-field assessment is not 
needed.  
 There are no specific testing guidelines for testing microbial plant protection products 
on beneficial organisms. Requirements for microbial pesticides are given in Directive 
2001/36/EC. Information on non-target toxicity, infectiveness, and pathogenicity must be 
reported for the active ingredient as well as for the formulated product. This is required for 
bees and for arthropods which may be exposed to the plant protection product, with special 
attention for organisms used for biological control. The Directive does not specify which 
testing methods to use.  
 MPCPs have been incorporated in the IOBC side-effect testing programmes. Since 
1980, standard guidelines for testing the side-effects of chemical pesticides on natural 
enemies and for rearing methods of beneficial arthropods have been developed. Results of 
laboratory, semi-field, and field experiments, and of the joint programmes to test the side-
effects of pesticides on beneficial organisms have been published in the IOBC/WPRS 
Bulletin, the EPPO Bulletin, and various international scientific publications, see 
http://www.iobc-wprs.org/wg_sg/index.html. The IOBC Database on selectivity of pesticides 
lists all available information, including test results of biopesticides on natural enemies and 
bees (http://www.iobc.ch/news.html). The effects of chemical pesticides on microbial 
insecticides have been tested, mainly on entomopathogenic fungi (B. bassiana, B. 
brongniartii, L. muscarium and M. anisopliae), and on entomopathogenic nematodes (S. 
carpocapsae and S. feltiae). Effects on bacterial and viral products have not been tested. The 
effects of microbial insecticides (Bt and L. muscarium) on beneficial arthropods have been 
tested as well. Only a limited number of MPCPs has been part of the testing programme of the 
IOBC WG; baculoviruses have not been incorporated until now. The IOBC Working Group 
has also started to study the effects of fungal insecticides on beneficial organisms. 
 Generally, MPCPs appear to be harmless for natural enemies. Bt’s and baculoviruses are 
safe to natural enemies while fungi and nematodes may affect some natural enemies. These 
effects are usually limited to some natural enemies and are minor. Many studies have been 
published on compatibility of entomopathogens and natural enemies, however, reports on 
tests on greenhouse beneficial arthropods are limited. For instance, Sterk et al. (2003) tested 
the effects of PreFeRal (I. fumosorosea), a whitefly pathogen, and Scutello (Bt subsp. 
kurstaki) and Xentari (Bt subsp. aizawai) on four greenhouse natural enemies. There were no 
adverse effects found on Phytoseiulus persimilis, Macrolophus caliginosus, Aphidius spp. and 
Encarsia formosa. I will briefly review the effects of each type of entomopathogen on 
greenhouse natural enemies, followed by overall recommendations for testing side-effects of 
MPCPs on these organisms. Side-effects of chemical pesticides and MPCPs on natural 
enemies, as well as side-effects of chemicals on MPCPs can be found on websites of the 
larger producers of natural enemies like Biobest and Koppert Biological Systems, and on the 
website of the IOBC/WPRS. Manufacturers and distributors of biopesticides study side-
effects in order to know their product well and to give proper advice (Ravensberg et al., 1994; 
Sterk et al., 1995a).  
 
 
 
Implementation in an IPM programme 
___________________________________________________________________________ 
 197
Side-effects of entomopathogenic bacteria on natural enemies 
Subspecies and strains of Bt are highly specific to their respective hosts and have no effect 
through direct infection on natural enemies. Melin and Cozzi (1990) and Glare and 
O’Callaghan (2000; 2003) reviewed safety of Bt’s to beneficial insects. The IOBC Working 
Group “Pesticides and Beneficial Organisms” has tested Bt on many natural enemies and 
found it to be harmless. Overall, Bt has rarely been found to be toxic to natural enemies at 
field dosages. Contradictory effects have been reported for some predators such as Chrysopa 
spp.: a brief review of these studies is given by Glare and O’Callaghan (2000). A direct toxic 
effect has been found on one predatory mite, Metaseiulus occidentalis from Bt subsp. 
tenebrionis (Chapman and Hoy, 1991). Furthermore, various interactions between Bt and 
parasitoids and predators do occur with the same host. Egg parasitoids are fully compatible 
with Bt, but the interaction with larval parasitoids can be deleterious. The outcome of the 
competition is dependent on the interval between Bt infection, the ingested dose and the 
oviposition of the parasitoid. Indirect effects are reviewed by Navon (1993; 2000). In general, 
Bt has no or little toxic or pathogenic effects on natural enemies and Bt’s can be safely 
integrated in an IPM programme.  
 
Side-effects of entomopathogenic fungi on natural enemies 
These fungi can have a broad host spectrum and direct effects on natural enemies may occur. 
Particularly, strains of the species M. anisopliae and B. bassiana generally have a relatively 
broad host range, and testing on negative side-effects is indispensible for use within an IPM 
programme. Many papers report on non-target effects of fungi, including beneficial 
arthropods. Goettel et al. (1990) reviewed the non-target effects of entomopathogenic fungi 
and concluded that they “do pose inherent, albeit minimal risks”. Indirect effects on 
parasitoids and predators may occur by reduction of host populations, but these are usually 
not lasting effects. A more recent overview of the safety of Hypocrealean (formerly 
Hyphomycetes) fungi on non-target organisms, including natural enemies used in 
greenhouses, is given by Vestergaard et al. (2003). The authors reviewed the information 
from laboratory studies and field studies of direct and persistent effects. They concluded that 
these fungi generally are remarkably safe to non-target organisms. This is exemplified by a 
detailed study on the combined use of Amblyseius cucumeris and the products Botanigard and 
Naturalis-L (both based on strains of B. bassiana) which illustrated the safety of this fungus to 
this commonly used predatory mite for control of F. occidentalis in cucumber (Jacobson et 
al., 2001). Other studies demonstrated negative effects for a number of insecticidal fungal 
species and strains, including registered mycoinsecticides, which are used in greenhouse 
crops. Effects were strongly dose dependent. The least harmful were strains of L. muscarium 
and L. longisporum, whereas strains of B. bassiana, M. anisopliae were harmful to non-target 
beneficial insects. I. fumosorosea had intermediate properties. Two kinds of studies were 
conducted: direct exposure and indirect exposure (i.e. via the host plant). As expected, direct 
exposure resulted in higher mortalities. Predatory mites were less susceptible than most of the 
other beneficial arthropods, they were even resistant to all the fungal species and strains tested 
(T. Butt, pers. comm.). Direct and sub-lethal effects are dose and species dependent as shown 
by Roy et al. (2008) with B. beauveria and three species of coccinellids. This study illustrated 
that grouping closely related natural enemies based on investigations of one species does not 
give reliable results. This calls for testing of each relevant species of natural enemies when 
dealing with broad-spectrum microbials. The study also showed that reduction in fecundity 
can be considerable. This warrants assessing sub-lethal effects besides mortality. 
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 Regulators review all the tests carried out for determining the side-effects on non-target 
organisms and may come to more generic conclusions. This is illustrated by the product 
Botanigard (B. bassiana) which has been approved in the Netherlands for use in greenhouse 
crops, but has a warning on the label stating that: “it cannot be excluded that after application 
of the product at high humidity conditions beneficial insects can be infected by Beauveria 
bassiana. The effect of the product on beneficial insects should be monitored to prevent 
damage to the IPM system” (www.ctbg.agro.nl). The product Bio1020 (M. anisopliae) has 
been approved in the Netherlands for control of black vine weevil in strawberries, other berry 
crops, and ornamentals by means of a soil application. The label also has a warning stating: 
“This product is harmful to non-target arthropods. Avoid exposure”. There are no such 
warnings on the products Mycotal (Lecanicillium muscarium) and PreFeRal (Isaria 
fumosorosea). The latter has been shown to be harmless for a range of natural enemies (Sterk 
et al., 1995a; 2003). In sum, the above illustrates that adverse effects of entomopathogenic 
fungi can not be excluded beforehand and that they need to be tested on beneficial insects 
used in an IPM programme. 
 
Side-effects of baculoviruses on natural enemies 
Baculoviruses are very host-specific and natural enemies are not susceptible to virus 
infections. Direct adverse effects of baculoviruses on beneficial insects have never been 
reported. An overview of tests and observations showing that deleterious effects do not occur 
is given by Gröner (1990). Hassan and Gröner (1977) tested direct effects of the Mamestra 
brassicae NPV on C. carnea and the egg parasitoid Trichogramma cacoeciae and found no 
direct harmful effects on both natural enemies. The nucleopolyhedrovirus of Anticarsia 
gemmatalis has been demonstrated to be safe to predators such as predatory bugs (Young and 
Yearian, 1987) and pentatomid predators (Abbas and Boucias, 1984). Carabid predators do 
not discriminate between healthy and diseased larvae of the cabbage moth M. brassicae and 
since virus infectivity was maintained after passage through the predator’s gut, the beetles 
transfer the nucleopolyhedrovirus in the environment (Vasconcelos et al., 1996). The codling 
moth granulovirus showed no harmful effects on Orius laevigatus, an important predator used 
in greenhouses, after exposure to residue and by ingestion (Angeli et al., 2005). Baculoviruses 
have been used on many crops for many years and negative side-effects on non-targets have 
not been reported (Cory, 2003). Testing for direct negative side-effects is therefore not 
relevant when baculoviruses are used as an inundative approach in an IPM system.   
 
Side-effects of entomopathogenic nematodes on natural enemies 
When nematodes are applied to the soil, exposure to natural enemies is limited. Only for soil-
dwelling biocontrol agents, or when natural enemies have a soil-dwelling life stage, is there a 
potential risk. When nematodes are applied to the foliage, many natural enemies are exposed 
and testing is necessary to establish a potential risk. Compatibility of nematodes with 
parasitoids and predators, and with bees has been reviewed by Akhurst (1990), Bathon 
(1996), Ehlers (2003a) and Koppenhöfer and Grewal (2005). Under laboratory conditions, 
nematodes appear to pose problems to many non-target insects; however, field evaluations 
showed that the use of nematodes had negligible impacts on natural non-target populations. 
Effects on larval stages of parasitoids depend on the time of infection by the nematode 
respectively the oviposition of the parasitoid of the host insect, and this could lead to reduced 
progeny of the parasitoids. Direct effects on the parasitoids have not been reported. Effects on 
predators are usually negligible in the field. Nematodes applied to foliage only survive for a 
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short period of time, generally less than a few hours, and effects will be limited due to this 
fact and their limited mobility on leaves. Detailed studies on foliar applications and non-
targets have not been performed. It can be safely assumed that direct negative effects of 
nematodes on beneficial insects in greenhouses will be limited and short-term. 
 
Side-effects of entomopathogens on pollinators 
Honeybees and bumblebees are commonly used as pollinators in greenhouse crops, 
particularly in tomato, eggplant and strawberry. For the registration of pesticides it is 
obligatory to test contact and oral toxicity on honeybees. When a product is used in 
greenhouses, the effects on bumblebees are also required. This includes microbial pesticides. 
Given the pathogenicity to insects, harmful effects to bees cannot be excluded, particularly 
long-term effects on the development of the brood. The potential harmful effects of MPCPs 
on these beneficial insects need to be tested for registration and for integration of pollinators 
with MPCPs. Exposure of MPCPs is limited since these pollinators only visit flowers; they 
may be directly hit, however, during spraying. Bees may also collect entomopathogens by 
collecting contaminated pollen which is used as food for their brood. Indirect effects need to 
be considered too. 
 Bt’s are reported to be safe for honeybees. Many studies have investigated direct effects 
on adult bees and on brood; a review is given by Glare and O’Callaghan (2000). Under field 
application conditions, the use of Bt is harmless to honeybees. Bt’s have also been studied on 
bumblebees by Sterk et al. (2003). They found no harmful effects of Bt products on adult 
workers and on brood.  
 Entomopathogenic fungi can have a broad host range, depending on the species and the 
strain. Sterk et al. (2003) also tested fungal products on bumblebees. The fungi I. 
fumosorosea (PreFeRal) and Trichoderma harzianum (Trichodex) were completely safe to 
directly treated workers. In earlier work, Sterk et al. (1995b) tested PreFeRal on bumblebees 
through various ways of exposure: oral toxicity, ad libitum feeding, contact toxicity, direct 
spraying and inhalation toxicity, on workers and on brood, with three times the recommended 
field dose. There were no significant adverse effects found. But B. bassiana (Botanigard) 
showed detrimental effects on Bombus terrestris workers when the fungus was administered 
via sugar water or by direct topical contact. Another B. bassiana based product, Naturalis, 
was much less toxic to workers indicating that strain or product differences can be 
considerable, and testing each product is required to get reliable information. Sublethal effects 
on foraging behaviour were also observed. All these studies were laboratory studies and these 
indications suggest the need for further studies before conclusions about compatibility in the 
field can be drawn (Mommaerts et al., 2007; 2009). Hokkanen et al. (2003) investigated the 
effects of B. bassiana and M. anisopliae on several bumblebee species in laboratory as well as 
field studies and found that both fungi are potentially harmful to bumblebees. Honeybees are 
less susceptible to these fungi, although this depends on dose and strain (Butt et al., 1994). 
The product Botanigard (B. bassiana) has been approved in the Netherlands for use in 
greenhouse crops, but not in tomato. The label warning states: “Dangerous for bees. Remove 
or cover honeybee or bumblebee hives during the application of the product and during 16 
hours after the treatment” (www.ctgb.nl). 
 Baculoviruses are considered completely safe for honeybees and bumblebees. Few 
studies actually have been performed to test possible side-effects. Sterk et al. (2002) tested 
viral products on bumblebees. The Cydia pomonella GV (Granupom) and Adoxophyes orana 
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GV (Capex) were completely safe when applied as a topical treatment and by feeding 
workers.  
 Beneficial nematodes are not applied in tomato, eggplant and strawberry as foliar 
treatments, so bees are not exposed to EPNs. Negative effects, however, can not be excluded, 
and in case foliar applications with EPNs take place, side-effect testing on workers and brood 
is recommended.   
 
Integrated use and interactions between microbial pest control products and natural 
enemies  
In most cases, the use of MPCPs in IPM systems in greenhouse crops implies interactions 
with natural enemies, either direct or indirect. The outcome of these interactions will be 
negative, neutral or positive in terms of pest control. A MPCP could have direct negative 
effects on natural enemies that have been released to control the same pest as well as on 
natural enemies released for other pests. Pathogens with a broad host spectrum may infect 
natural enemies and kill them, or cause sub-lethal effects. These negative interactions are 
usually referred to as side-effects (see above). Indirect interactions among pathogens and 
natural enemies may impact populations of the natural enemy as well as the pathogen through 
competition-related effects. These intraguild interactions may also have consequences for the 
overall efficacy of biological control. For an extensive overview of trophic and guild 
interactions in relation to biological control, I refer to Brodeur and Boivin (2006). Intentional 
combinations of natural enemies and a MPCP to control the same pest will obviously be 
aimed at achieving enhanced efficacy. Another reason for using a MPCP may be the need as a 
corrective measure where a natural enemy is not able to suppress the pest sufficiently. Often, 
applications are temporally or spatially separated. Temporal is relative in this situation since 
most natural enemies are present in the crop for a large part of the season and interactions are 
bound to occur. But the release of a natural enemy and the application of a MPCP are usually 
separated in time. Next to spot treatments for corrective measures, MPCPs may be applied as 
a blanket treatment.  
 The purpose of intentional combined use is to enhance biological control. Wraight 
(2003) presented a detailed overview of synergistic interactions between insect pathogens and 
entomophagous insects. He also reviewed the terminology used describing these interactions 
and introduced clear definitions for synergistic, additive and negative interactions. I will use 
the definitions given by Wraight. A synergistic interaction results in a higher mortality rate 
than the level of combined independent uncorrelated joint actions (the combination of 
independent probabilities predicts a combined rate that is less than the arithmetic sum of the 
probabilities). An independent additive interaction is defined as when the effect equals the 
level of two independent uncorrelated joint actions. When the result is less than this, Wraight 
called this additive or sub-additive. When the effect is unchanged from the more effective 
agent, the interaction is called non-additive or neutral. When the effect is less than the effect 
of the more effective agent alone, it is called negative. Wraight considered the term 
antagonistic inappropriate to describe effects that are potentially beneficial even when they do 
not achieve a level of synergism. I agree with him and would use the term antagonism in the 
context of biological control when the purpose of the agent is to produce negative effects on a 
pest such as in biological disease control with biocontrol agents.  
 In the development of effective biological control programmes in which MPCPs are 
integrated with other natural enemies, an understanding of their interactions is imperative. 
Brooks (1993) reviewed interactions between hosts, parasitoids and pathogens. He elaborately 
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described direct and indirect deleterious and beneficial aspects of interactions between 
baculoviruses, bacteria and fungi, and host insects and parasitoids. Parasitoids may be directly 
affected at the organismic level when they develop in infected hosts, as well by indirect 
effects at population level. A beneficial effect is when there is an increase of susceptibility for 
the pathogen in parasitized hosts, but this usually is at the expense of the parasitoid. Dispersal 
and transmission of pathogens may be increased by parasitoids. Wraight (2003) reviewed the 
various beneficial effects of interactions between control agents and hosts such as interactions 
that affect host immunity, host development, host behaviour, and host population dynamics. 
He also reviewed effects between natural enemies and pathogens such as interactions that 
affect natural enemy behaviour or development, pathogen dispersal and intraguild effects. 
Regarding combined use in glasshouse crops, Gillespie et al. (2006) reviewed three cases 
with predators and entomopathogenic fungi. In two cases, the predator Dicyphus hesperus 
was affected by the fungus (by B. bassiana and by I. fumosorosea) through sublethal effects 
and competition. In the case of Aphidoletes aphidimyza, a predatory gallmidge, in 
combination with L. muscarium, an additive mortality of aphids was observed.  
 
Entomopathogenic bacteria and natural enemies 
Today, the only bacterium used in greenhouse crops is B. thuringiensis, either for control of 
caterpillars, the Colorado potato beetle or Sciaridae. Subspecies and strains of Bt are safe to 
natural enemies. Interactions with Bt do occur with larval parasitoids and with predators, 
however. These indirect effects are reviewed by Navon (1993; 2000). Trichogramma and 
other egg parasitoids are fully compatible with Bt, but the interaction with larval parasitoids 
can be deleterious. The outcome of the competition is dependent on the interval between Bt 
infection of the host and the oviposition of the parasitoid, and of the ingested Bt dose (Mohan 
et al., 2008). Sequential use is possible, and in cases where large caterpillars are not 
susceptible to Bt, parasitoids may be complementary. Pentatomid predators and the use of Bt 
showed a synergy in the control of the Colorado potato beetle in field trials (Cloutier and 
Jean, 1998).  
 In general, Bt can be safely integrated. In greenhouse crops, however, there are currently 
no natural enemies used against caterpillars or against the Colorado potato beetle. Bti can be 
used against Sciaridae larvae in the soil, but this use is only approved in some countries. 
Natural enemies used against sciarids are Hypoaspis mites, but combined uses of Bti and 
natural enemies are rarely applied.   
 
Entomopathogenic fungi and natural enemies 
Interactions between entomopathogenic fungi and natural enemies have been studied by many 
researchers. An overview of these studies is given by Roy and Pell (2000). The authors 
reviewed the possible effects of these interactions in relation to biological control, particularly 
between fungi and insect natural enemies. Enhancing effects can occur through an increased 
pathogen susceptibility, non-host transmission and dispersal. Foraging predators may spread 
propagules to new hosts or to new leaves or leaf parts where host insects may come in contact 
through secondary pick-up. Parasitoids and predators also may cause disturbance and 
movement of pest insects by which transmission of spores or contact with sporulating 
cadavers may be increased. These phenomena have been observed, for example, in aphids 
(Roy et al., 1998). Clearly these interactions are complex and unpredictable. Only few studies 
have been dedicated to this subject and most of them studied Entomophthoralean fungi which 
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are not available as a biopesticide. Investigations with mycoinsecticides focused on these 
synergistic effects are lacking.   
 In contrast, negative effects have been studied for many mycoinsecticides. Direct 
infection could have an adverse effect on natural enemy populations. Furthermore, 
competition for hosts between a pathogen and a natural enemy may lead to decreasing 
numbers of either of them or both. Many mycoinsecticides are based on Hypocreales, and 
many species/strains have a wider host range than just the pest insect(s). Side-effects often 
occur and may have consequences for biological control efficacy. Natural enemies of the pest 
insect for which the fungal pathogen is applied too may be adversely affected. If the natural 
enemy is largely decimated this will have consequences for the longer term. It is much worse 
when natural enemies of another pest are affected and when this leads to a resurgence of the 
pest. In both cases new releases are needed. These unintentional effects must to be known as 
they have direct implications for the entire IPM system.  
 There are many investigations focussing on the side-effects of an entomopathogenic 
fungus on natural enemies of the same target insect. Fransen and van Lenteren (1993) studied 
the complementary activity of Encarsia formosa and Aschersonia aleyrodis on the 
greenhouse whitefly and the interaction between both beneficial organisms. They showed that 
the parasitoids were able to recognize and reject infected whitefly larvae in a certain life stage 
of the fungal infection. When whitefly larvae in a very early stage of infection were not 
rejected and parasitized, progeny would not develop and the fungus would develop and kill 
both the pest insect and the parasitoid. Whitefly larvae which had been parasitized by E. 
formosa and allowed to develop and where afterwards spores of A. aleyrodis were applied 
were less or not susceptible to fungal infection anymore, depending on the age of the 
developing parasitoid larvae (Fransen and van Lenteren, 1994). This example shows that 
interactions can be complex and that by understanding the mutual effects, complementary use 
can be designed in an IPM system by using them with known intervals to minimize negative 
effects. Similar effects were found by Jazzar and Hammad (2004) in studies performed with 
L. muscarium and E. formosa and by Avery et al. (2008) who studied the compatibility of I. 
fumosorosea and E. formosa. The authors of both studies concluded that despite the negative 
effect, implementation of these biocontrol agents can succeed if precisely timed. Other 
examples are listed by Roy and Pell (2000). 
 Interactions between predators and fungal infection have also been reviewed by Roy and 
Pell (2000). In most cases intra-guild predation is caused by the pathogen through direct 
infection of the natural enemy. Predators, however, sometimes reduce the pathogen by 
consuming infected prey (Roy et al., 1998). Regarding greenhouse biocontrol, interactions 
with mirid predators have been investigated in detail. The predatory mirid bug Dicyphus 
hesperus, which preys amongst others on whitefly larvae, avoids feeding on larvae that have 
been infected by the fungus B. bassiana, particularly when the infection reached an advanced 
stage (Labbé et al., 2006). D. hesperus is only moderately susceptible to I. fumosorosea and is 
able to discriminate between infected and uninfected whitefly larvae (Alma, 2005). Alma et 
al. (2007) studied the interaction between D. hesperus and the use of I. fumosorosea, with 
multiple applications, on control of the greenhouse whitefly on tomato in small greenhouse 
compartments. The combined use resulted in a mortality that was almost the same, but lower, 
than the independent additive mortality of both control agents, suggesting that interference 
was minimal. This study illustrated that with the combination of a generalist predator and 
entomopathogenic fungus increased pest mortality can be reached and that negative 
interference or competition has a minimal effect. Similar results were found with applications 
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of B. bassiana and concurrent use of D. hesperus and E. formosa for control of the 
greenhouse whitefly on tomato (Labbé et al., 2009). 
 
Baculoviruses and natural enemies 
Baculoviruses are safe to natural enemies and therefore side-effects are rarely tested. Indirect 
interactions between baculoviruses and larval parasitoids and predators, however, do occur. 
Harper (1986) reviewed the interactions with parasitoids. With parasitoids, premature host 
death is the most common phenomena and competition for the host often results in death of 
the parasitoid. This interaction is usually unidirectional where the parasitoid ‘loses’. The 
outcome of the ‘competition’ is dependant on the sequence of and the interval between 
oviposition and virus infection. Some examples of investigations of these interactions are 
given by Matthews et al. (2004) and Nguyen et al. (2005). A case relevant for glasshouses 
was studied by Matthews and colleagues who investigated interactions between Laconobia 
oleracea, a pest in glasshouses, the Laconobia oleracea granulovirus and the parasitoid 
Meteorus gyrator. Combined use of the LoGV and the parasitoid in a glasshouse trial did not 
result in a significant reduction in damage compared to the LoGV alone. 
 The pentatomid bug Podisus sagitta readily feeds on virus-infected and virus-killed 
larvae of Spodoptera exigua and also aids in the dispersal of virus. Combined use of the 
predator and the SeMNPV gave better control of the beet army worm than the separate use of 
both control agents in chrysanthemums (Smits, 1987). With these exceptions, few studies on 
the implications of combined use of baculoviruses and natural enemies in relation to 
enhancing biocontrol efficacy have been performed.  
 Natural enemies may increase dispersal and transmission; they are considered important 
players in the dispersal of baculoviruses in natural environments (Fuxa, 2004). Matthews et 
al. (2004), however, only found 1.5% transmission by the parasitoid in a bio-assay test in the 
example mentioned above, and no transmission was found in the case studied by Nguyen et 
al. (2005). For commercial biocontrol, increased dispersal of pathogens is not relevant in 
terms of reliable pest control. 
 
Entomopathogenic nematodes and natural enemies 
Few studies have investigated the use of EPNs in combination with natural enemies. EPNs 
have a broad host range and harmful effects to natural enemies cannot be excluded. On the 
other hand, most natural enemies are used in the plant canopy, while nematodes are generally 
applied against soil-inhabiting life stages of insects. Interactions occur in some cases where 
predators are soil-inhabiting and nematodes are applied to the soil. An example is control of 
the western flower thrips Frankliniella occidentalis with the predatory mites Hypoaspis 
aculeifer and H. miles and entomopathogenic nematodes (Premachandra et al., 2003). Both 
the mites and the nematodes exploit the pupal stages of thrips in the soil, which could lead to 
competition. Still, combined use of EPNs and H. aculeifer gave better control than use of 
either of the biocontrol agents alone. The combined effect, however, was less than the 
independent additive. Direct harmful effects of EPNs on predatory mites are highly unlikely 
given the size of the mites, and to my knowledge it has never been tested. A study in cut 
chrysanthemums showed that a combination of Amblyseius cucumeris with S. feltiae or with 
L. muscarium (Mycotal) can be safely used and that either combination resulted in a higher 
reduction of the western flower thrips F. occidentalis than any of the treatments alone 
(Beerling and van den Berg, 2005). 
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 Interactions between parasitoids and nematodes occur when life stages of the host of the 
parasitoid are found in the soil, or when nematodes are applied on the foliage. This may occur 
when leafminers are parasitized by larval parasitoids. Head et al. (2003) investigated the 
compatibility of nematodes and larval parasitoids of leafminers, the ectoparasitoid Diglyphus 
isaea, and the endoparasitoid Dacnusa sibirica, using foliar applications of Steinernema 
feltiae on lettuce. They found that the nematode infected all parasitized stages of the leafminer 
(from both parasitoids). The potential of wasps to survive to the adult stage was reduced by 
this interaction. When nematodes were applied first, D. isaea did not discriminate between 
infected and uninfected leafminer larvae for host-feeding, but it did discriminate for 
oviposition. The discriminatory behaviour of D. sibirica was not tested. The combined use of 
S. feltiae and D. isaea did not result in improved control compared to the use of the nematode 
alone. The nematodes had a detrimental effect on the parasitoids in this study. The authors 
concluded that this strategy would be uneconomical given the fact that S. feltiae alone causes 
a very high mortality of leafminer larvae. Similar intra-guild interactions were found for D. 
begini and S. carpocapsae in laboratory experiments with L. trifolii (Sher et al., 2000).  
 Interactions between parasitoids of lepidopteran caterpillars and nematodes are likely to 
occur too. The interaction between two parasitoids of the codling moth with S. carpocapsae 
has been investigated by Lacey et al. (2003). Developing larvae of the parasitoids are very 
susceptible to the nematode while full grown diapausing larvae are well protected by their 
cocoon. The adult parasitoids showed a strong preference for non-infected codling moth 
larvae over nematode-infected larvae. The authors concluded that the parasitoids can enhance 
the control of the codling moth larvae in combination with the entomopathogenic nematode. I 
have not found any study with regard to greenhouse caterpillar pests. 
 
Integrated use of microbial pest control products and natural enemies  
In biocontrol, most studies initially consider the host-parasitoid or host-predator interaction. 
Integrated use of two or more biocontrol agents against one host insect or against multiple 
hosts increases the complexity of the interactions involved, sometimes including guild 
interactions. In an ecological setting, but also in an agricultural setting in which IPM is 
applied, these interactions occur in the short and long term. For a more elaborate review of 
these interactions involving pathogens, parasitoids and predators, and the consequences for 
biological control the reader is referred to Thomas et al. (2006). Understanding these multiple 
species interactions better could help in improving the efficacy of biological control using 
these organisms. On the other hand, the use of biopesticides in greenhouse crops aims for a 
rapid reduction of the host population and long term ecological effects play a minor role. In 
developing an IPM programme, a pragmatic approach is needed where direct negative and 
enhancing effects on the overall control of a pest need to be considered, rather than long-term 
ecological interactions. The grower can interfere in the system by releasing natural enemies 
again or by using a biopesticide again. This should, of course, be done with the goal of control 
of the pest in an effective and economical way. 
 Few studies have been performed on establishing the effect on the biocontrol efficacy of 
combinations of a MPCP and one or more natural enemies. The interactions have been 
studied in a number of cases in the laboratory or small greenhouse tests. Studies under 
commercial conditions are not available in the literature. When combinations are applied in 
practice, the goal is to enhance control of the pest, or to achieve a quicker control. When 
bioinsecticides are used in greenhouse vegetables, almost always multiple species effects are 
present. Jandricic et al. (2008) reviewed the effects of intraguild effects in greenhouse 
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floriculture and concluded that, although the number of studies is small, the benefit of 
releasing two BCAs usually outweighs the risk of disruption of biocontrol. In practice, results 
of combined applications are assessed and monitored by the IPM advisors and the growers. 
With the help of the field expertise of the advisor and the experience of the grower they 
interpret the results and intervene again when necessary. The adverse effects of intraguild are 
usually difficult to detect in the field and I do not consider them relevant for the overall 
control in most cases. Combined use, however, is highly valuable where biocontrol agents 
complement each other, like in the case of L. muscarium and E. formosa where the fungus 
kills unparasitized larvae and does not affect parasitized larvae. 
 The application of a microbial pesticide in greenhouses as an inundative treatment 
instantaneously impacts the availability of prey and host insects for natural enemies. When an 
entomopathogen has direct harmful effects on a natural enemy, it should not be used. But if 
there is no other option to control the pest, natural enemies could be re-released. This solution 
is then preferred over the use of a chemical pesticide. Where host numbers have decreased 
and a part of the pest population is still present, the effects on the populations of natural 
enemies should be monitored in order to check whether the balance between those natural 
enemies and the pest re-establishes and control is maintained. If this is not happening, an 
extra release of the natural enemy must be considered, or another treatment with the microbial 
product. Using a combination is often carried out when control is insufficient or partial. It 
may be recommended when different life stages of the pest are controlled by the natural 
enemy respectively the pathogen, or when pest levels are too high and additive effects are 
quickly required. Understanding the consequences of combined use for the biological control 
of the pest is imperative for the grower or his consultant. Following the application, the crop 
must be monitored regularly to ensure a continuous effective pest control. 
 
Combinations and mixtures of microbial pest control products 
MPCPs can be used together to achieve enhanced control of an insect pest, either by a 
combined application as a tank-mix or as alternate treatments. The goal is to achieve an 
additive effect when applied together or even a synergistic effect. When used alternatively, 
effects can also be additive or synergistically. Alternating applications may be chosen when 
tank-mixes are not compatible, or when simultaneous use results in reduced effects. 
Numerous studies have been carried out on interactions between insect pathogens. Many of 
those are laboratory studies investigating the mechanisms of the interactions. Only few of 
them are field studies which attempt to elucidate the combination effects in terms of an 
enhanced biocontrol. Below examples of combined pathogen applications are given to 
illustrate their potential.   
 
Entomopathogenic bacteria and other entomopathogens 
Interactions and joint action of Bt with other microbial pest control agents has been studied by 
many researchers. A brief overview is given by Navon (1993) and by Glare and O’Callaghan 
(2000). Interactions with other pathogens were found to be variable and rarely synergistic, 
and Bt competed with other pathogens for the nutrition provided by the host insect.  
 A combination of Bt with EPNs did not give an additive effect. The nematode S. feltiae 
could not produce progeny in Bt diseased larvae of the silkworm Bombyx mori (Kaya and 
Burlando, 1989). On the other hand, Koppenhöfer and Kaya (1997) demonstrated synergism 
and additive effects between Bt subsp. japonensis and Heterorhabditis bacteriophora and S. 
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glaseri for control of white grubs. The effects of the interaction depended on the order of 
infection and the interval between the two pathogens. 
 Mixed applications of Bt and B. beauveria against the Colorado potato beetle gave low-
level synergism in field trials (Wraight and Ramos, 2005). The authors, however, could not 
exclude that the synergistic effects were caused by formulation materials in the commercial 
products.  
 Negative effects have been reported for the combination of a Bt mixed with a 
baculovirus. Ingestion of Bt causes a feeding arrestment which prevents larvae from ingesting 
sufficient viruses to enhance the lethal effect of Bt. The combined use of a Bt and a 
baculovirus with a time interval between applications may not have this reduced effect 
because of the loss of viability of propagules over time. Obviously, the intended enhanced 
effect is not achieved. Various combinations with sublethal dosages have been studied and 
this may give better results than with the normal dose of either pathogen alone (Navon, 1993). 
In greenhouse crops, baculoviruses are used to control the beet armyworm S. exigua in 
chrysanthemum. The slow speed of kill still allows considerable plant damage after the 
application of the SeMNPV. A combination with Bt subsp. aizawai was investigated by 
Geervliet et al. (1991) in order to improve control and to reduce plant damage. Laboratory 
studies with mixtures of both pathogens revealed a negative interaction, even with sublethal 
Bt concentrations. Only low concentrations of both pathogens gave some synergism. This 
study showed that considerable research on fine-tuning is needed for successful use of mixed 
applications.  
 
Entomopathogenic fungi and other entomopathogens 
The combined use of fungi with other entomopathogens has been studied in a few cases only 
(Inglis et al., 2001). Fungus-fungus interactions and the effects of mixed infections have 
rarely been studied (Thomas et al., 2003). In a study with M. anisopliae and B. bassiana and 
the desert locust Schistocerca gregaria, the complexity of such an interaction was shown. An 
avirulent pathogen may alter the insect’s susceptibility to the virulent pathogen or alter the 
speed of kill. Co-infecting pathogens may act antagonistically, synergistically or 
independently, depending on the order of infection, the infective dose and the environmental 
conditions (Thomas et al., 2003). In terms of biocontrol, the result of the combination of 
fungal pathogens cannot be predicted and needs to be studied. Investigations concerning 
biocontrol of greenhouse pests with co-applications of mycoinsecticides are not available, but 
potentially enhance control.  
 
Baculoviruses and other pathogens 
Many naturally occurring multiple infections involving baculoviruses and other 
entomopathogens have been reported, and many studies on intentional multiple infections 
have been studied in the laboratory and the field (Harper, 1986). Results varied considerably 
and were often additive, but no generalizations can be made in terms of insect control. The 
use of a combination of a baculovirus and entomopathogenic nematode has been investigated 
for the control of S. exigua on soybean. The combination of S. carpocapsae and SeMNPV 
resulted in significantly higher larval mortality than either pathogen used alone. The 
justification for a simultaneous application is that the virus is more effective on younger 
stages while the nematode is able to kill older stages. Another advantage is that when multiple 
caterpillar pests are present, these may be killed by the nematode too (Agra Gothama et al., 
1996). This combination has rarely been tested. Sequential use of a baculovirus and EPNs has 
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been studied for the control of codling moth in fruit trees. The virus is applied during the 
summer on the trees to achieve direct control, whereas EPNs are used to kill larvae on the 
trunk or in the soil and even in fruit bins. This complementary approach aims at a reduction of 
the overwintering population, resulting in enhanced overall control (Lacey et al., 2007).   
 
Entomopathogenic nematodes and other entomopathogens 
Various combinations have been investigated on various insects. These combinations are 
reviewed by Koppenhöfer and Grewal (2005). The application of EPNs combined with other 
nematodes, fungi or viruses generally results in additive effects, while the nematode-bacteria 
combination effects range from negative to synergistic. Nematode-nematode interactions 
generally lead to competition without any additive effect. Combinations may be additive 
when two nematode species have a different searching behaviour or pathogenicity towards 
different life stages of a target insect. Or, obviously, when multiple pests are present which 
differ in susceptibility to any of the nematode species. 
 Nematode-bacterium interactions can result in negative effects. Nematodes did not 
produce progeny in hosts infected with Bt. Alternating applications of Bt and nematodes (S. 
carpocapsae) achieved better control results than a combined application in cabbage against 
the diamondback moth in Indonesia (Schroer et al., 2005a; Yi and Ehlers, 2006). Combined 
use of S. carpocapsae and Bti against early instars of Tipula paludosa did not give any 
synergistic effect in field trials (Oestergaard et al., 2006). 
 Nematode-fungus combinations generally are additive with regard to target mortality or 
at least give accelerated speed of kill. The use of L. muscarium and S. feltiae against Thrips 
palmi gave additive effects on the thrips population. S. feltiae caused a high mortality of 
juvenile stages of the thrips, whereas L. muscarium caused mortality in juveniles and adults 
(North et al., 2006). This offers the possibility to develop an IPM programme targeting all life 
stages of thrips on foliage as well in soil. This strategy is also exploited with the same 
pathogens in chrysanthemum for the control of western flower thrips, Frankliniella 
occidentalis (Beerling, 2008). Sequential applications as well as tank-mixes may be used 
depending on the structure of the thrips population. When all life stages are prevalent, tank-
mixes may be the best. Preferably synergistic effects are obtained, but this has not yet been 
documented. The interaction between the fungus M. anisopliae and various entomopathogenic 
nematode species, and the combined use was investigated for the control of the larvae of the 
Scarabaeid Hoplia philantus (Ansari et al., 2004; 2006) and larvae of the black vine weevil 
Otiorhynchus sulcatus (Ansari et al., 2008b, 2010). The researchers concluded that the effects 
ranged from additive to strong synergistic effects depending on the interval between the 
applications of the fungus and either of the nematodes. Effects differed also between 
nematode species. 
 The beet armyworm S. exigua is a difficult pest to control and combinations of 
pathogens have been studied in order to improve its management. The use of S. carpocapsae 
combined with the SeMNPV in soybean gave additive mortality on the larvae of beet 
armyworm in a field trial, indicating the potential of a combined scenario (Agra Gothama et 
al., 1996). Nematodes successfully produced progeny in moribund hosts infected with an 
NPV (Kaya and Burlando, 1989). Progeny from such hosts carried enough viruses to infect 
healthy insect larvae. 
 Negative effects between nematodes and other MPCAs may occur. This was 
demonstrated in laboratory tests by Ansari et al. (2005) who exposed entomopathogenic fungi 
to bacterial symbionts of EPNs. Photorhabdus luminescens bacteria inhibited growth and 
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sporulation of several fungi, but Xenorhabdus poinarii bacteria did not. Crude extract of M. 
anisopliae inhibited growth of the bacteria, but had no effect on the dispersal of S. glaseri and 
H. megidis. This study highlighted the possible negative interaction between pathogens. In 
field experiments, however, the combined use in sequential applications of M. anisopliae and 
four weeks later of S. glaseri on Hoplia philanthus larvae gave synergistic effects resulting in 
high mortality rates (Ansari et al., 2006). This demonstrates that laboratory results should be 
considered as a worst-case scenario, and that ultimately applications in the field should be 
investigated on combination effects. 
 The result of an application consisting of a combination of a nematode and a pathogen 
can be additive or negative depending on the order of the infections and the interval between 
applications of them. Combined infections generally are a competition for resources where 
only one is able to successfully produce progeny. 
   
Considerations for the combination of entomopathogens 
Any combination of entomopathogens is theoretically possible. The result of a two-agent 
system can be negative, neutral, additive or synergistic. In most cases mortality is increased 
(Koppenhöfer and Kaya, 1997 and references therein); however, often the effect is additive, 
e.g. less than the sum of the agents alone. I have not found any study of a three agent system 
with pathogens. The aim of a two agent system is to enhance biocontrol, or to reduce costs. 
Reduced dosages of one or of both of the agents may be possible and still give good control of 
the pest. This could be done for cost reasons. I have, however, found very few studies 
investigating this with pathogens (Ansari et al., 2008b; Wraight and Ramos, 2005). 
Simultaneous use (but also sequential use) of two or more entomopathogens can be 
considered in different situations: 
• when several larval stages of a pest are present with a different susceptibility. For 
instance, small stages may be susceptible to a baculovirus or to Bt, whereas large larvae 
are no longer susceptible. In this case a nematode or a fungus may induce mortality of 
larger stages; 
• when the speed of kill is slow, combined use may hasten death of the pest. In most fungi 
and baculoviruses it takes considerable time before the insect dies, while an enhanced 
activity may be reached with EPNs, or a feeding arrestment with Bt, or there may be 
reduced crop damage; 
• when larval stages and pupae are located in different parts of the plant or in the soil. 
Some pathogens are used on the foliar plant parts while others may be more effective in 
the growing medium. Simultaneous use may be targeted at these various life stages and 
accelerate reduction of the population; 
• two pathogens may increase the susceptibility of a pest and cause an accelerated death; 
• a combination can be targeted at multiple pest insects which each have a different 
susceptibility to a pathogen, so only one application is needed. 
In practice, few combinations of pathogens are used in greenhouse systems to control pests, 
and even fewer tank-mixes. An example that seems successful is the sequential or alternate 
use of nematodes and fungi for the control of thrips in chrysanthemums and some other 
ornamental crops in the Netherlands, UK, Denmark and some other countries.  
 
Combined use of microbial pest control products and other pesticides  
The combination of MPCPs with chemicals, preferably at low dosages, has been frequently 
suggested to improve the overall effect. This idea has been based on observations that the pest 
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target is weakened by the chemical insecticide and becomes more susceptible to pathogens. 
Another possibility is that the insect’s behaviour has been modified resulting in more 
movement and an increased exposure to the pathogens. Even low dosages of either, or both 
control products may give additive or synergistic effects. On the other hand, use of low 
dosages of chemicals may be difficult to register due to efficacy and resistance issues. The 
agrochemical industry may also be reluctant to do this for commercial reasons. Combinations 
may be advantageous when two control products have different effects on different life stages 
of the target. The costs of control may also be reduced when combinations are successful, 
particularly application costs. This is an important reason to investigate combined use. A 
prerequisite of this approach is that the chemical have no side-effects on the microbial agent. 
The same approach can be followed with natural pesticides such as neem based products or 
products based on plant extracts, fatty acids, etc., although the availability of this kind of 
products is limited. I will briefly review examples from the literature with the four groups of 
pathogens. This is focussing on combined use where the aim is to enhance control of the pest 
through a direct interaction between both applied control means. These can be tank-mixes or 
sequential applications within a short interval, i.e. more or less simultaneously applied control 
means. Alternating applications of products with longer intervals as commonly done in IPM 
are not considered here. 
 
Entomopathogenic bacteria and chemical pesticides 
Various combinations of Bt’s and chemical insecticides have been tested and synergistic as 
well as negative effects have been reported. Brief overviews have been given by Navon 
(1993) and by Glare and O’Callaghan (2000). In general, chemicals enhanced Bt activity. 
When the activity of the chemical pesticides depended on the uptake of the material, the 
feeding arrestment caused by Bt resulted in a reduced effect. This was the case with IGRs and 
neem. The combination with contact insecticides such as pyrethroids and organophosphates 
generally resulted in synergistic effects, even with low dosages of the chemicals (Navon, 
1993).   
 
Entomopathogenic fungi and chemical pesticides 
The combination of entomopathogenic fungi and chemicals has been investigated for many 
pests. Brief overviews have been given by Zimmermann (1994) and by Inglis et al. (2001). 
Some studies reported additive and synergistic interaction between fungi of the genera 
Beauveria and Metarhizium and sublethal doses of imidacloprid and other chemical 
insecticides for various insects (Quintela and McCoy, 1998; Jaramillo et al., 2005; Shah et al., 
2007a). Sequential use of a chemical whitefly insecticide, followed after 24 hours by an 
application with L. muscarium did not increase mortality of whitefly larvae (Cuthbertson et 
al., 2005b). Although these treatments were compatible, it did not give any additive effect. 
Using sublethal doses of chemicals can lead to a change in behaviour of the pest insect 
resulting in an increased pick-up of spores and in a higher mortality. By using L. longisporum 
(Vertalec) with one percent of the recommended dose of imidacloprid, applied systemically, 
aphid movement increased dramatically and the number of mycosed insects was significantly 
higher than without the use of the insecticide (Roditakis et al., 2000). Caution is warranted 
since some chemicals could repel insects and reduce the exposure to fungal spores (Kepler 
and Bruck, 2006). Most of these studies were laboratory or small scale studies. Few studies 
have reported the use of such combinations under commercial conditions. Mycotal (L. 
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muscarium) has been used in combination with IGR’s (buprofezin, pyriproxifen) for control 
of whitefly in greenhouse vegetables with good results (J. Rodenrijs, pers. comm.).  
 
Baculoviruses and chemical pesticides 
Many studies have investigated the interaction and the combined use of baculoviruses with 
chemical pesticides. Often the slow kill of the virus was the incentive to study potential 
additive effects, including use of low doses of chemicals. An overview of these studies is 
given by Harper (1986) and McCutchen and Flexner (1999). Results can go either way and 
each combination needs to be studied. Synergistic effects have been obtained, even with low 
concentrations of chemicals, indicating the interesting potential of these combinations.  
 
Entomopathogenic nematodes and chemical pesticides 
The combined use of nematodes with chemicals has been investigated for control of soil 
pests. An overview of these studies and the results are given by Koppenhöfer and Grewal 
(2005). Combined use of EPNs with chemical insecticides and the results on insect control 
can be additive or synergistic, but the authors warned that lab results are not always checked 
in the field. Simultaneous applications as well sequential applications of imidacloprid and H. 
bacteriophora resulted in strong synergistic effects on white grubs (Koppenhöfer and Kaya, 
1998). Further research indicated that the level of synergism varied with the nematode species 
and that results in the field were more variable than in greenhouse trials (Koppenhöfer et al., 
2000). Combined uses are useful when target pests become more susceptible to a pathogen 
due to the effect of the chemical. The combined use of nematodes and chemicals was 
investigated by Cuthbertson et al. (2003; 2008b) on foliage of tomato and verbena. When 
nematodes were exposed for 24 hours to the chemical spray solution, there was a large 
reduction of infectivity. The nematodes were not affected by the one day old residue of the 
chemicals on the foliage. Sequential applications of a chemical insecticide and S. feltiae or S. 
carpocapsae increased whitefly larvae mortality in some cases.  
 
Microbial pest control products and natural pesticides 
Natural products have also been investigated in combination with MPCPs. For instance, neem 
enhanced the efficacy of M. anisopliae against the black vine weevil. Even a 100-fold lower 
dose of the fungus in combination with neem produced similar mortality to the recommended 
fungal dose without neem, and protected plants from black vine weevil damage (Shah et al., 
2008). This offers a potential benefit to growers with regard to efficacy and costs. Neem also 
improved the efficacy of the nematicidal fungus Paecilomyces lilacinus against plant parasitic 
nematodes (Nagesh et al., 2003). Since neem has anti-feeding effects, usage in combination 
with pathogens that need to be ingested, like Bt and baculoviruses, is not recommended. 
Nevertheless, laboratory studies showed additive and synergistic effects of combined 
ingestion of Bt and neem in the larvae of the Colorado potato beetle, even with reduced doses 
of both (Trisyono and Whalon, 1999). Additive effects of the combination were found in 
Helicoverpa armigera larvae (Singh et al., 2007). The IGR mode of action of neem makes it 
potentially more interesting for combinations with entomopathogenic fungi (Walters, 1999).  
 The combination of nematodes with insecticidal soap has been investigated for 
simultaneous control of soil and foliage pests when sprayed as a tank-mix. Immediate 
application after preparing the mix was harmless to the nematodes, but longer exposure 
periods killed nematodes (Kaya et al., 1995). The combination of both control means to 
control different pests occupying different habitats is feasible, but there was no additive or 
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synergistic effect on either of the pests. Investigations on combinations of other natural 
products, apart from neem and soap, with MPCPs are hardly available. 
 
Microbial pest control products combined with other control techniques   
Few studies report the use of a pathogen combined with other non-pesticide tools. In a study 
of Ludwig and Oetting (2002) the efficacy of B. bassiana in combination with insect 
attractants was investigated. Attractants were tank-mixed with the fungus and applied three 
times in chrysanthemum at bud break to control F. occidentalis. The attractants were either 
behaviour-influencing compounds or feeding-stimulants/stickers and had no adverse effect on 
the fungus. Thrips populations were not reduced in any combination of the fungus with the 
attractants compared to the treatment with B. bassiana alone. The use of attractants and baits, 
possibly in combination with autodissemination devices, has been advocated as a way to 
improve biocontrol with entomopathogens (Butt and Brownbridge, 2001; Roy et al., 2007). 
Similarly, using trap plants and treating those to control the pests has been suggested by many 
authors. This is often called the push-pull strategy. However, these technologies are not yet 
used with entomopathogens in protected crops (Cook et al., 2007). 
 
Use of insects as vectors to disseminate microbial pest control products  
Pollinators such as honeybees and bumblebees have been studied as vectors to disseminate 
MPCAs. Bees can spread small particles of powder formulations of bacteria, fungi and 
baculoviruses (which they can accumulate by means of a dispenser) to flowers. The 
prerequisite is safety of the material to the foraging bees as well as to the bee colony. Bt’s are 
safe for honeybees; a review is given by Glare and O’Callaghan (2000). Bt’s and 
baculoviruses are also safe for bumblebees (Sterk et al., 2002). Entomopathogenic fungi, 
however, can have detrimental effects on bees (Butt et al., 1994) and caution is required when 
using them with bees.  
 Kovach et al. (2000) demonstrated that the use of honeybees and bumblebees for 
disseminating spores of T. harzianum to strawberry flowers reduced Botrytis disease 
incidence in the field. Honeybees were successfully used in sunflower to disseminate Bt to 
flower heads to control the banded sunflower moth (Jyoti and Brewer, 1999), and to 
disseminate Heliothis NPV to crimson clover flowers (Gross et al., 1994). Carreck et al. 
(2007) showed that honeybees can be used to deliver inoculum of M. anisopliae to flowers of 
oilseed rape for control of the pollen beetle and the cabbage seed weevil. There was no 
evidence of any adverse effect on the honeybee colonies. 
 More recently bumblebees have been studied as a vector of fungal agents in greenhouse 
tomato and sweet pepper crops (Kapongo et al., 2008; Kevan et al., 2007; Shipp et al., 2008). 
Dissemination of the combination of an entomopathogenic fungus with an antagonistic fungal 
agent was also investigated by Shipp et al. (2008). Results indicated that this method is 
potentially appropriate for dispersal of inoculum to flowers and plants for pests and diseases 
such as whitefly, Lygus bugs, and grey mould. Mortality of bees is a critical factor when using 
entomopathogenic agents with a broad host spectrum such as B. bassiana (Shipp et al., 2008) 
and, requires detailed side-effect testing. This dissemination method is still in its infancy and 
commercial applications have not yet been successfully applied in greenhouse crops, nor have 
they been approved by regulatory authorities. Approval of this method may be a challenge 
due to greenhouse personnel exposure to spores on the plants, and due to direct non-target 
effects on bees. 
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 The predatory bug Orius laevigatus has been studied for use as a vector for fungal 
entomopathogens in greenhouse crops. Bugs artificially surface-dosed with conidia of L. 
longisporum or L. muscarium successfully disseminated conidia around a plant, resulting in 
infected pest insects and a higher reduction in aphids respectively thrips than with the fungal 
pathogen alone. There was no additional effect in the case of whitefly larvae. The benefits of 
using bugs contaminated with the pathogens were not significant due to the predatory 
behaviour of the vector (Down et al., 2009). I doubt whether this method can be developed 
into a practical application resulting in enhanced control of pests. 
 
 
Resistance and microbial pest control products 
 
Resistance against entomopathogens 
For a long time, resistance to entomopathogens had been considered improbable due to the 
complex and multi-site targeting mode of action that has evolved with the host insects. 
Pathogens do not represent a new selection pressure in nature, and novel resistant mutants 
were not likely to occur. This is in contrast to chemicals, which offer a new selection pressure 
on often single-sited mode of actions, and thus new mutants were to be expected (Homan, 
1981). Nevertheless, resistance to bacteria and to viruses was recognized by Homan (1981) as 
a possibility. This hypothesis was based on theoretical considerations about possible 
mutations inducing increased resistance by the insect to infections. This possibility was 
confirmed when resistance to Bt was found in the field in the diamond back moth Plutella 
xylostella in the late 1980’s (Tabashnik et al., 1990). Resistance had developed because of 
repeated applications against this major pest in continuous cropping of crucifers in large areas 
in subtropical and tropical regions. A review on the occurrence of resistance to Bt in various 
insects is given by Tabashnik (1994) and by Glare and O’Callaghan (2000). For details on the 
biochemical and genetic mechanisms of this phenomenon I refer to Van Rie and Ferré (2000). 
Even cross-resistance between Bt strains has been reported, and for Bt resistance management 
programmes have been designed to avoid this problem. Resistance to Bt has also been found 
in greenhouse crops in Canada in the cabbage looper, Trichoplusia ni, due to overuse and 
using rates above the recommended ones (Janmaat and Myers, 2003; Janmaat, 2007). 
 Factors influencing resistance to baculoviruses by insects have been elaborately 
discussed by Briese (1986); he first recognized the risks of reduced susceptibility to virus 
infections. Recently, resistance in a baculovirus in the field has been found. The use of Cydia 
pomonella GV in apple orchards in Europe as the main component for control of the codling 
moth for many years has lead to a high degree of resistance in some populations (Sauphanor 
et al., 2006; Frisch et al., 2007). This is the first example where field resistance to a 
commercially applied baculovirus has been documented (Eberle and Jehle, 2006). These cases 
illustrate that also with entomopathogens there is a risk for the development of resistance 
when products are overused, or used as a single or predominant control method. I have, 
however, not found any examples of field development of resistance to entomopathogenic 
fungi or nematodes. This is confirmed by Shelton et al. (2007) who gave an overview of cases 
of resistance to insect pathogens. Studies indicate that the mechanisms of natural resistance to 
fungi (Wilson et al., 2001; Wilson et al., 2002) as well as to nematodes (Kunkel et al., 2004) 
are present in insects, indicating that resistance to these pathogens is not impossible.  
 The above illustrates that with the use of MPCPs a resistance strategy also needs to be 
developed. These cases of resistance concerned lepidopteran pests, but most pest insects and 
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mites in greenhouses have a history of developing resistance to chemical insecticides. 
Resistance concerns should be raised when insects have many generations in one cropping 
season and when a pathogen is frequently applied, or applied as a single control method. 
General recommendations for the use of MPCPs should include recommendations to avoid 
resistance. These resistance management recommendations are similar to the ones for 
chemical pesticides: alternate insecticides with a different mode of action, reduce the number 
of applications and do not apply dosages higher than the recommended ones (Shelton et al., 
2007).  
 Resistance management tactics for biopesticides, particularly for Bt’s, in agriculture are 
given by Roush (1999, 2000). In general, the solution is to develop an IPM programme with 
different control methods and to use MPCPs with care. This approach should start at the 
launch of every new product and should be proactive rather than reactive. The monitoring of 
resistance is important and as soon as products seem to fail to give sufficient control, any 
suspicious populations should be tested for susceptibility. In my experience, resistance to 
biopesticides has not occurred in greenhouse crops in Europe to date. Biopesticides have not 
been used to a large extent, except Bt. Decreased susceptibility to Bt in the tomato looper, 
Chrysodeixis chalcites, has been suspected, but resistance has not been documented. In 
Canada, resistance to Bt developed in T. ni in greenhouses due to heavy reliance on Bt 
(Janmaat and Myers, 2003). The relative containment of the moth populations in greenhouses 
may be highly conducive to resistance development (Janmaat and Myers, 2003). In the 
laboratory the high level of resistance to Bt rapidly declined in some populations once the 
selection pressure was no longer present (Janmaat and Myers, 2003). This example shows that 
when biopesticides are commonly used in greenhouse crops, resistance management must 
become part of the application strategy. 
 
Use of microbial pest control products in resistance management programmes  
In pest control programmes where pest insects have developed resistance to commonly used 
pesticides, or in cases where a new pesticide is likely to develop resistance due to its mode of 
action, MPCPs are an appropriate tool to prevent resistance. Resistance management 
programmes should be designed that incorporate rotation schedules of control products with 
different modes of action. Many insects have developed resistance to chemicals and many 
insect groups are notorious for doing so. Due to the particularly favourable conditions for 
population growth of pests in greenhouses, treatment must take place frequently, and as a 
result, the development of resistance in greenhouses will take place more quickly than 
outside. Numerous examples have been documented, and all the key pests such as whitefly, 
spider mites, thrips, aphids, leafminers, sciarids and caterpillars are capable of quickly 
developing resistance (see http://www.pesticideresistance.org/DB). In addition to the use of 
natural enemies, which often are the backbone of an IPM programme in greenhouse vegetable 
crops, MPCPs can be used as corrective tools for pest control or as additional products 
besides the beneficials. Chemical insecticides should only be used in IPM when no other 
methods are available anymore. This also helps to prevent resistance to these chemicals and 
keeps them efficacious for a longer period. Selective chemicals can be essential in IPM 
programmes when used as corrective measures and the development of resistance is 
unfavourable for the growers as well as for the manufacturer. 
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Practical aspects of side-effect testing 
 
Side-effects of chemical pesticides on entomopathogens 
Several standard procedures have been developed to test side-effects of chemicals on 
pathogens by members of the IOBC Working Group “Pesticides and Beneficial Organisms”. 
They differ per class of pathogen. Methods have been developed for EPN (Rovesti, 1991; 
Vainio, 1992; Peters, 2003), and for fungi (Hokkanen and Kotiluoto, 1992; Coremans-
Pelseneer, 1994; Keller, 1994, Tuset, 1985). The Working Group has not developed methods 
for testing effects of chemicals on bacteria and baculoviruses, and consequently has not tested 
side-effects on these pathogens. The most likely reason for this is the lack of susceptibility of 
bacteria (in the case of Bt both spores and proteins) and baculoviruses towards chemical 
pesticides. Furthermore, there are no chemical bactericides and virucides available for the 
control of plant diseases that could have adverse effects on beneficial bacteria and viruses. 
The developed methods generally describe laboratory tests. Testing methods with plant 
material or with whole plants or with soil are often not available. There is a need to go beyond 
such laboratory tests to generate data that reflect ‘real world’ conditions. Given that side-
effects of chemicals, particularly fungicides, are the most critical group for entomopathogenic 
fungi, I will illustrate this need by discussing the case of fungi. 
 Testing of side-effects of chemicals on entomopathogenic fungi is usually carried out by 
in vitro Petri-dish agar tests and/or by in vivo bio-assays. The latter are preferred since they 
simulate more closely the interaction in the field. In the case of L. muscarium, many authors 
have reported side-effects of fungicides, and most of them refer to germination and mycelial 
growth inhibition on agar, incorporated with the chemical test compound. For an overview of 
results, see Schuler (1991). Recently, Cuthbertson et al. (2005b) tested the side-effects of four 
chemical insecticides for whitefly control on L. muscarium (Mycotal). They tested the effect 
of 24 hours exposure of spores in the insecticide solution on germination, a worst-case 
scenario. Only one chemical did not influence germination. The others reduced it greatly. 
Tests that were conducted on plants (tomato and verbena) which had been sprayed with an 
insecticide and followed 24 hours later by the application of the fungal product showed no 
difference in either whitefly mortality or in mycelial growth for any of the insecticides. This 
indicated that tests on plants showed compatibility of the insecticides with L. muscarium. This 
example illustrates that caution needs to be taken when translating laboratory data into a 
compatibility profile for practical use. The negative results from the 24 hour exposure of 
spores to a fungicide are not very relevant either because the producer’s recommendation for 
Mycotal precludes tank-mixing. Even if a grower wants to spray a combination, it would 
normally not take more than 8-10 hours before the tank will be emptied. Leaving a spray-
solution overnight is strongly discouraged in all cases.   
 Testing on plants is required to get relevant data for commercial conditions, particularly 
when laboratory results show harmful effects. Hall (1981b) and Ravensberg et al. (1994) 
tested side-effects directly with host insects in bio-assays and on whole plants. Direct effects 
as well as persistent effects can be tested in this way and the results are easier to compare to 
the field situation. Testing compatibility of pathogens with chemicals should follow this 
approach rather than just conducting agar tests.  
 For fungi applied to the soil, Keller (1994) proposed a semi-field and a field test 
including a bio-assay with bait insects in the presence of the pesticide, because results then 
directly indicate effects on virulence and efficacy. This was based on earlier work where 
Keller et al. (1993) had found that in vitro results are difficult to extrapolate to the field. 
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Despite complete inhibition of mycelial growth of the fungus B. brongniartii by some 
fungicides in in-vitro tests, soil sprayed with the fungicides was much less inhibitory to the 
growth of the fungus.     
 EPNs are often tank-mixed with other products, thus compatibility testing is required. 
Peters (2003) discussed the methodology of testing harmful effects of pesticides on 
nematodes. He suggested a short exposure of nematodes to the chemical in a water solution, 
followed by an assessment of mortality. This is the high level exposure. The low level 
exposure is encountered in the substrate and can be assessed in a bio-assay by infectivity and 
fecundity of the nematodes on lesser mealworm larvae. According to Peters (2003), the 
methods used earlier tend to overestimate the pesticides’ effects on nematode survival and 
underestimate the effect on infectivity. The proposed new method supposedly gives more 
realistic results. Nematode propagation is measured also as this may be important in some 
cases for prolonged pest control by the following generation of nematodes. This is seen in 
control of white grubs in turf. 
 Since there are no specific methods developed for bacteria and baculoviruses, the 
method for fungi can be used and adapted where necessary. The laboratory in vitro test can be 
performed with bacteria (viability), but not with baculoviruses. Bio-assays and field tests used 
for fungi can be used for both these types of pathogens. 
 For testing compatibility a tiered approach should be chosen. For fungi and bacteria, this 
starts with agar tests to assess germination and growth. When inhibitory effects are noticed a 
bio-assay with plant material, or where relevant with soil, and insects is recommended. For 
baculoviruses and EPNs, the first step is a bio-assay. When harmful effects are seen in the 
bio-assay, a semi-field greenhouse test should follow. To test persistent effects, I recommend 
testing this under commercial conditions in the crop and region for which it is relevant. In 
laboratory in vitro tests a concentration range can be easily tested. The slope of the graph will 
give information on the dose-effect relationship and help estimate how serious the effects can 
be. In greenhouse or field tests I recommend to test the label rates only because of time and 
costs. Side-effect testing should also be done with the formulated products because 
formulation compounds may influence the results. 
 
Side-effects of entomopathogens on beneficial organisms 
Natural enemies and bees can be adversely affected by various entomopathogens. This 
concern needs to be addressed by testing putative negative side-effects of MPCPs on these 
non-target organisms. Relevant considerations and guidelines for testing are given by Hajek 
and Goettel (2008). The most significant one concerns the method of testing the pathogens’ 
host range. For the IPM practioner, the ecological host range is relevant, rather then the 
physiological host range. Often, laboratory studies are carried out under optimal conditions 
for the pathogen such as high humidity conditions for entomopathogenic fungi, high dosages 
and/or direct exposure routes. In these ‘worst-case’ scenario tests, ‘physiological 
susceptibility’ is shown, but this does not necessarily represent the ‘ecological susceptibility’, 
e.g. effects under field conditions. Differences between laboratory and field studies with 
entomopathogenic fungi, reviewed by Roy and Pell (2000), illustrate that side-effect testing 
methods should reflect the conditions of use.  
 Besides direct effects, indirect effects may also occur such as reduced longevity or 
fecundity. Test methods should also take this into consideration. There are no standardized 
testing methods for microbials. Methods developed for chemical pesticides (OECD and 
ESCORT guidelines, see above) can be used and they should be adapted where necessary. For 
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registration purposes official OECD guidelines are required. Testing is particularly difficult 
when the host or the prey is directly affected by the pathogen. Several examples are discussed 
above. For predators, additional prey animals can be added during the test. For parasitoids, the 
relative timing of the pathogen application and the moment of release of the parasitoids is 
often decisive, and the trial design needs to take this into consideration. Direct effects of the 
pathogens as well as residual effects must be investigated, the latter only when directs effects 
are present. A tiered approach (table 6.3) for testing side-effects is also suggested for this type 
of studies. 
 
 
Table 6.3.   Tiered approach for side-effect testing. The subsequent test is only 
       required in case the previous test shows harmful effects. 
 
Test 
location 
Type of test Effect Testing method 
Laboratory 
tests 
1) Petri dish  
     agar test 
Direct effects Worst case testing on germination 
and growth 
 2) Bio-assay Direct effects 2.1) Topical spray on insects and  
       detached leaf 
  Indirect effects 2.2) First the leaf is sprayed and insects 
       are transferred once residue is dry 
  Indirect residual 
effects 
2.3) As 2.2:  after x days on aged residue
Field tests 3) Experimental 
    greenhouse 
Direct effects 3.1) On whole plants: spray on plants 
       and insects   
  Indirect effects 3.2) On whole plants: spray on plants, 
        insects introduced once residue is 
       dry  
  Persistent effect 3.3) On whole plants: spray on plants, 
       insects introduced after x days   
 4) Commercial 
    conditions 
Field 
persistence 
Crop treatment on plants and insects, 
under slow degradation conditions 
(North Europe, winter) 
 5) Commercial 
    conditions, 
    various regions 
Field 
persistence 
As 4; under different climates, testing  
different degradation conditions 
 
 
Results from these tests need to be seen as indicative for the side-effects, and 
monitoring of the interactions in commercial greenhouses should be carried out in order to 
validate the data. The indicative character is also reflected by the IOBC classification of a 
side-effect, and expressed as mortality or reduction in beneficial capacity caused by a 
pesticide. The side-effect level is given in the following categories:  harmless or slightly 
harmful: reduction 0-50%; moderately harmful: 51-75% reduction, and harmful: > 75% 
reduction. Based on experiences in the field, the effect level may need to be adapted. The 
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large variation of relevant parameters (environmental conditions, application strategy, cultural 
practices, pest and disease control measures, etc.) influence the interaction, and gathering 
information from commercial usages needs to be ongoing to ensure proper advice over time.  
 
 
Implementation of microbial pest control products and knowledge transfer 
 
Adoption of a microbial pest control product 
Adoption of a new product requires growers to change their current IPM practices. In general, 
changes are perceived as undesired, unless the benefits, technical and/or economical, are 
clear. Adoption of innovations is reviewed and described for conservation biological control 
for farmers by Pannell et al. (2006). He distinguished three main elements that play a role: the 
process of learning, the relative advantage of the innovation over existing practices, and the 
‘trialability’ of the new product, which refers to the ease of testing and learning before 
adoption. Cullen et al. (2008) argued that demonstrating the economic benefits of 
conservation biocontrol to farmers is crucial in order to change their practices. Much of this 
discussion is true for the adoption of biopesticides. The biocontrol industry needs to show the 
benefits of the change to the user such as cost savings, better yield or better market access. It 
is crucial to motivate a grower to start with something new. This should be the focus of 
marketers and salespeople involved in biopesticides. An interesting example of this approach 
has been described by Kirkpatrick and Georgis (2007) who demonstrated in field trials the 
cost-benefit of using Bt products in IPM programmes to cabbage and tomato farmers in 
Florida. They showed that it is worth changing to a new technology since it delivered a higher 
percentage of marketable produce with reduced pesticide costs.  
 
Implementation of a microbial pest control product in an IPM system 
Biopesticides act differently than chemical pesticides. Growers’ expectations of control 
agents are still often based on the chemical paradigm where a single product gives a quick 
knockdown and control of the pest(s). Biocontrol products are often new to the users and the 
users need to be properly informed about these products. Growers need to understand the 
strengths and weaknesses of each biopesticide and they have to have a realistic view of what 
to expect and what not to expect (Straus and Knight, 1997; Warrior, 2000). MPCPs are 
knowledge-intensive and implementation in an IPM system requires understanding the 
product as well the biology of the pests in much more detail than with chemicals. Growers 
must be provided with effective use strategies to ensure that the product is used in an optimal 
way. If the grower’s perspective of the product is incorrect, the product is bound to fail and 
the grower will be disappointed and not adopt the new product in his IPM system. Many 
authors have discussed this critical element of biological control, and of biopesticides 
(Waage, 1996; Straus and Knight, 1997; Williamson, 1998; Whalon and Norris, 1999).  
 It is well understood that proper training of the practical aspects of a biological product 
for all stakeholders in the chain, from manufacturer to end-user, should be part of the 
development of a biopesticide and an IPM programme. The role of the distributors should not 
be underestimated, since they often have direct contact with the growers. The various steps in 
the process from research to implementation in the field and the roles of stakeholders are 
described for natural enemies by Onillon and Gullino (1999); this is basically the same for 
microbial BCAs. An extended review on the IPM implementation process is presented by 
Wearing (1988). He focussed on insect and mite pests in various cropping systems from all 
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over the world. Despite more than twenty years of IPM developments, this process is still 
rather slow and many of the obstacles described by Wearing that hamper adoption of IPM, are 
still valid. He concluded that IPM must be designed in such a way that it fits the farmer. And 
he recommended that the primary objective be that “the farmer’s confidence be nurtured and 
maintained”. There are very few papers treating this subject in such an elaborate manner and 
therefore it is worth taking notice of it for the IPM worker. Biopesticides have not been 
reviewed is such a way, but implementation into an IPM system needs similar considerations 
as those mentioned by Wearing. Vital aspects are that the product fit the farmer, is simple to 
implement, and has a cost advantage.  
 
Stakeholders’ involvement, with emphasis on growers 
Key to the success of a biopesticide is growers’ involvement in the learning process of using 
and integrating a biopesticide in their pest and disease control programme. De Buck and 
Beerling (2006) presented an interesting case of implementation of biological control in the 
Netherlands in which the key role of growers’ networks is exemplified. This process is 
complex and involves many different stakeholders. Another example, in this case from 
Finland, showed that knowledge transfer and participative learning by growers are essential 
elements in the process of implementing IPM (Vanninen et al., 2008). But what can an 
individual MPCP company do? The role for manufacturers of biopesticides is to participate in 
these processes and to present all information required to make growers understand the 
benefits of a biopesticide. Demonstration trials at commercial holdings are a convincing tool 
for all stakeholders. These should be done at the launch of the product, but also over time to 
maintain interest, and to adapt implementation strategies where necessary with new practices, 
cultivars, pesticides, etc.  The presentation of data should be accessible by growers in the 
form of technical booklets (see Box 6.1), websites, articles in growers’ magazines, 
presentations at grower meetings, etc.  
 
 
Box 6.1   Mycotal manual: the contents of the booklet with vital users information 
 
EFFECTS 
Appearance of control 
Effects in various crops  
Testing new applications 
 
PRODUCT INFORMATION   
Mycotal- Microbial insecticide  
Active ingredient – Verticillium lecanii 
Formulation     
Mode of action  
Quality control  
Storage             
Disposal  
 
 
COMPATIBILITY   
Biological control organisms  
Pollination by bumblebees 
Chemical pesticides 
 
TROUBLE SHOOTING 
 
 
ENVIRONMENT AND SAFETY  
 
 
DIRECTIONS FOR USE 
Crops  
Timing and number of application  
Dosage    
Application   
Environmental conditions 
  REFERENCES 
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The above refers to interactions with individual growers. Furthermore, producers should 
communicate and interact with distributors, extension services, and research institutes 
concerning the product in order to promote it and to gain a better understanding of the product 
and its role in the ever-changing practices of an integrated pest control programme. 
Biocontrol with natural enemies in greenhouses used this approach and was very successful 
(van Lenteren, 2007). For biopesticides a similar approach is required, and we can use the 
lessons learned with natural enemies. Without effective transfer of knowledge there will be no 
successful innovation of technology, e.g. no successful adoption of new biopesticides.  
 
Ecological effects versus direct effects  
Many authors highlighted the fact that biopesticides are different from chemicals. In addition 
to killing the pest by the “numerical response” there are sublethal effects and the potential to 
reproduce and to continue the control effect over time on the pest population by the 
“functional response” (Waage, 1997b; Gelernter and Trumble, 1999; Thomas, 1999; Inglis et 
al., 2001). They argued that this extra benefit is not exploited enough, and therefore 
biopesticides cannot escape from the pesticide paradigm. This ecological approach may be 
valid in field crops, but in greenhouse crops it is not a relevant phenomenon. I have seen 
epizootics with entomopathogenic fungi, but they are unpredictable with regard to time and 
scope. Naturally-occurring epizootics have been reported from Entomophthoralean fungi and 
baculoviruses in agro-ecosystems, and in some cases they provided significant control of 
pests (Steinkraus, 2007). There are, however, no reports of epizootics giving a predictable and 
considerable contribution to control of the pest following the application of a MPCP.  
 The same can be said about sub-lethal effects caused by pathogens. Various parameters 
of the pests’ biology may be affected by the pathogen, such as fecundity, feeding patterns and 
developmental rate. Many of these effects are not obvious and consequently are not 
appreciated as part of the product’s effectiveness. Only in the case of Bt where feeding ceases 
quickly after oral uptake, and thus the damage to the plants does not become larger, is this 
sub-lethal effect appreciated.  
 I do not want to neglect or underestimate the potential of the “functional response” of a 
MPCA, but in seasonal and annual greenhouse crops the reality is that MPCPs are used as the 
inundative approach. Microbials can only be advised based on their known direct 
effectiveness, and they need to be repeated when the pests re-appear.  
 
Successful implementation requires continued efforts  
No matter how much research has been conducted with the product in the developmental 
phase, only when it has been used on a large scale in commercial greenhouses will its 
strengths and weaknesses become apparent. Advisers need to communicate with each other 
and the developers of the product in order to find the best way of using the product and the 
best ways of integrating it successfully in each cropping system. For a grower, the initial use 
of a microbial product is not an easy job and first-hand advice from a specialist is required. 
When an adviser visits a grower, not only does the grower learn how to use this new 
microbial, but also the adviser comes across many different situations from which he again 
learns more about the product and how best to integrate it in various cropping systems and 
pest situations. This ultimately leads to a well-balanced use of the microbial. Nevertheless, 
this should be an ongoing process since many changes occur over time in commercial 
horticulture and feedback should lead to a cycle of continuous improvement of the use of the 
microbial product. This is an essential element in the commercial development of any new 
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product, but particularly so with a knowledge-intensive microbial pesticide. This requires 
considerable effort of the sales and marketing team of a producer. It can be called ‘technical 
marketing’ of a biopesticide. This element is often forgotten or neglected in the commercial 
marketing of a new biopesticide, but it is indispensible for the successful uptake of a product.   
 
 
Conclusions and recommendations  
 
Application and implementation strategy 
A microbial pest control product and its proper and effective application are two elements that 
cannot be seen separately. Therefore, application and implementation of the product needs 
considerable research within the total development programme of a MPCP (table 6.4). The 
introduction of a new tool in a complex multi-component IPM system is likely to impact 
many other components. This calls for identification of the relevant interactions, and for 
studying the effects, and makes the system highly knowledge-based. Elements that are 
imperative in the development of an IPM system with a new product are listed in table 6.5. 
 
Compatibility profile of microbial pest control products  
A “two-sided” compatibility profile must be established for products based on 
entomopathogens. On one side, they are susceptible to various chemical and natural 
pesticides, and knowledge of these effects needs to be generated. On the other hand, microbial 
products may affect natural enemies depending on their mode of action, their host range, and 
the conditions of use. Side-effect testing should be performed when there are indications for 
harmful effects on any natural enemy or pollinator. 
 In general, negative effects of biopesticides are of minor importance to natural enemies 
and pollinators. Nevertheless, for each new MPCP a compatibility profile must be developed 
since the formulation, the dose, the application strategy, and the conditions of use may lead to 
effects that are different from those of other strains or products. Often, laboratory studies are 
carried out under optimal conditions for the pathogen, but side-effect testing methods should 
reflect the conditions of use. Recommendations on testing methods and conditions are given 
the paragraph “practical aspects of side-effect testing” above and in table 6.3. Only testing 
under relevant conditions generates reliable information that can be used to give advice on the 
side-effects under commercial conditions. 
 
Microbial pest control products and interactions with other control components 
Combinations of pathogens and natural enemies are often used to enhance biological control 
or to reduce high pest levels, but this generates interactions in various forms. Many 
interactions have been studied in the laboratory or in small scale field trials, often in a two 
agent-one host system. But many of these interactions have not been demonstrated to result in 
synergism in terms of pest or damage control in commercial settings. Wraight (2003) 
concluded that: “any attempt to exploit laboratory-discovered synergism or other beneficial 
interactions among natural enemies certainly warrants caution”. At the same time, negative 
effects and interference are more likely to occur than synergistic effects since control agents 
target the same pest. Natural enemies of the pest insect for which the pathogen is applied may 
be adversely affected. This, however, is of relative importance if control by the pathogen is 
effective. It is much worse when natural enemies of another pest are affected by the pathogen 
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and when this leads to a resurgence of that other pest. These unintentional effects must be 
known because they have direct implications for the whole IPM system.  
  
 
Table 6.4.   Interaction matrix between four types of entomopathogens and various system 
   aspects: importance with regard to the knowledge needed for successful 
   implementation of a microbial insecticide within an IPM programme 
 
System factor /pathogen Bacteria Fungi Baculo-
viruses 
EPN 
Target pest(s) 5 5 5 5 
Application strategy 3 5 4 3 
Equipment 3 4 3 4 
Host plant  3 4 2 1 
Cropping system 2 4 2 1 
Growing mediuma 5 5 - 5 
Environmental factors 
- temperature 
- humidity 
- UV radiation 
 
3 
3 
2 
 
4 
5 
2 
 
3 
2 
4 
 
4 
5 
3 
Chemical insecticides 2 2 1 2 
Chemical fungicides 1 5 2 1 
Natural pesticides 1 3 1 3 
Parasitoids 
- direct effects 
- indirect effects 
 
1 
4 
 
3 
4 
 
1 
4 
 
1 
4 
Predators 
- direct effects 
- indirect effects 
 
1 
4 
 
2 
3 
 
1 
3 
 
1 
2 
Pollinators 1 3 1 1 
Resistance 4 2 3 1 
Knowledge-intensive 2 5 2 4 
Technology transfer 2 5 2 4 
Costs 
- product 
- application 
 
2 
2 
 
4 
3 
 
3 
2 
 
4 
4 
Combination potential 2 4 3 4 
1 : not important   4 : very important 
2 : slightly important   5 : critical 
3 : moderately important   a  : in case of application to the root system 
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IPM systems are much more complex than a two-agent/single host system and understanding 
all those interactions in detail is impossible. It is therefore pivotal to identify those 
interactions that hamper or impede effective control, or those that enhance control 
significantly. Only those require further investigation in order to optimize the integration of 
various IPM components. Over time, concerns or promising effects may be encountered in 
practice and those need to be studied to see if they can be avoided or exploited. 
 
 
Table 6.5.  Essential elements of the implementation process of microbial pest control  
      products in an IPM programme  
 
     Requirements for the successful use of a microbial insecticide 
• Develop an efficient application strategy for the product 
• Develop a two-sided compatibility profile of the product 
• Identify relevant interactions with other control agents 
• Study the impact of these interactions and develop a strategy to 
optimize using the MPCP: exploit positive ones, avoid negative ones 
• Develop simple and manageable recommendations for use  
• Keep the costs of the product and the applications acceptable 
• Ensure that transfer of knowledge is sufficient and efficient  
• Involve all stakeholders in biocontrol, emphasize growers’ 
involvement 
• Detect problems and concerns in practice and find solutions 
• Treat implementation and optimization of the IPM system as an 
ongoing process and as imperative for sustainable use of the MPCP 
• Position the product as part of a season-long IPM system, not as a 
single temporary solution for a pest problem 
 
 
Advantages and disadvantages of microbial pest control products in IPM programmes 
The use of a MPCP has the following advantages: they are easy to apply; they act relatively 
quickly; are generally compatible; have a limited persistence, with few if any lasting adverse 
effects; are selective; and are relatively cheap compared with natural enemies. They are also 
generally safe to workers, to the crop, to natural enemies and pollinators. In addition, there is 
no MRL (maximum residue level); a short or no re-entry period; no pre-harvest period; and 
they can be tank-mixed. Furthermore, they are a valuable tool in resistance management 
programmes and they may give the grower a position as a preferred partner for a supermarket. 
 They have a few disadvantages as they are knowledge-intensive; relatively expensive 
compared with chemicals; have a narrow spectrum; are slow-acting, and it can be difficult to 
evaluate their effect. These disadvantageous are considered negative when one compares 
biopesticides with chemicals which have their own disadvantages. In a biocontrol focussed 
crop protection system, MPCPs are a good fit as a complementary or corrective component 
and in some cases as a stand-alone control means.  
 
 
Implementation in an IPM programme 
___________________________________________________________________________ 
 223
Costs of IPM implementation  
A biopesticide producer needs to communicate the cost of the implementation of a MPCP to 
the grower. IPM programmes have been become quite complex in greenhouse crops. To adopt 
a new product into this system, the monetary aspect is a significant factor for a grower’s 
decision. It is not the decisive factor, but the costs need to be in the range of products that the 
grower typically uses. This means not just the product end-user price, but also the labour 
involved in the application and the potential advantage in the market. Demonstrating the costs 
and benefits to the grower is vital for the adoption of the product and the IPM programme. 
 The implementation of a biopesticide means costs for a biopesticide producer. For a 
successful uptake of a new MPCP in IPM systems, considerable efforts are needed. Education 
and training is required for its sales force, its distributors and the end-users. Training 
materials, leaflets, website information, promotional talks, demonstration trials for growers 
and regularly visiting growers are all part of this. Knowledge acquisition and marketing 
activities cost money and within the development of a biopesticide these should be budgeted. 
Since it is an ongoing exercise, these costs must be considered as part of the product price 
(see chapter 3 section “A cost price model for biopesticides”). It is difficult to estimate the 
extent of these costs. It will depend on the type of pathogen and the targets.  
 
The potential of combinations 
Combinations of MPCPs with other control agents have been investigated in numerous 
studies for their putative enhancing effects in control of the target (Wraight and Ramos, 2005; 
and references discussed by them). Few of these studies have demonstrated improved control 
in field tests, and few of these ideas are practiced by growers. Moreover, biopesticides are 
generally not cheap, and mixtures must enhance control in order to justify the higher costs for 
the grower. Still, the potential of enhanced effects is worth investigating. 
 The potential of low dosage effects should not be overlooked either. The focus should 
be on reducing costs of products and labour, on simultaneous as well as sequential use, on 
avoiding negative interactions, and exploiting positive interactions. I believe that the value of 
these areas of study is still underestimated. It is much easier and cheaper to develop better 
biocontrol in this way then to develop new products. More research is required, particularly to 
study the effects under commercial conditions. Results should be followed by efficient 
knowledge transfer and 'technical marketing’. This element of IPM implementation could 
offer new solutions in the short term to growers and could increase the use of microbial pest 
control products in general. 
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Abstract 
Commercialization is the final and most difficult step in the development and the introduction 
to the market of a microbial pest control product. I have defined commercialization as the 
management process that provides structure in the developmental process. The critical factors 
that determine success or failure are identified for a company as well as for a product, and 
recommendations are provided that will facilitate success. In the forty years of the history of 
commercial activities with biopesticides, numerous companies have been involved, but few 
achieved success. Highlights of the history of companies and their products are provided, as 
are the currently active manufacturers and an overview of the available products, with 
emphasis on Europe. Figures on the global biopesticide market are reviewed. The European 
market is estimated to be €57 million at end-user level, and the market in the Netherlands at 
€5-6 million. The European biopesticide market comprises less than 1% of the total European 
crop protection market. Most biopesticides are used in protected crops and in orchards; use in 
agricultural crops is starting. Bacillus thuringiensis products are the most successful, for other 
types of biopesticides, profitability seems to be low or lacking. Success and failure factors are 
identified for a biopesticide company. Essential requirements are a full corporate 
commitment, a realistic business plan and sufficient financial resources, an in-depth market 
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knowledge, a profound understanding of the crop-related IPM system in which the 
biopesticide will be used, and knowledge of competitive products. Entrepreneurs who 
contemplate the development and commercialization of a biopesticide need realistic data on 
five key aspects to make their decision: market demand, market size, profit margin, time to 
market, and time to volume. The adoption of a decision process, a stage-gate process, ensures 
a transparent decision-making process that could lead to a more successful business. 
Examples of scorecards are presented to quantify decisions and render them objective by 
rating them on technical and economic probability of success. The outcome will determine 
whether the investment can be returned in an acceptable time frame. Six business models 
have been described from this field of activity. The model that performs best seems to be a 
small company which follows an incremental and manageable growth of the organization. A 
company’s activities can engage various types of biopesticides and related products. It can be 
concluded that the way companies operate and handle risks is decisive for success or failure. 
General limitations as well as strengths are identified for microbial pesticides. The analysis of 
these product features and external factors assists in recognizing the product’s value in the 
market. New technologies can lead to a breakthrough in product development, and improved 
products provide opportunities in new markets. Examples are presented of improvements in 
production and formulation. Total developmental costs and time to market are essential for a 
company’s success. Costs amount to €10-15 million for a company that still needs to be built; 
in an existing company, costs reach €5-10 million. Time to market including registration is 
five to seven years. Collaboration between private and public organizations is imperative, and 
reduces expenses for a company. To introduce a product effectively in the market, committed 
distributors are pivotal. Distributors, who play a crucial role in sale strategies, need to be 
intimately involved before the actual launch. In conclusion, five determinants are identified 
for successful commercialization. These are acceptable expenses and time to market, a high 
quality product that provides function and value, a sufficiently large market, a profit margin 
that allows new development of markets and products, and, the appropriate business 
approach. Only when these conditions are met, a sustainable and profitable business can be 
run. Ten recommendations are provided that increase the chances to become a successful 
enterprise in the field of biopesticides. Requirements for a company to be successful include 
intelligent management, development of a clear strategy, the right balance between risks and 
growth, and a profound knowledge of the product and the market. 
 
 
Introduction  
 
The development and commercialization of biopesticides has attracted many companies 
during the last forty years. Many products have reached the market, but the majority has not 
really been successful. Overall, biopesticides only comprise a small share of the world market 
for crop protection products, 1-2%. Many companies have failed and left this business; some 
remain, but the profitability of the survivors is doubtful. Nevertheless, the biopesticide market 
is steadily growing, by approximately 10% annually. Many people consider the future for 
these products to be positive, due to environmental awareness and the negative perception of 
chemical pesticides in general. Microbial control agents offer an array of opportunities for the 
development of crop protection products. Academic scientists as well as industrial researchers 
have made enormous progress over the years in improving all kinds of biological and 
technical features. Entrepreneurs who are contemplating the development of microbial pest 
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control products, however, face a complex matrix of biological, technical, regulatory and 
commercial challenges. The first two have extensively been addressed in previous chapters, as 
is registration which is still a major hurdle before products can be introduced in the market. In 
this chapter I will address the critical factors in the process of commercialization that 
determine success or failure. I consider a company successful when the production and sale of 
a biopesticide provides a sustainable, growing, and profitable business which is able to 
develop new markets and products. Both product and company determine whether success 
can be achieved.  
 The concept commercialization is frequently mentioned in papers on the development 
and use of biopesticides. In general, authors refer to commercialization as the whole process 
of product development including all its stages, and further, registration and market 
introduction (Törmälä, 1995; Carlton, 1996; Cross and Polonenko, 1996; Stewart, 2001; 
Montesinos, 2003; Fravel, 2005). This broad concept is confusing and meaningless, and in no 
way assists in understanding what it takes to commercialize a new product in a business 
environment. I separate new product development, as described in chapters two, three, four 
and six, from the commercialization process. To distinguish these developmental and 
operational aspects from the task of bringing a new product to the market I will use a 
narrower definition here: commercialization is the management process that provides 
structure in developing and bringing a new product to the market. Effective implementation of 
this step-by-step process is needed to coordinate the gathering of information, the 
establishment a project plan, the taking of decisions, and the translating of these into 
resources, operational requirements and functions, and the coordination of these activities to 
bring the product to the market in an economical and profitable way.  In this chapter I will 
focus on the business and management aspects of this commercialization process. Further, the 
history of biocontrol companies and entomopathogenic products is presented with an 
emphasis on the European market. The currently active companies as well as the available 
products based on bacteria, fungi, baculoviruses, and nematodes will be briefly presented. 
 Reliable data on the size of the biopesticide market are hard to find. Only direct industry 
surveys have been able to report reliable data (CPL, 2007a). Recent data will be reported, 
particularly for the most important protected crop markets, the Netherlands and Spain. 
Microbial pest control products are predominantly used in niche markets which will be 
reported. Use in agricultural crops is limited, but it is slowly increasing. This demonstrates 
that these products have a role to play in any crop. For a long time, the Bt products have been 
the most successful products. The importance of products based on other entomopathogens is 
briefly discussed. An analysis is made on the profitability of the industry based on the total 
sales and the number of available products in the European market. This analysis leads to the 
question why some companies are successful and others not. The most critical factors from a 
commercial point of view will be highlighted. 
 Companies that are contemplating the development of a microbial product need to make 
a final decision to start. Determinative factors related to the new product and the potential 
market will be identified and discussed. A decision process that facilitates making the right 
decision will be introduced. Various types of enterprises from small to large multinational 
companies have engaged in developing biopesticides. Gelernter (2005) reviewed the history 
of this field of business where many failed. I will present an analysis on which business 
model is most suited to perform well in the challenging area of biological crop protection. 
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 Microbial pesticides are often criticized on many of their characteristics which limit 
their adoption in the market. Their strong and weak aspects will be reviewed, as well as new 
developments and technological breakthroughs that could lead to better products.  
 The development and registration are expensive and lengthy procedures that need to be 
conducted before any sales will generate income. A realistic estimate of the expenses and the 
time to market is critical for a company in the business plan and will influence the decision 
process. Every product is unique and forecasts provided in the literature vary greatly. I will 
provide an estimate for various situations and types of products. 
 The development and commercialization of each microbial pest control product is 
different and unique. Five decisive success factors are identified and discussed in the 
conclusions. When these five factors are carefully observed, the likelihood that a company 
will perform well, increases. Finally, I will provide ten recommendations that facilitate the 
development of a successful product, and company requirements that are necessary to 
accomplish a profitable and sustainable business.   
 
 
The historical development of biopesticide companies and microbial pest control 
products  
The development of a biopesticide company and a microbial pest control product are 
inextricably linked. The development of a novel product to solve a pest problem, or a 
fortuitous discovery that potentially leads to an innovative product could lead to the 
establishment of a new company, or a new department in an existing company. Potential 
products that can be commercialized will be the incentive. In the early days of this industry, 
research ideas from public research generally motivated committed persons to initiate product 
development and commercialization, and often lead to the establishment of a company. The 
early steps in applied insect pathology leading to the development of microbial insecticides 
have been reviewed by Lord (2005). He highlighted the discovery and the initial use of 
entomopathogenic bacteria, fungi, nematodes, and viruses, and the commercialization of the 
first products around the world. His review predominantly focussed on the research side of 
microbial insect control. Reviews on commercialization of microbials and the companies 
involved have been presented by many authors. Comprehensive overviews are provided by 
Burges (1971, 1981b), Payne (1987), Rodgers (1993), Starnes et al. (1993), Hall and Menn 
(1999), Butt (2002), and Szewczyk et al. (2006). The commercial development of nematode-
based products and the producers are reviewed by Georgis (2002), Ehlers (2003, 2007) and 
Kaya et al. (2006). Important historical discoveries and events in the biopesticide industry are 
listed by Thakore (2006). Success stories in biocontrol, including microbial biocontrol, are 
reported by Gurr and Wratten (2000). Interesting and instructive cases that involve 
companies’ stories are provided by Vincent et al. (2007).  
 
History of the biopesticide industry 
Numerous enterprises have been active in the field of biopesticide production and marketing. 
Lisansky (CPL, 2006b) listed nearly four hundred companies worldwide which manufactured 
and/or marketed biopesticides (broad definition) between 1980 and 2006. The companies 
involved in the early period of biopesticides and some of their histories have been presented 
in papers of Lisansky (1997), Lisansky and Coombs (1994), Rodgers (1993), Starnes et al. 
(1993), Gelernter (2005), and for nematodes, in papers of Georgis (2002) and Ehlers (2007). 
More than 200 companies have been active in the last two decades in this field (Harwood et 
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al., 2007); a considerable number remains active to date. In Europe eighty-two manufacturers 
were identified, and their activities and products have been described in The Biopesticide 
Companies of Europe (CPL, 2007b). The earlier edition of this report (2002) listed just twenty 
companies. Many different types of companies such as companies primarily active in the field 
of agrochemicals, pharmaceuticals, fertilizers, and several other areas, have engaged in the 
production of microbial pest control products. Others just specialised in biocontrol. Interest in 
the development of biopesticides increased in the 1980’s and early 1990’s, when large 
(agrochemical) companies and venture capital companies became active in this area, 
predominantly in the USA. Business interest in biocontrol was peaking and research resources 
seemed inexhaustible (Gelernter, 2005). Large agricultural markets were envisaged, but 
projections of sales never met expectations (Lisansky, 1997). Many companies overestimated 
their insight in crop protection markets, and most of these companies left the biocontrol field 
or went bankrupt. Interest waned in the large agrochemical companies; they changed their 
focus to transgenic crops. Small biocontrol companies continued the effort.  
 Gelernter (2005) reviewed fifty years of biocontrol products and companies. She 
divided this period in three eras: the pioneering era; the era in which large agrochemicals and 
venture capital companies explored this field without success; and the period since 1995 
where primarily small companies try to be successful. She concluded that the incorrectly 
perceived size of the market has been leading these developments. With a more realistic 
approach, a small group of ‘feet on the ground’ entrepreneurs continue to develop the 
biocontrol market. The biopesticide industry, if one could call it this, consisted and still 
consists of a diverse group of players. It has gone through periods of turmoil and many 
changes. This illustrates that this sector is a young sector which faces many challenges in a 
field where survival and sustainable business is far from easy to achieve. However, the 
agrochemical world has gone through many of the same challenges and many companies have 
disappeared. Only a handful is still active and developing new products (Pallet, 2005).  
 
Currently active biopesticide manufacturers 
An accurate picture of the currently active biopesticide manufacturers is very difficult to 
provide. Every year, new ones enter this field and others leave. Acquisitions of products and 
whole companies occur frequently. The status of companies in North America and Western 
Europe is well known, but for the rest of the world it is impossible to provide reliable 
information. There are two industrial associations of the biopesticide industry. The global 
International Biocontrol Manufacturers Association (IBMA), founded in 1995, has about 
hundred sixty members from all over the world. In Europe, approximately thirty members are 
producers of microbial pesticides. The Biopesticide Industry Alliance (BPIA) in the USA has 
more than fifty members, of which about ten produce of microbial pesticides. Other members 
of these associations have activities in the field of macrobial pest control products, 
pheromones, and natural or biochemical plant protection products. 
 Detailed information (history, products, and markets) on individual biopesticide 
manufacturers has been provided in a small number of market reports such as Frost and 
Sullivan (2001) and The 2007 Biopesticides Study of CPL (CPL, 2007a). The Frost & 
Sullivan Study (2001) presented an elaborate picture of the main companies with background 
information, products, and market shares. The CPL study described history, structure, 
products and markets of a company in a detailed manner in the volumes on biopesticides 
companies (CPL, 2007a). BCC Research (BCC, 2006) provided mainly information on 
American companies including transgenic crop producers. These reports are very expensive 
Critical factors in successful commercialization 
___________________________________________________________________________ 
 
231 
and not widely available in libraries. A worldwide list of manufacturers of microbial 
pesticides is provided in the Directory of Microbial Pesticides for Agricultural Crops in 
OECD Countries (Tabaluk and Gaznik, 2007). In general, these reports focussed on the 
biocontrol industry in the Western world. The latest report of CPL (CPL, 2007a) provided 
volumes with company information for Europe, for North America, for Latin America, for 
Africa and the Middle East, and for Asia and Oceania. Most companies nowadays provide a 
website with elaborate information on their history and on their current products and 
activities. 
 I will focus on manufacturers of microbial insecticidal products in Europe, and on non-
European manufacturers that market microbial insecticides in Europe. It is, however, not 
always clear whether companies manufacture products themselves, or whether production 
and/or formulation are out-contracted, or whether products are purchased and marketed. I 
present here the companies involved in bioinsecticide production in table 7.1 and 7.2. The 
types of bioinsecticides are mentioned in the order of importance within a certain company. I 
only list those who are active in Europe with officially registered products (see also chapter 5, 
table 5.1), and the producers of entomopathogenic nematodes. EPNs are produced by three 
large producers, Becker Underwood, Enema, and Koppert. All three market their products on 
the European and American market. Three small producers, Andermatt, Bionema, and 
Owiplant, mainly sell in their domestic market. The first three produce three to nine species, 
and use submerged fermentation for the manufacturing process, while the small ones only 
produce one species, using the solid medium technology. 
 
 
Table 7.1.   European manufacturers of microbial pest control products 
 
Company Production Company Production 
Andermatt (CH) BV, Fungi (I), EPN Koppert (Nl) EPN, Fungi (I, F) 
Agrifutur (It) Fungi (I, F) NPP-Arysta (Fr) BV, Fungi (I) 
Biocolor (Sp) BV Owiplant (Po) EPN 
Bionema (Sw) EPN Probelte (Sp) Bt 
Becker Underwood (UK) EPN Probis (Ge) BV 
Enema (Ge) EPN, Bact (I), Fungi (F) Schweizer (CH) Fungi (I) 
FuturEco (Sp) Fungi (I) Sipcam (It) BV 
Intrachem (It) Bt, Fungi (I, F) Sourcon Padena Bacteria (F) 
BV- baculoviruses;  EPN- entomopathogenic nematodes;  I - bioinsecticide;  F- biofungicide; 
 
Table 7.2.   Non-European manufacturers of microbial pest control products, 
         active on the European market 
 
Company Production 
Becker Underwood (USA) EPN, Fungi (I) 
Certis USA Baculoviruses, Bt, Fungi (I, F) 
Laverlam (Colombia) Fungi (I, F) 
Novozymes (USA) Fungi (I) 
Valent BioSciences (USA) Bt 
   EPN- entomopathogenic nematodes;  I- bioinsecticide;  F- biofungicide 
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 A number of companies produce other microbial pesticides such as products for control 
of foliar and soil-borne diseases, for post-harvest diseases, or for control of nematodes. The 
following European companies are active with this type of biocontrol products: Agrauxine 
(Fr), Arcadis (Nl), Binab (Sw), BioAgri (Sw), Bio-ferm (At), Bionext (Be), Biopreparaty 
(Cz),  Isagro (It), NewBiotech (Sp), Prophyta (Ge), Sourcon-Padena (Ge), and Verdera (Fi). 
Two American companies are active in the European market with biofungicides: Agraquest 
and BioWorks. Bioherbicides are not manufactured in Europe.  
 A small number of companies are active in various biocontrol activities, while others 
specialize in one type of products. For instance, Koppert produces macrobial, microbial and 
natural products for plant protection. Andermatt Biocontrol produces mainly baculoviruses; 
Prophyta only fungal products, and Verdera microbial fungicides. A specialization in 
production technology occurs as well as a specialization in market approaches with 
bioinsecticides or biofungicides. Many combinations of activities are found in manufacturing 
activities as well as in the marketing of products. Certis, Isagro, Natural Plant Protection-
Arysta LifeScience and Sipcam also manufacture and market chemical pesticides. Some 
producers present themselves as toll manufacturers only, such as Vitalin (Ge) and ELPE (It). 
Others like Enema and Prophyta produce their own products as well as products or 
unformulated active ingredients for third parties. Remarkably, more new companies are 
starting in the field of disease control than in insect control. Examples are Agrauxine, Bio-
ferm, BioNext, NewBiotech, and Sourcon-Padena. Occasionally, companies from other parts 
of the world try to market their products in Europe. Companies from India, South-America, 
Israel, Kenya, and South Africa have tried to market their products in Europe, but the difficult 
and expensive registration procedure withholds them still. When this will become easier in the 
future, these companies will surely become active on the European market. I do not expect 
that in the next decade.  
  
Overview of currently available products 
A comprehensive overview of available products worldwide is provided by Copping in 
subsequent editions of the Biopesticide Manual/Manual of Biocontrol Agents (Copping, 1998, 
2001, 2004, 2009). These editions listed 59, 96, 110 respectively 149 microorganisms on 
which biopesticides are based. Product availability per country is provided in the market study 
in the Biopesticide series of CPL (CPL, 2007a). A list of products and producers is provided 
in the Directory of Microbial Control Products and Services of the Society of Insect 
Pathology (Shah and Goettel, 1999) and in the Directory of Microbial Pesticides for 
Agricultural Crops in OECD Countries (Tabaluk and Gazdik, 2007), but both lists are not 
very accurate with regard to currently registered and available products. The situation is 
continuously changing, however, and a correct picture of the producers and distributors and 
the registered products is difficult to provide. Producers may stop, may be taken over or 
merge; products may fail, may be withdrawn, but are still listed as registered. At any time, a 
report on this subject may be outdated soon after publication. There are no official data banks 
that provide regularly updated information. Data bases of regulatory authorities provide the 
number of registered products, but products are not necessary “alive” as is the case for 
instance with Bt products in the USA: only about 230 out of 469 registered labels are 
marketed actively (Braverman, 2007). Nor do the IBMA and BPIA provide any commercial 
information due to confidentiality.   
 Many authors described the commercial developments with microorganisms as MPCPs 
and listed the available products at a certain time. I will only refer to papers that describe the 
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situation over the last ten to fifteen years since the registration status and commercial 
availability of products change frequently. Authors that reported a general overview are Butt 
et al. (1999, 2001), Copping and Menn (2000), Wraight et al. (2001), Hynes and Boyetchko 
(2006), Rosell et al. (2008); and for nematodes Ehlers (2003) and Kaya et al. (2006).  For an 
overview of products based on entomopathogenic bacteria, I refer to Glare and O’Callaghan 
(2000) and Navon (2000). A comprehensive overview of the status of fungal products for 
control of insects and mites is presented by De Faria and Wraight (2007). They listed 171 
products and 80 manufacturers and updated availability and the registration status of these 
products worldwide. Approximately 43% of the products were developed in South America. 
Swewczyk et al. (2006) presented the worldwide historical development and the current 
situation of insecticides based on baculoviruses. Kaya et al. (2006) outlined the status of 
EPNs and their uses for most regions of the world. 
 Below I will describe the history of microbial insecticides in Europe, and the situation at 
present. Biofungicides seem to be the largest group of products on the market currently. For 
an overview of microbial disease control products I refer to Whipps and Davies (2000), 
Stewart (2001) and Fravel (2005). The status of microbial products for control of foliar and 
soil-borne diseases in greenhouse systems is reported by Paulitz and Bélanger (2001) and 
Ravensberg and Elad (2001). Bioherbicides are conspicuous by their absence in both the EU 
and elsewhere (Hallett, 2005). One bionematicide, BioAct, is registered in the EU, but sales 
are small and limited to greenhouse crops (www.prophyta.de). Two microbial products for 
post-harvest disease control are available on the market. A few have disappeared and some 
are under development. The use of those products is limited and their commercialization faces 
many obstacles and constraints similar to the ones for other biopesticides (Droby et al., 2009).   
 The development and commercial availability of microbial products has also been 
described per region and per country. The situation for the USA is described by Carlton 
(1996). The use of entomopathogenic microbials in greenhouse crops has been presented by 
Lipa and Smits (1999) for Europe, USA and Japan. In Canadian greenhouses, use of 
biopesticides is limited to Bt and nematodes for control of fungus gnats (Shipp et al., 2007). 
An overview of all available microbial biopesticides in Canada is provided by Bailey et al. 
(2009). The current status of microbial control in South-East Asia is provided by Gelernter 
(2007) and Skovmand (2007). The status of microbial insecticides for Japan is reported by 
Kunimi (2007), for China by Huang et al. (2007) and Li et al. (2010), for India by 
Vasantharaj David (2008), for South America by Alves et al. (2003), for Latin America by 
Rodríguez and Niemeyer (2005), for Brazil by Li et al. (2010), and the use and perspectives 
for Africa are provided by Cherry and Gwynn (2007). Some information on the use of Bt and 
baculoviruses in Spanish greenhouses is provided by Van der Blom (2009). The availability 
and use of biopesticides in the UK is provided by Gwynn (2009). The status and use of 
entomopathogenic nematodes is provided by Kaya et al. (2006) for many regions in the 
world. For many countries and regions recent overviews on the availability and use of 
microbial pesticides are lacking.  
 
Bacterial insecticides 
The first bacterial insecticide was based on Bacillus popilliae (=Paenibacillus popilliae) and 
developed for control of larvae of the Japanese beetle. It was developed by the USDA in the 
mid-1940’s, and the first registered biopesticide in the USA in 1948. The product ‘Milky 
Spore Powder’ was produced by Fairfax Laboratories until recently (Lord, 2005), and is still 
available through St. Gabriel Laboratories (www.epa.gov). The first bioinsecticides on the 
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European market were Bacillus thuringiensis (Bt) products. The history of the development of 
Bt as a bioinsecticide has been reviewed by numerous authors (e.g. Burges, 1981, 2001; 
Beegle and Yamamoto, 1992; Navon, 2000; Federici, 2005; Coté, 2007). Lord (2005) 
summarized the highlights with regard to applied aspects and reviewed the development of 
the first products. The first commercial product, Sporeine, was developed in France in 1938, 
but it was only briefly available just before World War II. Later, in the 1960’s, a number of 
companies around the world commercialized Bt products with various degrees of success 
(Lambert and Peferoen, 1992; Lisansky and Coombs, 1994). Thuricide was the first registered 
product for control of caterpillars in the USA in 1961. In Europe, the development and 
production was started by large agrochemical companies, such as Solvay (Belgium) and 
Sandoz (Switzerland). Thuricide was registered in 1964. In the 1970’s Dipel and Bactospeine 
reached the market. Solvay marketed their Bt through their affiliates Biochem Products and 
Duphar, but sold the business to Novo Nordisk (Denmark). Novo Nordisk sold its Bt business 
in 1995 to Abbott Laboratories. Valent BioSciences (USA), which is part of Sumitomo 
Chemical (Japan), took over the Bt business from Abbott Laboratories in 1999, and became 
the largest Bt producer worldwide. Sandoz merged with Ciba Geigy and later became 
Novartis, which merged with Zeneca into Syngenta. The Sandoz/Syngenta product line was 
acquired by Thermo Trilogy in 1997. A few years later, the biopesticide business of Thermo 
Trilogy was acquired by Certis USA, a subsidiary of Mitsui & Co, Japan. Certis also 
purchased Ecogen‘s product line in 2002, which also contained products based on 
transconjugant and recombinant Btk strains.  
 A number of companies currently market Bt products in the European market. Valent 
BioSciences markets their products, mainly Dipel and XenTari, through distributors. Certis 
uses its subsidiaries and distributors for their product Turex. Intrachem, Isagro and Probelte 
are marketing their own Bt products. Intrachem developed three formulations based on one 
strain EG 2348: Lepinox Plus, Rapax and Wormox. The strain is included on Annex I and 
product registrations have been obtained in a number of European countries (Ladurner et al., 
2008).  
 
Fungal insecticides 
The first fungal insecticide, actually an acaracide, was Mycar, a product based on the fungus 
Hirsutella thompsonii, for control of rust mites in citrus in Florida, USA. It was manufactured 
by Abbott Laboratories, and was registered in 1981. The product was, however never 
commercially successful and was withdrawn in 1985 (McCoy et al., 2009). At the same time, 
similar developments started in Europe. Tate and Lyle, a large food ingredient and sugar 
manufacturer, started with the development of entomopathogenic fungi and Bt’s in the mid 
1970’s in the United Kingdom. Two fungal products were registered in 1981 in the United 
Kingdom and marketed in the greenhouse sector: Vertalec for the control of aphids, and 
Mycotal for the control of whitefly. A third product for the control of thrips, Thriptal, never 
made it to the market. All products were based on strains of Verticillium lecanii. In 1984 the 
biopesticide department was turned into an independent small venture capital company called 
Microbial Resources Limited (MRL), because the interest of the parent company in this 
business faded due to lack of revenue. MRL did not make it and all the registrations and 
technical know-how were sold in 1986 to Novo Industria (S. Lisansky, pers. comm.). This 
Danish company did not develop the products any further and in 1988 Koppert bought the 
intellectual property rights of the fungal products and initiated the production and marketing 
of Mycotal and Vertalec. Tate and Lyle as well as Koppert investigated the production of 
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Aschersonia aleyrodis for whitefly control, but a product was never brought to the market. 
Production was complicated and expensive, and the efficacy was not greater then that of 
Mycotal. A Danish company, Christian Hansen’s Biocontrol, also developed products based 
on V. lecanii. The product MicroGermin consisted of an aphid and whitefly strain and was 
produced and marketed in Denmark for some time, but production was later discontinued 
(Butt et al., 1999). Currently, there are two products on the market: Vertalec and Mycotal, 
both produced and marketed by Koppert. Vertalec will have to be withdrawn from the EU 
since the strain has not been defended; the Mycotal strain is included on Annex I. 
 The large German agrochemical company Bayer showed an interest in biopesticides and 
developed a product based on Metarhizium anisopliae strain F52. Their first product was 
Bio1020 for control of black vine weevil larvae (Reinecke et al., 1990). The intention was to 
develop more products based on this fungus for control of whitefly and thrips, but this did not 
succeed. The management lost interest in this kind of products and a new company was 
formed, Taensa (USA), that took over the business. This small company failed and was 
bought by EarthBiosciences (USA). After a few years, all IP was again sold to Novozymes 
(USA). In 2008, this company re-launched Bio1020 in Germany and the Netherlands and 
seems committed to continuing with these products. They defended the strain in the EU re-
registration process successfully. There are two formulations: a granular and an emulsion 
concentrate. The product was launched as Met52 in the USA, and they also market a product 
Tick-Ex against ticks in the USA. Agrifutur, Italy, produces a granular formulation called 
Granmet for control of white grubs. Currently, there are two products on the EU market: 
Bio1020 and Granmet, based on the same strain, Bipesco5/F52, which is included on Annex I. 
In Switzerland, a third product, Metarhizium Schweizer produced by Schweizer Seeds, is 
available for grub control. 
 In 1999, Biobest received approval for Certis’ product PreFeRal, a mycoinsecticide 
based on Isaria fumusorosea (=Paecilomyces fumosoroseus) strain ‘Apopka 97’ for control of 
whitefly in greenhouse crops in Belgium (Sterk et al., 1996). This was the first 
microorganism to obtain Annex I inclusion in 2001 according to the new EU Directive 
91/414/EC. Futureco (Spain) submitted a dossier for strain ‘Fe 9901’ of I. fumusorosea (P. 
fumusoroseus) in 2005 for Annex I inclusion, and applied for provisional approval for the 
product Nofly for whitefly control in several countries. Approval has been obtained in 
Belgium. Currently, there are two products on the European market: Preferal and Nofly. 
 The first product based on the fungus Beauveria bassiana was developed in France by 
Natural Plant Protection, a subsidiary of Calliope, now part of Arysta LifeScience, Japan. The 
product Ostrinil was a granular formulation for control of the corn borer in corn. It was 
registered in France in 1993. Production was discontinued for sometime, but the product will 
be re-launched for control of the palm borer Paysandisia archon (Besse, 2008). Boverol was 
produced and registered by Fytovita in the Czech Republic for use against the Colorado 
potato beetle and the spruce bark beetle, but this strain was not defended in the re-registration 
programme of the EU and therefore will have to be withdrawn from the market. Botanigard is 
another product based on B. bassiana and developed by Mycotech, USA, which was acquired 
in 2004 by Laverlam, Colombia. It was brought to the European market by Certis Europe for 
the greenhouse market. There is a liquid formulation and a wettable powder, both for whitefly 
and thrips control in vegetables and ornamentals. These were first registered in the 
Netherlands and are now available in a few more countries. Naturalis, another product based 
on a different strain of this fungus, was developed in the USA by Troy Biosciences and was 
marketed in Spain and Italy by subsidiaries of Intrachem, Switzerland. Troy Bioscience no 
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longer exists and the IP is now in the hands of Intrachem. Currently, there are two products on 
the European market: Botanigard and Naturalis based on annex I included strains. 
 Some products have been developed and commercialized based on B. brongniartii. 
These were Melocont, produced by Agrifutur, Italy, and marketed by Kwizda, Austria. This 
strain was not defended and the product will have to be withdrawn. In Switzerland, two 
products were developed, Beaupro produced by Andermatt Biocontrol, and Beauveria 
Schweizer from Schweizer Seeds. All these products were applied to control white grubs of 
the May beetle. Currently, there are two products on the market, but only in Switzerland. The 
one that is marketed in the EU will have to be withdrawn by 2014 at the latest. 
 
Baculovirus-based insecticides 
The first product, Elcar, was developed by Sandoz in the USA and marketed from 1975-1982. 
It was later re-launched in 1996 by Biosys as Gemstar. Currently, it is sold by Certis USA. It 
is applied against Heliothis and Helicoverpa species in field crops. The past and present of 
baculovirus products have been reviewed by Arif (2005) and by Szewczyk et al. (2006). 
Many baculovirus products have been developed for agricultural crops around the world 
(Hunter-Fujita et al., 1998; Moscardi, 1999; Copping, 2004, 2009). In Europe, the main use of 
viruses is with products based on Cydia pomonella GV against of the codling moth, in apple 
and pear orchards. Baculovirus products have been developed for control of Lepidopteran 
larvae and sawfly larvae in forestry too. Production and application were often conducted by 
public forestry departments, some products were developed by companies. Most of these are 
no longer produced and sold (Evans, 1997b; Moscardi, 1999).   
 For protected crops, the first baculovirus product, Spod-X, was registered in 1994 in the 
Netherlands for control of the beet army worm (Spodoptera exigua) in greenhouse vegetables 
and flowers. It was first produced by Crop Genetics, USA; currently it is produced and 
marketed by Certis USA. The registration is pending for the product in Spain for use in 
greenhouse vegetables. Other Spodoptera exigua NPV products developed are Virex and 
Spexit, produced by Biocolor, Spain, respectively Andermatt Biocontrol, Switzerland. Today, 
there are nine products on the market in the EU, the three mentioned SeNPV products, and 
five CpGV-based products: Madex (Andermatt), Cyd-X (Certis Europe), Carpovirusine 
(Natural Plant Protection (NPP)), Granupom (Probis) and Virgo (Sipcam). Furthermore, 
Andermatt produces Capex, which is based on the Adoxophyes orana GV, for control of 
summer fruit tortrix in apples. It is available in five European countries. Two other virus 
products, Littovir based on the Spodoptera littoralis NPV, for control of S. littoralis and, 
Helicovex based on the Helicoverpa armigera NPV, for control of cotton bollworm, are being 
developed by Andermatt (Kessler, 2008). 
 
Entomopathogenic nematode-based products 
The first nematode-based product contained Steinernema glaseri and was produced by the 
USDA in the USA. It was released on large areas for grub control in the 1930’s (Lord, 2005). 
The commercialization of nematodes started in the 1980’s after Bedding had developed a 
semi-artificial medium (Bedding, 1984). The company Bioenterprises in Tasmania was the 
first to sell nematode-based products with H. bacteriophora. Simultaneously, commercial 
production started in Europe in the Netherlands. Koppert and De Groene Vlieg started 
production of H. megidis and S. feltiae on ‘the Bedding-system’ in the mid 1980’s and sold 
nematodes for control of black vine weevil and Sciarid larvae. Koppert produces three species 
today: S. feltiae, S. carpocapsae and H. bacteriophora. De Groene Vlieg stopped the 
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production of nematodes in the nineties. Research in the UK also led to commercial interest, 
and the company AGC MicroBio started to produce and sell nematodes (S. feltiae) for 
horticulture and mushroom production in 1989. Later, they developed a nematode product for 
slug control. MicroBio was taken over by Becker Underwood, USA, in 2000. At present they 
produce eight different species of entomopathogenic nematodes and one slug-parasitic 
nematode. Bionema, a small Swedish company, produced nematodes from 1988 until today. 
They produce S. feltiae and S. carpocapsae, and sell to the non-professional market.  
Andermatt Biocontrol started to produce nematodes on solid medium in 1989 and still 
produces H. megidis, a species that is difficult to produce in fermentors. In Poland, Owiplant 
started producing S. feltiae in 1994 for use in horticulture and mushrooms. The three latter 
mentioned companies still produce nematodes on a small scale on solid medium. Enema, 
Germany, was founded 1997 (Ehlers, 2007), and currently produces three species: S. feltiae, 
S. carpocapsae and H. bacteriophora. 
 In the USA, two venture capital enterprises were established to produce nematodes, 
among others. Both Biosys and Ecogen were founded in 1983. Biosys was the first to produce 
nematodes by large-scale liquid fermentation, and launched a S. carpocapsae-based product 
in 1988. Later, four other species were developed: S. feltiae, S. glaseri, S. riobrave, and H. 
bacteriophora (Georgis, 2002). Ecogen took over Bioenterprises in 1992 and set up 
subsidiaries in Germany, Israel, and Italy in order to develop nematode-based products, in 
addition to other biopesticides. Ecogen also started production in submerged fermentors and 
developed several products. Both companies failed eventually. Biosys went bankrupt in 1996 
(Georgis, 2002), and was bought by Thermo Trilogy. This company was acquired by Mitsui 
& Co, Japan, in 2001 and was renamed Certis USA. Ecogen closed its subsidiaries in 1996 
and scaled down its research and activities on nematodes. The company sold its remaining 
nematode business in 2002 to Certis. In 2005, Becker Underwood acquired Certis’s nematode 
business.  
 Some small producers in the USA produce nematodes on solid medium such as 
BioLogic Company, or even on insects, such as Hydro-Gardens (Kaya et al., 2006). In 
Europe, three companies produce nematodes in large-scale submerged fermentors. These are 
Enema, Koppert, and Becker Underwood, USA, which has its production facility in the UK. 
They dominate the world market today. Ten species of entomopathogenic species (five 
Steinernema and five Heterorhabditis species) are being produced at present (Kaya et al., 
2006). The various uses of these nematodes are provided by Georgis et al. (2006). Companies 
generally produce a single strain per species; various companies use the same strain. Also, 
local strains have been developed and are produced. Strain identification is usually not 
mentioned by companies nor is it clear which strain is present in a product. Species that are 
commercially available in Europe are H. bacteriophora, H. megidis, S. carpocapsae, S. 
feltiae, and S. kraussei. A new species, H. downesi, is under development for control of the 
pine weevil (Dillon et al., 2007) by several companies. 
 
 
Overview of current use of microbial pest control products 
 
Global microbial pesticide market 
Reliable figures for the global use and markets for biopesticides are not available. At best, 
fragmented information is available. Information on sales in Europe and North America is 
probably the most reliable. Gelernter (2007) estimated these markets together to value $200 
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million in 2003, and sales in the rest of the world to be equivalent or more. Sales of 
biopesticides in South America and Asia are probably considerable, but figures are lacking. 
There are limited sales in Oceania, while estimates of sales in Africa are low. Industry 
organizations such as IBMA and BPIA do not collect market data. Only scattered information 
is available from some governmental authorities. The EU (Eurostat) tried to collect data on 
biological plant protection systems, but the survey did not deliver the required information. 
Companies did not want to share their information due to competition and confidentiality in a 
difficult market. Business consultants such as Frost & Sullivan (2001), Agrow (Evans, 
2004b), BCC Research (2006) and CPL (CPL, 2007a) which work with direct industry 
surveys, probably gather the most reliable data. 
 In 2000, the world market for biopesticides neared $300 million, less than 1% of all 
pesticides. In this study on biopesticides, Frost & Sullivan (2001) included all non-synthetic 
chemical crop protection products such as microbial pesticides, beneficial arthropods, natural 
pesticides, and pheromones. Bt for caterpillar and mosquito control accounted for the majority 
of the microbial sales. Jarvis (2001) estimated the global biopesticide (true microbials) market 
at $160 million in 2000; over 90% were Bt sales. This meant about $16 million for microbials 
world-wide, excluding Bt sales. This estimate seemed lower than that of Frost & Sullivan 
(2001). Guillon (2004) reported a worldwide market for biopesticides (bacteria, fungi and 
viruses) of $235 million, with $31 million in Europe and $109 million in the NAFTA region. 
In a global market study on biopesticides, Thakore (2006) reported a turnover of biopesticides 
of $672 million in 2005. It is, however, not clear which product categories have been included 
in this figure. It seems to be a broad definition including natural enemies, but the table with 
formulation types is confusing since these refer to true microbials. According to the author, 
the share of biopesticides has risen from 0.2% in 2000 to 2.5% of the total pesticide market in 
2006. This share is expected to increase to 4.3% in 2010, reaching greater than a billion 
dollar. Bt had a market share of 70% of the microbials; bacterial biopesticides represented 
74% of all biopesticides, followed by 10% fungal biopesticides, 5% viral, 8% natural 
enemies, and 3% “others”, including nematodes. Harwood et al. (2007) reported the global 
biopesticide (true microbials) market to be about $280 million in 2007. In the past, Bt 
dominated this market with a 90% share, but this has gone down to 60%. This is partly 
accounted for by the rise of transgenic Bt-crops, and partly because the use of other 
biopesticides has increased. Evans (2008) reported that annual sales of microbial pesticides 
are $750 million globally, amounting to 2.5% of the chemical market. The crop protection 
market is increasing considerably after years of declining sales. The total of pesticide sales in 
2008 was over $40 billion with a growth rate of 21% (CPM, 2009a).  
 Few of the authors that report data on the use of biopesticides clearly presented how they 
defined biopesticides. Nor is it indicated whether amounts mentioned refer to manufacturer 
level or end-user level, and this makes quite a difference. Generally, figures of end-use 
markets are provided. Obviously, there are no reliable data on the biopesticide markets. 
Nevertheless, trends can be observed and sales are steadily increasing from about $150 
million in 2000 to more than $500 million in 2008 (table 7.3).  
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 Table 7.3.  Overview of reported worldwide sales per annum of biopesticides 
 
Year of 
sales 
Sales (in  
million $) 
Definition of 
biopesticides 
Source 
2000 300 broad Frost & Sullivan, 2001 
2001 160 microbials Jarvis, 2001  
2003 235 microbials Guillon, 2004 
2005 672 broad (?) Thakore, 2006 
2006 280 microbials Harwood et al., 2007 
2006 400 microbials Gelernter, 2007 
2008 750 microbials (?) Evans, 2008 
 
 
The European microbial pesticide market 
In Europe, sales of biopesticides including beneficials, microbial pesticides and pheromone 
products were $97 million in 2000 - about 2% of the total European pesticide market. Sales of 
microbials were $25 million. In the category of microbials “soft” pesticides were also 
included such as fatty acids (Frost & Sullivan, 2001). The authors expected annual growth of 
11.7 % leading to about $210 million in 2007 for all biopesticides in Europe. Guillon (2004) 
reported that in Europe in 2004 the market for biopesticides (bacteria, fungi and viruses) 
amounted to $31 million. According to Thakore (2006), the European market is estimated to 
represent $135 million in 2005; this market is expected to grow the fastest to $270 million by 
2010. This figure is most likely based on a broad definition of biopesticides. 
 Lisansky (CPL, 2006a) reported that in Europe annual sales of microbial- and 
nematode-based pesticides were estimated to be around $43 million at user-level in 2005. The 
share of Bt-based products has declined from an estimated 90% in 2000 to 72.4% in 2005. 
The fastest growing products have been nematodes and baculoviruses; where sales of both 
may have doubled since 2000 to reach $6 million and $5.45 million respectively. By 
comparison, the North American market for microbial- and nematode-based biopesticides is 
estimated to be worth US$110 million at user-level in 2004, with a Bt share of 67%. The total 
pesticide market in Europe was $12.8 billion in 2008 as a reference (CPM, 2009a). Thus the 
microbial pesticide market is approximately 0.5%. The largest individual European 
biopesticide market is Spain, followed by France and Italy. Although overall growth in the 
biopesticide market has not met expectations of the past, Lisansky (CPL, 2006a) expected the 
potential to remain high and that the total market could rise to $200 million by 2015. Table 
7.4 provided the most recent estimates for the European market. In the project ENDURE (the 
European Network for the Durable Exploitation of Crop Protection Strategies, a network of 
excellence funded by the EU) IBMA made an estimate of the biopesticide market in Europe 
through a farmers survey, figures are presented in table 7.4 (B. Blum, pers. comm.).  
 Literature provides little data on the total nematode market. From the report of Frost & 
Sullivan (2001) a $7 million market in 2000 for Europe can be deducted. CPL (2007a) 
reported a worldwide market of $14.65 million for 2005: $8.25 million for the USA and $6 
million for Europe, while almost none for the rest of the world. IBMA estimated the market to 
be around €12 million at the manufacturer level, while my own estimate of  €8 million is 
much lower, even at market level. All these estimates vary greatly, indicating the difficulty of 
obtaining reliable data on the sales of nematode products. Apparently, the competition in the 
market causes producers to keep their information very confidential.  
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Table 7.4.   Estimated sales per annum of microbial and nematode-based pesticides in Europe 
 
Organism Sales estimate 1) in 
2005 (in US $) 
(CPL, 2007b) 
Sales estimate 2) in 
2008 (in €) (IBMA) 
Sales estimate 1) in 
2008 (in €) 
(this author) 
Bt products 26.7 30 
Other bacteria 2.6 3.5 
Fungi  2.2  8 
Baculoviruses 5.5 
 
 
52* 
7.5 
Nematodes 6.0 12 8 
Total 42.9 64 57 
1)- market level;  2)- manufacturer level;  * - total sales of bacteria, fungi and baculoviruses 
 
 
Microbial pesticide market in the Netherlands 
Nefyto, the association of agrochemical companies in the Netherlands, provides figures on the 
use of crop protection products in terms of kg active ingredient. In 2007, biological 
insecticides (in kg a.i.) were reported to be < 0.7 % (biofungicide use is negligible) of the total 
use of insecticides/acaracides (Nefyto, 2008). If microbial pesticide sales from non-members 
were included, the total might be between 1-2%. Annual sales of pesticides account for 
approximately €330 million, biological pesticides only comprise €5-6 million (at end-user 
level). The Netherlands is probably number four or five in the European biopesticide market. 
The use of Bt has decreased tremendously the last few years due to new chemicals against 
caterpillars (J. de Hoog, pers. comm.). Table 7.5 provides sales estimates per pathogen group. 
 
 
Table 7.5.   Estimated sales of microbial pest control products and their main uses in the 
       Netherlands in 2008 
 
Type of pathogen  Sales  Main pests Products Main uses 
Bacteria (Bt) €1 million caterpillars Delphin, Dipel, 
Turex, Xentari,  
Scutello 
protected 
vegetables and 
ornamentals 
Nematodes €1 million thrips, 
Sciaridae, 
black vine 
weevil, 
slugs 
Bionem, Entonem, 
Larvanem, Nemasys, 
Nematop, Nemaplus, 
Nemagreen 
Nemaslug 
protected 
ornamentals, 
nursery, field 
vegetables 
Baculoviruses €1,5 million codling 
moth 
Carpovirusine Plus, 
Cyd-X, Madex 
apple, pear 
Entomopathogenic 
fungi 
€300,000 whitefly, 
thrips 
Botanigard, Mycotal, 
Preferal 
protected crops 
Antagonistic fungi €1,5 million root 
diseases 
Contans, Mycostop, 
Trianum 
protected 
crops, field 
vegetables 
Various €300,000 various Bio 1020, Cerall, 
Dutch Trig, Spod-X 
various crops 
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Figure 7.1.   Division of microbial pesticides in Europe (left) and in the Netherlands (right) 
     in 2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microbial pesticide market for protected crops 
The area under protection for vegetables, ornamentals and soft fruit is estimated to be 
approximately 2.4 million hectares (Van Lenteren, 2006a). Data from China alone reveal that 
about over 2 million hectares of protected crops are grown (Zheng et al., 2005). The 
worldwide acreage of protected crops is still increasing. Biological control with natural 
enemies is successfully used on about 32,000 ha out of the estimated 2.4 million ha in 2006 
(van Lenteren, 2006a). This has increased recently since the adoption of biocontrol in sweet 
pepper in Spain (Van der Blom et al., 2008) to over 40,000 ha. The use of microbials in 
greenhouses is briefly described by Lipa and Smits (1999), Paulitz and Bélanger (2001), 
Ravensberg and Elad (2001), Zheng et al. (2005), Van Lenteren (2006b), Shipp et al.(2007) 
and Van der Blom (2009). Some information is provided by Van Lenteren (2006b) on the use 
of biological control, including microbial insecticides, in various regions and countries.  
 Little information is available specifically on the use of biopesticides in greenhouses. 
Quantitative data in terms of hectares or product sales are lacking in the literature. The main 
products used are bioinsecticides as part of an IPM system (table 7.6). The use of Bt for 
control of caterpillars represents by far the greatest use of microbial products in protected 
crops. Baculoviruses and nematodes are used to some extent against caterpillars. Bti and Btt 
are used on a very limited scale against sciarids, respectively Colorado potato beetle. 
Entomopathogenic fungi are chiefly used for control of whitefly, and to a lesser extent against 
thrips and aphids. Some use is against capsid bugs. Nematodes are used for black vine weevil 
larvae, sciarid larvae, and some other soil-dwelling insects or insects living in cryptic habitats 
such as borers. There are no microbials available for important pests such as spider mites and 
leafminers. Bt is the standard solution in the case of caterpillar control. For other pests, 
microbials are mainly used as corrective or additive measures.  
 Microbial control of diseases is still in its infancy. A number of products is available, 
primarily for soil diseases, but the use of these products is limited (Paulitz and Belanger, 
2001; Ravensberg and Elad, 2001; Stewart, 2001; Fravel, 2005). The use of microbial 
insecticides in greenhouse crops in the Netherlands consists largely of products based on Bt, 
entomopathogenic fungi and nematodes (see table 7.5). The size of the market is estimated to 
be around €3 million at end-user level. Spain and The Netherlands comprise the majority of 
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the protected crops in Europe where microbial insecticides are being used. In Spain, Bt is 
used in greenhouse vegetables against Spodoptera spp. and Helicoverpa armigera, and since 
2009, the market has more than doubled due to the sudden demand for control of Tuta 
absoluta, a new invasive pest in tomato. The total market is approximately €11-12 million at 
end-user level in 2009. Baculoviruses are used against S. exigua in sweet pepper and the sales 
are about €1.3 million in 2009 (J. van der Blom, Coexphal, pers. comm.). Estimates for 
entomopathogenic fungi and nematodes are difficult to provide, but sales are most likely only 
a few hundred thousand Euros for each group. 
 
 
Table 7.6.   Entomopathogens used as bioinsecticides in protected vegetable and ornamental 
    crops in Europe 
 
Micro-organism Target pests Used since Extent 
Bacillus thuringiensis caterpillars 1972 wide scale use  
Bacillus israelensis sciarids 1985 very limited 
ornamentals 
Bacillus tenebrionis Colorado potato beetle 1990 very limited 
Lecanicillium muscarium whitefly, thrips 1981 limited  
Lecanicillium longisporum aphids 1982 very limited 
Beauveria bassiana whitefly 2002 Limited 
Paecilomyces fumosoroseus whitefly 1999 very limited 
Metarhizium anisopliae black vine weevil  2008 very limited 
Spodoptera exigua NPV beet army worm 1994 limited, increasing 
Steinernema feltiae sciarids, thrips  1984 Increasing 
Heterorhabditis megidis black vine weevil  1984 very limited 
Heterorhabditis bacteriophora    black vine weevil 1995 Limited 
Steinernema carpocapsae caterpillars, tipulids  2003 Limited 
 
 
The main crops for microbial pesticides 
Bt products account for about 70% of the bioinsecticide sales. The Bt markets obviously 
represent the main markets for biopesticides: forestry, field vegetables, protected crops, and 
the use for vector control. The use of viruses in orchards is an increasing market. Nematodes 
are used in a variety of crops such as protected crops, mushrooms, lawns, hardy ornamentals 
and forestry (Georgis, 2004). Use of slug nematodes is an example of use in agricultural crops 
such as wheat, Brussels sprouts, and potatoes. These nematodes are also sold for use in home 
gardens. Entomopathogenic fungi are mainly used in protected vegetables. Biopesticides have 
predominantly been used in niche markets, like high value crops such as protected crops, 
berries, and fruit crops. Thakore (2006) stated that orchard crops represent the largest share of 
biopesticide use at 55%. MPCPs used in orchard systems are reviewed by Lacey and Shapiro-
Ilan (2008). Biopesticides have had great successes in forestry where chemical insecticides 
are not practical or acceptable. This is likely to be an expanding market for biopesticides  
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although application techniques and budgets are limiting factors. Currently, however, use in 
agricultural crops is increasing and this is a promising signal. Disease control products like 
Contans and Cedomon are used in agricultural crops such as oil-seed rape and sunflower, 
respectively cereals. The use in forestry is also developing with disease control products and 
nematodes. The organic market represents just a small proportion of the biopesticide market; I 
estimate less than 10%. Braverman (2007) reported that only 3% of all biopesticides used in 
the USA are applied in the organic market.  
 
Successful entomopathogenic products 
The most successful bioinsecticides are undoubtedly the Bt products. They are “the simplest 
to produce and use” (Burges, 1981), and applied in many crops and environments on a 
worldwide scale. Sales are estimated to be between €60-80 million worldwide (Federici, 
2007) and $100 million (Phillips McDougall, 2008). The latter refers to use in agriculture and 
forestry. Figures reported by CPL indicated that the total world market is greater than $150 
million. The market for Bt products is approximately $160 million, which represents around 
60% of the total microbial insecticides (Avé, 2008). The use of Bt in China and export from 
China is estimated to exceed $100 million (Huang et al., 2007). Little information is available 
on the use of Bti for control of dipteran pests. The overall worldwide market is most likely 
over $200 million considering all uses of Bt products. Nevertheless, sales have been declining 
as a result of transgenic Bt-crops and new chemical and natural insecticides. On the other 
hand, Avé (2008) believes that the market potential for Bt products is likely to increase in the 
next few years due to the demands of the regulatory agencies and the general public for safer 
food and for crop protection products with no detrimental effect on the environment.  
 The second most successful group of entomopathogens is the nematodes although there 
is a huge gap between sales of Bt and nematodes. Sales in Europe are estimated to be around 
$6 million (Lysanski, 2007). Here too, it is very difficult to provide figures on the various 
markets where they are used such as greenhouses, outdoor ornamentals, soft fruit, 
mushrooms, turf, and upcoming markets like top fruit, forestry, and home gardens (Blum, 
2001). The most important target insects are the larvae of Sciaridae and the black vine weevil. 
 Baculoviruses have increasingly become popular and the use of CpGV in fruit orchards 
is the largest market. Their usage in greenhouses for control of S. exigua has also increased, 
mainly in Spain (Van der Blom, 2009). The number of products remains small. 
 The use of entomopathogenic fungi has slowly grown, yet the total market in Europe is 
limited when compared to the sales of the other three groups of pathogens (CPL, 2007b). 
Figures are provided in table 7.4 and 7.5. There are about ten products in Europe, and most of 
them have a small market share.  
 From the above it is clear that the order of success of entomopathogens is bacteria, 
EPNs, baculoviruses and fungi. I think that this ranking can be explained by comparing 
efficacy, costs, and user-friendliness of biopesticides to traditional chemicals. The more these 
parameters reflect the characteristics of a chemical pesticide, the easier the adoption of a 
biopesticide in the market.  
 
Sales and profitability of producers  
Estimates of sales of microbial pesticides have been presented by a few authors. Information 
on profitability is not available due to confidentiality. Still, some conclusions can be drawn 
from the sales figures and the number of products on the market. When I compare the figures 
from Frost & Sullivan (2001) - $25 million for all microbials, including B.t., in Europe - with 
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Jarvis (2001) - $16 million for all microbials world-wide excluding B.t. - and estimating the 
non-Bt microbials market in Europe (10-20%), this might have reached $2.5 - $5 million in 
2000. It is a small amount, and considering that it represents the total of 20-30 microbials 
(viral insecticides, fungal insecticides and fungal and bacterial fungicides) one can see that the 
turnover per microbial is very low. On top of this, these sales are spread over a number of 
countries for most products, giving small turnovers per country and relatively high marketing 
expenses. When I take into account development and registration costs, it is apparent that the 
biopesticide industry is small and has difficulty being a profitable business.  
 When a similar approach is taken with figures from 2005 from CPL (CPL, 2007b) a 
comparable picture appears. The total of microbial- and nematode-based products was $43 
million in 2005 at end-user level. Bt’s accounted for $30 million, nematodes for $6 million 
and baculoviruses for $5.45 million. Fungi and other bacteria generated sales of about $2.2, 
respectively $2.6 million. If it is assumed that 70-80% of these figures is returned to the 
manufacturer, and that these overall figures represent the sales of a number of products over a 
number of manufacturers, it is obvious that the turnover per product is very low. Particularly 
in the case of fungi-based products where about ten products account for this turnover of $2.2 
million, it is apparent that profitability is minimal. For the Bt products, the profitability looks 
much better since there are fewer products and fewer manufacturers. The same is true for the 
baculoviruses. Gelernter (2005) estimated annual sales to be between $100,000 and $5 million 
per biocontrol product.  
 Manufacturers of biopesticides in the developed world can be characterized as companies 
with an industrialized production that needs a high initial capital input. There is a limited 
number of companies which typically are small-sized enterprises; there are a few larger 
players. Companies that have existed for more than a decade seem to be successful and 
therefore should be profitable. Expectations for a sustainable business and financial success 
need, however, to be reflected by the current industry position and profile.  
 
 
Critical success and failure factors for a biopesticide company 
 
Successful and unsuccessful companies 
Numerous companies have entered the field of production and marketing of microbial 
pesticides over the last forty years. This field attracted investors and entrepreneurs every 
where in the world. Obviously, its perspective from the outside must have been of a 
promising area where profits could be made in a relatively short period of time. Many 
companies though, once active in the field, could not meet product objectives and market 
projections, and registrations took too long and delayed income. As a result, many, who 
started optimistically, failed (Gelernter, 2005; CPL, 2007c). On the other hand, some 
companies have been in business in this area for a decade or even much longer and have been 
expanding. Examples from Europe are: Andermatt Biocontrol, Enema, Intrachem, Koppert, 
NPP, Prophyta, Verdera (formerly owned by Kemira, now part of Lallemand), and from the 
USA: Agraquest, Becker Underwood and BioWorks. Some have multiple areas of activity. 
Whether these companies are profitable is hard to say. Their survival over a long period 
suggests that their business is profitable. Examples of companies, large and small, which 
failed and stopped or sold the biopesticide activity are: Bayer, Ciba Geigy, MicroBio, MRL, 
Novo Nordisk, Novartis, Sandoz, Solvay, Tate and Lyle, all from Europe; and from the USA: 
Abbott, Biosys, CropGenetics, Ecogen, Ecoscience, Eastman Kodak, Mycogen, Mycotech, 
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Taensa, Thermo Trilogy, Troy Biosciences, WR Grace, and many more. Surely, the reasons 
are various, but details have usually not been provided. Lack of revenues versus high 
investment has certainly been an important reason in most cases. This is exemplified by the 
case of Biosys, a venture capital company active in the field of nematodes in the 1980’s and 
1990’s. Details of the company’s foundation, its achievements, and its failure have been 
described by Georgis (2002).   
 The above raises two questions: 
 
1)  why have companies decided to enter the microbial pesticide market?  
Incentives are manifold. Lisansky (CPL, 2006c) provided putative reasons for pesticide 
companies, fermentation companies, new companies funded by external capital, spin out 
companies, biocontrol (natural enemies) companies and commodity companies (Bt 
producers). He also discussed advantages and disadvantages for each type of company. 
Excellent perspectives have been predicted for biocontrol products by numerous authors. 
Obviously, each company has its own valid reasons and objectives to start in this business 
field. As long as the reason(s) match the company objectives, success can be achieved. I will 
provide two examples to illustrate this. When a company has excess fermentation capacity, it 
could start producing a microbial agent and sell it through a partner or distributor. The main 
objective is then to use the fermentation to its full capacity and spreading operating costs as 
efficiently as possible over various products. Success in the biopesticide market is then less 
essential. Another objective for the development of a biopesticide could be to safeguard an 
IPM system in which the company has a vested interest. This was exemplified by Koppert 
who in the early days of Mycotal initiated this development to ensure whitefly control with 
natural enemies. A product as Mycotal was used as a corrective means when control with 
parasitoids was less effective. In this case, profit is not just measured over the activity with 
Mycotal alone, but over the IPM system for whitefly control and sales of natural enemies. Of 
course, in most cases biopesticides are being developed in order to create a stable and 
profitable business. 
 
2)  why have some companies been successful while others failed?  
A company can only be successful when the product is successful, and a product is only 
successful when the company succeeds in marketing it for a considerable period of time and 
is profitable in doing so. These two conditions lead to a sustainable and growing business and 
that is what I consider the definition of a successful enterprise. After all, the basic objective of 
a company is to be profitable in order to remain and grow in business. Many companies have 
failed in the biopesticide area as described above; however, a considerable number is active 
today. Even when the product is successful, a company could still fail when it cannot meet its 
financial objectives. This creates two new questions: Which factors determine success or 
failure? Can we learn from the past and develop a pathway that leads to success?   
 A list of factors determining the success or failure of a biopesticide comprises the 
attributes of the product, and can be easily drawn up. In fact, many authors have reported the 
advantages and disadvantages of a biopesticide. A list of factors determining whether a 
company will be successful is more difficult to provide, and few authors have attempted or 
succeeded to do so in a systematic way, in my opinion. In the book of Gurr and Wratten 
(2000) where ten chapters described cases of successful biological control, the criteria for 
success are various, predominantly biological and even conflicting. Little attention is paid to 
commercial success. First of all and obviously, a product must be biologically and technically 
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successful before it can become commercially successful. Commercial success for the 
manufacturer relies on the ability to sell. There is, however, a matrix of interlinked factors 
which are ultimately responsible for a profitable and sustainable business activity. Lisansky 
(CPL, 2006b) provided nineteen success factors for a company to consider in order to 
optimize its chances of success. Companies that failed committed three main mistakes: they 
assumed that a biopesticide would be easy to find and develop; they expected that they would 
outperform others; and they underestimated budgets and time (CPL, 2007c). Below I will 
present and discuss the critical commercial success factors which I consider the most 
important (table 7.7).  
 
Critical commercial success factors 
 
Commitment from the top 
The development of a new biopesticide is a lengthy and costly challenge. Ultimately, sales 
need to generate a reasonable profit so that a sustained business is possible. The whole project 
costs many millions of Euros, and takes on average five to eight years to come to a break-
even point, and even more years to reach a sales volume that provides the desired profit. This 
business field requires understanding, motivation, patience, and perseverance in order to 
become successful. Management needs to be aware of this from the outset. ‘Quick profit 
making’ is not a standard feature in this business. Many investors have experienced this and 
have withdrawn from this business (Gelernter, 2005). It is imperative that the long and 
winding road to success be understood and accepted, and that the vision and commitment be 
present in the company top in order to achieve success.  
 
The business plan and allocation of financial resources 
An accurate business plan with realistic profit projections is a prerequisite for the project. The 
calculation of the potential revenues from six to ten years in the future is a difficult task and 
must be done conservatively. Minimum to maximum sales need to be projected accurately 
and carefully, and extensive knowledge of the market is critical. Furthermore, it is imperative 
to establish as accurately as possible the resources that the development of the business or the 
product will require; not only the costs of initiating, but also the costs of staying in business. 
It is important to realize that it will take a considerable amount of time before there is any 
return on investment. This means that sufficient resources need to be available to cover all 
costs until sales can eventually pay back these costs and generate profit. A common mistake 
of many failed businesses has been to underestimate the necessary time and resources. 
Product development and registration costs are obvious expenses and most companies realize 
this. The requirements and costs involved for market adoption and reaching sales volume are 
often underestimated or even neglected, and many companies have failed in this phase in the 
past (CPL, 2007c). Business plans should allow for a low penetration percentage of the 
market, particularly in the first years. The financial support must be guaranteed during the 
product developmental period and the initial sales period. 
 
Qualified management and personnel 
A good scientist is not necessarily an able entrepreneur. If the company is a spin-off from a 
research organization, the emphasis should be given to management skills. If a large company 
is new to the field of biopesticides, the management does not always understand this type of 
business. The management should fit with the type and size of the company or invest 
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sufficient time to understand the field of biopesticides. In new businesses, poor management 
is often cited as the principal reason for failure. The owners of a new small company 
frequently lack relevant business and management expertise in areas such as finance, 
purchasing, selling, production, and the management of employees. All these aspects are 
crucial to the survival and success of the business. The development of a biopesticide requires 
a multi-disciplinary team with sufficient knowledge and expertise in the areas of research, 
production, registration and marketing. Ideally, a company will have all these experts in-
house for a well-planned and time-efficient developmental project. The lack of careful, 
methodical planning could be expensive and jeopardize the project. 
 
Knowledge of the market  
In-depth knowledge of the pest and the potential market is elementary and seems so obvious. 
But many companies have overestimated the potential share of the market and as a 
consequence failed dramatically. Pest damage figures cannot be transferred directly to market 
potential, a grower is willing to spend about one-third of the damage for control measures 
(CPL, 2007a). Poor understanding and insufficient knowledge about the pest problems, 
customers, cropping systems, current practises, prices, competition, and the requirements to 
promote a new product will lead to errors and slow penetration in the market. Generally, 
biopesticides need to be implemented as part of an IPM system and this can be complex. 
Time and money for the study of the correct positioning of the product and the education of 
the users is often neglected in business plans. Many companies have had an unrealistic 
expectation of the true market potential and their ability to sell the product. Biopesticide 
markets are generally niche markets. Annual sales may range from a few hundred thousand 
Euros to a few million Euros (Ravensberg and Elad, 2001; Gelernter, 2005). Unrealistic sales 
expectations caused many companies to abandon biopesticides. Experience with biopesticides 
tells us that adoption in the market is a slow process; biopesticides are received with some 
scepticism and have to prove themselves. The increase in sales does not come overnight, but 
takes considerable efforts and time. 
 
Insight into the competition 
Biopesticides have to conquer their position in the market and justify their place. Chemical 
pesticides are still the main competition due to price and efficacy, and also because of 
grower’s routine, and ease of use. Users must be convinced that a new product achieves 
similar results as their usual practises. It is essential to understand the competition well and to 
develop ways to position the biopesticide as a replacement or as an alternative product. This 
needs demonstrations, education, and comparative trials. Because of competition, the market 
share may be small initially and only increase with efforts over time. Be conservative in 
market share assumptions, I would say, around a few percent. This may increase, but the 
market will have to be divided between many products. Initially, the focus should be on the 
development of suitable and accessible markets with few competitive products. 
 
Other business factors 
When a company does everything right and the product is a good product, does this guarantee 
a sustainable business? Obviously, Bt’s are successful products that are well accepted by 
users and are the most sold biopesticides. Still, large companies have stopped their activity 
with Bt and sold that activity. Examples from the past are Sandoz, Novartis, Novo Nordisk, 
and Abbott. From the outside, these companies appeared to be successfully producing and 
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marketing these products. Corporate decisions, however, led to the abandonment of the 
biopesticide field completely. VC companies are under pressure to generate revenues within a 
short timeline which may lead to leaving the business even if the product has potential. A 
company’s objectives, whatever they are, may have a decisive impact on their perception of 
success. Many external factors continuously influence the company and its activities in the 
market with biopesticides. This is an ever-changing environment to which the company must 
adapt and be flexible in order to maintain success with biopesticides. This requires advanced 
entrepreneurial skills and expertise, and a close view of the market.   
 
 
Table 7.7.  Success and failure factors in a novel biopesticide enterprise 
 
 
Success factors Failure factors 
Do your homework well: make an accurate 
business plan, focus on data integrity;  
explore best-case and worst-case scenarios 
Assume that biopesticides are easy and 
cheap to develop and market 
Be fully committed to the project Overestimate own capabilities and 
knowledge 
Start small, with modest investments  Start with high VC investment and many 
people, e.g. with a large R & D group 
Focus strongly on one product Do it ‘on the side’ 
Work according to a proper project 
management process; enforce timelines, 
milestones and decisions 
Lack of efficient project planning 
Develop deep market and customer 
knowledge  
Assume that the market will just adopt a 
new ‘wonderful’ biopesticide 
Allocate sufficient budget for the product 
development and for the market development 
Lack of resources until sales grow; 
overestimation of the market size and 
market penetration 
Estimate registration costs, time to market, 
and time to volume as realistically as possible
Underestimate costs of registration and 
time to registration in each country 
Use existing distributors that are well 
introduced in the market; train distributors 
well, develop a long-term interest between 
partners; involve distributors early in project 
Assume that distribution will be easy and 
simple. Shortage of demonstration trials to 
convince users 
Develop knowledge on compatibility and 
integration in IPM systems 
Underestimate efforts to incorporate the 
product into IPM systems 
Develop the company step by step; expand 
when the market demand is well understood 
Overestimation of the market potential 
may lead to over-expansion of the 
company 
Balance risks, progress, and debts; estimate 
profit margin, break-even point, and profit  
Count on quick and large sales volumes 
and profits 
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Factors that influence the decision to develop and commercialize microbial pesticides 
 
Product and market related factors 
Factors that determine the decision whether to initiate the commercialization of a new 
biopesticide need to be understood extremely well. The difficulty regarding this decision is 
that it must be made when most information is only indicative. The decision should in most 
cases be market-driven. Is there a pest problem that asks for a solution, for a new product? 
And if so, how big is this market and what is a grower willing to spend to solve the pest 
problem? A decision could, on the other hand, also be product-driven when an innovative 
research idea can be transformed into a valuable product that has a good chance to penetrate 
an existing market because of its novel character with improved control, or other desired 
features. The key factors concern market need, market size, cost price and market price, time 
to market, and time to volume. These factors determine when return on investment can be 
obtained and whether a company can become profitable. Market size and competitiveness 
were regarded by Burges (1981a) as vital. According to Lisansky and Hall (1983) profit-rate 
and market size determined the willingness of a company to develop a product. Lisansky 
(1985) identified the need, the market size and the competing products as subjects for a 
feasibility study on which the decision to proceed would be based. Carlton (1990) considered 
four aspects to be relevant for the decision to commercialize a biological product: market 
need, market size, price, and competition. Later, Lisansky (CPL, 2006b) stated that key to the 
biopesticide business is a cost-competitive product and understanding the market. I believe 
that the efficacy of the product is the most relevant factor. Without reliable and consistent 
efficacy, no product will become successful. Further, the market factors are determinative and 
an accurate analysis of the market situation is crucial. The following five factors should be 
carefully investigated. They are similar to the ones mentioned by Carlton (1990), but I have 
not factored competition separately in, it is an inherent dimension of all mentioned market 
aspects.    
 
Market demand 
The need for a product must be estimated at the start of the project and over a period of five to 
ten years in the future when the product will reach the market. Elemental is the answer to the 
question: “Is there a need or a place in the market for a new product?” Product development is 
interesting when there is a demand for a solution for a certain pest or disease. The actual need 
for a new or an alternative product must be as concrete as possible. A confirmed market 
demand is the ideal situation, but this is rarely the case. When the need is expected in the 
future, it will make the decision more uncertain. On the other hand, when a solution is needed 
directly, the situation may have changed once the foreseen product is ready to be launched. 
This takes many years and in the meantime other solutions may reach the market. This can 
never be fully foreseen and the decision to commercialize is always risky in this sense. This 
aspect should certainly be taken into consideration. When a new product can be developed 
that offers an opportunity, a novelty that has advantages over existing products, this may be 
another reason to develop and commercialize a product. Both cases could be the starting point 
for a new activity.  
 Market demand could be generated by various factors: occurrence of a new pest, lack of 
pesticides, resistance to available pesticides, and withdrawal of pesticides. These factors are 
directly related to the pest. Indirect factors from society can also play a role. Examples are 
human health and environmental concerns, residue concerns by supermarkets and consumers, 
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and political motives. Socio-economic considerations are relevant for a society, but for a 
manufacturer of biopesticides these ‘green credentials’ should not be driving the decision-
making process. In some cases, political, and societal, and environmental factors have been 
determinative as in the development of Green Muscle for locust control (Lomer et al., 1999; 
Douthwaite et al., 2001). This is however, not a standard situation in the commercial 
biopesticide business. Some of the market incentives may be more concrete than others; a 
realistic estimation of these incentives is difficult, but still useful. The end-point must be the 
grower’s demand and incentive to choose the new biopesticide. 
 
Market size 
Biopesticides are still niche products. Bt products could be considered an exception, but their 
market share is still small within the entire pesticide business. Thus, when a company 
considers whether or not to initiate a biopesticide development, a market study is extremely 
important. The size of the market is determined by the importance of the pest(s), the number 
of crops in which this pest is a serious problem, and the extent of these crops. The size of the 
market in hectares, and the number of applications per season (together often called ‘super 
hectares’), and the competing products, with their application costs, need to be estimated at 
best. The spectrum of pests that can be controlled with the product has a great influence on 
the market potential. Does the new product fill a hole in the market or does it have to 
penetrate a market with existing products? The size of the market and the potential growth of 
the market profoundly impact the decision on commercialization. Potential sales should be 
large enough to allow for return of investment. Market shares for biopesticides will only be 
partial and a careful estimate of the market share should be made, including the time to reach 
a projected market share. Great market shares have frequently been expected, but proven 
completely out of scope resulting in a failure of the company (Cross and Polonenko, 1996; 
Gelernter, 2005). Market shares should be estimated in a conservative way, and best-case and 
worst-case scenarios should be examined. Biopesticides have rarely been developed for the 
major agricultural crops, rather for small crops or sectors.  
 
Profit margin 
The cost price and the potential selling price determine whether the product can be sold in a 
profitable way. The calculation of the cost price has been provided in detail in chapter 3. The 
selling price depends on the demand of the product in the market and the price of other 
competing control measures, in other words, the market value. Pricing should also allow for 
margins for distributors. A selling price can be established in two ways. The first is to see 
what margins are required to make a profit on the product. A second is to see what the market 
value is and what price will be accepted in the market. The product price is often set high for 
the first years after its launch in order to obtain the return on investment within a short period. 
Later on, the price may become lower because of competition and in order to expand the area 
of use. Most biopesticides are used in high-value crops, which generally contain a limited 
acreage. These crops, however, allow growers to spend more money per unit area on, amongst 
others, crop protection, and therefore offer an interesting niche market for biopesticides. 
Nevertheless, biopesticides also face competition from both synthetic chemical pesticides as 
well other IPM control measures, including other biocontrol agents: both arthropods microbial 
agents. Favourable properties of biocontrol products such as less or no residue, short or no re-
entry periods, safety to humans and the environment, etc, are difficult to exploit in a selling 
price. Competition is predominantly based on traditional factors; efficacy and costs. “Feel-
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good factors” do not automatically allow charging higher prices. Selling prices should 
therefore be estimated based on a realistic approach to the current market coupled with 
traditional product performance characteristics.  
 
Time to market 
The developmental time of a product and the time to registration need to be estimated as 
accurately as possible. The first is in the hands of the manufacturer, at least to a large extent, 
and an estimate can be made. The second depends on the regulatory authorities and 
predictions have proven very difficult to make. In general, registration of the active ingredient 
has taken more than five years in Europe, and many years more to obtain national 
authorizations that open the market. More details on the registration and the time periods are 
given in chapter 5. For entomopathogenic nematodes, registration is different and time to 
market much faster. Average periods for microbials from start to market are provided below. 
It should be realized that it will take many years before the product is on the market and that 
the situation has changed considerably in many ways. The pest problem may have been 
partially solved by other products, new cultural practices, resistant cultivars, etc. It is only 
possible to foresee these developments in a limited way. An efficient and affordable product, 
however, will find its place in a changing environment.  
 
Time to volume 
Once a product has been registered, sales can begin. The adoption of a new product in the 
market is usually slow and needs a substantial effort of the producer and his distributors to 
initiate and increase sales. The details of this process are provided in chapter 6. Time to 
volume is pivotal with regard to return on investment; the faster the better. Within a three-
year period of sales, profits should pay back the investment for the development and 
registration expenses of the product. Subsequent sales should generate margins that allow for 
new product developments or other investments. Product development should only be 
initiated when the projected sales and profits are sufficient to guarantee return on investment 
within an acceptable time period. This determines the success of a company. Investors will 
require a sound business plan where these factors are realistically provided. Time to volume is 
often neglected in business plans or assumed to happen automatically. This, however, is a 
misconception and market penetration can take many seasons. Users need to obtain positive 
results from their first trialling experiences with the product before they use it on their whole 
acreage and continue to buy the product. The lifetime of a MPCP should be also considered. 
The projected length of the lifetime depends on the efficacy, user satisfaction, and price of the 
product. Resistance is unlikely although not impossible. Competition will change overtime, 
but new uses may be developed and new opportunities may come along. The lifetime is 
difficult to predict, and it cannot be used as a solid criterion in investment decisions.  
 
The decision process  
If the above-mentioned market aspects have been investigated and analysed in a feasibility 
study, a decision should be taken. However, for any given product and for any company the 
results of the market analysis may lead to a different outcome depending on the company’s 
strategy and objectives. Therefore, it is not possible to give exact decision criteria. It is 
possible though to start product development and take ‘go/no go’-decisions along the way. At 
any phase in the project, company management should be courageous enough to make such a 
decision and perhaps decide to stop the project. Considerations may differ per company. For 
Chapter 7 
___________________________________________________________________________ 
 252
an agrochemical company, the situation is quite different than for a small start-up company. 
Froyd (1997) discussed the reasons for a large agrochemical company, American Cyanamid, 
to develop biopesticides, in the mid 1990’s. He considered the less complicated registration 
requirements, rapid market entry, possibility to become active in a new market segment, 
residue-free products, public opinion, and public funding for a part of the development 
important incentives. Other requirements considered relevant were product performance and 
profitability for the company. The company believed in the potential of genetically improved 
baculoviruses, but thought that field performance of biofungicides needed much more 
research. Today this company is not active in biocontrol products; apparently the potential 
was insufficient to reach the expected economic results. This picture has been seen with many 
of the large agrochemical companies. The incentives for small companies can be 
characterized by passion and commitment. Many survived despite the modest sales and 
profits. They learned to take the right decisions and found a balance between their costs and 
revenues, and they continued in speciality markets (Gelernter, 2005). 
 A positive decision to develop a new product will please the persons involved because 
that was the intention from the beginning, and it fits with the (usual) goals of the company: 
develop new products and markets and grow. It is often seen that people focus on the “best-
case” scenario, but a “worst-case” scenario should also be analysed. A negative decision is, in 
my experience, much harder to take since all those involved have the mindset of starting this 
new project. Making such a ‘no go’-decision is difficult and requires solid and objective 
arguments to make everybody understand and accept, despite certain disappointment. It needs 
courage to make such a decision and doubting too long will bring unnecessary costs, 
particularly when such a decision has to be taken in an advanced stage in the project. But 
management should realize that “a correct kill is a success- it just saved the company a bag of 
money and a heap of trouble” (Cooper and Edgett, 2006). Many companies struggle on and in 
the end are not successful. Efforts put in one project exclude working on another one, and this 
is a crucial element to keep in mind in the decision process. The positive attitude to develop a 
new product is a potential pitfall for a company and one tends to continue with something that 
was started. A regular critical evaluation of  “where do we stand” during a project is an 
absolute need in order to keep on track with budgets, timelines and goals, followed by a 
‘go/no go’-decision. Most companies who failed showed overconfidence on their own 
performance, and blamed the products or the market for not being successful rather than being 
critical of themselves (CPL, 2007c). 
 Taking the right decisions is vital for a company, and it is often a process full of 
struggles. This is not just the case for biopesticide companies, but for all companies that 
develop new processes and new products. The development of a MPCP can be considered a 
technology development (TD) project. These projects are usually characterized by many 
uncertainties and ‘difficult to predict’-outcomes. To facilitate decision-making, a systematic 
process has been developed for moving a new product project through the various stages and 
steps from idea-to-sales, and making decisions between these stages, at the gate of a new 
stage. This Stage-Gate process is a management tool that facilitates outlining the process in 
steps, and making the right decisions at the right time (Cooper et al., 2002; Cooper, 2007; 
www.stage-gate.com). To make the decision process more objective and quantifiable, 
scorecards can be developed that help rating and prioritizing TD projects. It needs to be 
custom-designed for each individual company and product. This systematic approach can be 
used to decide whether or not to start a project, or to decide between two or more projects. 
Tables 7.8, 7.9 and 7.10 provide examples that could be used in the biopesticide industry.  
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Table 7.8.   An example of a scorecard rating various elements of the development of a  
                   biopesticide, as a tool to estimate the probability of a technical success 
 
Rating scale 
Key Factors 1 4 7 10 Rating 
Technical 
“Gap” 
Large gap between 
current expertise and 
objective; must invent 
new technology 
“Order of 
magnitude” 
change proposed 
Step-change 
short of  “order 
of magnitude” 
Incremental 
improvement; 
most technology 
present 
 
Product 
complexity 
Difficult to define; 
many hurdles 
Easy to define; 
many hurdles 
A challenge, 
but “do-able” 
Straight forward  
Technology 
skill base 
Technology new to the 
company; (almost) no 
skills 
Some R&D 
experience, but 
probably 
insufficient 
Selectively 
practiced in 
company 
Widely practiced 
in company 
 
Availability of 
people and 
facilities 
No appropriate 
people/facilities; must 
hire/build 
Acknowledged 
shortage in key 
areas 
Resources are 
available, but in 
demand, must 
plan in advance 
People/facilities 
immediately 
available 
 
           (modified after Cooper et al., 2002) 
 
 
Table 7.9.   An example of a scorecard rating the various elements of the market of a 
       biopesticide, as a tool to estimate the probability of commercial success 
 
Rating scale 
Key Factors 1 4 7 10 Rating 
Market demand Extensive market 
development 
required; no 
apparent demand 
Demand must be 
highlighted for  
customers; 
product tailoring 
and market 
penetration  
required 
Clear relationship 
between product 
and need; market 
penetration needed  
Product 
immediately 
responsive to 
customer need; 
no other control 
means available 
 
Market size Partial niche 
market 
Small market Modest market  Large market 
potential 
 
Competitive 
intensity 
High  Moderate/high Moderate/low Low  
Development 
and commercial 
skills 
Must develop; 
new to company 
Must develop 
beyond current 
limited use 
Need to tailor to 
proposed program 
Already in place  
Commercial 
assumptions 
Low probability/ 
low impact 
Low 
predictability/ 
low impact 
High probability/ 
high impact 
High 
predictability/ 
high impact 
 
Regulatory, 
social and 
political impact 
Negative Neutral Somewhat 
favourable  
(e.g. less chemicals 
available) 
Positive impact 
on high-profile 
issues (e.g. food 
safety, no 
residues) 
 
           (modified after Cooper et al., 2002) 
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Table 7.10.   An example of a scorecard rating various financial elements of a biopesticide 
     and the income expectations 
 
Rating scale 
Key Factors 1 4 7 10 Rating 
Sales (five-year 
cumulative income 
from first sales 
 
< €1 M 
 
 
< €5 M 
 
 
< €10 M 
 
 
< €20 M 
 
 
Technology 
payback period 
> 10 years 8 years 5 years < 3 years  
Time to market > 7 years 5 years 3 years < 1 year  
Certainty of 
return/profit 
estimates 
low; pure 
guess, < 20% 
probability 
40 % 
probability   
70% 
probability 
highly certain, 
> 90% 
probability 
 
                (modified after Cooper et al., 2002) 
 
 
This exercise forces management to define success criteria and to commit to the project when 
these criteria are met and evaluated at moments of ‘go/no go’. The Lubilosa project seems to 
have worked with a similar system where funding had to be approved for each successive 
phase (www.lubilosa.org). Adopting a Stage-Gate process ensures a better and more 
transparent decision-making process within an organization and could lead to a more 
successful business.  
 
 
Is there a successful business model for a biopesticide company? 
 
Business models in the biopesticide industry 
Friedman (1990) described three business models prevalent in the field of biocontrol. The first 
is the owner equity model in which the owner invests to a limited level and development is 
gradual. The second type is the social investment model where large investments are 
conducted before any sales occur and development can be quick. Funding from governmental 
and non-profit organizations supports this model. An example is the Lubilosa project. The 
third model is the venture capital (VC) investment model with levels of investment that 
greatly exceed any sales, and the developments are large and fast. In this model patent-based 
technology is a prerequisite to safeguard the investment from competition. In his opinion, the 
best model was a combination of a VC company in collaboration with public research and 
governmental funding. Friedman illustrated this model with Biosys where he was working at 
the time. In the end, Biosys, however, was not successful due to unrealistic market projections 
and had to be sold (Georgis, 2002). Many more VC companies and large agrochemical 
companies left the field of biocontrol mainly because market forecasts were unrealistic 
(Gelernter, 2005). 
 The three models mentioned by Friedman can still be recognized today, although his 
second model is rarely seen. I distinguish a fourth model as the large multinational company 
model that projected biopesticides as an attractive new opportunity for profit and established a 
business unit to develop this potential. Two categories can be separated: 1) the large 
agrochemical companies that envisaged new products next to their chemical crop protection 
products, and 2) large pharmaceutical or food companies, new to the crop protection area, that 
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hoped to exploit their expertise and technology in production for developing biopesticides. 
Usually, resources were allocated internally to investigate this new activity. Examples of the 
first group are Bayer, Cyanamid, Monsanto, and BASF; examples of the second group are 
Tate & Lyle, Novo Nordisk, and Abbott. Almost none of these companies are any longer 
active in this field. Lisansky (CPL, 2006b) described six basic types of companies involved in 
biopesticides; his categories have many similarities with the ones mentioned above. His sixth 
type is a commodity production company from the Far East.  
 Currently, most biopesticide companies are small to medium-sized organizations and 
originate from the owner equity model. The best performers seem to follow an incremental, 
stepwise, and manageable growth of the organization. They are cautious with large 
investments and only invest when the market demand is foreseeable. Relatively small growth 
can be controlled, the changes are still manageable, and new activities can be well integrated 
into the existing organization. They strive for profitability and try to avoid large debts and 
risks. Expansion is, in general, financed in a conservative way, usually by banks or small 
private investors, but not by venture capital. Shares are usually held within the company itself 
and/or by some external shareholders. If possible, the majority of shares are kept by the 
owners for reasons of influence and decision-making. The motto seems to be “stick to what 
you are good in” and “expand your core business when opportunities are discovered and 
considered low risk”. Core business relates to products and markets in which understanding 
and experience are built up over a considerable period of time. New markets are entered step 
by step and without taking large risks. This strategy seems to give the best chance for survival 
and growth over time in the current world of crop protection. 
 
Characteristics of successful biopesticide companies 
Successful companies can be characterized by their commitment and belief in the products 
they make. Their enthusiasm and entrepreneurial skills help them succeed. Within the field of 
biopesticides it is pivotal to find your niche in the market where competition is limited. This 
seems to be the strategic decision that allows a company to establish its position and to 
gradually become successful. Examples are Becker Underwood and Enema which specialized 
in the production and commercialization of entomopathogenic nematodes. Others focussed on 
production methods for certain organisms. This is illustrated by Valent BioSciences which 
specialized in Bt production, and Prophyta which specialized in fungal spore-based products. 
Andermatt seems to have chosen to become a specialist in baculoviruses. A strong focus on a 
particular market can also be a key factor that makes a business grow as demonstrated by 
Bioworks (Evans, 2004a).  
 Others have chosen for a broad range of products and seem to be successful in that way. 
This is illustrated by Koppert which produces natural enemies, microbial products and 
bumblebees; by Intrachem which produces and markets microbial products, natural enemies 
and plant nutrients; and by Certis which commercializes chemical as well as biological 
pesticides. Some companies are only active in biopesticides, some have broader activities in 
agriculture; others have several business areas, even not closely related areas, such as Becker 
Underwood and Novozymes. Many players in this field have not survived in the past, 
particularly when they were founded with venture capital, or when biopesticides were a side-
activity. Few VC companies are active nowadays, Agraquest is one of them and they seem to 
do well. The large agrochemical and pharmaceutical multinationals failed and have left this 
field. The most common mistakes made were unchecked assumptions of how easy and cheap 
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it is to develop and sell a biopesticide, overestimation of their own capabilities, followed by 
under-budgeting of the new activity (CPL, 2007a).  
 
Key components of a successful business model  
Several business models could be successful; there is not one straightforward model that 
guarantees a profitable business. Key factors are to have a responsible, dedicated and 
committed management with core competence in the products and the target markets. 
Successful companies are more carefully investigating the market potential than before and 
this is key-information, besides the ability to supply cost-competitive products (CPL, 2007). 
Biopesticides are unique products in many ways, and understanding these products and the 
way to commercialize them is indispensible in order to succeed. Cost-effective and reliable 
products with a demand in the market have a high probability of becoming successful. Crucial 
is the ability of the company to survive years when income is limited and to be able to accept 
a stepwise growth of the organization. Gelernter (2005) called the smaller companies value-
driven entrepreneurs and considered them as the core of the future successes in biological 
control. The current portrait of the biocontrol companies proves this to be right. 
 Biopesticides can be developed by many types of companies, from small spin-offs from 
universities to large multinationals in agrochemicals, and even other businesses. The owner 
equity model, however, performs the best at present since it implicitly comprises all the 
required characteristics: drive, motivation, passion, determination, perseverance, and 
knowledge and skills. Together with this model, there is one approach, one strategy that is 
obviously the best option. This has been proven many times in the last fifty years. This 
approach is the incremental growing company which has an excellent understanding of the 
product and a realistic view on the market and that is financially able to cover the 
developmental period until revenues come in effectively. And it keeps a focus on slow and 
steady growth as the optimum, after careful research and an accurate market analysis, 
avoiding large risks. Growth is often perceived in business as success, but too rapid expansion 
has caused many bankruptcies. Still, growth is required in order to establish a firm position in 
the market and to be come stronger with respect to competitors.  
 
 
Critical success and failure factors for a microbial pesticide  
Successful commercialization of a biopesticide poses a great number of challenges for a 
company of which many are described in this thesis. Success cannot be described as just one 
factor, but as an overall outcome of a number of attributes of a product, and the role it plays in 
the crop protection market. The decisive criteria are first, customer satisfaction based on the 
balance between reliable and consistent efficacy of the product in relation to the costs and 
ease of use, and second, profitability for the manufacturer. When these two conditions give 
rise to a sustainable business, I consider that a success from a manufacturer’s point of view. 
Above I have presented success and failure factors for a company. I will present these factors 
separately for a product. Which factors determine success and failure of a product? Can we 
learn from the past and can we identify factors that are determinative in the path to a 
successful product? 
 
Requirements for a successful microbial pesticide 
Microbial pesticides are often compared with synthetic chemical pesticides and in that context 
many authors have reported the advantages and disadvantages of microbial pesticides. The 
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disadvantages are frequently highlighted as the reason why biopesticides only cover such a 
small percentage of the total crop protection market. Requirements for and constraints of 
microbial products have been presented by many authors. For biopesticides in general see 
Cross and Polonenko (1996), and Marrone (2007). For bioinsecticides, I refer to Jaronski 
(1986), Lisansky and Coombs (1992), Froyd (1997), Straus and Knight (1997), Butt and 
Copping (2000), Hokkanen and Menzler-Hokkanen (2000), Navon (2000),  Van der Pas et al. 
(2000) and Bateman (2004).  Comparable constraints have been presented for nematodes by 
Kaya (1986), Georgis (1992, 2004), Grewal et al. (2005c) and Georgis et al. (2006). Similar 
limitations have been presented for biofungicides (Powell and Faull, 1988; Davies, 2000; De 
Vrije et al., 2001; Paulitz and Belanger, 2001; Stewart, 2001, and Krause et al., 2006). For 
bioherbicides requirements are even more stringent (Cross and Polonenko, 1996; Hallett, 
2005; Ash, 2009).  Powell and Faull (1988) have presented a list of scientific and commercial 
requirements for aspects such as control, registration, and commercialization. Many of these 
topics have been discussed before in the previous chapters. The list illustrates the 
development of such a product as a daunting exercise, and Powell and Faull (1988) even said 
“that it will take nothing short of a miracle to obtain a successful BCA”. More than two 
decades later, there is still some truth to this comment. Surely, it is an enormous challenge, 
but a successful BCA can be developed.    
 The factors of success and failure of microbial insecticides have been analysed by a 
number of authors during a SIP symposium in 1998 in Japan (Gelernter, 1999). The key 
issues addressed were: 1) factors (biological, economical, environmental, political, 
educational, and others) that have the greatest influence; 2) a framework to predict success; 
and 3) pathogen/pest/cropping system that hold the most promise for success. Several cases 
were analysed such as soil-dwelling pests (Jackson, 1999), pests in vegetables (Gelernter and 
Trumble, 1999), migratory pests (Lomer, 1999b), pests in forestry (Evans, 1999b), and pests 
of turf grass (Grewal, 1999). The main influencing factors were considered biological and 
economical, wherein scientists viewed the biological as decisive, while industry and farmers 
saw the economical aspect as the most relevant. The answer to the second issue was that the 
best chance for success is when a multi-disciplinary team with enough resources develops a 
MPCP analogue to the method of the agrochemical industry. Third, a number of sectors were 
identified as promising for a successful exploitation of a microbial pesticide: forestry, urban 
pest control, high value horticulture and vector control. Gelernter and Lomer (2000) analysed 
a number of other cases of microbial insecticides. They rated success by means of five 
parameters: technical efficacy, practical efficacy, commercial viability, sustainability, and 
public benefit. They came to the conclusion that commercial viability was the most essential 
factor. Commercial viability was defined as the generation of sufficient profit for a 
manufacturer to sustain itself in biopesticides; this was also perceived as the most difficult.  
 In such analyses, aspects of the product, the company, and the market are often mixed 
up. I have separated those, and above I have made an analysis of factors influencing company 
performance. Regarding products, I will present the factors that influence success by means of 
distinguishing true product attributes, and external factors from the market and society in 
general. Analysing these factors forces the developers to critically consider a product’s pro’s 
and con’s, and to try to exploit the positive features and improve the limiting features. 
Further, a forecast on success of a product depends on its attributes that are most appreciated 
in the market, particularly by customers. Key factors that determine the predictability of a 
successful product are identified below. Some examples are provided of technological 
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breakthroughs that led to the creation of new and successful biopesticides as well as ideas for 
new technologies and foreseen products.   
 
Strengths, weaknesses, opportunities and threats 
A list of factors that determine the success or failure comprises the attributes of a biopesticide.  
The chance for success is not only dependent on the product, but also on the environment in a 
broad sense in which it is to be used. These internal and external factors are often referred to 
as the SWOT (strengths, weaknesses, opportunities and threats) factors, and a SWOT analysis 
can be made for each product. Such an analysis identifies the internal and external factors that 
have a favourable and unfavourable influence on the chance to achieve success. In table 7.11 
these factors are provided for biopesticides in general. When a specific new product is being 
developed, it is more interesting to list these SWOT factors specifically for this particular 
product. It provides more insight into the product in a broader context. A disadvantage of 
these factors is that they are only qualitative which could lead to subjective interpretations and 
valuing of these factors. An attempt should be made to rank them in order of relevance. A 
SWOT analysis can be a useful tool, and together with the five market considerations 
mentioned above, which are quantitative parameters, the potential of the product can be 
determined in a more reliable way.  
 The list of weaknesses of biopesticides is long, this cannot be ignored. And chiefly for 
this reason the use of biopesticides is restricted to niche markets at present. On the other hand, 
biopesticides have unique strengths, and the opportunities to exploit these will increase. Some 
weaknesses can turn into strengths, for instance, a small host spectrum makes them safe to use 
with natural enemies. Although many factors need to be considered by a company developing 
these products, a small number of factors can be decisive for its success. Honesty about the 
product is critical; over-promising will backfire at some point. Users may decide to use a 
biopesticide for just a small number of reasons. Examples are a short re-entry period or pre-
harvest interval. Demands from the retailer to deliver residue-free produce may be another 
incentive for a grower to choose for a biopesticide, regardless of some disadvantages of the 
product. Still, costs and efficacy remain the most important features for a grower. 
 
How to predict success of a microbial pesticide? 
A pathway can be developed that substantially increases the chance to achieve a successful 
microbial pest control product. But there is no guarantee. Each product and each company 
will face all the challenges from idea to launch to repeated sales. The steps along that pathway 
have been treated in this thesis, and the focus should be on developing an efficacious product 
that can compete on price with other crop protection means. An ideal biopesticide does not 
exist and the limitations must be known and accepted, and communicated in the market. How 
the product is marketed is pivotal to its success. But the product must demonstrate a number 
of key characteristics that convinces not only users, but also marketing and salespeople, 
including distributors and pest control advisers. Key components of a successful product are 
reliable and consistent field performance, a balanced cost price-effectiveness that can compete 
with chemicals, high and stable quality, user-friendliness, availability at all times, and 
sufficient knowledge on the product’s activity that can be transferred to the user where 
necessary. When these conditions are met, customer satisfaction can be obtained and repeated 
sales foreseen, which will make the product successful.     
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Table 7.11.   Strengths, weaknesses, opportunities and threats for biopesticides 
 
          Strengths     Weaknesses 
• Specific host range 
• Unique mode of action (EPNs) 
• Excellent tool in IPM systems 
• No residue (exempt of MRL) 
• No or short pre-harvest interval 
• No or short worker re-entry interval 
• Compatible with natural enemies, 
pollinators 
• Compatible with other microbial pest 
control agents 
• Probability of (cross-) resistance low  
• Excellent tool in resistance management 
programmes 
• Safe for humans and the environment 
• Safe for plants 
• Approved for organic production 
• Efficacy moderate and variable 
• Relatively high end-user price 
• Narrow target spectrum 
• Speed of kill slow and insect stage-
dependent  
• Short residual activity 
• Sensitive to abiotic factors 
• Limited storage stability (at low temp.)  
• Refrigeration requirement 
• More complicated application technology, 
spraying necessary, good coverage 
essential 
• Not very user-friendly 
• Incompatibility with chemical pesticides 
• Knowledge-intensive products that demand 
know-how transfer 
• Often only work as part of IPM programme 
     Opportunities     Threats  
• Growing demand for residue-free or 
minimum residue food  
• Withdrawal and reduction of use of  
chemicals due to new regulations 
• Developmental costs low to reasonable 
• Combination with chemicals extend the 
product life of risk-resistant pesticides 
• BCAs are a natural resource and offer 
sustainable crop protection 
• Environmental benign, no environmental 
pollution due to production and use 
• Increase or maintain biodiversity since they 
are more target-specific than chemicals 
• Consumer awareness 
• Harmonization of registration 
• Organic food production 
• Growing of sustainable agriculture and IPM 
• Increasing availability of high quality 
biopesticides, thereby increasing users’ 
confidence in biopesticide use in general 
• Increasing markets where use of chemicals 
is forbidden, such as forestry, amenity 
areas, home and garden, natural 
environments, etc. 
• Novel safer chemical pesticides  
• Growers’ scepticism based on expectation 
level of chemicals 
• Small market sizes 
• Transgenic crops 
• Increasing regulatory burden 
• Biodiversity and access benefit sharing 
regulations 
• Bioterrorism regulations  
• Fear of microbes by the public 
• Limited public research funding  
• Lack of user education and extension 
services 
• Weak economic position of farmers  
• Unregistered ineffective “snake oils” 
• Import of low quality products 
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Breakthroughs in technology lead to successful products 
Scientists are constantly trying to elucidate more fundamental aspects of entomopathogens 
with regard to their mode of action, virulence factors, mass production, etc., in order to 
improve the efficacy and other aspects of biopesticides. Some prominent examples illustrate 
that a new technical discovery can lead to the development of successful biopesticides that 
were previously not in sight.   
• The production of entomopathogenic nematodes in an artificial medium instead of in 
insects was discovered by Bedding (1984). This gave rise to a more cost-effective and 
industrial mass-production system, followed by a commercialization of nematodes for 
broad use. This step was later followed by the ability to produce nematodes in 
submerged fermentors. Scaling-up advantages reduced the cost price again and 
nematodes became affordable pest control agents (Georgis, 2002; Ehlers, 2007); 
• Formulation of fungal spores of M. anisopliae in mineral oil demonstrated long shelf-
life at ambient temperatures, an improved adherence, and an extended activity at 
extreme low humidity conditions (Bateman et al., 1993). This discovery opened the 
possibility to utilize this fungus against desert locusts under arid conditions, and in the 
Lubilosa project the product Green Muscle was developed for large scale use 
(Langewald and Kooyman, 2007). Following this invention, two other oil-based 
mycoinsecticides were developed, Naturalis-L and Botanigard ES. However, these oil-
based formulations have not resulted in a wide use of these products. 
New molecular techniques enable researchers to investigate regulation of genes, stability 
factors, immune response factors, etc.  Some new discoveries have been reported that may 
improve a particular aspect of a pathogen so that its potential to become a successful product 
increases considerably. I will present a few examples. 
• The discovery of a synergist, a new protein that increased the effectiveness of Bt’s 
(Abdullah et al., 2009). This product could widen the spectrum and the commercial use 
of Bt. It is said to enhance the speed of controlling the larvae, increase efficacy against 
older larvae, control insect species that are not susceptible to current Bt products, and 
remain viable and effective on the treated plants for extended periods. The product will 
be marketed by Insectigen, USA, as BtBooster, and has great potential according to the 
company; 
• Prospects of genetic improvement of pathogenicity of fungal entomopathogens have 
been discussed by St. Leger and Screen (2001). Examples of improved strains have been 
documented (Lu et al., 2008; Pava-Ripoll et al., 2008) and these strains have been 
offered to biopesticide companies in Europe for development into products. These 
improvements in terms of virulence lead to lower LD50 values and possibly to more 
effective and cheaper products. Genetic improvement is a promising road for all 
microbial control agents. For now, this is not an option in the EU, but it could be 
developed for other regions, or for later in the EU; 
• The use of Bt in transgenic crops has become a multi-billion Euros business which 
indirectly emerged from the insect pathologists’ research and knowledge (Federici, 
2007). Although still controversial, this development reduces the use of conventional 
pesticides and offers enormous potential for a more sustainable agriculture. Other 
entomopathogens may be used in a similar way. 
In some areas, the industry is awaiting a breakthrough due to some serious constraints, for 
example, with the labour-intensive mass production of baculoviruses.  
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• In vitro production of baculoviruses has been investigated for a long time. At present 
this technology is not yet commercially feasible for these viruses (see chapter 3) and in 
vivo production is still the only method. A breakthrough in this area would increase the 
potential for viruses enormously; 
• Genetic modification of baculoviruses could improve the speed of kill and lower the 
required dose. This development needs to go hand in hand with in vitro production so 
that production remains economically feasible. In vivo production of modified viruses 
would give low yields (Inceoglu et al., 2001; Szewczyk et al., 2006). On the other hand, 
acceptance and regulation of a genetically modified organism is at present a huge hurdle 
(Vlak, 2009). 
Broader use of existing products could provide companies with a larger market and improved 
return on investment. Examples are entomopathogenic fungi to control plant diseases and 
nematodes as well (Goettel et al., 2008), the use of entomopathogenic fungi as endophytes 
against insects (Vega, 2008) and plant diseases (Ownley et al., 2008), and the use of 
microbial disease control agents that also demonstrate insecticidal activity (Keel and 
Maurhofer, 2009).  
 New discoveries could widen the potential of entomopathogens considerably. Improved 
products that are active in a more cost-effective way will satisfy customers and will be more 
competitive with chemicals. Those products will improve the economic situation for 
biocontrol companies. More basic and applied research is needed to achieve this. 
 
 
Developmental costs and time of a microbial pest control product 
 
Total developmental costs  
The most wanted information for decision-makers in companies who contemplate the 
development of a new microbial pest control products is what are the total costs? There is no 
simple straightforward answer to this question, but an indication must be provided for a sound 
business decision. Each case is unique, but it is possible to provide a general figure for a 
certain type of entomopathogen and its foreseen purpose. For each company, the investment 
will be different since expertise, facilities and equipment, R & D, and presence in the market 
will be unique too. Many authors have attempted to come up with an indication of the total 
costs for various kinds of microbial pest control products. The difficulty with many of these 
estimates is the failure to clearly describe which expenses are included in the amount 
reported. Are registration expenses counted, and if so, to what extent are in-house expenses, 
contract research expenses, and registration costs in various countries included? I have 
provided more detailed estimates for registration costs in chapter 5. The estimates in the 
literature range from developmental costs, usually R & D and registration costs, up to total 
investment costs for setting up a biopesticide company. A general estimate has been made by 
Lisansky (CPL, 2006b): “A company that wants to go into biopesticides needs to be able to 
allocate $30 million”. He analysed that on average, R & D costs will be around $6 million, 
not including registration and marketing costs. An economic analysis for the commercial 
production of Btk has been presented by Rowe and Margaritis (2003). This is one of the few 
studies that investigated in depth the economic feasibility of manufacturing Bt based 
insecticides by a state-of-the-art bioprocess design on a large scale. The investment needed to 
produce 8-15% of the world demand for Bt’s was approximately CA$18 million for a stand-
alone plant, including equipment costs of about CA$12 million. They calculated the rate of 
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return on the total capital investment versus co-varying the product selling price and the 
annual production scale for two different fermentation processes. The outcome strongly relies 
on the correct market and selling price assumptions. This approach could be used for 
obtaining capital and operating cost estimates for a preliminary budget approval as in a 
business plan. Figures were reported concerning the Lubilosa project: “Green Muscle was 
commercially available after 12 years of research involving at least 40 scientists and costing 
£15 million” (Moore, 2008). Calculations for a small biopesticide plant in developing 
countries such as Nicaragua (Grimm, 2001) and Madagascar (Swanson, 1997) demonstrated 
that an investment of less than one million Euros could be sufficient.   
 The above-mentioned amounts include the establishment of a new company, and to 
make an estimate of those costs is very difficult. Amounts for product development are 
considerably lower. Woodhead et al. (1990) estimated the costs for a microbial biopesticide to 
be under $5 million, but it is not clear whether the registration costs of $2.5-3.5 million are 
included in this figure. Törmälä (1995) assumed that “overall development cost may be 
anything between $1-10 million” based on R & D budgets of some biocontrol companies. 
According to Cross and Polonenko (1996) total development costs of a bioherbicide and 
registration in Canada are in the range of $5-8 million. Marrone (1999) mentioned costs to be 
between $2-4 million (in the USA) in 2-4 years of development. The developmental costs of a 
Bt insecticide are estimated to be $3-5 million (Navon, 2000). Jarvis (2001) estimated 
development costs for a microbial around $3 million, and when registration costs of at least 
$0.5 million are added, total costs are about $4 million. More recent figures have been 
provided by a few authors involved in commercial activities. Krause et al. (2006) estimated 
the registration and commercialization of a new biopesticide to cost €6-8 million over the 
course of 6-8 years. The development and registration of a baculovirus product will need an 
investment of several million Euros according to Kessler et al. (2008) and it will take four to 
eight years before any revenues will return to the company. Furthermore, the restricted host 
range allows for small markets and this makes it “extremely difficult” and “a financial risk 
and a tightrope walk” for small and medium size companies to become successful (Kessler, 
2008). Lucarotti et al. (2007) estimated that the development from isolation to registration has 
cost around CA $6 million for the balsam fir sawfly NPV product Abietiv. The costs of 
developing a new microbial control agent typically exceed $25 million according to Gelernter 
(2007). A current estimate from Agraquest claims that developing and registering a 
biopesticide globally costs about $15-20 million (CPM, 2009b).  In a company survey in the 
REBECA project among 52 biocontrol companies, registration expenses amounted to an 
average of almost €2 million. R & D expenditure has been €15 million in one case 
(Hokkanen, 2007).  
Figures provided in the literature and consultant reports range from $2 million to $30 
million. Clearly, this is useless as an estimate for those considering the initiation of the 
development of a new microbial control agent. If an established biocontrol company with 
experience and available production facilities, researchers, and marketing and sales people, 
starts with a new product, costs will be substantially lower than when a new company needs 
to be founded, built, equipped and staffed. In the first case I estimate that full developmental 
costs range between €2-5 million, in the second case an investment of €10-15 million will be 
needed until sales reach the break-even point. In both situations total research and registration 
costs could be considerably lower, in the order of a few million Euros, when much 
information has been generated by public research. I will discuss the role of public research 
below. In case a new company starts with the labour-intensive production system versus the 
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capital-intensive model (see chapter 3), for example with in-vitro production of baculoviruses 
or production of fungi in bags, starting up costs can be reduced by several millions. By 
comparison, developmental costs for a chemical pesticide range between $180 - 200 million 
for an established R & D agrochemical multinational and it takes about 9-10 years before it 
can be launched (see e.g. www.agro.basf.com; www.ecpa.be).  
Obviously, each situation is different depending on the company, the pathogen, the 
target pest(s) and the sector(s) and countries in which the product will be registered and 
marketed. Above-provided estimates are only general. A better way to estimate the costs 
could be by dividing the developmental process into phases and calculate the costs per phase. 
An example for developmental time and costs without registration fees, is provided in figure 
7.2. 
 
Time to market 
The development time and the time it takes to obtain registration of the plant protection 
product in one or more countries determines when selling can begin and a company starts to 
receive income from the product. This period must be overcome by income from other 
company activities or by external resources. The length of this period influences the 
investment through interest, and the longer the period, the riskier the project. Changes in the 
market over this period such as a changed pest problem, new competitive products, resistant 
cultivars, etc., also influence the potential of the product. Therefore, it is pivotal to make the 
most accurate estimate of this period. The development period can be estimated at best by the 
researchers and depends on the available information on the new strain, the experience of the 
developers, and the size of the team. Few authors report on the development time for a 
product. The development of Green Muscle took about 12 years which is very long (Moore, 
2008). The development of Invade (Serratia entomophila) took four years (Jackson et al., 
1992). Marrone (1999) mentioned two-four years. I believe that, on average, a product can be 
developed in two to four years. The generation of the registration dossier should start as early 
as possible, and will overlap the developmental period to a certain extent. This will take about 
two years. In total, this accumulates to three to five years after which the registration can be 
applied for.   
 Registration in the EU is a two-step procedure. First, the new microorganism must be 
approved as a new active substance and placed on Annex I of 91/414/EC. This process takes 
on average six years until now. However, when the dossier is declared to be complete (the 
official term is six months), provisional national authorizations can be obtained for three 
years, and this can be extended for another three years. National approval can be obtained 
after about one year. This means, theoretically, that after about two years following the 
submission of the dossier to a Rapporteur Member State, approval to sell could be granted. In 
practise this will take longer and not all Member States approve provisional authorizations 
and prefer to wait till Annex I inclusion. If the last procedure is followed, national approval 
can only be obtained after more than seven to eight years. This was also reported in the 
company survey done within REBECA: greater than 75 months to Annex I and 24-36 months 
for country approval (Hokkanen, 2007). The mutual recognition procedure can be followed 
after Annex I inclusion and should lead to national approvals in several months. Until now, 
however, mutual recognition is rarely successful. Altogether, the time to market can be 
extremely long and this period is usually underestimated. Surely, the management of a 
company likes to see products being developed as quickly as possible and optimistic estimates 
have a better chance for a positive decision than long-lasting, riskier scenarios: a case of  
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wishful thinking. In the USA, the registration period is much shorter (Hauschild and Speiser, 
2007; Kiewnick, 2007). Therefore, time to market is quicker, it is estimated to be two to four 
years (Marrone, 1999). A realistic picture of the time from idea to market in the EU is 
between five to seven years when provisional registrations can be obtained. Registrations in a 
large part of the EU after Annex inclusion will take some years more.  
 The long period to market in Europe is very difficult for companies to bridge and it 
deters many companies from developing biopesticides or from registration. It is surely a 
reason why so few products are available in the European market compared to the American 
market. The period from idea to market introduction is a key factor in business success. The 
shorter the period, the greater is the chance to reach the market ahead of competitors and the 
earlier a break-even point can be reached and profit can be generated.  
 
The role of public and industrial research in the development of microbial pesticides 
Generally, the initial research on a microbial control agent is performed by public research. 
This could comprise the discovery and screening of strains, the identification, the unravelling 
of the mode of action, the host range spectrum, even basic research on production and 
formulation, initial application and efficacy testing. In the process of the commercial 
development of a new biocontrol agent this research is extremely important. Very few 
companies are able to perform this early work themselves because of a lack of knowledge and 
resources. On the other hand, the focus of a public research institute is not the same as that of 
a commercial enterprise. Often, particularly in the past, this has resulted in uncoordinated 
research efforts that did not favour the development and use of biopesticides (Dent, 1997). An 
example is the development of a baculovirus for control of S. exigua in the Netherlands while 
no company could be found to commercialize it. Only many years later when there was a 
market demand the product was registered and marketed (Smits and Vlak, 1994). 
 Some researchers have expressed self-criticism with regard to their attitude towards 
research on biocontrol agents and are calling upon colleagues to maximize efforts to attain 
more commercial successes (Fravel, 1999; Stewart, 2001). Collaboration in an early phase 
when commercialization is foreseen is highly desired. In this way, research goals can be 
compared and adjusted in order to prevent omissions and overlap in research. Several authors 
have advocated partnership between public and private organizations (Carlton, 1990; Riba et 
al., 1996; Waage, 1997; Butt, 2000; Ravensberg and Elad, 2001; Whipps and Lumsden, 2002; 
Gelernter, 2005, 2007; Fravel, 2005; Krause et al., 2006; Cherry and Gwynn, 2007; Ash, 
2009; Peters, 2009). Fortunately, we see this kind of collaboration more and more and 
governmental funding increasingly requires involvement of industry and relevance for 
society. The value of public research results can be millions of Euros and will help biocontrol 
companies to develop products successfully. In some cases, part of the revenues has to be 
paid back, and most companies agree to this once revenues allow for it.  
 In my experience, it is not always easy to establish collaborative projects since the goals 
of scientists (often demanded by funding agencies) and industry researchers can diverge. The 
first are mainly oriented towards the organism and new knowledge that can be published. The 
second focus on market- and product-driven research with a strong emphasis on cost-
effectiveness, registration, market size, and the investment needed. A balance must be found 
between the scientific research topics and the industry requirements. Disclosure and 
publication of data can be a delicate issue and clear agreements need to be made in advance. 
The same is true for exploitation of project results, patents and licenses. Nevertheless, I 
believe that collaboration between scientists and industry is crucial in order to develop these 
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products, and contacts between these two groups are necessary from the outset of the 
development of a microbial. Such collaboration is very valuable for a biocontrol company, 
and fruitful relationships with public institutes are indispensable for the industry. On the other 
hand, a company must take it own decisions and stick to its own agenda, even when this is not 
always appreciated by scientists.  
 The discovery of new strains is a sensitive issue that has come up frequently. 
Researchers often prefer to work with their own, locally found strains, and will present them 
as better adapted, and therefore providing superior control under the local circumstances. Is a 
new strain significantly better so that it justifies developing a new product? This may or may 
not be true. It is, however, impossible to develop multiple products based on local strains for 
different regions, given the time and costs for such a development. Therefore, company 
management has to make choices and work with one strain that is best suited for many 
circumstances. This is an unavoidable compromise. Products can only be developed for 
relatively large markets.  
 Interactions between public and private scientists are numerous as can be seen within 
the IOBC, the SIP and at many conferences. Many biocontrol companies have relationships 
and cooperative projects with research institutes and universities. I assume that for the large 
majority of biocontrol products, public research has been the basis of the development and 
that this will continue in the near future. As a result of university research, new biocontrol 
companies have been established as spin-off companies, and close ties between the two 
organizations remain in place. Recent examples are Bio-ferm, Austria, and Bionext, Belgium.  
 On the other hand, research organizations tend to patent new inventions with the goal of 
licensing technology to companies. However, this often had the opposite effect of deterring 
small biocontrol companies from developing the products because of royalty payments. This 
trend is mainly seen in the USA and needs readjusting (Gelernter, 2007).  
 In the current market, biopesticide companies are still relatively small, and the 
assumption that they can afford to develop new products on their own is unrealistic. The 
collaboration with public research is essential if our society wishes to have continued progress 
in this field (Gelernter, 2007).  
  
 
Distribution and sale strategies 
 
Various models for distribution 
There are several options for selling biopesticides. The choices that can be made depend on 
the size and nature of the manufacturer. A large agrochemical company may use its own 
outlets for distribution. A small biopesticide company generally does not have its own 
distribution organization, and needs to assign other companies as their distributors. The same 
is true for manufacturers outside agriculture, such as pharmaceutical companies. Few 
biopesticide companies have developed their own distribution organization. Examples are 
Koppert and Intrachem, but both have more activities next to microbial pesticides that justify 
such an organization. The advantage is that subsidiaries are committed to their own products 
while others may be less so. Microbial pest control products require more attention and user 
education than chemical products do, and this demands a versatile and flexible distributor. 
Big agrochemical distributors may have a better understanding of the markets in general, but 
they lack the ability to deal with niche products. The use of large agrochemical companies as 
distributors has not resulted in successful sales of biopesticides according to Lysanski (2007-
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guide). Collaboration with small local companies has been more successful, although sales 
have rarely become large. Companies with their own infrastructure have done the best 
(Lysanksi, 2007). Pricing and margins play an important role too in this choice. The extent of 
the target market and crops is also a determinative factor. Different distribution strategies are 
required for greenhouse crops versus top fruit or versus agricultural crops, due to the size of 
the markets and the nature of crop protection in those sectors. Greenhouse crops face an 
almost year-round pest and disease problem that needs frequent interventions and visits of 
IPM consultants. Direct contact with the growers has been the cornerstone of the success of 
biocontrol with natural enemies in protected crops (Bolckmans, 1999), and the same can be 
said for microbials.    
 
The role of a distributor 
The distribution of crop protection products may be set up very differently per country and/or 
per sector. The role of the distributor can be limited to the ordering, invoicing and shipping on 
the one hand; to the storage, shipping, and provision of intensive support on an IPM system 
and cultivation techniques to the grower on the other hand. In the case of biopesticides, proper 
storage and transport are essential elements due to the vulnerability of the products, 
particularly at high temperatures. For biopesticides in greenhouses, a distribution system that 
has been established for natural enemies and pollinators (Ravensberg, 1992; Bolckmans, 
1999) can be used. The advantage is that these distributors are accustomed to handling 
sensitive products and they call often directly on growers to provide technical advice. 
 The proper use of a biopesticide needs a careful implementation in an IPM programme 
and the knowledge needed for this needs to be disseminated to distributors too, this is 
described in detail in chapter 6. Distributors must be aware of this crucial function, and they 
must be trained and updated on a regular basis. Distributors play a vital role in increasing the 
grower’s awareness of the product and how to use it. If a distributor is not willing to play this 
role, then a producer should considered not to choose him for the sale of a biopesticide. 
Further to this role, storage facilities and keeping track of expiry dates of products are also a 
task for distributors. Finding distributors that are able and willing to handle microbial 
products can be a challenge, but it is an imperative factor in the chain from producer to end-
user (Benuzzi, 2004). In the Netherlands, distributors are organized in the branch association 
Agrodis and the primary goals are maintaining the intermediary function between producer 
and end-user, improving the flow and transfer of knowledge, strengthening the role of the 
adviser, stimulating the use of IPM, and increasing the commitment of advisers 
(www.agrodis.nl). Distributors with this kind of commitment are needed in the field of 
biopesticides, and since distributors that call on growers are often considered key-influencers 
of growers’ decisions, they must be closely involved.  
 Few authors have discussed the role of distribution in the success of biopesticides. But 
this aspect of the use of biopesticides should not be underestimated. The perception of 
biopesticides can be a barrier to the adoption of such products, and the role of distributors and 
pest control advisors is pivotal for a successful biopesticide (Marrone, 2007). A new product 
is typically tried on a small scale on the grower’s premises under supervision of the 
distributor’s advisor, and the relationship between both determines whether a grower is 
willing to try this or not. Marrone (2007) recommended that biocontrol companies invest in 
the education of customers and distribution channel partners to improve adoption of 
biopesticides. Another important factor is the feedback from the distributor to the 
manufacturer on the customer’s satisfaction or complaints. Complaints need to be handled 
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with care and with the correct follow-up. New uses may also be developed by distributors. In 
some cases, manufacturers ask local distributors to register their product in countries not well 
known to the product owner. Such relationships between producer and distributor are seen in 
international collaborations, and a much closer business partnership is required in such 
situations.  
 
The distribution channel 
Distributors generally sell both biopesticides and chemical pesticides. The latter are easier in 
terms of storage, shelf-life, ease of use, and advice. Moreover, market sizes are larger. All this 
makes selling pesticides a profitable business for distributors. To interest distributors to sell 
more complicated products such as biopesticides is not easy. Novel products are interesting 
for distributors to demonstrate that they are well-informed and active in finding new and 
better solutions for their customers. Nevertheless, profit margins should be high enough to 
persuade distributors to start selling biopesticides. Biopesticide manufacturers have to 
calculate this in when they make market projections based on end-user prices. The 
distribution channel should be as short as possible.  
 Ideally, a producer markets his product directly to the end-user for two reasons: it keeps 
the costs down, and knowledge transfer is direct and efficient. Every extra link in the 
distribution channel increases the costs due to margins and reduces the quality of knowledge 
transfer. To have just one partner between producer and user is optimal because of these two 
factors, and because of practical reasons. In the market analysis of Cross and Polonenko 
(1996) for a microbial herbicide they assumed that biopesticides are usually sold as 
agrochemical products and follow a four-step distribution path; manufacturer→wholesaler→ 
distributor→retailer→end-user. Further, they assumed that every distribution step required a 
100% marking up because of a profit margin. This renders the end-user price much too high. 
Such a distribution channel should be avoided for biopesticides. In general, biopesticides are 
sold in a short channel from manufacturer→distributor→end-user, or with an extra partner 
between manufacturer and distributor for international sales. This keeps the channel short, 
efficient and affordable. When an extra link is used in the distribution channel, their task is 
different from the distributor who calls on customers. This last role requires more knowledge 
and work and therefore a higher margin than a wholesaler. The situation, however, may be 
different in various countries due to established ways of working, and adaptation to the local 
distribution system should be considered.  
 Direct sales by a manufacturer are generally limited since only a limited number of 
growers can be reached. Often, a biopesticide company is small and new, and a sales team is 
not available. Developing a large sales team is extremely costly. A distribution network using 
established local distributors that have a strong relationship with their customers is therefore 
the most preferred and used option for selling biopesticides. And it is also the most likely and 
practical way to start sales quickly after registration has been obtained. Actually, the 
distribution channel should be involved long before the product can be sold; proper and 
timely introduction of the product to the distributors increases the chances of a successful 
product launch in the market. Identification of effective distributors is the key to success; they 
should not be considered as just a link in the process from manufacturer and end-user. They 
are essential in the promotion of the product and should be regarded as real partners in a 
collaborative project.  
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Conclusions and recommendations 
 
Successful biopesticide companies and products 
In more than 30 years of commercialization of biopesticides, many companies have been 
active in this field and many products have been developed and sold in the crop protection 
market. The historical picture presents outstanding failures as well as ongoing success stories. 
Particularly in the 1990’s in the USA, large venture capital biopesticide companies failed to 
develop a sustainable business. Most of the world’s largest agrochemical companies had a 
brief encounter with biocontrol, but they all abandoned the field. Small and committed 
entrepreneurs have been able to continue, albeit with difficulties. Investment has been high 
and risky, time to registration too long, and adoption in the market too slow. Nevertheless, a 
few dozen companies seem to be successful, and new ones are regularly founded. Several 
hundred biopesticides have been developed, some very successfully, but the majority are 
small products, however, and many never saw the light of day. Many ideas are still on the 
shelves of scientists and are not being developed further by companies. The development and 
commercialization of biopesticides is ongoing, maybe now more then ever, and apparently it 
is still an attractive business field. On the other hand, the development of a biopesticide is still 
perceived as a risky adventure illustrated by titles of papers such as: Developing new 
baculovirus products or “How to walk a tightrope” (Kessler, 2008), and “The long and 
winding road- discovery to commercial product: are we there yet?” (Brownbridge, 2008). In 
this chapter I have identified the commercial factors that are critical in the route to success for 
a company and a product. There is no guaranteed route to success, but lessons from the past 
should be taken seriously, and recommendations for do’s and don’ts are provided below that 
will stimulate and help new projects, products and companies to be successful.      
 
Five determinants for success or failure  
To develop a successful product and to become a profitable company in the area of 
biopesticides is an enormous challenge. The many critical aspects described in this chapter 
provide a matrix of product attributes and market features that need to be profoundly 
understood and weaved together. The complicated commercialization route demands 
biological and technical expertise, understanding of the market, and entrepreneurial 
intelligence, next to commitment and perseverance. On the other hand, if the prospects for a 
product are not convincing, management must be so courageous to abandon the project in 
time, to prevent serious loss of money and time. This may be the most difficult decision since 
everyone involved is focussed on developing a new product. Therefore, it is elementary to set 
up a stage-gate system, and to make decisions transparent based on quantifiable factors. 
Resources can only be used once, and it is essential for a company to spend them on the right 
project. The lack of resources or ill-judged use of them has caused many companies to fail 
(Lisansky, 1997; Gelernter, 2005). Decisive factors that determine success or failure are: 
• the expenses and time for development and registration; 
• the quality of the product in terms of efficacy and price, measured in customer’s 
satisfaction; 
• the size of the market(s), and a realistic estimate of the sales volume;  
• the margin between full cost price and the end-user price that provides a sustainable and 
profitable business and resources to grow and develop new products; 
• a company’s strategy regarding expansion and taking financial risks. 
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These five factors are briefly discussed below and recommendations are deduced which, in 
my opinion, when followed will increase successful commercialization of a biopesticide.   
 
Developmental expenses and time  
The estimation of the developmental and registration costs and time to market must be as 
accurate as possible for a realistic business plan. Due to the fact that each biopesticide is 
unique, and its potential markets different, only a rough estimate can be provided. The 
accuracy also depends very much on the company’s experience in biopesticide development 
and registration procedures. Estimates are provided above. Initially, the uncertainties will be 
many, but as time progresses and investments increase, the uncertainty level should drop. If 
this is not the case, the decision to continue should be re-evaluated seriously since the 
financial risks may become dangerous for a company. The total expenses are high for a small 
company and often a barrier. Collaboration with public research is essential and should be set 
up from the outset of a project. The idea for a new product often originates from a research 
organization and co-development with the help of public resources will reduce costs and time, 
and increases the chance for success considerably.   
 
Product quality  
Biopesticides face a number of limiting factors which need to be considered during the 
commercialization. These are biological (mode of action, dependence on environmental 
conditions), technical (production, formulation, shelf-life), and economical and market-related 
(competition with chemicals, efficacy, costs, sales potential) (Van der Pas et al., 2000). Some 
of these are hard to overcome and are inherent to entomopathogenic organisms. The ideal 
biopesticide does not exist, and we have to accept that biopesticides do have advantages and 
disadvantages. Both need attention in the developmental phase. The advantages should be 
exploited where possible; the disadvantages should be recognized early on and improved 
where possible. Neglecting those can cause disappointments when it is too late.  
 A product should fulfil the following conditions: reliable and consistent field 
performance, a balanced cost price-effectiveness that can compete with chemicals, high and 
stable quality, user-friendliness, and availability at all times. Products are successful when 
customers are satisfied with their performance and use them repeatedly. Biopesticides are 
price-sensitive, but more and more, other attributes are appreciated in the market. Good 
products should offer economic benefit and value for the grower. So-called weaknesses of 
biopesticides (table 7.11) can also be advantages, particularly in IPM systems and in food 
crops. In positioning the product, these ‘weak’ attributes can possibly be exploited in the 
market. A profound understanding of the strong and weak aspects of the product will allow an 
optimal market positioning. But a good product is not necessarily a successful product. It is 
the demanding task of a company to promote and sell the product in substantial amounts. 
 
Market development 
The success of a product is decided in the market, and only there. Many companies 
underestimate this part of the business and have not succeeded because of that. Lisansky 
(1985) stated that “selling the products is the most difficult task of all”, and this is probably 
still true. Most biopesticide companies are technology-based and product-driven and have 
sufficient skills to develop good quality products. Marketing skills are less often available and 
are sought outside the company, with distributors. But this is often only seriously undertaken 
once the product is developed. This is generally too late, and as it takes years to reach sales 
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volumes, this could bring the company in trouble. As rightly said by Moore regarding the 
slow uptake of Green Muscle, “The lesson that inventing the better mouse-trap is not enough 
has been understood” (Moore, 2008). Similarly, Cross and Polonenko (1996) concluded, after 
having developed a highly efficacious bioherbicide that “the possession of great technology 
doesn’t necessarily guarantee commercial success”. The adoption of a new product in the 
market must be taken seriously in an early phase of the project. Market research should be 
carried out prior to the product development stage, and the outcome could lead to a ‘no go’-
decision of a project. Market research should be continued since the market is always in 
motion. When necessary, the original plan must be adapted and decisions re-evaluated.  
 Early involvement of distributors is indispensible. The distribution channel is a key 
aspect in successful commercialization. Marketing and distribution services are indispensible 
to reach the end-user. Understanding the product, and distributor and grower training is 
decisive in the promotion and selling of the product. A comprehensive and excellent analysis 
of why the commercialization of a bioherbicide failed in Canada is provided by Cross and 
Polonenko (1996). They concluded that in particular their unrealistic estimate of the market 
size, and of the market penetration percentage, was the reason for failure. This analysis 
exemplifies how projects are often run, and I have frequently seen this approach taken, 
unfortunately. A solid market analysis is the foundation of a successful market introduction. 
Effective marketing requires that a considerable part of the resources be allocated for the 
product’s field development and this aspect should not be underestimated. Market research 
should continue after product introduction in order to identify new opportunities that could 
maximize revenues from the product.  
 
Profit margin is a must 
In most cases biopesticides need to compete with chemicals and generally they are more 
expensive. Market penetration and sales volume is imperative for return on investment and for 
a profitable business. The market price needs to allow a profitable margin for the 
manufacturer and distributor. Lowering the market price may increase sales, but jeopardizes 
the profit margin. A balance needs to be found, and other attributes of the product need to be 
emphasized in the market to promote the use of the product. This requires an inventive 
marketing strategy and the involvement of all stakeholders without increasing the marketing 
and sales expenses too much. Profit is an absolute necessity for a company and determinative 
of the success or failure ultimately. Therefore, profit calculation is vital early in the project 
and must be strongly weighed in ‘go/no go’-decisions.     
 
Successful business model 
All kinds of companies from very small to large multinational companies have been active in 
biopesticides. Those that have developed a sustainable business are mostly small enterprises, 
specialized, and committed to a certain niche market, particularly when they first started. 
Examples are companies who only produce nematodes, or baculoviruses; or just for a certain 
niche market like greenhouse vegetables, or outdoor ornamentals. Apparently, it is not just 
what and where a company does it, but mostly how a company does it. It is essential to 
understand the route from the first step in the project up to the marketing and sales of the 
product. The prerequisite is a full commitment to the whole route and the ascertainment of 
resources. Companies active with microbial control agents, where registration is required, as 
well as companies active with entomopathogenic nematodes have demonstrated that this 
approach performs well. A small company who knows its products and markets in depth, who 
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steadily develops the company in terms of expansion into new markets and new products, and 
who carefully judges the risks it takes, is the successful business model today.  
 On the other hand, it is remarkable that three large Japanese companies are successfully 
active in the biopesticide field through their affiliates. These are Arysta LifeScience, Mitsui & 
Co, and Sumitomo Chemical, through respectively Natural Plant Protection (NPP) in France, 
Certis in USA and Europe, and Valent BioSciences (VBS) in the USA. These parent 
companies produce and market chemical pesticides and they position pesticides in IPM 
programmes next to their biological products. There seems to be a difference in strategy; 
where Certis is active in both biopesticides and chemicals, NPP and VBS are solely active in 
biopesticides. The success of these Japanese companies in biopesticides may be explained by 
their long-term vision and commitment, that is a general characteristic of Japanese business. 
This illustrates again that success in biopesticides depends on “how a company does it” and 
that long-term commitment is determinative. Businesses focussed on short-term money-
making did not and will not succeed in biopesticides to date.   
 
Recommendations for successful commercialization of a microbial pesticide 
Each biopesticide development and commercialization route is different and each company 
has its own strategy and objectives. A general pathway to a successful product can be 
provided, but it needs to be tailored in each case. New product development is a difficult 
process in any industry and one of the weakest facets is effective project selection and 
resource allocation (Cooper and Edgett, 2006). Learning from the mistakes made in the past 
by others as well as inside one’s own company is essential. I have deduced ten operational 
recommendations from the biopesticide industry and from other industries which face similar 
challenges (table 7.12). Following these general recommendations will, in my opinion, 
increase the chances of developing and selling a biopesticide in a profitable and sustainable 
way for a biopesticide company.  
  
 
 Table 7.12.   Ten recommendations for the commercialization process of a biopesticide 
 
• Ensure that the project fits the company’s strategy and capabilities 
• Draw up a proper business plan with accurate information and market data 
• Be conservative in the estimation of the market potential 
• Set clear objectives, and allocate resources 
• Obtain genuine commitment from all decision-makers in the company 
• Install a systematic idea-to-launch-to-sale-volume process, and make the gates 
work 
• Develop a rating system for quantifiable and objective decisions  
• Define success criteria and ‘go/no go’-decision moments up front 
• Involve all functional fields in the decision team: R & D, M & S, finance, and 
corporate management  
• Continuously evaluate progress, expenses and expected revenues 
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Requirements for a company to be successful 
For a company to be successful, it is necessary to have a vision, to have the required 
knowledge, skills and resources, and to develop an appropriate business plan. If any of these 
requirements is insufficient or lacking, the project may end in confusion, anxiety or 
frustration and eventually failure. A company must develop a strategy, and follow it. Making 
choices at the right time is a crucial management attribute. When a company wants to develop 
new products and grow, it must have a critical look inside, and consider whether the current 
organization is fit for its future outlook. It is vital to have the internal organization structures 
and procedures in place when growth is the objective. If only growth is pursued, this can 
easily frustrate an organization and give rise to large difficulties. Growth and 
internationalization must be encouraged in predictable markets that can be developed without 
taking too high risks. Continuous improvements on all terrains are necessary to stay 
competitive. Costs must be vigilantly observed, and progress strictly monitored, new markets 
developed as speedily as possible to increase income. Profitability is required, so new projects 
can be started and new products developed and registered. Only profitability can ensure return 
on investment, new investments and new projects for the future, and that a company can 
remain competitive, innovative and sustainable. All this is a great challenge for all those 
involved, and at the same time also highly motivating and fascinating. This should drive 
entrepreneurs to continue in the field of biopesticides and to make it a successful and 
sustainable business. 
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Abstract 
The development of a microbial pest control product requires a structured project plan. The 
building blocks of the entire process are identified and essential aspects highlighted. The 
selection criteria for a microbial pest control agent are defined as well as critical parameters 
for the development of the product. Quality control is a significant tool in optimizing 
production and product, and benefits the producer and its customers. Implementation of the 
product into an integrated pest management programme is pivotal for a substantial uptake of 
the product in the market. Three phases are distinguished for successful uptake in the market: 
an appropriate application strategy, an optimal implementation strategy, and an adoption 
strategy. Key success and failure factors are identified. Determinants for successful 
commercialization are: acceptable expenses and time to market, a high quality product that 
provides function and value to the customer, a sufficiently large market, a profit margin that 
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allows development of new markets and products, and an appropriate business approach. 
Registration is a major hurdle for biopesticides. Salient registration issues are mentioned and 
suggestions for improvements are proposed. The road to a successful product is designed and 
the process is divided in phases and steps. Diagrams illustrate the stepwise approach of the 
entire process, the selection phase, the product development phase, and the implementation 
phase. A future perspective on the biopesticide market is presented with limiting and 
promotional factors and trends. The significant drivers for success are food safety concern, 
new research and technology, changes in the regulatory climate, and the occurrence of new 
invasive pests. The biopesticide industry has reached a sufficient level of maturity and critical 
mass to form a base for further expansion. This will allow the biopesticide market to steadily 
grow. The roadmap proposed in this study will assist developers of biopesticides in 
accomplishing their goals in a cost- and time-effective way, which will result in successful 
and sustainable products and expanding biocontrol companies. 
 
Introduction  
 
The development and commercialization of a microbial pest control product is an extremely 
complex process. The total project from idea to market entry can take many years, and costs 
may amount to a few million Euros. Therefore, it is necessary to have from the outset an 
extensive overview on how such a project will be developed, and which critical issues will be 
encountered. A complete and structured project plan is required which oversees all phases, all 
decisions, and the consequences thereof. Such a complete project plan has not yet been 
described in the literature. This study aimed to produce a complete roadmap for the 
development and commercialization of an entomopathogenic microbial pest control product, 
with an emphasis on commercial and economic issues.  
I will briefly summarize the most important results of my study and highlight the pivotal 
issues. Diagrams are presented illustrating the relevant building block and routes in entire 
developmental process. Further, I will report the limiting and promotional factors and trends, 
and present a future perspective on the biopesticide industry and market. Suggestions are 
provided to overcome obstacles to a successful uptake of biopesticides. 
 
Identification of selection criteria  
In the first phase of the project the objectives must be established (chapter 2). It must become 
clear what type of product will be developed, against which pest(s), and in which cropping 
system(s). An elaborate description of the pest problem provides direction to the search for a 
microbial pest control agent. The collection of entomopathogenic pathogens is the first 
concrete step in the process, followed by a screening process to select the best candidate 
strain(s). The first level of selection is the type of pathogen: bacteria, fungi, viruses, protozoa 
and entomopathogenic nematodes. The second level of selection is at the species and strain 
level. Biological features of a potential agent are crucial, but these need to be evaluated in this 
selection phase along with economic factors. I consider relevant selection criteria for a 
commercial MPCP to be: mortality, production efficiency, and safety. Favourable features 
related to mortality and economics are: a low LC50 dose, a broad host range, good 
persistence, low sensitivity to environmental influences, and a quick speed of kill. Strains 
with positive productivity indications as a high yield and low production costs are promising. 
A selective mode of action suggests safety to humans and non-target organisms and this may 
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keep registration costs low. The absence or presence of metabolites will greatly influence 
registration expenses too.  
 Efficacy tests used in the selection process need to reflect the ultimate commercial 
conditions. A tiered approach is recommended (see table 2.3). The gathered information 
allows the developing team to make a ‘go/no go’-decision: i.e. have strain(s) been found that 
offer sufficient promise for the following phases in the developmental process? The best 
strain(s) will be a compromise of biological parameters and economic factors in the decision 
whether to continue, and economic considerations should be leading. 
 
Critical parameters in product development 
The following step is the examination of the feasibility of an economic mass production of the 
selected strain(s) and the development of a stable product (chapter 3). Biological and 
technical options together with economics (table 3.2) determine the choice of the production 
system. Preferably, it will be an in vitro process because that offers more control of the 
production process than an in vivo process. In both, production efficiency and cost-
effectiveness are the key-factors.  
 The challenge in process development is the extrapolation and realization from 
laboratory scale techniques to commercial and large-scale technology. I propose therefore that 
production research is initiated as early as possible in large-scale bioreactors. Economy of 
scale is essential to decrease costs in three areas: capital, labour, and materials. Improvements 
in production technology as well as the reduction of production costs should be a continuous 
research objective. Equipment should be versatile allowing the production of various insect 
pathogens or other biocontrol agents. 
 Formulation research is required for the development of a stable product that delivers 
effective pest control. Formulation is linked with the production system, the medium 
composition, and the down-stream process. Formulation serves four functions: stability of the 
propagules, effective delivery, on site protection of the propagules, and safety for the 
applicator. These four functions need to be investigated and can be optimized by manipulation 
of process parameters in the production phase as well as in the down-stream phase. Medium 
composition influences the quality of the propagules, and co-formulants can protect the 
propagules and improve other product properties. Formulation can improve efficacy, shelf-
life, and user-friendliness of the product. Solutions for the four functions are not always 
compatible and the final formulation is a compromise between all these demands. 
Formulation is specific to a certain type of pathogen (table 3.5) and its specific use, so it 
demands a case by case approach. 
Field testing links all the phases in the developmental process (table 3.7). Its results 
provide information on whether the selected strain is sufficiently effective, on the quality of 
the produced propagules, on the formulation, on the application strategy, on efficacy required 
for registration, on the implementation of the product in an IPM system, on compatibility, and 
on the marketability of the final product. Results from field tests provide a continuous circle 
of feedback that allows improving aspects of each of the steps of the entire process. Field tests 
must allow the final selection of the best strain. The method of testing is crucial and it must 
reflect ‘real world’ conditions. Often, the relevance of field testing is underestimated and it is 
insufficiently executed. Field testing, however, is an imperative step in the product 
development and sufficient resources must be allocated to conduct high quality field tests. 
A cost price model for biopesticides is presented with costs factors involved from 
production to product (table 3.9), and from product to market (table 3.10). I report key 
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considerations for an economic analysis of a biopesticide production (table 3.12). I 
recommend making an analysis of production economics and the calculation of final product 
costs as early as possible in the developmental process for a reliable decision on whether the 
product could be produced in a profitable manner.  
Key factors that determine the feasibility of an economical mass production and 
formulated product are investments, economy of scale, capacity usage, stability of production 
process, production yield and application dose, product shelf-life, level of efficacy, user-
friendliness, full product cost price and end-user price.  
 
Quality control procedures 
Quality control (QC) provides feedback on the production and formulation processes and the 
final product. The continuous process of improvements will ultimately decrease costs and 
improve performance of the production system and the product (chapter 4). Production 
control and process control refer to internal quality control of the production, and ensure a 
stable production process with a minimum of failures. Product control refers to the quality of 
the final product that will leave the factory. Parameters checked per batch are the number of 
effective propagules, microbial purity, presence of toxins, technical properties, and efficacy. 
Product specifications must be met until the end of the claimed shelf-life. Post-shipment 
product quality control is particularly warranted for nematode-based products.  
A biocontrol company should implement QC procedures, at the same time they will be 
required for registration. Both industry and regulators face the lack of officially recognized 
standard QC criteria and methods. Guidance documents need to be developed as soon as 
possible. I argue, however, that a standardization of efficacy for all microbial pesticides 
should not be established since this has not succeeded for Bt’s after thirty years of research, 
comparative testing, and discussions. Further, I recommend that the tolerance range for the 
number of active propagules be set at ± 25%. Biocontrol companies should ensure that 
product quality is maintained through the entire distribution chain and that end-users receive 
high quality products. In that way, both the biocontrol industry and its customers benefit from 
proper QC.  
 
Implementation in an IPM system 
The implementation strategy of the product in an IPM programme is a basic element of the 
use of any MPCP (chapter 6). The positioning of a product implies a good understanding of 
all components of an IPM system and their interactions with the new product, in any given 
cropping system. This phase requires a considerable amount of research which should be 
conducted before market launch. I have experienced that many companies underestimated or 
even neglected this part of product development. The application strategy, compatibility, and 
knowledge transfer to the user are key factors for a cost-effective implementation of a 
microbial pest control product, and are determinative for rapid product adoption.  
The first element is an optimal application strategy of the product itself. This has to be 
studied for each type of entomopathogen, target pest(s) and cropping system. Label 
recommendations need to be established for proper use and advice by sales people, and for 
registration. This usually receives enough attention from product developers since it has a 
direct impact on the overall field results of the product. 
The second element is the incorporation of the microbial pest control product in an IPM 
system. For proper positioning in an IPM system many interactions have to be identified and 
investigated, but often, only limited research is conducted due to lack of availability of 
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facilities and restricted budgets. In my opinion, this phase is paramount for good market 
introduction, and needs appropriate resources.  
The third element of implementation is a carefully designed adoption strategy. The 
benefits of the new product need to be demonstrated to the grower. Efficient knowledge 
transfer and training are essential. I recommend that all stakeholders participate in this 
process, particularly those in the distribution channel, but I emphasize on direct involvement 
of growers.  
I suggest the study of alternate and simultaneous applications of two types of microbial 
pest control products. I consider using multiple biopesticides a useful strategy when larval 
stages have a different susceptibility towards two pathogens, when speed of kill may be 
enhanced, when insect stages are in different locations on the plant, when two pathogens 
increase insect susceptibility, and when multiple pests are targeted. Combinations of a 
microbial with a chemical or another pest control means offer increased control, but this is not 
often applied in practice either. The use of pollinators as vectors for entomopathogens is 
another potential combination. These possibilities warrant further research since they allow a 
reduction of use of chemical pesticides and an enhanced biocontrol efficacy. 
Field resistance has been reported for Bt and for one baculovirus. Thus, resistance 
management must become part of the application strategy, and biopesticide producers need to 
take this seriously.  
The methodology used in compatibility tests for chemical as well as biological control 
agents may influence the outcome, and the relevance for field conditions is often debatable. I 
propose a tiered approach that results in reliable data for commercial conditions (table 6.3).  
Successful implementation of a MPCP depends on how well relevant interactions are 
studied and translated into practical recommendations for the grower. This phase continues 
after market introduction. It requires a continuous effort from producer, distributor and 
customer to ensure that product adoption will increase, and satisfied customers will remain 
using the new product in their IPM system.  
 
Key success and failure factors in the commercialization process 
Commercialization is the final and most difficult step in the development and the introduction 
in the market of a microbial pest control product (chapter 7). This is not just the case for bio-
insecticides, but also for microbials for control of diseases, weeds, and postharvest pest and 
diseases. I estimate that the global biopesticide market is approximately $500 to $700 million 
in 2009 while the total pesticide market was about $40 billion (CropLife, 2009). Biopesticides 
are predominantly used in protected crops, orchards, forestry, and for vector control; use in 
agricultural crops is just beginning. Bacillus thuringiensis products are the most successful. 
My estimate is that commercialization of baculoviruses and EPNs is a profitable business for 
the manufacturers. Sales of both groups are expanding. Business in entomopathogenic fungi 
seems to be marginal or unprofitable. I have identified the common success and failure factors 
for a biopesticide company (table 7.7). 
 The biggest mistake companies still make today is a misjudgement of the potential 
market size and the expected market adoption rate. They underestimate the efforts, time, and 
costs to introduce a novel product successfully in the market. I recommend that product 
developers use realistic insights in the target markets, and that decisions should also take 
conservative market projections into account. I propose the use of a stage-gate process with 
objective, quantifiable, and transparent tools in decision-making which can assist companies 
in understanding the key issues and moments. Score-cards as presented in table 7.8, 7.9 and 
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7.10 will help in this process. Many companies discover too late that the developed product 
does not live up to its expectations. A ‘no-go’-decision is also a valuable decision, and time 
and money can then be spent on a better project. A careful approach in biopesticide activities 
explains that the model that currently performs best seems to be a small company which 
pursues an incremental and manageable growth of the organization. 
 Microbial pesticides have limitations as well as strengths (table 7.11). A SWOT 
analysis of these products together with an analysis of external factors assists in recognizing 
the product’s value in the market. The challenge is to position the product in the market with 
its pro’s and con’s and not to ‘overpromise’. 
 Total developmental costs and time to market are significant factors of a company’s 
success. Costs amount to € 10-15 million for a company that still needs to be built; while in 
an existing company, costs may reach € 5-10 million for a biopesticide project. Time to 
market including registration is five to seven years (figure 7.2). Collaboration between private 
and public organizations is imperative, and reduces time and expenses for a company. I 
recommend both parties to work together from the outset of the project so that poor transfer of 
ideas from the lab to the market can be significantly improved. 
 Economics is the key to success. I have identified five determinants for successful 
commercialization. These are: 1) acceptable expenses and time to market; 2) a high quality 
product that provides function and value to the customer; 3) a sufficiently large market; 4) a 
profit margin that allows development of new markets and products; and, 5) the appropriate 
business approach. Only when these conditions are met can a sustainable and profitable 
business be run.  
 
Salient regulatory topics 
Registration (chapter 5) is not an integral part of the chain of steps in the developmental 
process of a MPCP, but it can be seen as an umbrella process that provides a framework, with 
conditions and limits, in which a new product can be developed. This is particularly the case 
with microorganisms, but much less with entomopathogenic nematodes. The registration 
dossier is built up with information obtained from each step in the developmental process. 
The entire developmental process and the final product must be considered in light of 
registration as many aspects may have consequences and increase registration costs. Product 
developers must be well aware of the impact of registration requirements. These requirements 
differ between countries. Guidance documents are lacking as well as clear criteria for many 
studies. This renders the development of a product for an international market difficult and 
complex. I recommend the familiarization of the registration requirements from the outset. 
When these are not clear, a pre-submission consultation meeting with the evaluation authority 
should be requested. This will minimize trouble, time, and costs in a later phase, for both the 
applicant as well as the regulator.  
 Registration is perceived as the main hurdle to the development of a biopesticide. And 
surely it is a great challenge, for newcomers, and even for experienced companies. In my 
experience the generation of a dossier for a microorganism is not the greatest challenge, but 
the inconsistency and unpredictability of the product approval timeframe and costs are the 
most difficult to manage. This can significantly impact company growth, and even survival. 
Therefore, there is an urgent need to streamline the registration process and make it more 
transparent and predictable in terms of costs and time. Regulators and industry need to 
continue the dialogue that was started with the REBECA project, and assist each other 
improving this awkward situation. 
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Import and export regulations affect the use of microorganisms. Here as well, many 
different rules apply depending on the country, particularly for nematode-based products. The 
same is true for other invertebrate BCAs. At the risk of repeating myself, regulators and 
industry need to begin a dialogue to keep trade in biopesticides manageable. A similar case is 
developing around Access and Benefit Sharing which may create a further impediment for 
biocontrol (Cock et al., 2009). 
Investment and IP with regard to MPCPs can be protected by a patent. It may be 
worthwhile to investigate this option in order to safeguard the position of a company. 
Nevertheless, patents are expensive and whether to apply for a patent needs careful 
consideration. Registration also offers protection.  
Registration and regulations are a great challenge for biopesticide companies. On the 
one hand, they should safeguard them in the market from unlawful products. On the other 
hand, many products are illegally sold in the market and often are products with poor quality. 
Authorities should inspect this aspect more rigorously since it has a negative effect on 
biocontrol in general. 
 
 
Roadmap to a successful microbial pest control product 
A new product development project is extensive and it is difficult to oversee. The process 
consists of hundreds of various aspects and steps. An analysis of the various phases facilitates 
overseeing the entire process. I distinguish an exploratory phase in which an enterprise 
contemplates and investigates the development of a MPCP. It is predominantly a theoretical 
phase in which essential business information is gathered from the market. Together with 
considerations reflecting the internal capabilities, this forms the basis for the decision whether 
to proceed to the executive phase. This first phase requires the knowledge of what needs to be 
conducted in the following phases. During these, there must be a constant feedback to the 
objectives of the project.  
 In figure 8.1 a schematic view is presented which illustrates the main influences and 
processes in the development and commercialization of a MPCP. The external factors from 
governments, society, and the market influence the strategy, mission and vision of the 
biopesticide company. The company’s strategy, expertise, and facilities govern the direction 
and design of the development and positioning of the product. The development process is 
divided into a number of phases that are addressed in sequence. However, parts of processes 
can be dealt with simultaneously. It is not a simple stepwise linear process. Parallel working 
is important since this saves time. Planning is paramount for a time- and cost-efficient route to 
the market. In the optimization of processes it is necessary to go back to the preceding phase 
to improve the outcome until a satisfactory answer is provided. This feedback loop frequently 
occurs as illustrated in figures 8.2 to 8.4. Each answer or result impacts the following 
processes. Between phases, decisions should be made whether to continue with the next 
phase. Commercialization as defined in this study is an overall process that sets conditions for 
the product and the investments, the costs of the product, and margins in the market. 
 Registration provides an external set of requirements and conditions. It is also 
influenced by the internal constraints of registration, i.e. how much is a company able to 
spend on registration studies and how much of this can be implemented as part of the cost 
price still allowing an acceptable final cost price. The number of target crops as well as the 
number of countries in which sales are anticipated influence registration costs. The generation 
of the registration dossier should be initiated early in the process. This is not a distinct phase 
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at some point in the process, but a continuous activity that provides input and demands output 
for the registration dossier. When field testing has been completed with satisfactory results, 
external toxicology and ecotoxicology studies can be conducted. During the evaluation period 
by the authority, implementation and adoption of the product can be studied and prepared. 
Finally, when the company’s management concludes that profitability can be achieved, and 
when regulatory approval is obtained, sales can be initiated. After-sales service is imperative, 
and provides feedback information too that could improve the product and the strategy of use. 
 
 
Figure 8.1   General model which illustrates the main external influences and internal  
         processes and phases in the development and commercialization of a MPCP  
BIOPESTICIDE COMPANY
macro-environmental factors
government, society, legislation, market, research
selection product ipm
sales
commercialization
exploration
registration
ercialization
strategy, mission and vision
high 
probability of 
profitability
approval
selection product de-velopment
implementation
adoption
new product development
 
Figures 8.2 to 8.4 illustrate the pathways of the selection phase, the production and product 
development phase, and the implementation phase. The diagrams show the interactions 
between the steps and illustrate the entire process. The information that needs to be generated 
within each step, and the criteria that need to be satisfied are provided on the top level as 
input conditions into the activity blocks. The outcome of an activity is illustrated by an output 
arrow on the left of each process block. This outcome is input for the following activity. 
Returning information is illustrated by arrows from the underside of blocks. At the end of 
each phase a no/no-go decision has to be made before entering the next phase. Continuous 
feedback information is imperative for improvements and optimization in any process. The 
diagrams present the essential building blocks of the development and commercialization of a 
MPCP. Its stepwise structure outlines the entire process architecture and provides a roadmap 
for product developers. 
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Future perspective 
The driving forces in pest management are varied, and they continue to develop and change. 
The main forces that influence biological control and IPM are legislation, environmental and 
food safety concerns, science and technology, and economics (Uri, 1998; Dent, 2000; 
Marrone, 2007; Bale et al., 2008; Bailey et al., 2009). Governmental policy has direct and 
indirect influences on crop protection through legislation, funding of research and extension, 
environmental programmes, trading policies, biodiversity topics, etc. (Uri, 1998; Chandler et 
al., 2008a). Some are favourable, others unfavourable for the use of biopesticides.  
An analysis of macro-environmental factors and trends assists a company in 
understanding its business position, the market, and potential directions for new 
developments. At the present, many external factors occur simultaneously which cause pest 
management policy to change in such a way that this offers an improved climate for the 
biopesticide industry. I will present the major factors and trends that limit or stimulate 
biological control. Suggestions are provided to improve wider adoption of microbial pest 
control products. I will sketch an outlook on the market, and on the way forward with 
biopesticides and other biologically-based alternatives for crop protection. 
 
Limiting factors and threats  
Political factors 
As long as conventional pesticides are cheaper than microbial disease management products, 
they will continue to dominate the market for pesticides. Pimentel (2005) reported on the 
major hidden environmental and economic costs of the application of synthetic pesticides. 
Biopesticides do not cause these costs and this should be part of the equation when a new 
policy for crop protection is designed. Menzler-Hokkanen (2006) argued that a mechanism 
for price support in favour of biological control should be installed because of the socio-
economic benefits associated with the replacement of chemicals by biocontrol to the society. 
This good idea should be considered by policy-makers.  
The establishment of an agreement on Access Benefit Sharing regarding genetic 
resources could impede collection of new BCAs and form a threat to biocontrol (Cock et al., 
2009). Policy-makers should enable research and industry to continue with the development 
of sustainable pest management methods by providing a practical and workable framework.  
 
Societal and market-related trends 
The broad use of biocontrol with natural enemies and microorganisms may include a risk 
since any insect or ‘germ’ on food is perceived as highly undesirable by the public. Good 
communication will be necessary to avoid such a “food-scare” or a negative association of 
“man playing with nature” (Ritson and Kuznesof, 2006).   
Biopesticides need to break away from the single-technology approach of chemical 
pesticides and be implemented as key components of an IPM system. They should not be used 
in the same conceptual model as chemicals, and they should not be expected to out compete 
chemicals. Growers also need to change their use patterns in crop protection and think more 
about truly integrated approaches. The grower’s difficulty in adoption of biological 
alternatives is the increased knowledge to make it function as well as the costs. This is part of 
a larger problem of declining returns in agriculture. Growers need to receive better returns for 
their product if they are going to spend more capital on their inputs such as more biological 
and natural solutions for their pest and disease problems. If the consumer wants sustainable 
agriculture and safe food, he will have to be willing to pay more for his food. 
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Research needs 
Continued research efforts are required for a deeper understanding of the mode of action, 
ecological constraints and requirements, and other fundamental aspects of entomopathogens. 
More applied research is also needed on application methods, formulation and shelf-life, on 
interactions in the field, and combined uses of microbials. Although Bt’s are the most 
successful bioinsecticides, the market still asks for ‘faster killing’, ‘higher efficacy against 
mid-late instars, ‘longer field life’, and ‘rain-fastness tolerant’ Bt products (Georgis and 
Warrior, 2007). Better and more competitive biopesticides could be developed with more in-
depth knowledge of entomopathogens. More funds are required for this kind of research. 
Institutional scientists need to better understand registration requirements, and help 
industry with registration since in many areas they are the only experts. They have a role to 
play to provide regulators with sufficient relevant biological data to allow them to install a 
more relaxed regulation. An example is the paper of Scheepmaker and Butt (2010) which 
demonstrated that entomopathogenic fungi all decline to natural background levels after 
application and therefore do not pose a threat to the environment. Funding agencies should 
support this kind of work more. 
The assumption that the small biocontrol companies can support the bulk of the research 
is unrealistic as most have limited budgets. Collaboration between public and private sector 
needs to be stimulated. Institutions, however, increasingly require support from the private 
sector. Instead, more governmental support is needed for both public and private 
organizations to develop these products. The political responsibility is to further the 
development of biopesticides if society desires a reduction of the use of chemical pesticides. 
 
Regulatory issue 
Although regulatory innovation is taking place, its pace is much too slow. Governments need 
to give higher priority to a faster and wider adoption of biopesticides and other alternatives to 
accomplish economic and environmental sustainability of modern agriculture. Targeted active 
stimulation is required to achieve successful uptake of biological pesticides in the market. The 
needs for the realization of the envisioned crop protection has been assessed for the EU, and 
the outcome indicated the necessity for more research, more extension, and for harmonization 
in regulations to mitigate the current barriers for adoption of alternatives. An interesting 
recommendation is the “co-funding of the purchase of consultancy advice” (Chandler et al., 
2008b). These proposals need to be transferred into concrete measures. 
 
Promotional factors and trends 
Societal and market-related factors and trends 
Environmental groups and consumer organizations are increasing the pressure on retailers and 
growers to reduce the level of residues on fresh food. As a result, several supermarkets have 
even set chemical pesticide residue levels that surpass officially allowed levels, thereby 
limiting the number of active ingredients. GlobalGap, the global organization of food retailers 
and suppliers, has set standards for growers as “major musts” for crop protection measures 
including the use of IPM (www.globalgap.org). The role of retailers becomes the driving 
force from the market to reduce the use of synthetic pesticides. Biological alternatives could 
fill the gap.  
Biopesticides are becoming a preferred option for pest control due to resistance to 
chemicals, restricted entry intervals for workers, and residue concerns. They are also safe for 
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beneficial organisms, for the crop, and for the environment. Growers’ awareness of these 
benefits is increasing and this stimulates the adoption of biopesticides.  
Organic production of food has experienced worldwide growth surpassing 32 million 
hectares in 2007, and the area continues to expand (www.organic-world.net). It is Benuzzi’s 
(2009) and my own experience that only about 10% of the sales of biopesticides occur in 
organic agriculture. The use of microbials in organic production is allowed, but not 
recommended by the major regulations and standards (Speiser et al., 2006). I do not expect 
this to change dramatically, and biopesticides will continue to be mainly used in conventional 
agriculture.   
Genetically modified crops were cultivated on more than 125 million hectares in 2008 
(Stein and Rodríguez-Cerezo, 2009). Genetic engineering, however, is not a solution for all 
pests and diseases. A synergy between transgenic crops and biocontrol is promising since 
fewer chemicals are used, and secondary pests and diseases require sustainable solutions (Kos 
et al., 2009; Lundgren et al., 2009). This option deserves more research and field testing with 
existing biocontrol products.  
  
Scientific and technological trends 
Research continually delivers new ideas and options for biocontrol. Recently new 
opportunities were proposed for well-known fungal insect pathogens (Vega et al., 2009). 
They may be used as antagonists of plant pathogens (Ownley et al., 2008; Kim et al., 2009) 
and for control of nematodes (Goettel et al., 2008; Shinya et al., 2008), as endophytes against 
insects (Vega, 2008), and as plant growth promoting agents (Vega et al., 2009). Microbial 
disease control agents can also affect herbivorous insects through triggering the plant’s 
defence system (Van Wees et al., 2008; Keel and Maurhofer, 2009). Broader use of existing 
products offers companies larger markets and a better return on investment.  
Strain improvement by hybridization of fungal insect pathogens may deliver strains 
with a broader host range and better persistence on the plant (Aiuchia et al., 2007; Yamada et 
al., 2009). New discoveries in production technology with Metarhizium anisopliae producing 
microsclerotia offer potential for improved control of soil pests (Jackson and Jaronski, 2009). 
The discovery of a synergist, a new protein that increased the efficacy of Bt’s (Abdullah et 
al., 2009), could widen the spectrum and the commercial use of Bt.  
 Genetic improvement is a promising avenue for all microbial control agents and it has 
led to the development of more effective, faster acting baculoviruses, bacteria, fungi, 
protozoa, and nematodes at lab scale (Narayanan, 2002). Genetic improvement of 
pathogenicity has been demonstrated for bacteria (Federici, 2007), for fungal 
entomopathogens (Lu et al., 2008; Pava-Ripoll et al., 2008) as well as for baculoviruses 
(Inceoglu et al., 2006; Szewczyk et al., 2006). Strain improvement by transgenic technology 
in nematodes has been shown for enhancements in environmental tolerances (Burnell, 2002). 
Genetically improved MPCAs may become an option in the longer term in the EU. They 
could be developed today for other countries, like the United States, where they are less 
controversial. 
   
Changes in the regulatory climate 
Registration is still one of the greatest challenges for biopesticide companies, particularly in 
the EU. This is caused by the application of an inappropriate synthetic pesticides model 
(Chandler et al., 2008a), and by the double procedure of evaluation of the active ingredient by 
the EU and product registrations on national level. The new Regulation EC/1107/2009 (EC, 
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2009a) allows for zonal authorizations and mutual recognition. A category of low risk active 
substances has been established, but requirements and a procedure still have to be specified. 
These changes are expected to facilitate registration for biopesticides.  
Initiatives as the Biopesticide Scheme (UK) and the project Genoeg (NL) accomplished 
a substantial number of new approvals of biopesticides. The example of the regulatory 
innovation in the UK (Greaves, 2009) should be followed up by other EU member states to 
facilitate procedures. Similar projects in Canada, by the Pest Management Centre (Bailey et 
al., 2009), and in the USA, by the IR-4 project (www.ir4.rutgers.edu), assist applicants in 
registering their product and boosted approvals of biopesticides.  
The work currently undertaken by OECD to develop appropriate guidance documents 
and test protocols for biopesticides are crucial for harmonization of the regulatory process on 
a global scale. Ideas from the REBECA project should be implemented in a timely manner in 
official procedures and criteria. IBMA continues to lobby for a new registration model 
specifically developed for biopesticides (see Position Paper at www.ibma.ch). A step forward 
is the registration of baculoviruses at species level instead of at isolate level. 
The new Directive 2009/128/EC (EC, 2009b) established a framework to achieve 
‘sustainable use of pesticides’. Member States must “encourage the development of Integrated 
Pest Management and of alternative approaches or techniques in order to reduce dependency 
on the use of pesticides”. National Action Plans have to be developed in which the new crop 
protection aims will be laid down. Implementation is mandatory as from 2014. Both the new 
Regulation and Directive will impact the availability and use of synthetic pesticides. IPM will 
become the prevailing paradigm in pest management and this will create a momentum for 
increased use of biopesticides. Still, there is a need to increase awareness of biocontrol for 
policy-makers, and the biopesticide industry can play an active role here by participating in 
the design of the National Actions Plans.  
 
Biodiversity and environmental concerns 
The extensive use of chemical insecticides and fungicides in agriculture has a negative effect 
on biodiversity. Insecticides also reduce the biological control potential (Geiger et al., 2010). 
Through the implementation of the Convention of Biodiversity governments are required to 
improve conservation and sustainable use of biological diversity and to mitigate negative 
impacts and to support sustainable agriculture. The Directive 2009/128/EC (EC, 2009b) also 
states that due to the environment and biodiversity the use of pesticides should be minimized 
and that “biological control means shall be considered in the first place” (article 12). These 
regulations will further reduce the use of chemicals and promote biologically-based 
alternatives. 
  
Trends in the biopesticide industry 
Biopesticide manufacturers have made considerable progress in production efficiency, 
formulation, quality control, field efficacy, application strategies and marketing in the last 
decade. Products have become more reliable and cost-effective, and markets have expanded. 
Manufacturers realized that products must offer true economic benefit and value to the 
grower. Companies educated distributors and users, focussing on function and value, by 
which a wider adoption has been gained.  
A substantial biopesticide business has been created which forms the foundation for 
further progress. Furthermore, every year new companies are established. Industry has 
reached a sufficient level of maturity and critical mass that will help to increase and accelerate 
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future developments. For companies that have gained experience it becomes easier to develop 
and register new products. Successful companies will expand and cover larger markets. When 
more products are available and used by growers, the users will become more confident with 
microbials, and this will help adoption of new products. 
Noteworthy is the recent renewed interest of the large agrochemical industry in 
biopesticides. They seem to complement their portfolio with microbial products, perhaps to be 
ready when the changes in society today will force them into other directions. Some striking 
examples are the activities of Bayer, BASF and several Japanese companies. In 2009, Bayer 
CropScience acquired Agrogreen’s microbial product Bionem (B. firmus) for control of 
nematodes (CPM, 2009c), and their post-harvest biofungicide Shemer (Metschnikowia 
fructicola) (CPM, 2010). Bayer sells already XenTari (Bt subsp. aizawai) and Bio1020 
(Metarhizium anisopliae) in some countries. In April 2009, Agraquest assigned world wide 
distribution rights to BASF for their biofungicide Serenade (Bacillus subtilis) (CPM, 2009d), 
and to Bayer for the US home and garden market (www.agraquest.com). Three large Japanese 
companies, ArystaLifeSciences, Mitsui, and Sumitomo Chemical have played an active role 
in biopesticides for many years through their subsidiaries, respectively NPP, Valent 
Biosciences, and Certis.  
I expect a greater involvement of large chemical companies in IPM and biocontrol 
products in the near future. 
 
New invasive pests 
New invasive pests offer an opportunity for the use of microbial pesticides when no chemicals 
are available or registered, or because of resistance to chemicals. Recent examples in Europe 
are the western corn root worm Diabrotica virgifera virgifera (Pilz et al., 2009), and the 
South American tomato pinworm Tuta absoluta. Bt is applied in large quantities against T. 
absoluta (J. van der Blom, Coexphal, pers. comm.) and nematodes may be used (Morton et 
al., 2009). New non-agricultural pests are the red palm weevil Rhynchophorus ferrugineus 
against which Bt (Manachini et al., 2009) and nematodes (Llácer et al., 2009) are used, and 
the South American palm borer Paysandisia archon (Nardi et al., 2009) against which 
nematodes are used as well as Beauveria bassiana (Besse, 2008).  
  
 
Concluding remarks 
In conclusion, many factors influence the adoption of biopesticides in the marketplace. 
Changes in regulations, and in political, cultural and social perceptions all determine the 
demand for sustainable crop protection agents. Research and technological discoveries create 
new possibilities for development of better products. Globalization opens new markets and 
offers potential usages, but also creates more problems such as invasive pests and diseases. 
The current macro-environmental trends support the assumption that demand for alternative 
crop protection products will grow rapidly to replace conventional chemical pesticides. We 
have heard similar stories many times before, but they never materialized in terms of large 
sales of biopesticides. But this time, they all seem to fall in place, and the incentive to reduce 
chemical pest control is really coming from the market. I am confident that this will create a 
true demand.  
 
 
 
Roadmap to success and future perspective 
__________________________________________________________________________________________ 
 291
Market size and growth 
Biopesticides have been promised a bright future by many scientists and industrial investors 
since the beginning of their development. Reality is, however, disappointing. Sales of 
microbial pesticides were $268 million in 2005, and the market projection was $750 million 
by 2015 (CPL, 2007a). Thakore (2006) expected biopesticides to reach 4.2% of  the total 
pesticide market in 2010. My estimate is that today microbial sales are still less than 2% of 
the total market. Positive is, however, the growth rate of biopesticides which is about 10-15% 
per annum, and this is likely to continue. Until today biopesticides have predominantly been 
used in niche markets of high value crops. But expansion in agricultural crops is reality, 
particularly for disease control. Other areas of increased usage are forestry, public amenity 
areas, orchards, and vector control.  
I envision growth in the use of bacteria. In addition to Bt, bacteria for plant disease 
control (Bacillus subtilis, Pseudomonas spp) show promise. Secondly, baculoviruses are 
gaining terrain in orchards and also in greenhouse vegetables. The use of entomopathogenic 
nematodes is growing steadily for control of new target pests in orchards and in greenhouses. 
The development of the market for entomopathogenic fungi is the most difficult task. On the 
other hand, the use of fungal antagonists for plant disease control, such as Trichoderma spp. is 
rapidly expanding. Because of food safety and environmental issues new markets are 
expected to arise in China, India, North Africa, the Middle East, and in South America. 
Growth of the biocontrol industry with the current business model with small and 
medium-sized enterprises will continue. The large agrochemical companies will also exploit 
activities with biopesticides, currently as distributors, and maybe soon as producers. An 
alternative is that they will acquire existing biopesticide manufacturers. The distinction 
between chemicals and microbials is likely to blur as metabolites from microorganisms are 
developed as pesticides such as spinosad and spinetoram, and microbials are developed whose 
activity is mainly based on the associated metabolites such as Serenade. I foresee the 
distinction between the two industries to disappear over time. 
 
The way forward      
Increased legislation on the use of pesticides combined with reduced availability of synthetic 
pesticides, demands for sustainable agriculture and low-residues have become reality and 
offer great opportunities for, amongst others, biopesticides. The societal need for biological 
products is, however, something very different from actual customer demand. The putative 
desire from society for sustainable products still leaves the important task to manufacturers to 
decide which product they will develop. Political and societal trends can be strong 
promotional factors, but they should not be determinative. Specific market driven demand 
must remain the target for a company. 
“Biopesticides: the next revolution?” was the title of an article by Lisansky (1989). This 
revolution never occurred, and I do not think that we will see a spectacular growth soon. 
Biopesticides will, however, become a substantial part of the use of all crop protection 
products, and come closer to meeting their potential. I predict a steady and continued growth 
for the next decades. I am convinced that the biological products developed today will form a 
substantial part of the crop protection means of the future. Biopesticide companies need to 
grasp this chance and remain committed to the development of high quality cost-effective 
products. I am confident that the systematic roadmap with a strong focus on economics and 
market introduction proposed in this study will assist developers of biopesticides in 
accomplishing their goals.     
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Summary 
 
 
Microbial pesticides have been developed for a hundred years, but many of these biological 
crop protection products have not been successful in the market. This is illustrated in chapter 
1 by the history of microbial pest control products and the biopesticide companies producing 
those. In this thesis I recognize the need for a model that would facilitate the development and 
commercialization of biopesticides based on entomopathogenic bacteria, fungi, viruses, and 
nematodes. The aim of this thesis was to develop a rational and structured approach that will 
increase the chances of achieving success with microbial pest control products for control of 
arthropods.  
The initial step is finding a microbial pest control agent which has the potential to 
control the pest (chapter 2). The search for a novel agent is directed by an elaborate 
description of the pest problem. The first level of selection is the type of entomopathogen: 
bacteria, fungi, viruses, protozoa, and entomopathogenic nematodes. The second level is at 
the species and strain level. This study identified three decisive selection criteria for a 
commercial microbial insecticide: mortality, production efficiency, and safety to humans and 
the environment. The consecutive steps in the screening process have been identified as the 
collection of isolates, laboratory screening on efficacy in well-standardized bio-assays, and on 
production efficiency, assessment of mode of action and toxicological properties, and efficacy 
in small glasshouse trials. This selection process should deliver determinative information on 
which one or at the most three to four strains are chosen for further development.  
The next phase is the investigation of the feasibility of economic mass production of 
the selected strain(s) and the development of a stable product (chapter 3). Two phases are 
distinguished, the development of the production process, including medium development and 
downstream processing, and the development of the product, including formulation, 
packaging and field testing. Mass production is preferably an in vitro process because that 
offers more control than an in vivo process. Bacteria, fungi and entomopathogenic nematodes 
are generally produced in vitro, whereas baculoviruses must be produced in vivo. The critical 
technical and economic factors are identified and evaluated for these four types of pathogens. 
The goal is to produce the greatest number of infective propagules for the lowest cost.  
A stable product requires a formulation. The four main objectives in formulating the 
infective propagules are: to stabilize the propagules for reasons of packaging, shelf-life and 
shipping; to create a user-friendly product that can be effectively delivered to the target; to 
protect the propagule, once applied, to improve its persistence at the target site; and to 
minimize risks of exposure to the applicator. Formulation considerations and 
recommendations are presented per formulation function as well as per type of pathogen. 
 Field testing links all steps in the developmental process. It provides information on 
the efficacy of the selected strain, on the quality of the produced propagules, on the 
formulation, and on the optimal application strategy. Results from field tests provide a 
continuous circle of feedback that allows improvement of each of the steps of the entire 
developmental process. 
 The price of a product is an essential element and a cost price model for biopesticides 
is presented. The model provides a perspective on the makeup of the end-user’s price. 
Economy of scale, full use of the production capacity, and capacity planning are pivotal 
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factors to keep the costs low. Key elements to successful biopesticides are both production 
efficiency and product efficacy. 
Quality control (chapter 4) provides feedback on the production and formulation 
processes, and on the final product. The continuous process of improvements will ultimately 
decrease costs and improve performance of the production system and the product. Products 
must meet product specifications. Parameters checked per batch are the number of effective 
propagules, microbial purity, presence of toxins, technical properties and efficacy. 
Standardization and comparison with a reference product are prerequisites for proper quality 
control. Quality control is also required for registration, but standard methods and criteria are 
lacking. Therefore, guidance documents need to be developed. Biocontrol companies should 
ensure that product quality is maintained through the whole distribution chain and that end-
users receive high quality products. I showed that in that way, both the biocontrol industry 
and its customers benefit from proper quality control.  
In chapter 5 regulations for microorganisms are reviewed. Microorganisms, except 
nematodes, need to be registered as plant protection products for crop protection. Registration 
is perceived as the main hurdle to the development of a biopesticide. The procedures in the 
EU are presented and difficulties discussed. The issues relate to inappropriate data 
requirements, lack of guidance for applicants and regulators, testing methods for microbials, 
lack of experience in regulators, national registration procedures, and the inexperienced small 
biopesticide companies. Registration is expensive and takes many years. I presented 
registration cost estimates for each type of entomopathogenic product. Initiatives for 
improvements from the EU-REBECA project, from the OECD BioPesticides Steering Group, 
and some national projects are presented. I also provided recommendations for improvements 
for data requirements and regulatory procedures. New regulations may offer improved 
procedures in the near future. Various import and export regulations affect the use of 
microorganisms, and the need for harmonization is emphasized. The Convention of 
Biodiversity may, through Access and Benefit Sharing, create a further impediment for 
biocontrol. 
The patentability of an entomopathogen is discussed as well as the criteria for granting 
a patent: novelty, inventive step, and industrial applicability. I also discussed costs and other 
considerations whether to apply for a patent for a biopesticide. 
The implementation strategy of the product in an IPM programme is a basic element 
of the use of any microbial pest control product (chapter 6). Three phases are distinguished: 
the optimal application strategy of the product, the incorporation of the microbial pest control 
product in an IPM system, and a carefully designed adoption strategy. Determinative 
parameters for each phase, and for each type of product are identified. For instance, for a 
successful use, the compatibility with chemical pesticides and with natural enemies and 
pollinators needs to be investigated. Furthermore, knowledge transfer and training are pivotal 
elements. All stakeholders need to participate in this process. 
These phases require a considerable amount of research which should be conducted 
before market launch. Recommendations are provided for a tiered approach which results in 
reliable information for commercial conditions. Many companies underestimated or even 
neglected this part of product development. In my opinion, these phases are paramount for 
good market introduction. I reported the most relevant requirements for successful use of a 
microbial pest control product. Successful implementation of a microbial pest control product 
depends on how well relevant interactions are studied and translated into practical 
recommendations for the grower. This phase continues after market introduction. It requires a 
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continuous effort from producer, distributor and customer to ensure that product adoption will 
increase and satisfied customers will remain using the new product in their IPM system.  
In chapter 7, I noted that commercialization is the final and most difficult step in the 
development and the market introduction of a microbial pest control product. The factors that 
determine success or failure are identified for a company as well as for a product, and 
recommendations are provided that will facilitate success. 
Figures on the global biopesticide market are reviewed. The European market is 
estimated to be €57 million at end-user level, and the market in the Netherlands at €5-6 
million. The European biopesticide market comprises less than 1% of the total European crop 
protection market. Biopesticides are predominantly used in protected crops and in orchards. 
Companies which contemplate the development and commercialization of a 
biopesticide need realistic data on five key aspects to make their decision: market demand, 
market size, profit margin, time to market, and time to volume. The biggest mistake 
companies still make today is a misjudgement of the potential market size and the expected 
market adoption rate. I proposed the use of a stage-gate process with objective, quantifiable, 
and transparent tools in decision-making. Examples of scorecards are presented to quantify 
decisions. The business model that performs best at present seems to be a small company 
which follows an incremental and manageable growth of the organization. Total 
developmental costs and time to market are significant factors of a company’s success. Costs 
amount to € 10-15 million for a company that still needs to be built; while in an existing 
company, costs may reach € 5-10 million for a biopesticide project. Time to market including 
registration is five to seven years. I have identified five determinants for successful 
commercialization: 1) acceptable expenses and time to market; 2) a high quality product; 3) a 
sufficiently large market; 4) a profit margin that allows expansion in new markets and 
products; and 5) the appropriate business approach. 
A new product development project is extensive and it is difficult to oversee. In 
chapter 8 I have made an analysis of the various phases and I highlighted the most important 
topics in the development and commercialization of a microbial pest control product. This 
study demonstrated that the development of a microbial pest control product requires a 
structured project plan. The building blocks of the entire process are defined and essential 
factors emphasized. From this, I have divided the process in phases and steps, and designed 
the roadmap to a successful product. Three diagrams illustrate the stepwise approach of the 
entire process, the selection phase, the product development phase, and the implementation 
phase. Registration and commercialization are processes that relate to these phases during the 
entire developmental process. 
A future perspective on the biopesticide market is presented with limiting and 
promotional factors and trends. The significant drivers for success are food safety concern, 
changes in the regulatory climate, biodiversity and environmental issues, new research and 
technology, and the occurrence of new invasive pests. The biopesticide industry has reached a 
sufficient level of maturity and critical mass to form a base for further expansion. This will 
allow the biopesticide market to steadily grow. The roadmap proposed in this study will assist 
developers of biopesticides in accomplishing their goals in a cost- and time-effective way, 
which will result in successful and sustainable products and expanding biocontrol companies. 
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